Clinical Trial  Report 08 October 2019 
Protocol: ZP4207-[ZIP_CODE] Page 1 
Final 
CONFIDENTIAL 
  16. APPENDICES  
16.1 Study Information 
16.1.1  Protocol and Protocol Amendments 
The following protocols are provided in this Appendix:  
Clinical Study Protocol s and Protocol Amendments:  
Version  Date  
Final Version 5.0 04 Apr 2018  
Final Version 4.0 ([LOCATION_013] only)  [ADDRESS_1115095] 2017  
Final Version 2.0  31 Aug 2017  
Final Version 1.0  29 Aug 2017  
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 1 of 82  
CLINICAL TRIAL PROTOCOL 
 
A phase 3, randomized, double-blind, parallel trial to 
confirm the clinical efficacy and safety of dasiglucagon 
in the rescue treatment of hypoglycemia in subjects with 
type 1 diabetes mellitus (T1DM) compared to placebo 
and with reference to GlucaGen® 
 
Sponsor:  Zealand Pharma A/S  
Sponsor Protocol No.:  ZP4207 -[ADDRESS_1115096] No. : 2017 -002449 -31  
IND No : 127866  
Trial  Drug Name:  [CONTACT_807506] * injection  
Date of Protocol:  04-Apr-2018  
 
The trial will be conducted according to the protocol and in compliance with Good 
C
linical Practice (GCP), with the Declaration of Helsinki and with other applicable 
regulatory requirements. 
*Dasiglucagon is the proposed international nonproprietary name [CONTACT_807507]4207. 
U
pdate
d protocol, Final version 5.0 including: 
Proto
col, Final version 3.0, dated 06-Oct-2017 
Local protocol amendment 1 ([LOCATION_013]), Final version 1.0, dated 26-Jan-[ADDRESS_1115097] party, in any form, without prior written 
consent of an authorized officer of Zealand Pharma. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly C
onfidential    Page 2 of 82  
Declaration of sponsor or responsible medical officer 
Title:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes me
llitus (T1DM) compared to placebo and with reference to GlucaGen® 
This 
trial protocol was subjected to critical review. The information it contains is 
c
onsistent with current knowledge of the risks and benefits of the investigational product, 
as well as with the moral, ethical and scientific principles governing clinical research as 
set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice (GCP) 
(1). 
 
 
_____________________________________ _____________________ 
Name     [CONTACT_807508] A/S 
Smedela
nd 36 
2600 Glostrup, Denmark 
Phone:   
 
_____________________________________ _____________________ 
Name     [CONTACT_807509] A/S 
Smedela
nd 36 
2600 Glostrup, Denmark 
Phone:   

 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly C
onfidential    Page 3 of 82  
Declaration of the coordinating investigator 
[CONTACT_1641]:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes
 mellitus (T1DM) compared to placebo and with reference to GlucaGen® 
I have read this protocol. I approve this document and I agree that it contains all 
necessary details for carrying out the trial as described. I will conduct this trial in 
accordance with the design and specific provision of this protocol and will make a 
reasonable effort to complete the trial within the time designated. I will provide copi[INVESTIGATOR_807427] A/S to trial 
personnel under my supervision. I will discuss this material with them to ensure they are 
fully informed about the trial product and trial procedures. I will let them know that this 
information is confidential and proprietary to Zealand Pharma A/S and that it may not be 
further disclosed to third parties. I understand that the trial may be terminated or 
enrollment suspended at any time by [CONTACT_93442] A/S, with or without cause, or by 
[CONTACT_807442]. 
I agree that the trial will be carried out in accordance with GCP (1), with the Declaration 
of Helsinki (with amendments) (2) and with the laws and regulations of the countries in 
w
hich the trial takes place. 
 
 
_____________________________________ _____________________ 
Name       [CONTACT_807510]: + 
Fax: + 
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 4 of 82  
Declaration of the investigator 
Title:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes
 mellitus (T1DM) compared to placebo and with reference to GlucaGen® 
All documentation for this trial that is supplied to me and that has not been previously 
publish
ed will be kept in the strictest confidence. This documentation includes this trial 
protocol, Investigator's Brochure, Case Report Forms, and other scientific data. 
The trial will not be commenced without the prior written approval of a properly 
c
onstituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC). 
No changes will be made to the trial protocol without the prior written approval of the 
spons
or and the IRB or IEC, except where necessary to eliminate an immediate hazard to 
the subjects. 
I have read and understood and agree to abide by [CONTACT_348232]. 
 
_____________________________________ _____________________ 
Signature
      [CONTACT_1782] 
 
_____________________________________ 
Name (block letters) 
 
_____________________________________ 
Title (block letters) 
 
_____________________________________
 
Institution (block letters) 
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 5 of 82  
Table of contents 
DECLARATION OF SPONSOR OR RESPONSIBLE MEDICAL OFFICER  .......... 2 
DECLARA
TION OF THE COORDINATING INVESTIGATOR  ..............................  3 
DECLARA
TION OF THE INVESTIGATOR  ...............................................................  4 
T
ABLE OF CONTENTS  ................................ ................................................................ .. 5 
1 S YNOPSIS  ................................................................ ................................ ............ 11 
2 INTRODUC TION ................................ ................................................................  15 
2.1 B ackground ................................ ................................ ................................ ...... 15 
2.1.1 H ypoglycemia  ................................ ................................ ......................  15 
2.1.2 G lucagon  ................................ ................................ ..............................  16 
2.1.3 D asiglucagon ................................ ................................ ........................  16 
[IP_ADDRESS] Pharmac okinetics and pharmacodynamics of dasiglucagon ......... 17 
[IP_ADDRESS] Safety  of dasiglucagon  ................................ ................................ ... 17 
2.2 T rial rationale  ................................ ................................ ................................ .. 18 
2.3 Risk -benefit assessment  ................................ ................................ .................. 18 
3 T RIAL OBJECTIVES AND ENDPOINTS .......................................................  20 
3.1 P rimary objective  ................................ ............................................................  20 
3.2 S econdary objectives  ................................ .......................................................  20 
3.3 P rimary endpoint  ................................ ................................ ............................  20 
3.4 K ey secondary endpoints  ................................ ................................ ................ 20 
3.5 Oth er secondary endpoints  ................................ ................................ ............. 20 
3.6 E xploratory endpoint  ................................ ......................................................  21 
4 OVE RALL DESIGN AND PLAN OF THE TRIAL  ................................ ........ 22 
4.1 Over view  ................................ ................................ ................................ .......... 22 
4.2 Ju stification of the trial design  ................................ ................................ ....... 24 
4.2.1 J ustification for design and parameters ................................ ................ 24 
4.2.2 J ustification for drug, route, dosage and treatment duration  ............... 24 
5 T RIAL POPULATION  ................................ .......................................................  26 
5.1 Rat ionale for trial population  ................................ ................................ ........ 26 
5.2 P lanned sample size and number of trial centers  ................................ ......... 26 
5.3 In clusion criteria  ................................ .............................................................  26 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115098] ug accountability  ................................ .........................................................  36 
6.8 T reatment compliance  ................................ ................................ .................... 36 
6.9 P rior and concomitant medications  ...............................................................  36 
6.9.1 P rohibited medications ................................ ................................ ......... 37 
6.10 Loc al German requirements for insulin glulisine (Api[INVESTIGATOR_27976]®)  ........................  37 
7 P ARAMETERS AND METHODS OF ASSESSMENT  ................................ .. 38 
7.1 E fficacy parameters  ................................ ........................................................  38 
7.1.1 P harmacodynamic measurements  ................................ ........................  38 
7.1.2 P harmacokinetic measurements  ................................ ...........................  38 
7.2 S afety parameters  ................................ ............................................................  39 
7.2.1 A dverse events  ................................ ................................ ..................... 39 
[IP_ADDRESS] De finitions  ................................ ................................ ......................  39 
[IP_ADDRESS] C ollection, recording and reporting of adverse events  ................. 42 
[IP_ADDRESS] Follo w-up of adverse events  ..........................................................  44 
[IP_ADDRESS] C linical laboratory abnormalities and other abnormal 
assessments as adverse events or serious adverse events  .............. 44 
7.2.2 H ypoglycemia  ................................ ................................ ......................  45 
7.2.3 P hysical examination  ................................ ................................ ........... 45 
7.2.4 V ital signs  ................................ ................................ ............................  45 
7.2.5 Ele ctrocardiogram  ................................ ................................ ................ 46 
7.2.6 Lo cal tolerability  ................................ ................................ .................. 46 
7.2.7 C linical laboratory assessments  ................................ ...........................  47 
7.2.8 P regnancy  ................................ ................................ .............................  48 
7.2.9 P recautions  ................................ ................................ ...........................  49 
7.2.10 S afety committee  ................................ ................................ ................. 49 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115099]  ................................ ..............................................................  53 
8.1 S chedule of procedures  ................................ ................................ ................... 53 
8.2 P rocedures by [CONTACT_765]  ................................ ..........................................................  53 
8.2.1 V isit 1 (screening, Day -30 to Day -3)  ................................ ................. 53 
8.2.2 Ins tructions to subjects prior to the dosing visit (Visit 2)  .................... 55 
8.2.3 V isit 2 (dosing visit) ................................ ................................ ............. 56 
[IP_ADDRESS] Hy poglycemic clamp procedure and administration of trial 
medication  ................................ ......................................................  57 
8.2.4 V isit 3 (follow-up visit) ................................ ................................ ....... 60 
9 S TATISTICAL METHODS  ................................ ................................ ............... 61 
9.1 De termination of sample size  ................................ ................................ ......... 61 
9.2 T rial subjects  ................................ ................................ ................................ ... 61 
9.2.1 A nalysis samples  ................................ ................................ .................. 61 
9.2.2 D isposition of subjects  ................................ ................................ ......... 62 
9.2.3 P rotocol deviations ................................ ................................ ............... 62 
9.3 G eneral considerations  ................................ ................................ ................... 63 
9.4 De mographics and baseline characteristics  ................................ .................. 63 
9.5 E fficacy Analyses  ................................ .............................................................  63 
9.5.1 H ierarchical testing procedure  ................................ .............................  64 
9.5.2 P rimary confirmatory endpoint  ................................ ............................  64 
[IP_ADDRESS] Primary  analysis  ................................ ................................ ............ 64 
9.5.3 S econdary endpoints  ................................ ................................ ............ 65 
[IP_ADDRESS] C onfirmatory analysis  ................................ ................................ .... 65 
9.5.4 S econdary clinical efficacy (PD) endpoints  ................................ ......... 66 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints  ................ 66 
9.5.5 Ex posure (PK) endpoints  ................................ ................................ ..... 66 
[IP_ADDRESS] Analy sis of exposure (PK) endpoints  ................................ ............. 67 
9.6 E xploratory analyses  ................................ ................................ .......................  67 
9.7 S afety analyses  ................................ ................................................................ . 68 
9.7.1 A dverse events  ................................ ................................ ..................... 68 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115100]-treatment blood sampling times  ................................................................  59 
 
F
igures in text 
Figure 1 T rial design  ................................................................ ................................ ........ 23 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115101]  European Medicines Agency’s Clinical Trials Database  
FAS Full analysis set  
FDA  Food  and Drug A dministration  
GCP  Good Clinical Practice  
HbA 1c Glycated hemoglobin  
ICH International Conference on Harmonization  
ID card  Identification card  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IV Intravenous(ly)  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 10 of 82  
IWRS  Interactive Web Response System  
MedDRA  Medical Dictionary for Regulatory Activities  
NPH  Neutral protamine Hagedorn  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per protocol  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Safety analysis set  
SC Subcutaneous(ly)  
S[LOCATION_003]R  Serious unexpected suspected adverse reaction  
T1DM  Type [ADDRESS_1115102]  Upper limit of the normal range  
US [LOCATION_002] of America  
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 11 of 82  
1 SYNOPSIS 
Name [CONTACT_119019]:  
Zealand Pharma A/S  Trial ID:  
ZP4207 -[ZIP_CODE] 
Title of the trial:  
A phase 3, randomized, double -blind, parallel trial to confirm the clinical e fficacy and safety of 
dasiglucagon  in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) 
compared to placebo and with reference to GlucaGen® 
Trial design:  
The trial is a global, multicenter, randomized, parallel -group , double -blind, clinical trial confirming the 
efficacy and safety of dasiglucagon  for insulin -induced hypoglycemia in subjects with type 1 diabetes  
mellitus . The subjects will be randomized 2:1:1 to receive a single fixed subcutaneous 0.6 mg dose of 
dasigluc agon  (hereinafter dasiglucagon) , placebo  for dasiglucagon (hereinafter referred to as placebo) , or a 
1 mg dose of GlucaGen® (hereafter referred to as GlucaGen) and followed for at least 28  days after 
treatment.  
Clinical phase of development:  
Phase 3 
Tria l centers : 
This trial will be conducted at 4 to 6 sites in the [LOCATION_002] of America , Canada, and Europe . 
Planned trial start ( first subjec t first visit):  
Q4/2017 Planned trial end ( last subjec t last visit):  
Q3/2018  
Trial population:  
Male and female  adult  subjects  with type [ADDRESS_1115103] one year   
Key objectives:  
Primary objective:   
 To demonstrate superiority  of dasiglucagon  compared to placebo  following a single subcutaneous  
0.6 mg dose administered to subjec ts with type 1 diabetes mellitus  with insulin -induced 
hypoglycemia . 
Secondary objective:   
 To compare the glycemic response observed after  dasiglucagon  with that of  GlucaGen . 
Key endpoints:  
Primary endpoint:   
 Time to  plasma glucose  recovery. Plasma glucos e recovery is defined as first increase in plasma 
glucose of  ≥20 mg/dL  (1.1 mmol/L) from baseline  during the hypoglycemic clamp procedure  
without administration of rescue intravenous ( IV) glucose .  
Key s econdary endpoint s: 
 Plasma glucose recovery  within 30 minutes, within 20 minutes , within 15 minutes, and within 
10 minutes  after study drug injection  without administration of rescue IV glucose . 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes , within 15 minutes, 
and within 10 minutes  after study drug injection  or at the time of rescue . 
Clini cal efficacy  (Pharmacodynamic ) endpoints:  
 Time to first plasma glucose concentration of ≥70 mg/dL ( 3.9 mmol/L ) without administration of 
rescue IV glucose . 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 12 of 82  
 Plasma glucose response as  area under the curve  above baseline  from time zero to 30 minutes, 
AUC0-30min. 
Exposure (Pharmacokinetic) endpoints:  
 Area under th e drug concentration curve from time zero to 90 minutes , AUC 0-90 min. 
 Maximum plasma drug concentration (C max). 
 Time to maximum plasma  drug concentration (t max). 
Safety endpoints:   
 Adverse events, clinical laboratory assessments (biochemistry, hematology, urinalysis), vital signs, 
physical examination, electrocardiogram, and local tolerability.  
 Administration  of rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
 Time to first rescue infusion of IV glucose during the hypoglycemic clamp pr ocedure.  
Immunogenicity endpoint:  
 Occu rrence  of anti -drug antibodies  
Exploratory endpoint:  
 Plasma g lucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL (1.1 mmol/L) 
within 30  minutes after study drug injection  without administration of resc ue IV glucose . 
 Plasma insulin response as area under the curve above baseline from time zero to  60 minutes , 
AUC 0-60 min. 
Key inclusion criteria:  
 Male and female subject s with type [ADDRESS_1115104] one year, 
diagnostic criteria as defined by [CONTACT_807443] n. 
 Stable  insulin treatment 30 days prior to screening, defined as no more than a 10 -unit daily variation 
in total  daily insulin dose . 
 Hemoglobin A 1c <10%.  
 Aged between 18 and 75 years, both inclusive . 
Key exclusion criteria:  
 Previously treated with dasiglucagon . 
 Known or suspected allergy to trial product(s) or related products.  
 History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).  
 Previous participation (randomization) in  this trial.  
Sample size:  
Approximately  [ADDRESS_1115105]:  
Test product: dasiglucagon  liquid form ulation in pre -filled syringes . 
Comparator  product s: Placebo and GlucaGen® lyophilized powder . 
[LOCATION_013] only: Insulin glulisine (Api[INVESTIGATOR_27976]®), the challenge agent, will also be defined as an investigational 
medicinal product . 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 13 of 82  
 
Duration of treatment:  
Subjects will be randomized 2:1:[ADDRESS_1115106] 28 days after receiving treatment .  
Assessments:  
The plasma glucose profil e for evaluation of the primary and secondary clinical efficacy 
(pharmacodynamic) endpoints will be assessed based on plasma concentration data from samples collected 
at the dosing visit.  
The exposure to  trial medication (dasiglucagon , placebo , or GlucaGen ) for evaluation of pharmacokinetics  
will also be assessed based on plasma concentration data .  
Statistical methods:   
Due to requirements in the size of the safety database, the sample size is set to 78 subjects treated with 
dasiglucagon 0.6  mg. From phas e 2, the median time to an increase of 20 mg/dL of the 0.6 mg dose was 
approximately 10 minutes. With a 2:1:[ADDRESS_1115107] a difference between dasiglucagon and placebo with 90% power with a follow -up time 
of 45 minutes at a 5% sig nificance level with 78 subjects treated with dasiglucagon and 39 subjects with 
placebo. The median time -to-recovery for placebo is expected to be longer than 20 minutes, which means 
that the power will be greater than 90%.  
For the confirmatory analyses, t he primary and key secondary endpoints for the dasiglucagon 0.6  mg and 
placebo  treated subjects will be compared. A hierarchical procedure will be applied for the control of 
multiplicity  in statistical inferences . The primary and secondary endp oints will b e evaluated on the Full 
Analysis Set sample . The statistical inference comparisons with placebo will be conducted as superiority 
tests. The comparisons of  dasiglucagon versus GlucaGen will be summarized descriptively .    
The primary endpoint will be summar ized using Kaplan -Meier (KM) estimates stratified by [CONTACT_807444]. The treatment group difference between dasiglucagon and placebo will be evaluated 
inferentially using a pairwise two -sided log -rank test.  
In the primary analysis, recovery cannot be achieved in those subjects where IV glucose treatment is 
administered. Those subjects who receive IV glucose will be censored (i.e. set to ‘not recovered’) at 45 
minutes after dosing.  
In sensitivity analyses, the time to plasma glucose recov ery will be analyzed 1) without censoring for those 
subjects who require rescue IV glucose before 45 minutes and 2) with censoring at the time of 
administration of rescu e IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed us ing a Cox proportional hazards (CPH) time to event 
statistical model, if the hazards by [CONTACT_807445] a graphical 
comparison of log -minus -log survival curves and no more than two -thirds of the recovery times are 
censored  in each treatment group. The CPH model will be used for inferences, with treatment group and 
injection site modeled as categorical effects, and baseline plasma glucose modeled as a continuous 
covariate. The treatment group rate ratios, active versus place bo, will be estimated together with the 95% 
confidence intervals, and pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs 
placebo) will be evaluated using two -sided likelihood ratio tests.  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 14 of 82  
The key secondary incidence variables (plasm a glucose recovery within 30 minute s, within 20 minutes, 
within 15  minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive 
statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group com parisons will be 
assessed via pairwise tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo) using Fisher’s exact test for each pairwise comparison.  
The key secondary endpoints of plasma glucose changes from basel ine (CFB) within [ADDRESS_1115108] in those subjects who require rescue IV 
glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an 
Analysis of Covariance model, with treatment group modeled as a fixed effect and with the baseline plasma 
glucose modeled as a covariate. The dasiglucagon versus placebo treatment group difference will be 
evaluated inferentially as a least squares means contrast, using a two -sided t -test at the 0.[ADDRESS_1115109].  
The continuous clinical efficacy variables, the exploratory variables, and the pharmacokinetics variables 
will each be summarized des criptively by [CONTACT_1570]. The clinical efficacy variables will  be analyzed 
analogous to the plas ma glucose  CFB variables.   
The safety analyses will include by -treatment -group descriptive summaries of vital sign measurements, 
laboratory measures (including immunogenicity incidence), physical examination assessments, rescu e IV 
glucose (incidence and amount of glucose infused), and adverse events. The number and percentage of 
subjects reporting specific events, such as nausea and vomiting, will be presented by [CONTACT_430449].  
Further details will be included in the Statistical Analysis Plan, to be completed before dat abase lock and 
treatment unmasking.   
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential
    Page 15 of 82  
2 INTRODUCTION 
2.1 B ackground 
Zealand Pharma A/S (Zealand Pharma) is developi[INVESTIGATOR_807428], a physically and 
chemically stable peptide analog of human glucagon, in a ready- to-use liquid formulation 
for the acute treatment of severe hypoglycemia in patients with insulin-treated diabetes 
mellitus. Like native glucagon, dasiglucagon is comprised of 29 amino acids, but with 
7 substitutions which improve its physical and chemical stability in aqueous media. 
T
hese amino acid substitutions make dasiglucagon suitable for a liquid formulation, 
while providing similar efficacy and safety as compared with recombinant glucagon in 
the clinical se
tting of acute treatment of severe hypoglycemia. 
2.1.1 Hypogly cemia 
Hypoglycemia in patients with diabetes is defined as epi[INVESTIGATOR_807429] (3). T his is a common, unpredictable, and potentially 
dangerous side effect of treatment of diabetes mellitus, especially with insulin or 
sulfonylure
as. It is more frequent in patients with profound endogenous insulin 
deficiency, such as occurs in type 1 diabetes mellitus (T1DM) and advanced type 2 
diabetes mellitus (T2DM). Treatment of T2DM with insulin causes hypoglycemia 
progressively and more frequently over time, whereas in T1DM, hypoglycemia is 
experienced throughout the course of established disease ( 4).  
Symptoms and signs of hypoglycemia are not specific. Patients undergoing a 
hypoglycemic epi[INVESTIGATOR_460616], sweating, 
hunger, tremors, palpi[INVESTIGATOR_814], paresthesia, nausea and pallor. Depending on its severity, 
the hypoglycemia may lead to mild confusion, behavioral changes, loss of consciousness, 
seizures, coma, and death (5). 
The incidence of hypoglycemic events or even the fear of hypoglycemia influences 
patients’ adherence to prescribed treatment regimens for diabetes mellitus  (6). T his leads 
to inadequate glycemic control, which in turn may lead to an increased risk of diabetic 
complications ( 5). Serious clinically significant hypoglycemia is now defined as plasma 
gluc
ose <54 mg/dL (3.0 mmol/L), while the plasma glucose alert value is defined as 
<70 mg/dL (3.9 mmol/L) (7). W hen plasma glucose falls below these values, some kind 
o
f treatment strategy is needed. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential 
   Page 16 of 82  
2.1.2 Glucagon 
Glucagon is a naturally occurring hormone, secreted from the alpha cells of the 
pancreatic islets. Glucagon plays a central role in the regulation of glucose homeostasis 
and is the counterpart of insulin for controlling blood glucose levels (i.e. it acts in 
opposition to insulin in terms of effects on blood glucose levels) ( 8,9). G lucagon 
stimulates hepatic glycogenolysis and gluconeogenesis in hypoglycemic states, thereby 
[CONTACT_93406]. Glucagon receptor agonism has also been shown to exert 
effects on lipid metabolism, energy balance, body adipose tissue mass and food intake 
(10). Ins ulin decreases blood glucose levels and cases of hypoglycemia can be reversed 
by [CONTACT_41148]. Therefore, glucagon is indicated for the treatment of severe hypoglycemia. 
Besides intravenous (IV) glucose administration, an injectable form of glucagon is given 
as first aid in cases of severe hypoglycemia, when the patient is unconscious or for other 
reasons cannot t
ake glucose orally. The approved glucagon dose for an adult is 1 mg, 
given by [CONTACT_33813] (IM), IV, or subcutaneous ( SC) injection, which quickly raises 
bloo
d glucose levels. As current marketed recombinant glucagon is highly unstable when 
dissolved in solution, the injectable form has to be reconstituted prior to use in a 9-step 
procedure that requires a sterile diluent to be injected into a vial containing lyophilized 
powdered glucagon. When dissolved in a fluid state, glucagon can form amyloid fibrils 
(11), or tightly woven chains of proteins made up of the individual glucagon peptides. 
The reconstitution process makes the use of marketed glucagon products cumbersome 
(12), and a more patient-friendly formulation is needed. Currently, the Food and Drug 
Administration (FDA ) approved instructions for commercially available glucagon allow 
only for immediate usage of glucagon after the powder is reconstituted in aqueous 
solution ( 13). T herefore, a glucagon analog with enhanced biophysical stability may 
represent a leap forward in terms of convenient therapeutic applications. 
2.1.3 Dasigl ucagon 
Dasiglucagon (ZP4207) is a stable peptide analog of human glucagon, available in a 
ready- to-use liquid formulation. Dasiglucagon (hereinafter referred to as dasiglucagon) is 
in development for the
 treatment of severe hypoglycemia in insulin-dependent patients 
with diabetes mellitus. Dasiglucagon is a specific and full glucagon receptor agonist 
designed to mimic the effects of glucagon, having a fast absorption and elimination 
(minutes). It is a peptide of 29 amino acids, with 7 amino acid substitutions compared to 
native glucagon. The main purpose of the substitutions is to increase the physical and 
chemical stability of the glucagon analog compared to marketed glucagon products such 
as Lilly Glucagon or GlucaGen® (hereafter referred to as GlucaGen). Dasiglucagon 
e
xhibits improved physical and chemical stability and is available in an aqueous solution 
at neutral pH ( 14). 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115110] been completed with dasiglucagon: a first- in-human dose trial in 
heal
thy volunteers and subjects with T1DM (ZP4207-[ZIP_CODE]), a multiple-dose 
dose-escalation trial (ZP4207-[ZIP_CODE]) evaluating the safety, tolerability, pharmacokinetics 
(PK) and pha
rmacodynamics (PD) of dasiglucagon in healthy volunteers, and a phase 2 
cross
over trial to assess the PK and PD of a single dose of an optimized formulation of 
da
siglucagon administered SC in subjects with T1DM (ZP4207-[ZIP_CODE]) ( 14). 
[IP_ADDRESS] Pharmac okinetics and pharmacodynamics of dasiglucagon 
The results of the phase [ADDRESS_1115111] absorption with a peak plasma 
concentration obtained after 35 minutes. Thereafter, the plasma concentration rapi[INVESTIGATOR_807430]-life of 28 minutes. The median time to the maximum 
plasma c
oncentration (t max) was [ADDRESS_1115112] 70 mg/dL (3.9 mmol/L) as well as an increase in plasma glucose by [CONTACT_2669] 
20 mg/dL (1.1 mmol/L) within 30 minutes after dosing. The PD responses to 0.6 mg of 
da
siglucagon and 1 mg of GlucaGen were comparable. 
[IP_ADDRESS] Safety  o f dasiglucagon 
The safety data for dasiglucagon do not give rise to any safety concerns. No new signals 
we
re observed, beyond those related to the pharmacological effect of glucagon agonism. 
A
ll adverse events (AEs) recorded in the trials were of mild or moderate severity. The 
most frequently reported systemic AE was nausea, which is a known side effect 
following administration of glucagon. Headache was the next most frequently reported 
event, occurring in all dose groups in the phase [ADDRESS_1115113] (IMP) 
doses of at least 1 mg (4 with dasiglucagon and 1 with GlucaGen). This is not considered 
a sa
fety concern; however, hemodynamic changes after dosing will be considered an 
adverse
 event of special interest (AESI). 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly C
onfidential    Page 18 of 82  
The phase 1 and 2 results and the safety profile described to date do not give rise to 
specific safety concerns. For further information, please refer to the Investigator’s 
Brochure (14). 
2.2 T rial rationale 
The aim of the current trial is to confirm the superiority of dasiglucagon for the treatment 
of insulin
-induced hypoglycemia in subjects with T1DM as compared to placebo for 
dasiglucagon (hereinafter placebo) and to compare the clinical efficacy and safety of 
dasigluc
agon with reference to GlucaGen. A randomized, controlled trial design was 
used. 
See Section  4.[ADDRESS_1115114] s 
with known or suspected allergies to the trial medications or related products will be 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115115]
 relevant clinical effects in the acute severe hypoglycemia rescue setting and may be 
a
n effective and reliable emergency treatment for severe hypoglycemia. Overall, the 
antic
ipated benefits fo r subjects entering the ZP4207-[ZIP_CODE] trial are considered to justify 
the
 risks. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 20 of 82  
3 TRIAL OBJECTIVES AND ENDPOINTS 
3.1 P rimary objective 
 To demonstrate superiority of dasiglucagon compared to placebo following a single 
subcutaneous 0.6 mg dose administered to subjects with type 1 diabetes mellitus with 
ins
uli
n-induced hypoglycemia. 
3.2 S econdary objectives 
 T o compare the glycemic response observed after dasiglucagon with that of 
GlucaGen. 
3.3 P rimary endpoint 
 T ime to plasma glucose recovery. Plasma glucose recovery is defined as first increase 
in plas
ma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
clamp procedure without administration of rescue IV glucose.  
3.4 K ey secondary endpoints 
 Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
3.5 Other secondary endpoints 
 C linical e fficacy (PD) endpoints: 
­ Time to first plasma glucose concentration ≥70 mg/dL  (3.9 mmol/L) without 
a
dministration of rescue IV glucose. 
­ Plasma glucose response as area under the curve (AUC ) above baseline from time 
zero to 30 minutes, AUC0-30min . 
 Ex posure (PK) endpoints: 
­ Area under the drug concentration curve from time zero to 90 minutes, 
AUC 0-
90min. 
­  Maximum plasma drug concentration (C max) . 
­ T
ime to maximum plasma drug concentration (t max). 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 21 of 82  
 Safety endpoints:  
­ Adverse events, clinical laboratory assessments (biochemistry, hematology, 
urinalysis), vital signs, physical examination, electrocardiogram (ECG), and local 
tolerability. 
­ Administration of rescue infusion of IV glucose during the hypoglycemic clamp 
proce
dure. 
­ Time to first rescue infusion of IV glucose during the hypoglycemic clamp 
procedure. 
 Immunogenicity endpoint: 
­ Occurrence of anti-drug antibodies 
3.6 E xploratory endpoint 
 Plas ma glucose concentration ≥70  mg/dL (3.9 mmol/L) or increase of ≥2 0 mg/dL 
(1.1 mmol/L) within 30 minutes after study drug injection without administration of 
re
scu
e IV glucose. 
 P lasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC 0 -60 min . 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly
 Confidential    Page 22 of 82  
4 OVERALL DESIGN AND PLAN OF THE TRIAL 
4.1 Over view 
This trial is a global, multicenter, randomized, parallel, double-blind, clinical trial 
c
onfirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in 
subjec
ts with T1DM. The subjects will be randomized 2:1:[ADDRESS_1115116] 28 days after receiving treatment. A total of 156 subjects with T1DM are expected 
to com
plete the treatment visit. The trial will be conducted in the European Union ( EU) 
and North America. See  Figure 1 for an overview of the trial design. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 23 of 82  
Figure 1 Trial design 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115117] selection and in the evaluation of clinical assessments, 
subjects will be randomly assigned 2:1:[ADDRESS_1115118] been used to 
establish that 0.6 mg of dasiglucagon is an effective dose and also represents a 
therapeutically equivalent dose to 1 mg of GlucaGen (see also Section  6.1).  
Dasigluc
agon, placebo, and GlucaGen will be administered in the abdomen, buttocks, or 
thi
gh by [CONTACT_10530], as this is one of the intended routes of administration for 
da
sigluc
agon, besides IM and IV. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115119] 28 days after dosing in order to perform an adequate 
imm
unogenicity evaluation of treatment.  
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confi
dential    Page 26 of 82  
5 TRIAL POPULATION 
5.1 Rat ionale for trial population 
Dasiglucagon is in development for the treatment of severe hypoglycemia in 
ins
ulin-de
pendent patients with diabetes mellitus. In the present trial, subjects with 
T
1DM are included in the evaluation of efficacy and safety of dasiglucagon under 
hypogly
cemic conditions as this is part of the intended target population. Subjects with 
T1DM ar
e selected to avoid the endogenous glucagon counter-regulatory response to 
insulin-induced hypoglycemia that is present in patients with T2DM. The inclusion and 
exclusio
n criteria are set to include a trial population that represents the general 
population o
f subjects with T1DM.  
5.2 P lanned sample size and number of trial centers 
A total number of 156 subjects wit h T1DM are expected to complete the treatment visit 
(Visit 2). To quali fy as completed, the subject must be dosed and have blood drawn for 
the PK and PD assess ments described in the protocol. It is expected that up to 
[ADDRESS_1115120] 156 subjects completing Visit 2. Completion of 
156 subjects ([ADDRESS_1115121] s in each of the 
placebo and GlucaGen groups) would be expected to provide adequate power for the 
primary efficacy evaluation, as described in Section  9.1. 
T
he plann
ed date for first subject first visit is expected to take place in Q4, [ADDRESS_1115122] in Q3, 2018. 
This trial i
s planned to be conducted at 4 to 6 trial sites in the [LOCATION_002] of America 
[US
], Canada, and Europe. 
5.3 Inclusion criteria 
Subjects will be entered into this trial only if they meet all of the following criteria: 
1.
Informed consent obtained before any trial-related activities (trial-related
activ
ities are any procedure that would not have been performed during normal
management of the subject).
2. Female or male subjects with T1DM for at least 1 year, diagnostic criteria as
defined by
 [CONTACT_11026] ( 3).
3.
Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
(define
d as no more than a 10-unit daily variation in total daily insulin dose)
30 days prior to screening
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly
 Confidential    Page 27 of 82  
4. H emoglobin A 1c <10%. 
5. A ged between [ADDRESS_1115123] meet one of the following criteria: 
a. Participant is of childbearing potential and agrees to use one of the 
accepted contraceptive regimens throughout the entire duration of the trial 
from screening and until last follow-up visit. An acceptable method of 
contraception includes one of the following: 
i. Abstinence from heterosexual intercourse; 
ii. Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/ 
insertable hormonal birth control products, transdermal patch); 
iii. Intrauterine device (with and without hormones); or 
iv. Condom with spermicide; or 
b. P articipant is of non-childbearing potential, defined as surgically sterile 
(i.e. has undergone complete hysterectomy, bilateral oophorectomy, or 
tubal ligation), or in a menopausal state (at least 1 year without menses). 
7. A  male subject must meet the following criteria: Surgically sterilized or willing to 
refrain from sexual intercourse from screening and until last follow-up visit or, if 
sexually active, uses condom and partner practices contraception during the trial 
from screening and until last follow-up visit. 
5.4 E xclusion criteria 
Subjects meeting any of the following criteria during screening evaluations will be 
excluded from trial participation: 
1. P reviously treated with dasiglucagon (previously referred to as ZP4207). 
2. K nown or suspected allergy to trial product(s) or related products. 
3. H istory of anaphylaxis or symptoms of severe systemic allergy (such as 
angioedema). 
4. P revious participation (randomization) in this trial. 
5. F emales who are pregnant according to a positive pregnancy test, are actively 
attempting to get pregnant, or are lactating. 
6. H istory of hypoglycemic events associated with seizures in the last year prior to 
screening
. 
7. History of severe hypoglycemia (defined as plasma glucose <54 mg/dL 
[3.0 mmol/L]) in the last month prior to screening. 
8. R eceipt of any investigational drug within [ADDRESS_1115124] 5 years. 
10. Congestive heart failure, [LOCATION_001] Heart Association class II-IV. 
11. Inadequately treated blood pressure, defined as s ystoli c ≥160 mmHg or diastolic 
≥90 mmHg) at screening (15).  
12. C urrent bleeding disorder, including anti-coagulant treatment. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly
 Confidential    Page 28 of 82  
13. Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or 
insulinoma (i.e. insulin secreting pancreas tumor). 
14. Us e of a daily systemic beta-blocker drug, indomethacin, warfarin or 
anticholinergic drugs in the previous 28 days before Day 1 of this trial. 
15. As partate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the 
upper limit of the normal range (ULN), bilirubin >1.5 × ULN, estimated 
glomerular filtration rate <30 mL/min/1.73 m2 according to the Modification of 
D
iet in Renal Disease study definition (16), or a ltered electrolyte values of 
clinical relevance for cardiac conduction, as judged by [CONTACT_093]. 
16. C linically significant abnormal ECG at screening as judged by [CONTACT_093]. 
17. C linically significant illness within [ADDRESS_1115125] 2 months prior to 
screening. 
20. A  positive result in the alcohol and/or urine drug screen at the screening visit. 
Significant history of alcoholism or drug abuse as judged by [CONTACT_807446] [ADDRESS_1115126] ’s typi[INVESTIGATOR_93379], and 
should not exceed a near maximum intensity for more than [ADDRESS_1115127]. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 29 of 82  
4. Not fasting from 22:00 hours the evening prior to dosing, apart from water. Small
amounts o
f carbohydrates (up to 20 g) to prevent hypoglycemia are allowed.
5. The
 use of any non-prescribed systemic or topi[INVESTIGATOR_73201], except routine
vitam
ins and occasional use (as judged by [CONTACT_093]) of acetylsalicylic acid
and paracetamol within 2 weeks prior to dosing. Treatment with insulin, including
analo
gs, is allowed.
6.
Use of insulin Degludec or insulin Glargine U300 within 48 hours prior to dosing;
or use
 of other long-acting insulins (e.g., insulin Glargine U100 or insulin
Detemir) within 24 hours prior to dosing; or use of insulin Neutral protamine
Hage
dorn (NPH) within 16 h ours  prior to do sing.
7. Use of any short acting (bolus) insulin within 6 hours prior to dosing, except
insulin gluli
sine (Api[INVESTIGATOR_27976]®).
8. Changes in medical history or concomitant medication resulting in fulfillment of
clinic
al exclusion criteria, as judged by [CONTACT_093].
9. Plasma glucose value <50 mg/dL (2.8 mmol/L) within the last 24 hours or plasma
glucose va
lue <60 mg/dL (3.3 mmol/L) within the last [ADDRESS_1115128] has the right to withdraw from the 
trial at any time and for any reason. If he/she chooses to withdraw, the investigator must 
be informed immediately. The investigator has the right to terminate participation of any 
subject at any time if the investigator deems it in the subject's best interest. The reason 
and circumstances for withdrawal will be documented in the electronic case report form 
(eCRF). 
5.6.[ADDRESS_1115129] will be discontinued from treatment if the following applies: 
Withdrawal of consent by [CONTACT_1130].
If a protocol deviation occurs which, in the clinical judgement of the investigator, can
invalida
te the trial or endpoints or can interfere pharmacokinetically or
pharmacodynamically with the trial product, the subject will be discontinued by [CONTACT_31035].
Adverse events occur which are considered unacceptable by [CONTACT_807447].
If discontinuation occurs following administration of trial medication, every effort should 
be made to have the subject return and participate in the complete follow-up visit on 
Day 28 (see Table 3) to avoid missing data. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115130] complete the treatment visit (Visit 2). To qualify as 
c
ompleted, the subject must be dosed and have blood drawn for the PK and PD 
assessments described in the protocol.  
5.6.2 C enter discontinuation 
The center can be closed and the trial terminated for the following reasons: 
 The center is unlikely to be able to recruit sufficient subjects within the agreed time 
frame. 
 The center does not respond to trial management requests. 
 R epeat protocol violations. 
5.6.3 Trial  termination 
The sponsor reserves the right to modify or terminate the trial at any time. Possible 
reasons for termination are: 
 S afety reasons – the incidence of AEs in this or any other trial using the same trial 
medication indicates a potential health risk for the subjects. 
 New scientific knowledge becomes known that makes the objectives of the trial no 
longer feasible/valid. 
 Unsatisfactory enrolment of subjects. 
5.[ADDRESS_1115131] given written informed consent and meet all inclusion and none of the 
exclusion criteria will be randomized in a 2:1:1 ratio to either 0.6 mg dasiglucagon 
(n=78 ), placebo (n=39), or 1 mg GlucaGen (n=39) via an Interactive Web Response 
Sys
tem (IWRS).  Randomization will continue until [ADDRESS_1115132] code can be broken by [CONTACT_807448] (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 31 of 82  
investigator, preferably after consultation with the medical monitor. Emergency code 
breaks can be performed using the IWRS. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 32 of 82  
6 TRIAL D RUG  
6.1 Id entity 
The following trial drugs will be administered: 
Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a prefilled syringe.
Placebo, liquid formulation, 0.6 mL delivered in a prefilled syringe.
Recombinant glucagon hydrochloride, 1 mg for reconstitution (GlucaGen®, Novo
No
rdisk) in [ADDRESS_1115133]  
Name  [CONTACT_807511]® 
Active 
substance  Dasiglucagon  N/A Recombinant 
glucagon 
hydrochloride  
Formulation  Liquid formulation, 
0.6 mL  Liquid formulation, 
0.6 mL  Powder and solvent 
for reconstitution as 1 
mL solution for 
injection  
Strength  1 mg/mL  N/A 1 mg  
Device  Single use pre -filled 
syringe  Single use pre -filled 
syringe  Powder and solvent 
for reconstitution 
packed together in a 
plastic box. A “hypo -
kit”. 
Manufacturer  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Novo Nordisk A/S, 
Bagsværd, Denmark  
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115134]  
Stora ge 
requirements  Store between 2 and 
8°C Store between 2 and 
8°C Store between 2 and 
8°C 
The quantities of ingredients for dasiglucagon and placebo are provided in Table 2. 
Table 2 Quantities of ingredients in dasiglucagon and placebo injection 
Component  Amount per mL 
(dasiglucagon)  Amount per mL 
(placebo)  Function  
Dasiglucagon*  1.0 mg  N/A 
Sodium chloride  10.23 mg  10.23 mg  
Trometamol/Tromethamine  6.06 mg  6.06 mg  
Water for injection  To make 1 mL  To make 1 mL  
Sodium hydroxide  q.s. q.s. 
Hydrochloric acid  q.s. q.s. 
*The quantity of drug substance to be used is calculated according to net peptide content and purity.
q.s. = quantum sufficit (quantity required). 
6.2 T reatment assignment and randomization 
Subjects successfully completing screening and who fulfill entry eligibility and 
randomization criteria will be randomized to one of three treatment groups in a ratio of 
2:1:1: 
Te
st treatment: Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a
prefilled 
syringe.
Placebo treatment: Placebo, liquid formulation, 0.6 mL delivered in a prefilled
syringe.
Re
ference treatment: Recombinant glucagon hydrochloride, 1 mg for reconstitution.
Randomizati
on will be performed using a fixed-block randomization scheme. The 
randomization scheme will be generated prior to the initiation of the study by [CONTACT_76691]/programmer who will not be a member of the study team; all 
investigators will not be aware of the block size of the randomization scheme.  
Randomization will be stratified by [CONTACT_807449] (a bdomen, 
buttocks, or thigh) a
nd controlled via the IWRS.      

Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictl
y Confidential    Page 34 of 82  
Subjects will be randomized to study treatment using an interactive, automated system 
which has be
en validated for the intended use under the International Society of 
Pharma
ceutical Engineers Good Automated Manufacturing Process guidelines, 21CFR 
Part 11 (FDA regulation for Electronic Records and Electronic Signatures) and the 
International Conference on Harmonization (ICH) Guidance E6 for Industry on Good 
Clinical Practice (GCP).   
6.3 Adm inistration 
Dasiglucagon, placebo, and GlucaGen will be administered by [CONTACT_807450] 
a
bdomen, buttocks, or thigh.  
An unbli
nded person (appropriately trained) authorized to prepare the dose and 
administer the treatment in accordance with the randomization will prepare the treatment 
required 
for each subject on each dosing day. The dose will be administered by [CONTACT_807451], trained and qualified person. The content of the syringe has to be checked for 
clarity and absence of bubbles.. 
Syringes will be discarded after dose administration. Used GlucaGen vials will be stored 
in a lockable box (separated from unused vials) at ambient temperature. 
6.[ADDRESS_1115135] label will be compliant with local laws and 
regulations.  
The study drug label will describe the storage conditions for study drug. The labels will 
supply
 no information about the subjects. Each treatment kit (pre-filled syringe/vial for 
reconstitution) will have a unique Dispensing Unit Number for drug allocation, drug 
accountability, and traceability purposes. 
Labelling will be performed according to Annex [ADDRESS_1115136] ensure the availability of proper storage conditions. All study drug 
supplies provided for this study will be stored in a secure area with restricted access at the 
study site.  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115137] be stored in a refrigerator (at a temperature of 2 –8°C), 
a
nd should be handled in accordance with guidelines from the sponsor. GlucaGen must 
also be stored in a refrigerator (at a temperature of 2 –8°C), and should be handled in 
a
ccordance with the Summary of Product Characteristics ( 13).  
The
 unblinded person responsible for study drug handling must contact [CONTACT_807452].  
P
lease see the Pharmacy Manual for additional information on handling study drug. 
6.6 Blinding and breaking the blind 
This is a double-blind trial. As the trial products are not identical in appearance, 
dasiglucagon and placebo being available as a liquid formulation and GlucaGen as a 
pow
der f
or reconstitution, unblinded trial personnel will be responsible for handling, 
preparing (according to the prescription from the IWRS), and administering the trial 
m
edica
tion, as well as for keepi[INVESTIGATOR_807431]. To maintain double-blind 
conditions, all trial assessments at the trial center will be done by [CONTACT_807453]. However, exposure assessments 
and anti-drug antibody (ADA) assessments will be performed by [CONTACT_807454], to ensure that dasiglucagon, placebo, or GlucaGen administration 
is m
atched with the applicable bioanalytical assay. 
Treatment assignment will be kept strictly confidential and accessible only to authorized 
persons until after the time of unblinding. Codes with treatment assignment will, 
however, be readily available in the IWRS to the blinded personnel in case of an 
emergency. 
The code for a particular subject may be broken in a medical emergency if knowing the 
identity of the treatment allocation would influence the treatment of the subject. The 
emergency code break can be performed using the IWRS. Whenever a code is broken, the 
person breaking the code must record the time, date and reason as well as his/her initials 
in the source documents. The breaking of blinded codes in case of medical emergency for 
one subject should not unblind the trial personnel to the treatment information of other 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115138] be notified within 24 hours 
after the c
ode has been broken. 
The pharmacovigilance unit (safety contract research organization [CRO];  see the list of 
trial personnel in Section  12.1 ) will be able to break the code in case of a serious 
unexpected suspected adverse reaction (S[LOCATION_003]R).  
The c
entral and specialty laboratories will be provided with a copy of the randomization 
list. 
6.[ADDRESS_1115139] until approved by [CONTACT_1034].  
6.8 T reatment compliance 
A
ll trial medications will be prepared and administered by [CONTACT_93400]. 
PK assessments will support the surveillance of compliance with IMP administration.  
6.9 P rior and concomitant medications 
Prior glucagon exposure will be recorded in the eCRF at screening. All concomitant 
medications will be recorded and/or updated in the eCRF at each visit.  
Subjects using any new concomitant medication resulting in fulfillment of a dosing day 
exclusion criterion (see Section  5.5) will be excluded from the dosing visit, but can be 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 37 of 82  
rescheduled to one of the following days (1–7 days later). The dosing visit can only be 
rescheduled once. 
6.9.1 Proh ibited medications 
The use of anti-coagulant treatments and medications (prescription and non-prescription) 
that are known to cause QT prolongation are prohibited during the course of the trial. 
W
ithin 28 days prior to dosing, the use of daily systemic beta-blockers, indomethacin, 
warfarin, and anticholinergic drugs is prohibited. 
Within 2 weeks prior to dosing, the use of any non-prescribed systemic or topi[INVESTIGATOR_73264] (with the exception of vitamins and the occasional use of acetylsalicylic acid 
and paracetamol) is prohibited.  
Within 48 hours prior to dosing, the use of insulin Degludec or insulin Glargine U300 are 
pro
hibited. 
Within 24 hours prior to dosing, the use of long-acting insulin (e.g., insulin Glargine 
U100 or ins
ulin Detemir) is prohibited. 
Within 16
 hours prior to dosing, the use of insulin NPH is prohibited. 
W
ithi
n 6 hours prior to dosing, the use of any short acting (bolus) insulin, except insulin 
glul
isine (Api[INVESTIGATOR_27976]®) is prohibited.  
During the insulin-induced hypoglycemic procedure, continuous SC insulin infusion must 
be
 stopped. 
6.10 L ocal German requirements for insulin glulisine (Api[INVESTIGATOR_27976]®) 
Insulin glulisine (Api[INVESTIGATOR_27976]®), the insulin used to induce hypoglycemia, will according to 
local requirements be defined as an investigational medicinal product when used at 
German sites. The insulin will be provided by [CONTACT_807455]. In contrast to the trial drug for the 
randomized treatment, the insulin will be administered by [CONTACT_807456] [IP_ADDRESS]. 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115140] be available prior 
to sample analyses. A bioanalytical report for each analysis of trial PD and PK samples 
will be prepare
d. 
7.1.1 Ph armacodynamic measurements 
The plasma
 glucose profile for evaluation of the primary and secondary clinical efficacy 
endpoints will be assessed based on plasma concentration data (AUC 0-30min ) from samples 
collected at the dosing visit (Visit 2). The samples will be sent to the clinical laboratory 
and an
alyzed using a sensitive and validated assay for glucose measurements.  
Samples will be collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 
75, and 90 minutes after dosing (see the schedule of procedures in
 Table 3). The actual 
tim
e of blood sampling for evaluation of plasma glucose should not deviate from the 
nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point and by 
[CONTACT_726] ±1 minute for the subseque nt coll ection time points . Pre-dose is define d as 
within 2 minutes prior to dosing. 
7.1.2 Ph armacokinetic measurements 
The exposure to trial medication (dasiglucagon or GlucaGen) for evaluation of PK will 
be assesse
d based on plasma concentration data (AUC 0-90 m in, Cmax, tmax) from samples 
collected at the dosing visit (Visit 2).  
Samples (including back-up samples) will be collected pre-dose, and at 15, 30, 35, 40, 
50, 60, 90, and 120 
minutes after dosing (see the schedule of procedures in Table 3). The 
a
ctual time of blood sampling for exposure to trial medication should not deviate from 
the nominal time by [CONTACT_726] ±1 minute. Pre-dose is de fined as within 2 minutes prior 
to dosing. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confi
dential    Page 39 of 82  
7.2 Safety parameters 
7.2.1 A dverse events 
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an AE or serious adverse event (SAE), as provided in this 
protocol. During the trial, the investigator or center staff will be responsible for reporting 
AEs and SA
Es, as detailed in this section of the protocol.  
Based on the investigator’s clinical judgment it  will be determined whether an AE is 
related to
 treatment and of sufficient severity to require the subject’s removal from  
treatment or from the trial. A subject may also voluntarily withdraw from treatment due 
to what he or she perceives as an intolerable AE. If either of these situations arises, the 
subject should be under medical supervision until symptoms cease or the condition 
becomes stable. 
[IP_ADDRESS] De finitions 
Adverse event 
A
n AE is any untoward medical occurrence in a trial subject given an IMP which does 
not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and/or unintended sign (for example, an abnormal laboratory finding), 
symptom, 
or disease temporally associated with the use of an IMP, whether or not 
considered related to the IMP.  
In this trial, only treatment-emergent adverse events (TEAEs) will be collected and 
reported. TEAEs are events that occur from the first trial-related activity after the subject 
has signed the informed consent form until the end of the post-treatment follow-up 
period.  
AEs include: 
A clinically significant worsening of a concomitant illness.
A clinical laboratory abnormality which is clinically significant, i.e. any abnormality
that sugg
ests a disease and/or organ toxicity and is of a severity that requires active
management. Active management includes active treatment or further investigations,
for example change of medicine dose or more frequent follow-up due to the
abnormality.
Hypoglycemic epi[INVESTIGATOR_1841] (see Section  7.2.2 ).
Injection site reactions (see Section  7.2.6).
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictl
y Confidential    Page 40 of 82  
The following should not be recorded as AEs, if recorded at screening (on the Screening 
Form or eCRF): 
P
re-planned procedure, unless the condition for which the procedure was planned has
worsened from the first trial related activity after the subje ct has signed the informed
c
onsent.
Pre-existing conditions found as a result of screening procedures (pre-existing
conditions should be reported as medical history or concomitant illness).
Serious a dverse event 
An SAE is any untoward medical occurrence that at any dose: 
Results in death
Is life-threatening
Requires inpatient hospi[INVESTIGATOR_1081]
Results in persistent or significant disability or incapacity
Is a congenital anomaly or birth defect
Is medically important*
*Medical judgement must be exercised in deciding whether an AE is believed to be
‘medically important’. Medically important event s may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_807432]. 
Adverse drug reaction 
All noxious and unintended responses to an investigational product related to any dose 
should be considered adverse drug reactions. The phrase responses to an investigational 
product 
means that a causal relationship between an investigational product and an 
adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out. 
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) 
An AE fulfilling one of the criteria of seriousness and being assessed as related to IMP 
application, the nature or severity of which is not consistent with the applicable reference 
document (e.g. dasiglucagon Investigator’s Brochure or package leafl et/S ummary of 
Product Characteristics for GlucaGen ). 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115141] 
An AESI is an event which, in the evaluation of safety, has a special focus (e.g. required 
by [CONTACT_21652]). In this trial hemodynamic changes, as defined below, are 
considered AESIs: 
 P ost-dose clinical signs, or measured vital signs, indicating a clinical ly significant 
dro
p in blood pressure including signs of orthostatic hypotension, vasovagal 
responses or bradycardia.   
 P ost-dose change in pulse or blood pressure considered an event of hypo- or 
hypertension as judged by [CONTACT_093]. 
 
Intensity of an adverse event 
The maximum intensity (severity) of all AEs must be assessed by [CONTACT_807457]. Severity should be graded when the AE outcome is known: 
Mild :  A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living. 
Moderate :  A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to 
the subject. 
Severe :  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
A ‘severe’ reaction does not necessarily deem the AE as ‘serious’ and a n SAE may not 
necessarily be ‘severe’ in nature.  
Causality relationship to trial medication 
The causality of each AE should be assessed by [CONTACT_807458]: 
Probable: Good reason and sufficient documentation to assume a causal relationship. 
Possible: A causal relationship is conceivable and cannot be dismissed. 
Unlikely: The event is most likely related to etiology other than the trial product. 
Not related :  No relationship to trial product. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 42 of 82  
[LOCATION_013] only: The investigator should assess the causality to 
dasiglucacon/placebo/GlucaGen and to insulin glulisine (Api[INVESTIGATOR_27976]®) respectively. A 
special field applicable for [LOCATION_013] only will be present on the AE form in the eCRF to 
capture this data. 
Outcome of an adverse event 
The outcome of all AEs must be assessed by [CONTACT_807459]/her 
staff. The following definitions should be used: 
Recovered/resolved :  The subject has fully recovered, or by [CONTACT_807460]-related activity after 
the subject signed the informed consent.  
Recovering/resolving: The condition is improving and the subject is 
expected to recover from the event. This term is 
only applicable if the subject has completed the 
trial. 
Recovered/resolved with sequelae :  The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment 
or procedure. If a sequela meets an SAE criterion, 
the AE must be reported as an SAE. 
Not recovered/not resolved :  The condition of the subject has not improved and 
the symptoms are unchanged. 
Fatal :  This term is only applicable if the subject died from 
a condition related to the reported AE. Outcomes of 
other reported AEs in a subject before he/she died 
should be assessed as "recovered/resolved", 
"recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE 
with fatal outcome must be reported as an SAE. 
Unknown :  This term is only applicable if the subject is lost to 
follow-up. 
[IP_ADDRESS]  Collection, recording and reporting of adverse events 
All events meeting the definition of an AE must be collected and reported from the first 
trial related activity after the subject has signed the informed consent until the end of the 
post-treatment follow-up period. At each contact [CONTACT_49877] (visit or telephone, 
ex
cluding visits where the subject is not seeing the investigator or his/her staff [e.g. visits 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confide
ntial    Page 43 of 82  
to the laboratory]) the subject must be asked about AEs. All AEs, either observed by [CONTACT_299798], must be recorded by [CONTACT_36306]. 
The investigator should record the diagnosis, if possible. If no diagnosis can be made the 
investigator should record each sign and symptom as individual AEs. 
One single Adverse Event Form must be used per AE from start to resolution. For SAEs, 
the Serious Adverse Event form must also be completed. For AESIs, the AESI form must 
also be completed. 
AE information should include the following: 
Date and time of onset and resolution
Date and time of investigator’s first information on the (S)AE
Seriousness
Severity
Causal relationship with IMP
Interruption or withdrawal of treatment during IMP administration and other
meas
ures
 taken
Outcome.
All A
Es are coded; details are described in the trial-specific Data Management Plan. 
If an event classifies as a AESI, the investigato r mus t tick the AES I box on the AE form 
and complete the AESI form. The AESI form will capture if the event was associated 
with any signs or symptoms and capture the highest/lowest blood pressure and pulse 
measured during the event. The investigato r must report all AESIs to the sponsor ’s 
responsible pharmacovigilance unit (Safety CRO; see the list of trial personnel in 
Section  12.1) immediately (within 24 hours) after obtaining knowledge about the event. 
The investigator must report initial information electronically (e.g. in PDF format) on all 
SAEs to the sponsor’s responsible pharmacovigilance unit (Safety CRO; see the list of 
trial personnel in Section  12.1) immediately (within 24 hours) after obtaining knowledge 
about the event. The Safety CRO will inform the medical monitor and the sponsor about 
the reported SAEs. 
It is the responsibility of the Safety CRO to report all S[LOCATION_003]Rs (see Section  [IP_ADDRESS]) that 
occur in this trial to the Compete nt Authorities and Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) in accordance with the local requirements 
in force and ICH guideline for GCP . The tria l monito r must be informed accordingly. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 44 of 82  
[IP_ADDRESS]  Follow-up of adverse events 
All AEs that are ongoing at the end of the subject’s participation in the trial will be 
followed-up until the event is resolved or reaches a satisfactory outcome as deemed b y 
the investigator or until the last visit of the last subject enrolled in the trial, whichever 
o
cc
urs first.   
Follow-up actions for all SAEs will be performed according to appropriate clinical care 
practices and may depend on the nature of the event. These will be determined after 
internal review and/or sponsor review. 
The follow-up information should only include new (updated and/or additional) 
information that reflects the situation at the time of the investigator’s signature.  
Follow-up information on (S)AEs will be updated using the (S)AE form. If a non-serious 
event becomes serious during the follow-up the AE form and SAE form have to be used 
and reporting timelines follow those of an SAE. 
Th
e investigator must forward follow-up information on SAEs and if previously 
non-serious AEs become SAEs to the Safety CRO immediately (within 24 hours) after 
o
btaini
ng knowledge about the new information. 
The sponsor and/or CROs acting on behalf of the sponsor can upgrade a non-serious AE 
to an SAE. In these situations the investigator will be informed and asked to fill out an 
SAE form and forward to the Safety CRO immediately (within 24 hours). 
[IP_ADDRESS] C linical laboratory abnormalities and other abnormal assessments as adverse 
eve
nts or serious adverse events 
Abnor
mal laboratory findings (e.g. biochemistry, hematology, urinalysis) or other 
abnormal assessments (e.g. vital signs) that are judged by [CONTACT_807461]. 
Clinically significant abnormal laboratory findings or other abnormal assessments that 
are detected during the trial or are present at baseline and significantly worsen following 
the s
tart of the trial will be reported as AEs or SAEs. However, clinically significan t 
abnor
mal laboratory findings or other abnormal assessments that are associated with the 
disease being studied, unless judged by [CONTACT_807462] t’s condition, or that are present or detected at the start of the  trial and do not 
w
orse
n, will not be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confidenti
al    Page 45 of 82  
7.2.2 Hypoglycemia 
Hypoglycemia will be regarded as an AE and recorded and documented on an AE form 
(and SAE form, if
 applicable). 
Hypoglycemia is defined as a decline in plasma glucose to below 70 mg/dL 
(3.9 mmol/L). However, in the time period from initiation of the hypoglycemic clamp 
procedure 
(see Section  [IP_ADDRESS]) until 45 minutes after dosing, hypoglycemia is defined as 
a decline in plasma glucose to below 45 mg/dL (2.5 
mmol/L).  
During the dos ing v
isit, prior to administration of the IMP, a plasma glucose value of 
<45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463]. After administration 
o
f the IMP in the
 period from 8 minutes until 44 minutes after dosing, a plasma glucose 
value of <
45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463], and if a 
plas
ma glucose value of ≥70 mg/dL (3.9 mmol/L) is not achieved within the [ADDRESS_1115142] experiences symptoms of hypoglycemia, a plasma glucose measurement 
should be taken
 in order to classify the event (p lease refer to Section 7.4.2 fo r additional 
details).  
7.2.3 Ph ysical examination 
The physical examination will be carried out at screening (Visit 1) and at the follow-up 
visit (Visit 3; see Table 3).  
T
he phy
sic
al examination includes examination of the following body systems: head, 
ears, eyes, nose, throat, including the thyroid gland; heart, lung, chest; abdomen; skin and 
mucosae; musculoskeletal system; nervous system; lymph node; other findings. 
At the screening visit, any abnormality will be recorded and described in the eCRF, 
including the investigator’s assessment of clinical significance (‘abnorma l, not clinically 
significant’ or ‘abnormal, clinically significant’). Clinically significant findings at the 
screening visit should be recorded as concomitant illness. 
At subsequent visits , any clinically significant deterioratio n of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1). 
7.2.4 V ital signs 
An examination of the following vital signs will be performed at screening (Visit 1), the 
dosing visit (Visit 2) and at the follow-up visit (Visit 3):  
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confidential
    Page 46 of 82  
Diastolic and systolic blood pressure (mmHg) will be measured after at least
[ADDRESS_1115143]’s blood pressure in this trial.
Pulse (beats per min) measured after at least [ADDRESS_1115144] in a supi[INVESTIGATOR_2547].
Body temperature (°C).
At the dosing visit, measurements will be taken prior to the start of the insulin-induced 
hypoglycemic procedure (within 30 minutes) and at 30, 90, and 300 minutes after dosing 
(see Table 3). The actual time of the assessment should not deviate from the nominal 
time 
by [CONTACT_726] ±[ADDRESS_1115145] 12-lead ECG will be performed at the screening visit (Visit 1), the dosing visit 
(Visit 2; prior to the start of the insulin-induced hypoglycemic procedure [within 
30 minutes])  and at 20, 35, 45, 60, and 300 minutes after dosing) and at the follow-up 
visit (Visit 3; see Table 3). The actual time of the assessment should not deviate from the 
nom
inal time by [CONTACT_726] ±5 minutes.  
ECG param
ete
rs (heart rate, PQ, QRS, QT, QTcB) and any abnormality will be recorded 
and described in the eCRF including the investigator’s assessment of clinical significance 
(‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’).   
At subsequent visits , any clinically significant deterioratio n of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1). 
7.2.6 Loc al tolerability 
Immediately prior to treatment administration, it should be verified that the injection site 
is normal. To ensure all injection site assessments are performed at the injection site, the 
site will be marke d wit h a pen prior to injection. Assessment of local tolerability at the 
injection site will be performed at the dosing visit (Visit 2; at 30, 120 and 300 minutes 
after dosing), and at the follow-up visit (Visit 3) (see Table 3) and more frequently, if 
deemed necessary by [CONTACT_20616] r. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes . In the eCRF, the time of 
assessment a nd any inje ction site reactio n observe d will be rec orded. In case of an 
observation, the Local Tolerability form will be completed, a s well as the (S)AE form. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 47 of 82  
The local tolerability at the injection site will be evaluated by [CONTACT_807464]: spontaneous pain, pain on palpation, itching, redness, edema, 
induration/infiltration, and other. Each of these assessments will be reported on a scale of 
0 (none), 1 (mild), 2 (moderate), and 3 (severe). The evaluation and the actual time of the 
assess
ment will be recorded. The assessments will be performed by a trial physician or 
nurse.  
Digi
tal pi[INVESTIGATOR_807433], and 
thereafter as often as judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_807434] a 
subject identifier, visit number, time after dosing, and a ruler for scaling. 
7.2.7 C linical laboratory assessments 
The safety parameters that will be assessed at the clinical laboratory are listed in  Table 3. 
Routine clinical laboratory tests will be performed centrally. Samples fo r clinical 
laboratory parameters (biochemistry , hematology) will be co llecte d at screening (Visit 1), 
the dosing visit (Visit 2, prior to the start of the ins ulin-induced hypoglycemic procedure 
[within 30 minutes] ) and at 30 and 300 minutes af ter dosing), and at the follow-up visit 
(Visit 3). The actual time of the assessment should not deviate from the nominal time by 
[CONTACT_726] ±10 minutes . Samples fo r glycated hemoglobin (HbA 1c), C-pe ptide and 
coagulation parameters will be collecte d at screening only (Visit 1). Samples for 
urinalysis will be collected a t screening (Visit 1), at the dosing visit (Visit 2, prior to the 
start of the insulin-induced hypoglycemic procedure [within 120 minutes]) and at the 
follow- up visit (Vi sit 3). The following parameters will be assessed: 
Clinical biochemistry: sodium, potassium, calcium, glucose, urea, creatinine, total
bilirubin, AST
, ALT, gamma-glutamyltransferase, alkaline phosphatase, total protein,
C-reactive protein, HbA 1c, C-peptide.
Hematology: hemoglobin, red blood cell count (erythrocytes), hematocrit, platelet
count (throm
bocytes), total white blood cell count (leukocytes).
Coagulation: international normalized ratio, fibrinogen (at screening visit only).
Urinalysis: pH, blood (leukocytes and erythrocytes), protein, glucose, ketones, nitrite.
Pregna
ncy tests will be performed at each visit for women of childbearing potential only. 
A serum pregnancy test will be performed at screening (Visit 1) and urine stick tests will 
be performed at the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypogl
ycemic procedure) and the follow-up visit (Visit 3). Test sticks will be provided to 
the trial centers. 
Alcohol breath tests and a urine drug screen will be performed at screening (Visit 1) and 
at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confide
ntial    Page 48 of 82  
procedure ). Equipment for the alcohol breath test and uring drug screen will be provided 
to the trial centers.  
Re-assessment of laboratory parameters will be allowed on ly if handling issues, damaged 
sa
mples, or hemolyzed samples have confounded the measurement results.  
For further details of the clinical laboratory assessments, please refer to the laboratory 
m
anual.  
7.2.[ADDRESS_1115146]’s partner will be fully info rmed by a physician of 
her participation in capturing the outcome data, and will be asked to provide her written 
consent. 
The investigato r must report all informatio n on pregnancies on th e Initial Pregnancy 
form. The completed Initial Pregnancy form must be forwarded to the sponsor 
immediately (within 24 hours), according to the procedure stated in Section  [IP_ADDRESS]. Any 
(S)AEs in the mother, as well as other pregnancy complications (ectopic pregnancy) 
fulfilli ng the criteria of an (S )AE, must be reported on the (S)AE form.  
The foll
owing must be collected in the Initial Pregnancy form: 
Medical history of the mother
Family history
Course of the pregnancy, including expected delivery date.
The investigato r must follow the pregnancy until the pregnancy outcome and follow the 
newborn infant(s) until the age of [ADDRESS_1115147] informatio n on 
the pregnancy and pregnancy complications as well as the pregnancy outcome including 
the health of the newborn infant(s) on the Pregnancy Outcome form. The completed 
Pregnancy Outcome form must be forwarded to the sponsor according to the procedure 
stated in Section  [IP_ADDRESS]. Any (S)AEs in the newborn must be reported on the (S)AE 
f
orm. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115148] be reported include abnormal outcome, such as congenital 
anomalies, fetal death and termination of pregnancy (spontaneous or elective abortion), 
including any anomalies of the fetus observed at gross examination or during autopsy.  
The following must be collected in the Pregnancy Outcome form:  
 C ourse of the pregnancy 
 O utcome of the pregnancy 
 C ondition of the newborn 
 A ny AEs in the newborn infant must be followed until the age of [ADDRESS_1115149]’s participation in the trial, the 
investigator should ensure that adequate medical care is provided to the subject for any 
AEs, including clinically significant laboratory values related to the trial. The investigator 
should inform the subject when medical care is needed for intercurrent illnesses of which 
the investigator becomes aware.  
For further information on safety precautions for dasiglucagon and GlucaGen, please 
refer to the c
urrent version of the Investigator’s Brochure (14) and the Summary of 
Product Characteristics for GlucaGen (13), re spectively. 
7.2.[ADDRESS_1115150] the subjects. 
7.3 Demography, concomitant illness, medical history and concomitant 
medication
 
Demographics, body measurements, concomitant illness and medical history will be 
assessed only at screening (Visit 1). Concomitant medication will be assessed at 
scree
ning (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypoglycemic procedure) and at the follow-up visit (Visit 3). 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115151] d
emographics and body measurements will include: 
Age
Race, ethnicity
Sex
Height (m e ters or inch), without shoes
Body weight (kg or lb), only wearing underwear and measured using standard scales
Body mass index (kg/m2) calculated based on height and body weight (body
w
eight/height2).
7.3.2 C oncomitant illness and medical history 
A concom
itant illness is any illness that is present at the start of the trial (i.e. at the 
screening visit). Concomitant illnesses present at the start of the trial will be recorded in 
the
 eCRF at screening.  
Medical history is an account of medical events that the subject has experienced in the 
past, including prior medications. Relevant medical conditions/illnesses in the past 
obtained b
y asking the subject or by [CONTACT_315747]/her medical records will be recorded 
in the eCRF at screening. History of alcohol or drug abuse will also be recorded. 
The info
rmation collected for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution or continuation. 
Any change to a concomitant illness should be recorded during the trial, including end 
date, if applicable. A clinically significant worsening of a concomitant illness must be 
reported according to Section  7.2.1. 
A
ll prev
ious and concomitant diseases will be coded with Medical Dictionary for 
Regulatory Activities (MedDRA), the version of which will be provided in the clinical 
trial report. 
7.3.3 Diabe tes diagnosis and current treatment 
The date of diagnosis of diabetes will be recorded as will the current diabetes treatment 
(start date, product name(s), dose(s)). 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confidential  
  Page 51 of 82  
7.3.4 Concomitant medication 
A concomitant medication is any medication, other than the trial products and current 
diabetes treatment (including insulin glulisine [Api[INVESTIGATOR_27976]®] for dia betes therapy wash-out), 
which is taken during the trial, including screening and follow-up periods. 
Details of any concomita nt medicatio n must be recorded at trial entry (i.e. at screening). 
Any changes in concomitant medicatio n must be rec orded a t each visi t as they occur. The 
information collecte d for ea ch concomitant medication includes (at a minimum) trade 
name [CONTACT_18058], indication, start date and stop date or continuation. A change in 
medication due to an AE must be recorded and reported according to Section  7.2.1. If the 
change in medication influences the subject’s eligibility to continue in the trial, the 
sponsor a nd tria l monitor must be informed. 
7.[ADDRESS_1115152] dasiglucagon/GlucaGen will be measured at the dosing visit (Visit 2) 
and at follow-up (Vis
it 3). At the dosing visit (Visit 2), samples will be collected prior to 
the start of the insu
lin-induced hypoglycemic procedure.  
The clinical ADA assays, specific for dasiglucagon and GlucaGen, respectively, have 
been validated in accordance with existing guidelines and recommendations (17-21).  
C
onfirmed positive anti-dasiglucagon antibody samples (treatment-induced or 
treatment-boosted) from anti-dasiglucagon antibody-positive subjects will be evaluated 
for binding titer neutralizing potential and titer as well as cross-reactivity towards 
endogenous glucagon.  
No further serum sam
pling will be needed as the ADA samples can be used for 
neutralizing antibody analysis. 
The in vitro neutralizing effect of the antibodies will be measured using an assay based 
on glucagon receptor transfected human embryonic kidney cells (20,22). The calculated 
se
nsitivity in previous studies was about 51.8 ng/mL. The assay was also validate d for 
re
combinant glucago n with similar results ( 21,23) . In case of a positive result in th e 
neutraliz ing antibody assay, a titer estimatio n wil l be performed. The cell-based 
neutraliz ing antibody analyses will be performed by a special laboratory, BioAgilytix, 
Durham, NC, [LOCATION_003]. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly
 Confidential    Page 52 of 82  
Residual and additional antibody serum samples may be stored until approval of market 
authorization by [CONTACT_93420]. Further characterization of the antibody response 
may be requested by [CONTACT_93420]. 
7.4.2 Plasm a glucose measurements for safety 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site. After the start of insulin infusion, plasma glucose should be checked approximately 
ever
y 10 minutes while plasma glucose is above 110 md/dL, and approximately every 5 
minutes
 once plasma glucose is at or below 110 mg/dL and until after dosing when the 
subject’s plasma glucose is ≥70mg/dL (3.9 mmol/L) . Hereafter, plasma glucose should be 
checked approximately every 30 minutes until 300 minutes (5 hours ) after dosing. Plasma 
gluco
se concentrations will be measured using the US  FDA-approved glucose analyzer 
YSI 2300, Yellow Springs Instruments, Yellow Springs, OH or the Super GL analyzer, 
Dr. Müll
er Gerätebau GmbH, Freital, [LOCATION_013]. 
At the discretion of the investigator, additional plasma glucose measurements can be 
taken
 at any time during the trial, for example when there is a suspi[INVESTIGATOR_2798] (e.g. symptoms) 
of a hypoglycemic epi[INVESTIGATOR_1865]. 
Plasma glucose measurements for safety should only be recorded in the eCRF if they are 
re
lated to an AE (e.g. a hypoglycemic epi[INVESTIGATOR_1865]). 
In c
ase of persistent post-treatment hypoglycemia, subjects will receive rescue treatment 
with
 an IV glucose infusion (see Section [IP_ADDRESS]  for details). Blood samples for PD and 
PK assess
ments should still be taken at the specified timepoints. 
7.4.3 Plasm a insulin measuremen ts 
Samples for insulin assessment will be collected at the dosing visit (Visit 2, pre-dose and 
at 30 and 60 minutes after dosing). The actual time of blood sampling for evaluation of 
plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115153] 
8.1 Schedule of procedures 
The schedule of procedures is provided in  Table 3. Informed consent will be obtained 
prior to any trial-related procedures; see Section  10.8. 
8.2
 Procedures by [CONTACT_765] 
8.2.1 Visit 1 (screening, Day -30 to Day -3) 
V
isit
 [ADDRESS_1115154] between 3 and 30 days before Visit 2, Day -1 to Day 1 (dosing 
da
y). 
Inf
ormed consent can be obtained prior to or at Visit 1, however it must in any case be 
obtained prior to any trial related procedures. During the screening visit, the following 
assessments will take place: 
Informed consent (obtain or check)
Check of subject eligibility (inclusion/exclusion criteria)
Demography
Body measurements
Medical history, diabetes diagnosis, current diabetes treatment
Concomitant illnesses
Concomitant medications
History of alcohol/drug abuse
Physical examination
Vital signs
12-lead ECG
A
Es
Biochemistry, hematology, coagulation, HbA 1c
Serum pregnancy test (women of childbearing potential only)
Urinalysis
Urine drug screen
Alcohol breath test
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 54 of 82  
Table  3 Schedule of procedures 
Visit number  V1 V2 V3 
Trial day  -3 -1 and 1 28 
Visit type  Screeni ng Dosing  Follow -up 
Window  -30 to -3  +[ADDRESS_1115155] related information/assessments     
Informed consent  x   
Inclusion/exclusion criteria  x x1,2  
Demography  x   
Body measurements  x   
Medical history, diabetes diagnosis, and current diabetes 
treatme nt x   
Concomitant illness es x   
Concomitant medication s x x1 x 
History of alcohol/drug abuse  x   
Randomization   x1  
Withdrawal criteria   x1  
Dosing day exclusion criteria   x1  
Insulin -induced hypoglycemia   x  
Safety assessments     
Physical examin ation  x  x 
Vital signs  x x3 x 
12-lead ECG  x x4 x 
Local tolerability   x5 x 
Adverse events  x x x 
Laboratory     
Biochemistry, h ematology, coagulation, HbA 1c (coagulation 
and HbA 1c, at Visit 1  only)  x x6 x 
Pregnancy test (women of childbearing potentia l only)  x7 x1,[ADDRESS_1115156]  x x1  
PK/Clinical efficacy     
Plasma dasiglucagon /GlucaGen   x9  
Plasma glucose   x10  
Other assessments     
Antibodies against dasiglucagon /GlucaGen   x1 x11 
Plasma i nsulin  x12  
Trial material     
Administration of trial product  (during hypoglycemic clamp 
procedure)   x  
1Prior to the start of the insulin-induced hypoglycemic procedure. 
2Only check of dosing day exclusion criteria and changes between screening visit and Visit 2. 
3Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30, 90 and 300 minutes 
after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 55 of 82  
4Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 20, 35, 45, 60 and 300 
m
inutes after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±5 
minutes.  
5Local tolerability assessed at 30, 120, and 300 minutes after dosing. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes.  
6Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30 and 300 minutes after 
dosing . The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±[ADDRESS_1115157]. 
9Pre
-dose, and at 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling should not 
deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
10Pre-dose , and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, 90 minutes after dosing. The actual time of blood 
sa
mpling should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point 
and by [CONTACT_726] ±[ADDRESS_1115158] that tests positive for ADA will be monitored until the ADA levels return to baseline levels. 
12Pre-dose, and at 30 and 60 minutes after dosing. The actual time of blood sampling should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. P re-dose is defined as within 2 minutes prior to dosing.  
ADA = anti-drug antibodies; ECG = electrocardiogram; HbA 1c = glycated hemoglobin. 
Eligible or potentially eligible subjects (laboratory results pending) will be provided with 
an Identification card (ID card), stating that the subject is participating in the trial and 
w
hom to contact (site address, investigator name [CONTACT_41319]). The subjects 
should be instructed to return the ID card to the investigator at the last visit or to destroy 
the card after the last visit.  
8.2.2 In structions to subjects prior to the dosing visit (Visit 2) 
At the screening visit , the inve stigato r will inform the subject about the changes to his/her 
insulin therapy leading up to the start of the insulin-induced hypoglycemic procedure. 
The subject may be provide d with insulin NPH in the wash-out period to cover the need 
of basal insulin, if deemed necessary by [CONTACT_093]. The subject’s current insulin 
therapy will be washed out as defined in Section  5.5.: 48 hours prior to dosing and during 
the dosing visit, treatme nt wit h  insuli n Degludec and insuli n Glargine U300 are not 
a
llowed ; 24 ho urs prior to dosing and during the dosing visit, treatme nt with othe r long-
acting insulins (e.g., insulin Glargine U100 or insulin Detemir ) is not allowed; 16 hours 
prior dosing and during the dosing visit treatment with insuli n NPH is not allowe d; 6 
hours prior to do
sing and during the dosing visit, treatme nt with any short acting (bolus) 
insulin, except insulin glulisine (Api[INVESTIGATOR_27976]®), is not allowed. The basal rate of insulin pumps 
(continuous SC insulin infusion ) will be discontinue d on the morning of the dosing day 
(if using insulin glulisine [Api[INVESTIGATOR_27976]®]) OR at leas t 6 hours prior to dosing (if using other 
insulins). 
On the da
y prior to dosing (Day -1), the subjects will need to attend the clinical center 
and will be
 required to stay onsite overnight. On the morning of the dosing day (Day 1), 
patient
s are required to be in a fasting condition, defined as having consumed only water 
since 22:00 ho
urs the night before. However, the subjects are allowed to consume small 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly
 Confidential    Page 56 of 82  
amounts (up to 20 g) of carbohydrates to prevent hypoglycemia. The subjects must also 
not consume any alcohol within 24 hours prior to dosing (refer to Section 5.5 for all 
do
sing day exclusion criteria). 
8.2.3 V isit 2 (dosing visit) 
Visi
t [ADDRESS_1115159] on D ay -1 to Day 1. 
T
he subjects will attend the clinical center the day prior to dosing (Day -1) and subject 
eligibility is rechecked (check of changes between the screening visit and Visit 2) and 
those
 subjects eligible to participate should stay onsite overnight. To target a glucose 
level around 90-110 mg/dL (5.0-6.1 mmol/L) the following morning, subjects may be 
adm
inis
tered insulin glulisine (Api[INVESTIGATOR_27976]®) at the investigator’s discretion  either by [CONTACT_807465], SC bolus or continuous SC insulin infusion. Dosing will take place the 
follow
ing morning (Day 1). 
On Day [ADDRESS_1115160]: 
 D ocument all changes in concomitant medication (prior to the start of the 
insulin
-induced hypoglycemic procedure) 
 C heck of withdrawal criteria (prior to the start of the insulin-induced hypoglycemic 
procedure
) 
 C heck of dosing day exclusion criteria (prior to the start of the insulin-induced 
hypo
glycemic procedure) 
 V ital signs (prior to the start [within 30 minutes] of the insulin-induced hypoglycemic 
procedure
, and at 30, 90 and 300 minutes after dosing). 12-lead ECG (prior to the 
st
art [within 30 minutes] of the insulin-induced hypoglycemic procedure, and at 20, 
35, 45, 60, and 300 minutes after dosing) 
 Lo cal tolerability (at 30, 120, and 300 minutes after dosing) 
 AEs  
 B iochemistry, hematology (prior to the start of the insulin-induced hypoglycemic 
procedure [within 30 minutes], and at 30 and 300 minutes after dosing) 
 U rine stick pregnancy test (women of childbearing potential only; prior to the start of 
the insulin-induced hypoglycemic procedure) 
 U rinalysis (prior to the start of the insulin-induced hypoglycemic procedure [within 
120 minute
s]) 
 U rine drug screen (prior to the start of the insulin-induced hypoglycemic procedure) 
 Alcohol breath test (prior to the start of the insulin-induced hypoglycemic procedure) 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confidenti
al    Page 57 of 82  
Dasiglucagon/GlucaGen plasma concentrations:
­ Pre-
dose, 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time
o
f blood s
am
pling for exposure should not deviate from the nominal time by [CONTACT_26813] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
P
lasma glucose concentration s:
­ Pre-
dose
, 4, 6, 8 ,10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, and 90 minutes after
do
sing
. The actual time for blood sampling for plasma glucose should not deviate 
from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection 
time point and b
y more than ±1 minute for the subsequent collection time points. 
Pre-dose is defined as within 2 minutes prior to dosing. 
A
ntibodies against dasiglucagon/GlucaGen (prior to the start of the insulin-induced
hypo
glyce
mic procedure).
Plasma insulin concentrations:
­ Pre-
dose, 30 and 60 minutes after dosing. The actual time of blood sampling for
plasma insulin should not
 deviate from the nominal time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
[IP_ADDRESS]  Hypoglycemic clamp procedure and administration of trial medication 
The following procedure is based on precendent procedures for hypoglycemia induction 
in patients with T1DM [24, 25]. 
The treatment day (Visit 2, Day 1) will be conducted afte r a n overnight fast, targeting a 
starting plasma glucose around 90 to 110 mg/dL (5.0-6.1 mmol/L).   
Subjects who meet one or more of the dosing day exclusion criteria (Section  5.5) at the 
dosing visit will be excluded from the dosing visit, but the visit can be rescheduled 
1-[ADDRESS_1115161]’s current insulin therapy will be washed out as defined in Section  5.5. For 
s
ubjects using multiple daily injections, the date , time and the dos e of the last basal 
insuli n and the last short-acting insulin (except insulin glulisine [Api[INVESTIGATOR_27976]®]) administration 
prior to dosing will be captured. For subjects using an insulin pump, the time of 
discontinuation of the basal rate will be captured. Any use of insulin glulisine (Api[INVESTIGATOR_27976]®) 
in the last 5 hours prior to initiation of the hyp oglycemia induc tion procedure will also be 
captured.  
At approxi
mately 08:00 hours, an infusion catheter will be inserted into each arm 
(forearm cephalic vein) for the manual glucose clamp procedure, with the glucose 
infusion in one arm and the insulin infusion in the opposite arm (if IV insulin glulisine 
[
Api[INVESTIGATOR_27976]®] has been administered during the night the same infusion catheter can be used). 
A
 third cathet
er for blood sampling will be placed into a metacarpel vein for blood 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 58 of 82  
sampling. This hand will be warmed (55-65ºC) to arterialize venous blood. If there are 
issues w
ith blood sampling from the metacarpal vein for the purpose of glucose 
measurements, a new and more proximal IV access may be used at the discretion of the 
investigator. 
Hypoglycemia will be gradually induced by a fast-acting IV insulin glulisine (Api[INVESTIGATOR_27976]®) 
infusion (15 U [100 U/mL] in [ADDRESS_1115162]’s blood  or plasma), 
initially at 150% of the subject ’s usual basal rate and can be increased or decreased over a 
range of 0 % to 200% or more as judged necessary by [CONTACT_093], to achieve a 
controlled decline in plasma glucose, targeting a plasma glucose level of 55 mg/dL (3.1 
mmol/L).  
Plasma glucose concentrations will be measured using the US FDA-approved glucose 
analyzer YSI 2300, Yellow Springs Instruments, Yellow Springs, OH or the Super GL 
analyz
er, Dr. Müller Gerätebau GmbH, Freital, [LOCATION_013]. After the start of the insulin 
infusion, plas
ma glucose will be measured approximately every 10 minutes while plasma 
glucose is above 110 mg/dL, and approximately every 5 minutes once plasma glucose is 
at or below 110 
mg/dL. 
Once the glucose concentration declines to <60 mg/dL (3.3 mmol/L), the insulin infusion 
will be sto
pped, and 5 min later plasma glucose concentration will be measured at the 
glucose analyzer and blood samples for baseline assessment of plasma glucose, 
dasiglucagon/GlucaGen PK, and insulin PK will be collected. The samples are the 
baseline samples and should be collected within 2 minutes before IMP administration. 
If plasma glucose is ≥45 mg/dL and <60 mg/dL (2.5-3.3 mmol/L), study treatment
(I
MP) wil
l be administered, defining time, t=0. The study treatment will be delivered
in the abdom
en, buttock, or thigh (according to stratification) via SC injection.
If plasma glucose is <45 mg/dL (2.5 mmol/L), IV glucose solution will be
adminis
tered sufficient to raise plasma glucose to within the 45-60 mg/dL target
range. T
he run-in period will be adequately extended (at least 30 min) until the above
target is achieved and new baseline samples for plasma glucose,
dasigluc
agon/GlucaGen PK, and insulin PK will be collected. Glucose should not be
infused within [ADDRESS_1115163] should be reschedul ed for a new
treatment visit within 7 days (+ 2 days).
A
dmini
stration of IMP should not occur earlier than 9:00 hours in the morning or later 
than 12:00 hours. 
As shown in Table 4, serial blood samples for glucose will be collected at t=0, 4, 6, 8, 10, 
12, 15, 17, 20, 25, 30, 40, 50, 60, [ADDRESS_1115164]-dosing. Samples for assessing 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly Confide
ntial    Page 59 of 82  
plasma dasiglucagon/GlucaGen concentration will be collected  at t=0, 15, 30, 35, 40, 50, 
60, 90, and 120 minutes. Samples for assessing plasma insulin concentration will be 
c
ollected at t=0, 30, and [ADDRESS_1115165]-treatment blood sampling times 
Times  0 4 6 8 10 12 15 17 20 25 30 35 40 50 60 75 90 120 
Plasma glucose  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
PK 
Dasiglucagon/ 
GlucaGen  Y Y Y Y Y Y Y Y Y 
PK Insulin  Y Y Y 
Refer to Section 7.2.7  for details of laboratory safety sampling and to Section 7.4.2 for 
de
tails of blood glucose safety sampling.  
When the t=90-minute blood sampling for plasma glucose has been collected the subjects 
are allowed to eat moderately. Drinking of water is allowed ad libitum during the entire 
pro
cedure. 
Hypoglycemia Rescue Provisions 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site for safety reasons as described in Section  7.4.2. Subjects should receive 
post-treatment rescue glucose infusion to ameliorate persistent hypoglycemia, as follows. 
1.G
lucose infusion should be initiated if a subject experiences severe alarming
esca
lation of symptoms of hypoglycemia (e.g. symptoms suggesting a change in
consciousness) at any time during the trial; glucose infusion should be initiated
targeting a plasma glucose levels >70 mg/dL.
2. If plasma glucose is <45 mg/dL (2.5 mmol/L) between t=8 and t=44 minute s,
resc
ue glucos
e infusion (1 -2 mg/kg administered IV over about 5 seconds) should
be initiate
d to maintain plasma glucose between 45 mg/dL and 55 mg/dL
(2.5-3.1 mmol/L). Pause glucose infusion if plasma glucose is >55 mg/dL.
3.
If plasma glucose is <70 mg/dL at t=45 minutes, rescue glucose infusion
(2-3 mg/kg administered IV over about 5 seconds ) s hould be initiated to maintain
plasma glucose between 70 mg/dL and 80 mg/dL (3.9-4.4 mmol/L). Pause
glucose infusion if
 plasma glucose is >75 mg/dL (4.2 mmol/L).
Subjects should remain in bed until completion of the test procedure 300 minutes after 
dosing (bathroom v
isits are allowed).  
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115166] may stay at the trial center for a longer period. 
8.2.4 V isit 3  (follow- up visit) 
Visit [ADDRESS_1115167] on D ay 28 + [ADDRESS_1115168]: 
Document all changes in concomitant medication
Physical examination
Vital signs
12-lead ECG
Lo
cal tolerability
AEs
Biochemistry, hematology
Urine stick pregnancy test (women of childbearing potential only)
Urinalysis
Antibodies against dasiglucagon/GlucaGen.
After the
 follow-up visit the End of Trial form must be completed. Even if a subject is not 
able to attend the follow-up visit, the End of Trial form, the eCRF 
Accountability/Affirmation Statement form and the Drug Accountability form must be 
completed. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 61 of 82  
9 STATISTICAL METHODS 
Before database lock and treatment unmasking, a separate statistical analysis plan (SAP) 
will be
 finalized, providing detailed methods for the analyses outlined below. Further 
analysis details may be added or refined in the SAP. 
Any deviations from the planned analyses will be described and justified in the final 
clini
cal trial report. 
9.[ADDRESS_1115169] s 
treated with dasiglucagon 0.6 mg. From phase 2, the m edian time to an increase of 20 
mg/dL of the 0.6 mg dose was approximately 10 minutes.  With a 2:1:[ADDRESS_1115170] a difference between dasiglucagon and placebo with 90% power 
with a follow -up time of 45 minutes at a 5% sign ificance level with 78 subjects treated 
with dasiglucagon and 39 subjects with placebo. The median time -to-recovery for 
placebo is expected to be longer than 20 minutes, which means that the power will be 
greater than 90%.  
9.2 T rial subjects 
9.2.1 A nalysis samples 
For presentation of data and reporting of the statistical analyses, th e following analysis 
sa
mples will be used, depending on the context:  
 Safety analysis set (SAS): All randomized subjects who received at least one dose of 
trial medication.  
 Full analysis set (FAS): All randomized subjects who received at least one dose of 
trial medication. 
 Per protocol (PP) set: All subjects of the FAS for whom no relevant protocol 
devia
tions were documented. This sample will primarily be used for sensitivity 
analysis.  
The analysis of the primary endpoint and secondary endpoints will be based on the FAS. 
A secondary analysis of the primary endpoint will be based on the PP set. All safety 
anal
yses will be based upon the SAS. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 62 of 82  
The decision regarding whethe r a protocol deviation is releva nt or not for the exclusion of 
subjects from the PP set will be made case-b y-case in a data review meeting prior to 
treatment unmasking and database lock (see Section  9.2.3).  
9.2.[ADDRESS_1115171] the results will be identified and it will be evaluated if subjects and/or 
data should be excluded from the analysis. Protocol deviations will be classified as minor 
or major in a consistent way. Major deviations from the protocol may lead to the 
exclusion of a subject from the PP set. 
Major protocol deviations may include deviations related to trial inclusion or exclusion 
criteria, conduct of the trial, subject management or subject assessment. Unless explicitly 
decided otherwise during the masked data review, the following will be considered major 
protoco
l deviations: 
Violation of one or more major inclusion/exclusion criteria
Interruption of administration of trial product
Significant deviation from time windows
Incorrect treatment allocation
Missing primary endpoint.
The vio
lation of several major inclusion/exclusion criteria or the complete absence of 
efficacy data might lead to exclusion of the subj ect from FAS. In that case, the decision 
should be taken at the masked data review meeting, and the exclusion from efficacy 
analys
is justified in the signed notes of the meeting. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 63 of 82  
Obviously erroneous data points may be excluded from the analyses or re-analy zed (in 
c
ase of e.g. serum concentrations). The decision to re-analyze or exclude data points from 
the s
tatistical analysis is the joint responsibility of the sponsor and the trial statistician.  
The
 subjects or observations to be excluded and the reason for their exclusion will be 
documented and signed by [CONTACT_93440]. The 
documentation will be stored together with the remaining trial documentation. The 
subjects and observations excluded from analysis sets, and the corresponding reasons, 
will be described in the clinical trial report. 
9.3 G eneral considerations 
All data obtained in this trial and documented in the eCRFs will be listed and 
summarized with statistics or frequency tables as appropriate. In case of termination of 
the trial, all data collected up to that timepoint will be included in the analysis. 
Raw data listings and summary tables will be generated using the software SAS© version 
9.[ADDRESS_1115172] deviations, medians, 
coefficients of variation, and minimum and maximum values.  
Other summaries (e.g. quartiles, 95% confidence intervals [CIs]) may be used as 
appropriate. Categorical efficacy and safety variables will be summarized by [CONTACT_807466]. 
9.4 Demographics and baseline characteristics 
Ba
seline and demographic data will be summarized using descriptive statistics. Baseline 
ADA-positive subjects will be calculated as a percentage of the total number of subjects 
whose baseline samples were tested for ADA. 
All other data obtained in this trial and documented in the eCRF will be listed. 
9.5 E fficacy Analyses 
For the confirmatory analyses, the primary and key secondary endpoints for the 
dasiglucagon 0.6 mg and placebo treated subjects will be compared. A hierarchical 
proce
dure will be applied for the control of multiplicity. The primary and secondary 
endpoints will be evaluated on the full analysis set. In the primary analysis, those subjects 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115173] the null 
hypothesis for a dasiglucagon versus placebo comparison: 
 P rimary:  Time to plasma glucose recovery 
 K ey secondaries 1-4: Plasma glucose recovery within 30 minutes, within 20 minutes, 
within 15
 minutes, and within 10 minutes after study drug injection without 
administration of rescue IV glucose. 
 K ey secondaries 5-8:  Plasma glucose changes from baseline (CFB) within [ADDRESS_1115174] increase in 
plas
ma
 glucose of ≥20  mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
clam
p procedure without administration of rescue IV glucose.  
[IP_ADDRESS] Primary  analysis 
The primary endpoint will be summarized using Kaplan-Meier (KM) estimates stratified 
by
 [CONTACT_807467]. The treatment group difference between 
dasiglucagon and placebo will be evaluated inferentially using a pairwise two-sided 
log-rank test. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 65 of 82  
In the primary analysis, recovery cannot be achieved in those subjects where IV glucose 
treatment is administered. Those subjects who receive IV glucose will be censored (i.e. 
set to ‘not recovered’) at 45  minutes after dosing. 
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without 
censoring for those subjects who require rescue IV glucose before 45 minutes and 2) with 
censoring at the time of administration of rescue IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards 
(CPH) time to event statistical model, if the hazards by [CONTACT_807468] a graphical comparison of log-minus-log survival curves and no more 
than two-thirds of the recovery times are censored in each treatment group. The CPH 
model will be used for inferences, with treatment group and injection site modeled as 
c
ategorical effects, and baseline plasma glucose modeled as a continuous covariate. The 
treatment group rate ratios, active versus placebo, will be estimated together with the 
95% confidence intervals, and pairwise treatment group inferences (dasiglucagon vs 
pla
cebo, GlucaGen vs placebo) will be evaluated using two-sided likelihood ratio tests. 
9.5.3 S econdary endpoints 
 P lasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose.  
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
[IP_ADDRESS]  Confirmatory analysis 
The key secondary incidence variables (plasma glucose recovery within 30 minutes, 
within 20 minutes, within 15 minutes, within 10 minutes, in hierarchical order for 
inference) will be analyzed using descriptive statistics (frequency and percentage) by 
[CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise 
tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo ) using Fisher’s exact test for each pairwise comparison. 
The key secondary endpoints of plasma glucose CFB within [ADDRESS_1115175] in 
those subjects who require rescue IV glucose before plasma glucose ≥20 mg/dL recovery. 
Each of these CFB variables will be analyzed using an Analysis of Covariance model, 
with treatment group modeled as a fixed effect and with the baseline plasma glucose 
modeled as a covariate. The dasiglucagon versus placebo treatment group difference will 
be ev
aluated inferentially as a least squares means contrast, using a two-sided t-test at the 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115176]. 
9.5.4 S econdary clinical efficacy (PD) endpoints 
 T ime t o first plasma glucose concentration of ≥70 mg/dL (3.9 mmol/L)  without 
administration of rescue IV glucose. 
 P lasma glucose response as area under the curve above baseline from time zero to 
30 minutes, AUC 0 -30min . 
S
econdary clinical efficacy endpoints will be assessed based on plasma concentration 
data from samples collected at the dosing visit (Visit 2).  
Unl
ess otherwise stated, the population base of analysis will be the FAS. 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints 
1. T ime to first plasma gluc ose concentration ≥70 mg/dL from basel ine. This 
time- to-event endpoint will be evaluated using a Kaplan-Meier approach, with 
treatment group as a stratification factor, analogous to that used for the primary 
endpoint analysis. Differences between the KM curves (dasiglucagon versus 
place
bo, GlucaGen versus placebo) will be evaluated inferentially using pairwise 
two-sided log rank tests. If the ≥70 mg/dL endpoint is not met within [ADDRESS_1115177] valid plasma glucose measurement up to 45 
m
inutes will be the censoring time.  
2. T he AUC will be calculated as the baseline-adjusted area under the plasma 
gluc
ose profile over time: 
a. AUC 0-
30min: restricting the time window to the 0 to 30 minutes interval. 
3. T he log-transformed AUC endpoint will be analyzed using an analysis of 
covariance
 (ANCOVA) model with treatment as fixed effect and baseline plasma 
glucose
 modeled as a covariate. The least squares means treatment group 
differ
ences will be back-transformed (anti-logged) for presentation as a ratio of 
the trea
tment group geometric means, with their corresponding 95% CI. 
9.5.5 E xposure (PK) endpoints 
 Pla sma dasiglucagon and GlucaGen concentrations from time zero to 90 minutes:  
AUC 0-
90min, Cmax, and t max. 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
________________________________________________________________________ 
Strictly C
onfidential    Page 67 of 82  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints 
AUC will be derived as the area under the individual plasma dasiglucagon/GlucaGen 
concentration profile for PK from [ADDRESS_1115178] valid measurement if this 
measurement is assessed sufficiently close to 90 minutes (decision to be taken at the 
masked data review meeting). The standard trapezoidal method will be used, based on 
a
ctual rather than nominal timepoints.  
Cmax will be determined as the maximum of all valid plasma dasiglucagon/GlucaGen 
concentrations.  
Tmax will be determined as the timepoint where the maximum of all valid plasma 
da
siglucagon/GlucaGen concentration measurements for each measurement series is 
observed. 
The log-transformed PK endpoints AUC and C max will be analyzed in the same way as 
the AUC endpoints. 
As
 tmax is a highly discrete endpoint, Wilcoxon’s rank sum test for unpaired observations 
w
ill be used to assess differences between the two treatment groups.  
9.6 E xploratory analyses 
Exploratory analyses will include descriptive statistics and modeling analogous to that 
done for key secondary endpoints. However, treatment group comparisons will be 
summariz
ed without inference intent. 
Plasma g lucose c oncentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL
(1.1 mmol/L) within 30 minutes after study drug injection without administration
of rescue
 IV glucose.
Plasma insulin response as area under the curve above baseline from time zero to
60 minute
s, AUC 0-60 min .
Plasma insulin concentrations measured pre-dose and at 30 and 60 minutes after dosing 
(see Table 3) will be presented individually. A summary table per timepoint will be 
provided. The AUC 0-60min will be determined and a summary presented.  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115179] available version of the MedDRA, the version of 
which will be provided in the clinical trial report. AE summary tables will include the 
number
 and percentage of subjects who experienced AEs summarized by [CONTACT_42893] 
c
lass and preferred term. 
[LOCATION_013] only: The AE summary for AEs related to insulin glulisine (Api[INVESTIGATOR_27976]®) will be 
presented as an appendix to the clinical trial report, as insulin glulisine (Api[INVESTIGATOR_27976]®) is only 
defined as an IMP in [LOCATION_013]. 
An overall summary table will be provided showing the number and percentage of 
subjects with any: 
 TEAE 
 S evere TEAE 
 S erious TEAE 
 D rug-related TEAE 
 D rug-related severe TEAE 
 D rug-related serious TEAE 
 TEAE leading to withdrawal 
 T EAE with outcome death 
 A ESI 
Refer to Section 7.2.[ADDRESS_1115180] results will be flagged as to whether the result is below, within or 
above
 the respective reference range. The number of values outside of the reference range 
will be counted. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 69 of 82  
9.7.4 Other safety data 
Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure will 
be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. 
Inferential treatment group comparisons will be assessed via pairwise tests of 
independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus 
place
bo). 
Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure 
will be evaluated using a KM time to event statistical model, with treatment group and 
inje
ction site as stratification factors. Differences between the KM curves (dasiglucagon 
vers
us placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise 
two-sided stratified log-rank tests. If the endpoint is never met, the time of the last plasma 
glucose measurement will be the censoring time. 
V
ital signs, physical examination, 12-lead ECG and local tolerability data will be 
summ
arized using descriptive statistics. 
9.[ADDRESS_1115181] withdrawals and missing data 
Failure is defined for the primary time- to-recovery endpoint as censored with time to 
recovery set to the maximum follow-up time, here 45 minutes. Individuals will be set to 
‘f
ailure’ in case of  receiving rescue IV glucose, discontinuation due to treatment or 
disconti
nuation in connection with the induced hypoglycemia state. Only if an 
interm
ediate assessment is missing independent of rescue treatment, study treatment or an 
adverse event including hypoglycemia, interpolation can be applied to impute a missing 
value
. 
The same construct of imputation applies for the analysis of the plasma glucose AUC0 -
30min . 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115182] will be applied.  
9.10 In terim analyses 
N
o interim analyses are currently planned. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115183] be consistent with 
the s
ubjects ’ source documentation (i.e. medical records).  
The investigator will permit trial-related monitoring, IRB/IEC review, and regulatory 
inspections, providing direct access to source data /documents. Sponsor-authorized 
quality assurance personnel may carry out audits for which the investigator must provide 
support. 
T
he trial monitor or a representative of the sponsor will cross-check the data entered in 
the eCRFs with the source data at the trial center and observe the trial procedures in order 
to v
erify adherence to the trial protocol. Any queries will be resolved by [CONTACT_111140]/her delegate. 
All of the clinical data will be captured via electronic data capture (EDC) using a 
web-based tool.  
The investigator center staff will enter and edit the data via a secure network, with secure 
access features (username [CONTACT_2383]). A complete electronic audit trail will be 
maint
ained. The investigator will approve the data using an electronic signature (Ref: 21 
CFR Part 11), and this approval is used to confirm the accuracy of the data recorded. 
eCRFs will be used for all subjects. The investigator’s data will be accessible from the 
investigator’s center throughout the trial. The eCRFs must be kept current to reflect 
subje
ct status at each phase during the course of the trial. The eCRF will not capture 
personalized data. The investigator must make a separate confidential record of 
personalized details (name [CONTACT_93459]) on the subject identification and enrollment log. 
All changes to data are made by [CONTACT_15009]/her delegate through the EDC 
sy
stem.  
It is the responsibility of the principal investigator [INVESTIGATOR_807435]’s eCRF are also made on the subject’s medical records.  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115184]
aff will be given access to the software. Access to the software is restricted to staff 
participating in the trial and the extent of access will depend on the participants' user role 
in the 
trial. 
T
he subjects enrolled into the trial will be identified in the database by [CONTACT_807469]
l identification code. The investigator or delegate will enter subject data into the 
e
CRF promptly. All data is to be entered in English. Data recorded in the eCRFs will be 
accessible to the trial staff throughout the trial. 
After data entry, systematic data validation will be performed and data entry 
discrepancies will be presented electronically directly to the center staff. Queries for 
discrep
ant data may be generated automatically by [CONTACT_727915]/or 
generated manually by [CONTACT_807470]. All queries, whether 
gener
ated by [CONTACT_727917], will be in electronic format. 
All 
sections of the eCRF are to be electronically approved by [CONTACT_1720] a 
medically qualified delegate after the data has been entered and all queries have been 
resolved. Changes to any eCRF page subsequent to the approval require a new approval 
signature. 
All queries and changes/corrections to the data are documented in the eCRF. 
10.3  Access to source data 
D
uring the course of the trial, a trial monitor will make site visits to review protocol 
compliance, compare eCRFs with individual subjec t’s medical records, assess drug 
accountability, and ensure that the trial is being conducted according to pertinent 
regulatory requirements. 
Checking of th e eCRFs for completeness and clarity, and cross-checking with source 
documents, will be required to monitor the progress of the trial. Moreover, regulatory 
authorities of certain countries, IRBs/IECs, and/or the sponsor may wish to carry out such 
source data checks and/or on-site audit inspections. Direct access to source data will be 
required for these inspections and audits; they will be carried out giving due 
consideration to data protection and medical confidentiality. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly C
onfidential    Page 73 of 82  
10.4  Source documentation 
All source documents from which eCRF entries are derived should be placed in the 
subjec t’s medical records. If data are to be entered directly into the eCRF this must be 
s
pecified in a source data agreement prior to the start of the trial. 
eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that subject confidentiality is maintained. 
The trial monitor will check the eCRF for accuracy and completion and perform source 
da
ta verification. The trial monitor will document source data verification of all reviewed 
sections of the eCRF. 
10.[ADDRESS_1115185] (e.g. informed consent forms, laboratory slips, medication 
inventory records, and other pertinent information) must be retained by [CONTACT_807471]. 
10.7  Good clinical practice 
The procedures set out in this trial protocol are designed to ensure that the sponsor and 
investi
gator abide by [CONTACT_146018] ( 1), and of the 
Declaration of Helsinki (2008) ( 2). The trial also will be carried out in keepi[INVESTIGATOR_807436].  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115186] orally and in writing (subject information 
sheet) the nature, significance, risks and implications of the trial before inclusion. In 
particular, the subjects will be informed about the following: 
 T he possibility of withdrawing from the clinical trial at any time by [CONTACT_807472]. 
 How personal and health-related data will be collected and used during the trial. 
 T hat his/her medical records may be examined by [CONTACT_807473], by [CONTACT_6667]/IEC 
members, and by [CONTACT_6668]. 
All subjects will receive a copy of the subject information sheet and a copy of their 
signed and dated informed consent form, both of which will be in the subject’s local 
language. 
If
 a protocol amendment is required, the informed consent form may need to be revised to 
reflect the changes to the protocol. If the consent form is revised, it must be reviewed and 
approved by [CONTACT_69869]/IRB, and signed by [CONTACT_807474]. 
10.9  Protocol a pproval and amendment 
Bef
ore the start of the trial, the trial protocol and/or other relevant documents will be 
approve
d by [CONTACT_6179]/IRB/competent authorities, in accordance with local legal 
requirements. The sponsor must ensure that all ethical and legal requirements have been 
met before the first subject is enrolled in the trial. 
This
 protocol is to be followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive IRB/IEC/competent 
authority approval prior to implementation (if appropriate).  
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 75 of 82  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without 
the need for a formal amendment. All amendments will be distributed to all protocol 
recipi[INVESTIGATOR_840], with appropriate instructions. 
10.[ADDRESS_1115187] will be up to 63 days (including up to 
30 days for screening and up to 33 days until the follow-up visit).  
T
he trial will be closed when all subjects have completed Visit 3. 
10.11  Premature termination of the trial 
If the investigator, the sponsor (e.g. safety committee), or the safety medical monitor 
becomes aware of conditions or events that suggest a possible hazard to subject s if the 
trial continues, the trial may be terminated after appropriate consultation between the 
relevant parties. The trial may also be terminated early at the s ponsor’s discretion in the 
absence of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
 T he discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the trial 
 Failure to enroll subjects at an acceptable rate. 
 A  decision on the part of the sponsor to suspend or discontinue development of the 
drug. 
The trial can be terminated prematurely by [CONTACT_807475]: 
 T he center cannot comply with the requirements of the protocol. 
 It is not possible for the center to comply with GCP standards. 
10.12   Confidentiality 
All trial findings and documents will be regarded as confidential. The investigator and 
mem
bers of his/her research team must not disclose such information without prior 
written approval from the sponsor. 
The anonymity of participating subjects must be maintained. Subjects will be identified 
on eCRFs submitted to the sponsor by [CONTACT_139927]. On the SAE reports and all 
o
ther s
ource documents, the subject will be identified via subject number. Documents not 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115188] (e.g. the signed informed consent 
for
m) must be maintained in confidence by [CONTACT_093].  
10.13  Other ethical and regulatory issues 
If
 a significant safety issue is identified, either from an individual case report or review of 
aggregate data, then the sponsor will issue prompt notification to all parties : regulatory 
authorities, investigators and IRB/IECs. 
A
 significant safety issue is one that has a significant impact on the course of the clinical 
trial or program (including the potential for suspension of the trial program or 
a
me
ndments to protocols) or warrants immediate update of informed consent. 
10.[ADDRESS_1115189] resulted 
from participation in the clinical trial, or if he/she undergoes any other medical treatment 
without their consent before the clinical trial has been completely finished in so  far as the 
indi
vidual subject is concerned. 
A
ny injury to health, which might have occurred as a result of participation in the clinical 
trial must be reported by [CONTACT_807476]. The investigator is 
o
blige
d to make such a report in any case. 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictly C
onfidential    Page 77 of 82  
10.15   Publication policy 
By [CONTACT_752373], the investigator agrees with the use of results of the trial for 
the purposes of national and international registration, publication and information for 
medical and pharmaceutical professionals. If necessary, the authorities will be notified of 
the investi
gator's name, address, qualifications and extent of involvement. 
A clinical trial report will be prepared and reviewed by [CONTACT_807477]-operation with 
the
 coordinating investigator. The coordinatoing investigator will be appointed by 
[CONTACT_807478]. A summary of the clinical trial report (according to CPMP/ICH137/95) 
should be sent to the regulatory authorities and IRB/IEC according to the relevant 
guidelines. 
According to the Declaration of Helsinki (2) investigators and sponsors ‘have ethical 
o
bligations with regard to the publication and dissemination of the results of research’.   
The trial design and results may be published as one or more original research 
manuscripts/abstracts and presented at a scientific meeting. The original eCRFs and the 
data generated from the eCRFs or otherwise obtained during the trial under this trial 
protocol will become the property of the sponsor. Publication of the results of this trial by 
[CONTACT_807479]. 
Any material intended for publication will be given to the sponsor at least [ADDRESS_1115190] the right to comment on the intended 
publication and to take any reasonable measures for patent protection. Authorship on any 
publication(s) resulting from this clinical trial will be assigned according to the 
recommendations of the International Committee of Medicinal Journal Editors (26).  
Participating subjects will not be identified by [CONTACT_807480]. 
The sponsor is responsible for trial registration at ClinicalTrials.gov 
(www.clinicaltrials.gov) according to FDA requirements, as well as the European 
Medicines 
Agency’s Clinical Trials Database (EudraCT) .  
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115191]  
1.ICH Harmonise d Tripartite Guideline. International Conference on H armonisation. 
ICH Harmonise d Tripartite Guideline. Integrate d addendum to ICH E6(R1): 
Guideline for Good Clinica l Practice E6 (R2), Step 4. 09-Nov-2016. Available from: 
URL:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E  
6/E6_R2__Step_4.pdf
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical
Resea
rch Involving Human Subjects. 52nd WMA General Assembly, Edinburgh,
Scotland, October 2000. Last amended with Note of Clarification on Paragraph [ADDRESS_1115192] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.
Hypo
glycemia and diabetes: a report of a workgroup of the American Diabetes
Association and the Endocrine Society. Diabetes Care 2013 May;36:1384-95
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
5. Ame
rican Diabetes Association Position Statement. Standards of medical care in
diabetes 
- 2017. Diabetes Care 2017;40(Supplement 1):S1-S135
6.
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world
facto
rs affecting adherence to insulin therapy in patients with Type 1 or Type 2
diabetes mellitus: a systematic review. Diabetic Medicine 2013;30:512-24
7. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0
mmol/L 
(54 mg/dL) should be reported in clinical trials: a joint position statement of
the American Diabetes Association and the European Association for the Study of
Diabetes. Diabetes Care 2017;40(1):155-57
8.Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alph a-cell as target for type 2
diabetes therapy. Rev Dia bet Stud 2011;8:369 -81
9. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2
diabetes: the r
eturn of the alpha cell. Curr Diab Rep 2014;14:555
10. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The
metabo
lic actions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-97
11. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the
therape
utic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res
2004;21:1274-83
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.0  
  
 
 
 
________________________________________________________________________ 
Strictl
y Confidential    Page 79 of 82  
12. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. 
Drug Di
scovery Today 2015;20:122-8 
13. N ovo Nordisk Limited. SPC for GlucaGen Hypokit 1 mg. 2015. 
http:/
/www.medicines.org.uk/emc/medicine/4258/SPC/GlucaGen+Hypokit+1+mg - 
Acc
essed 13 Mar 2017 . 
14. Z ealand Pharma A/S. Dasiglucagon Investigator's Brochure, Edition 3, 12 Dec 2016.  
15. T he Task Force for the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 
ESH/ESC guidelines for the management of arterial hypertension. European Heart 
Journal 2013;34:2159-219 
16. Le vey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen BA, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of Internal Medicine 
2006;145:247 -54 
17. F ood and Drug Administration (FDA). Guidance for Industry on Bioanalytical 
Method Validation. Food and Drug Administration (FDA) [ADDRESS_1115193], Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. 
Quantitative bioanalytical methods validation and implementation: best practices for 
chromatographic and ligand binding assays. Pharm Res [ADDRESS_1115194];24:1962- [ADDRESS_1115195] biotechnology pro ducts. J Pharm Biomed Anal 2008 ;48:1267- [ADDRESS_1115196] neutralizing antibodies to ZP4207 
by [CONTACT_807481] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-004-REP.  2016. Report No.: Zealand Pharma, 
s
tudy 15-[ADDRESS_1115197] neutralizing antibodies to glucagon 
by [CONTACT_807481] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-005.  2016. Report No.: Zealand Pharma, Study 
15-040 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115198] glycemic control of insulin -dependent diabetes mellitus. 
N Eng J Med 1987; 316: 1376 -83. 
25. R ickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-
induced hypoglycemia in adults with type 1 diabetes: A randomized crossover 
noninferiority study. Diabetes Care 2016; 39: 264-70. 
26. ICMJ E. Recommendations for the conduct, reporting, editing, and publication of 
scholarly work in medical journals. Updated December 2016 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115199] of trial personnel 
Sponsor  
Clinical Trial Manager   
 
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:  
Medical Officer   
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Contract Research Organizat ion Chiltern International (Ltd)  
[ADDRESS_1115200]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:  +44 (0) [PHONE_16833]  
Project Manager   
Chiltern International (Ltd)  
[ADDRESS_1115201]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:    
Senior Medical Officer  and 
Safety medical monitor   
Chiltern International kft  
Canada Square Office House  
Ganz u  

 
 
Dasiglucagon (ZP4207)  Date: 04-Apr-2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 5.[ADDRESS_1115202]  
Hungary  
Phone:   
Pharmacovigilance unit  
Responsible for Serious Adverse 
Event (SAE) Mana gement and 24 -
hour SAE reporting    
PharmaLex  
Agern Allé 24  
2970 Hørsholm, Denmark  
Phone:   (8 a.m. to 4 p.m.)  
Phone:   (outside 8 a.m. to 4 p.m.)  
Fax:  
email: [EMAIL_7118]   
Central l aboratory  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (GlucaGen 
PK, insulin PK)  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (dasiglucagon 
PK, dasiglucagon ADA, 
GlucaGen ADA)  York Bioanalytical  Solutions (YBS)  
Cedar House  
Northminster Business Park  
Northfield Lane  
York, YO26 6QR, [LOCATION_008]  
Special laboratory  
(neutralizing antibodies)  BioAgilytix  
[ADDRESS_1115203] of all investigators, IECs and IRBs will be provided in a separate document and in  
the clini
cal trial report. 
 

 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 1 of 81  
CLINICAL TRIAL PROTOCOL 
 
A phase 3, randomized, double-blind, parallel trial to 
confirm the clinical efficacy and safety of dasiglucagon 
in the rescue treatment of hypoglycemia in subjects with 
type 1 diabetes mellitus (T1DM) compared to placebo 
and with reference to GlucaGen® 
 
Sponsor:  Zealand Pharma A/S  
Sponsor Protocol No.:  ZP4207 -[ADDRESS_1115204] No. : 2017 -002449 -31  
IND No : 127866  
Trial  Drug Name:  [CONTACT_807506] * injection  
Date of Protocol:  26-Jan 2018  
 
The trial will be conducted according to the protocol and in compliance with Good 
C
linical Practice (GCP), with the Declaration of Helsinki and with other applicable 
regulator
y requirements. 
*Dasiglucagon is the proposed international nonproprietary name [CONTACT_807507]4207. 
This protoc
ol version 4.[ADDRESS_1115205] party, in any form, without prior written 
consent of an authorized officer of Zealand Pharma. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 2 of 81  
Declaration of sponsor or responsible medical officer 
Title:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellit
us (T1DM) compared to placebo and with reference to GlucaGen® 
This trial protocol was subjected to critical review. The information it contains is 
c
onsistent with current knowledge of the risks and benefits of the investigational product, 
as well as with the moral, ethical and scientific principles governing clinical research as 
set out in the Declaration of Helsinki and the guidelines on Good Clinical Practice (GCP) 
(1). 
 
 
_____________________________________ _____________________ 
Name     [CONTACT_807508] A/S 
Smedeland 36 
2600 Glostrup, D
enmark 
Phone:   
 
_____________________________________ _____________________ 
Name    
 [CONTACT_807509] A/S 
Smedeland 36 
2600 Glostrup, D
enmark 
Phone:   

 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 3 of 81  
Declaration of the coordinating investigator 
[CONTACT_1641]:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellitus (T
1DM) compared to placebo and with reference to GlucaGen® 
I have read this protocol. I approve this document and I agree that it contains all 
necessary details for carrying out the trial as described. I will conduct this trial in 
accordance with the design and specific provision of this protocol and will make a 
reasonable effort to complete the trial within the time designated. I will provide copi[INVESTIGATOR_807427] A/S to trial 
personnel under my supervision. I will discuss this material with them to ensure they are 
fully informed about the trial product and trial procedures. I will let them know that this 
information is confidential and proprietary to Zealand Pharma A/S and that it may not be 
further disclosed to third parties. I understand that the trial may be terminated or 
enrollment suspended at any time by [CONTACT_93442] A/S, with or without cause, or by 
[CONTACT_807442]. 
I agree that the trial will be carried out in accordance with GCP (1), with t he Declaration 
of Helsinki (with amendments) (2) and with the laws and regulations of the countries in 
whic
h the trial takes place. 
 
 
_____________________________________ _____________________ 
Name       [CONTACT_807510]: + 
Fax: + 
 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 4 of 81  
Declaration of the investigator 
T
itle: A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mell
itus (T1DM) compared to placebo and with reference to GlucaGen® 
All documentation for this trial that is supplied to me and that has not been previousl y 
published will
 be kept in the strictest confidence. This documentation includes this trial 
protocol, Investigator's Brochure, Case Report Forms, and other scientific data. 
The trial will not be commenced without the prior written approval of a properly 
c
onstituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC). 
No changes will be made to the trial protocol without the prior written approval of the 
sponsor and the 
IRB or IEC, except where necessary to eliminate an immediate hazard to 
the subjects. 
I have read and understood and agree to abide by [CONTACT_348232]. 
 
_____________________________________ _____________________ 
Signature      [CONTACT_1782] 
 
_____________________________________ 
Name (block letters) 
 
_____________________________________
 
Title (block letters) 
 
_____________________________________
 
Institution (block letters) 
 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 5 of 81  
Table of contents 
DECLARATION OF SPONSOR OR RESPONSIBLE MEDICAL OFFICER  .......... 2 
DECLARA
TION OF THE COORDINATING INVESTIGATOR  ..............................  3 
DECLARA
TION OF THE INVESTIGATOR  ...............................................................  4 
T
ABLE OF CONTENTS  ................................................................ ................................ .. 5 
1 S YNOPSIS  ................................ ................................ ................................ ............ 11 
2 INTRODUC TION ................................................................ ................................  15 
2.1 B ackground ................................ ................................ ................................ ...... 15 
2.1.1 H ypoglycemia  ................................ ................................ ......................  15 
2.1.2 Gluc agon  ................................................................ ..............................  16 
2.1.3 Da siglucagon ................................ ................................ ........................  16 
[IP_ADDRESS] Pharmac okinetics and pharmacodynamics of dasiglucagon  ......... 17 
[IP_ADDRESS] Safety  of dasiglucagon  ................................ ................................ ... 17 
2.2 T rial rationale  ................................ ................................ ................................ .. 18 
2.3 Risk -benefit assessment  ................................ ..................................................  18 
3 T RIAL OBJECTIVES AND ENDPOINTS .......................................................  20 
3.1 P rimary objective  ................................ ............................................................  20 
3.2 S econdary objectives  ................................ .......................................................  20 
3.3 P rimary endpoint  ................................ ................................ ............................  20 
3.4 K ey secondary endpoints  ................................ ................................................  20 
3.5 Oth er secondary endpoints  ................................ ................................ ............. 20 
3.6 E xploratory endpoint  ................................ ......................................................  21 
4 OVE RALL DESIGN AND PLAN OF THE TRIAL  ................................ ........ 22 
4.1 Ove rview  ................................ ................................ ................................ .......... 22 
4.2 Ju stification of the trial design  ................................ ................................ ....... 24 
4.2.1 J ustification for design and parameters ................................ ................  24 
4.2.2 J ustification for drug, route, dosage and treatment duration  ............... 24 
5 T RIAL POPULATION  ................................ .......................................................  26 
5.1 Rat ionale for trial population  ................................ ................................ ........ 26 
5.2 P lanned sample size and number of trial centers  ................................ ......... 26 
5.3 In clusion criteria  ................................ .............................................................  26 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115206] ug accountability  ................................ .........................................................  36 
6.8 T reatment compliance  ................................ ....................................................  36 
6.9 P rior and concomitant medications  ................................ ...............................  36 
6.9.1 P rohibited medications ................................ ................................ ......... 37 
7 P ARAMETERS AND METHODS OF ASSESSMENT  ................................ .. 38 
7.1 E fficacy parameters  ................................ ........................................................  38 
7.1.1 P harmacodynamic measurements  ................................ ........................  38 
7.1.2 P harmacokinetic measurements  ................................ ...........................  38 
7.2 S afety parameters  ................................ ............................................................  39 
7.2.1 Adve rse events  ................................ ................................ .....................  39 
[IP_ADDRESS] De finitions  ................................ ................................ ......................  39 
[IP_ADDRESS] C ollection, recording and reporting of adverse events  .................  42 
[IP_ADDRESS] Follo w-up of adverse events  ..........................................................  44 
[IP_ADDRESS] C linical laboratory abnormalities and other abnormal 
assessments as adverse events or serious adverse events  .............. 44 
7.2.2 H ypoglycemia  ................................ ................................ ......................  45 
7.2.3 P hysical examination  ................................ ................................ ........... 45 
7.2.4 Vital si gns ................................ ................................ ............................  45 
7.2.5 Ele ctrocardiogram  ................................ ................................................  46 
7.2.6 L ocal tolerability  ................................ ..................................................  46 
7.2.7 C linical laboratory assessments  ................................ ...........................  47 
7.2.8 P regnancy  ................................ .............................................................  48 
7.2.9 P recautions  ................................ ...........................................................  49 
7.2.10 S afety committee  ................................ ................................ .................  49 
7.3 De mography, concomitant illness, medical history and concomitant 
medication  ................................ ................................ ................................ ........ 49 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115207]  ................................................................ ..............................  53 
8.1 S chedule of procedures  ................................ ...................................................  53 
8.2 P rocedures by [CONTACT_765]  ................................ ..........................................................  53 
8.2.1 Visi t 1 (screening, Day -30 to Day -3)  ................................ .................  53 
8.2.2 I nstructions to subjects prior to the dosing visit (Visit 2)  ....................  55 
8.2.3 Visi t 2 (dosing visit)................................ ................................ ............. 56 
[IP_ADDRESS] Hy poglycemic clamp procedure and administration of trial 
medication  ................................ ......................................................  57 
8.2.4 Visi t 3 (follow-up visit)  ................................ ................................ ....... 60 
9 S TATISTICAL METHODS  ................................ ................................ ............... 61 
9.1 De termination of sample size  ................................ ................................ ......... 61 
9.2 T rial subjects  ................................ ................................ ................................ ... 61 
9.2.1 Ana lysis samples  ................................ ..................................................  61 
9.2.2 Disposi tion of subjects  ................................ ................................ ......... 62 
9.2.3 P rotocol deviations ................................ ................................ ............... 62 
9.3 G eneral considerations  ................................ ...................................................  63 
9.4 De mographics and baseline characteristics  ..................................................  63 
9.5 E fficacy Analyses  ................................ .............................................................  63 
9.5.1 Hie rarchical testing procedure  .............................................................  64 
9.5.2 P rimary confirmatory endpoint  ................................ ............................  64 
[IP_ADDRESS] Primary  analysis  ................................ ................................ ............ 64 
9.5.3 S econdary endpoints  ................................ ................................ ............ 65 
[IP_ADDRESS] C onfirmatory analysis  ................................ ................................ .... 65 
9.5.4 S econdary clinical efficacy (PD) endpoints  ................................ ......... 66 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints ................  66 
9.5.5 Ex posure (PK) endpoints  ................................ ................................ ..... 66 
[IP_ADDRESS] Analy sis of exposure (PK) endpoints  ................................ ............. 67 
9.6 E xploratory analyses  ................................ .......................................................  67 
9.7 S afety analyses  ................................................................ ................................ . 68 
9.7.1 Adve rse events  ................................ ................................ .....................  68 
9.7.2 I mmunogenicity data  ................................ ................................ ........... 68 
9.7.3 C linical laboratory assessments  ................................ ...........................  68 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115208]-treatment blood sampling times  ................................ ................................  59 
 
F
igures in text 
Figure 1  Tr ial design  ................................................................ ................................ ........ 23 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115209]  European Medicines Agency’s Clinical Trials Database  
FAS Full analysis set  
FDA  Food and Drug A dministration  
GCP  Good Clinical Practice  
HbA 1c Glycated hemoglobin  
ICH International Conference on Harmonization  
ID card  Identification card  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
IMP Investig ational medicinal product  
IRB Institutional Review Board  
IV Intravenous(ly)  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 10 of 81  
IWRS  Interactive Web Response System  
MedDRA  Medical Dictionary for Regulatory Activities  
NPH  Neutral protamine Hagedorn  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per proto col 
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Safety analysis set  
SC Subcutaneous(ly)  
S[LOCATION_003]R  Serious unexpected suspected adverse reaction  
T1DM  Type [ADDRESS_1115210]  Upper limit of the normal range  
US [LOCATION_002] of America  
 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 11 of 81  
1 SYNOPSIS 
Name [CONTACT_119019]:  
Zealand Pharma A/S  Trial ID:  
ZP4207 -[ZIP_CODE] 
Title of the trial:  
A phase 3, randomized, double -blind, parallel trial to confirm the clinical efficacy and safety of 
dasiglucagon  in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) 
compared to placebo and with reference to GlucaGen® 
Trial design:  
The trial is a global, multicente r, randomized, parallel -group , double -blind, clinical trial confirming the 
efficacy and safety of dasiglucagon  for insulin -induced hypoglycemia in subjects with type 1 diabetes  
mellitus . The subjects will be randomized 2:1:1 to receive a single fixed subcu taneous 0.6 mg dose of 
dasiglucagon  (hereinafter dasiglucagon) , placebo  for dasiglucagon (hereinafter referred to as placebo) , or a 
1 mg dose of GlucaGen® (hereafter referred to as GlucaGen) and followed for at least 28  days after 
treatment.  
Clinical phas e of development:  
Phase 3 
Trial centers : 
This trial will be conducted at 4 to 6 sites in the [LOCATION_002] of America , Canada, and Europe . 
Planned trial start ( first subjec t first visit):  
Q4/2017 Planned trial end ( last subjec t last visit):  
Q3/2018  
Trial population:  
Male and female adult  subjects  with type [ADDRESS_1115211] one year   
Key objectives:  
Primary objective:   
 To demonstrate superiority  of dasiglucagon  compared to placebo  following a single subcutaneous  
0.6 mg dose administered to subjects with type 1 diabetes mellitus  with insulin -induced 
hypoglycemia . 
Secondary objective:   
 To compare the glycemic response observed after  dasiglucagon  with that of  GlucaGen . 
Key endpoints:  
Primary endpoint:   
 Time to  plasma glucose  recovery. Plasma glucose recovery is defined as first increase in plasma 
glucose of  ≥20 mg/dL  (1.1 mmol/L) from baseline  during the hypoglycemic clamp procedure  
without administration of rescue intravenous ( IV) glucose .  
Key s econdary endpoint s: 
 Plasma glucose recovery  within 30 minutes, within 20 minutes , within 15 minutes, and within 
10 minutes  after study drug injection  without administration of rescue IV glucose . 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes , within 15 minutes, 
and within 10 minutes  after study drug injection  or at the time of rescue . 
Clinical efficacy  (Pharmacodynamic ) endpoints:  
 Time to first plasma glucose concentration of ≥70 mg/dL ( 3.9 mmol/L ) without administration of 
rescue IV glucose . 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 12 of 81  
 Plasma glucose response as  area under the curve  above baseline  from time zero to 30 minutes, 
AUC0-30min. 
Exposure (Pharmacokinetic) endpoints:  
 Area under th e drug concentration curve from time zero to 90 minutes , AUC 0-90 min. 
 Maximum plasma drug concentration (C max). 
 Time to maximum plasma  drug concentration (t max). 
Safety endpoints:   
 Adverse events, clinical laboratory assessments (biochemistry, hematology, coagulation, urinalysis), 
vital signs, physical examination, electrocardiogram, and local tolerability.  
 Administration  of rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
 Time to first rescue infusion of IV glucose during the hypoglyc emic clamp procedure.  
Immunogenicity endpoint:  
 Occu rrence  of anti -drug antibodies  
Exploratory endpoint:  
 Plasma g lucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL (1.1 mmol/L) 
within 30  minutes after study drug injection  without administr ation of rescue IV glucose . 
 Plasma insulin response as area under the curve above baseline from time zero to  60 minutes , 
AUC 0-60 min. 
Key inclusion criteria:  
 Male and female subject s with type [ADDRESS_1115212] one year , 
diagnostic criteria as defined by [CONTACT_807443] n. 
 Stable  insulin treatment 30 days prior to screening, defined as no more than a 10 -unit daily variation 
in total  daily insulin dose . 
 Hemoglobin A 1c <10%.  
 Aged between 18 and 75 years, bo th inclusive . 
Key exclusion criteria:  
 Previously treated with dasiglucagon . 
 Known or suspected allergy to trial product(s) or related products.  
 History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).  
 Previous participation (rand omization) in this trial.  
Sample size:  
Approximately  [ADDRESS_1115213]:  
Test product: dasiglucagon  liquid form ulation in pre -filled syringes . 
Comparator  product s: Placebo and GlucaGen® lyophilized powder . 
[LOCATION_013] only : Insulin glulisine  (Api[INVESTIGATOR_27976]®), the challenge agent, will also be defin ed as an investigational 
medicin al product  
Duration of treatment:  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 13 of 81  
Subjects will be randomized 2:1:[ADDRESS_1115214] 28 days after receiving treatment .  
Assessments:  
The plasma glu cose profile for evaluation of the primary and secondary clinical efficacy 
(pharmacodynamic) endpoints will be assessed based on plasma concentration data from samples collected 
at the dosing visit.  
The exposure to  trial medication (dasiglucagon , placebo , or GlucaGen) for evaluation of pharmacokinetics  
will also be assessed based on plasma concentration data .  
Statistical methods:   
Due to requirements in the size of the safety database, the sample size is set to 78 subjects treated with 
dasiglucagon 0.6  mg. With a 2:1:1 randomization ratio for the three treatments, dasiglucagon  0.6 mg, 
placebo , and GlucaGen 1 mg, 78 subjects injected with dasiglucagon and 39 subjects with placebo will 
yield a power of 90% at a 5% two -sided significance level to detect a tre atment group difference in recovery 
incidence within 20 minutes, assuming as low as 80% and as high as 50% recovery incidence for the 
dasiglucagon and placebo groups, respectively.  
For the confirmatory analyses, the primary and key secondary endpoints for the dasiglucagon 0.6  mg and 
placebo  treated subjects will be compared. A hierarchical procedure will be applied for the control of 
multiplicity  in statistical inferences . The primary and secondary endp oints will be evaluated on the Full 
Analysis Set sample . The statistical inference comparisons with placebo will be conducted as superiority 
tests. The comparisons of  dasiglucagon versus GlucaGen will be summarized descriptively .    
The primary endpoint will be summarized using Kaplan -Meier  (KM)  estimates stra tified by [CONTACT_807444]. The tre atment group difference between  dasiglucagon and placebo will be evaluated 
inferentially using a pairwise two -sided log -rank test.  
In the primary analysis, those subjects who require rescue IV glucose wi ll be censored at the time of plasma 
glucose recovery. This approach is based on the assumption that rescue IV glucose administration will 
shorten the time to recovery. This assumption implies that censoring at the time of recove ry after rescue 
therapy is valid as a time to recovery without rescue would be longer than the observed duration. If recovery 
has not occurred at 45 minutes after study drug injection, censoring will be applied irrespective of the use of 
rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without censoring at the 
time of recovery for those subjects who require rescue IV glucose before 45 minutes and 2) with censoring 
at the time of administration of rescu e IV glucose before 45 minutes.    
The primary endpoint will additionally be analyzed using a Cox proportional hazards (CPH) time to event 
statistical model, if the hazards by [CONTACT_807445] a graphical 
comparison of log -minus -log survival curves and no  more than two -thirds of the recovery times are 
censored in each treatment group. The CPH model will be used for inferences, with treatment group and 
injection site modeled as categorical effects, and baseline plasma glucose modeled as a continuous 
covaria te. The treatment group rate ratios, active versus placebo, will be estimated together with the 95% 
confidence intervals, and pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs 
placebo) will be evaluated using two -sided likelihood ra tio tests.  
The key secondary incidence variables (plasma glucose recovery within 30 minute s, within 20 minutes, 
within 15  minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 14 of 81  
statistics (frequency and percent age) by [CONTACT_1570]. Inferential treatment group comparisons will be 
assessed via pairwise tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo) using Fisher’s exact test for each pairwise comparison.  
The key secondary endpoints of plasma glucose changes from baseline (CFB) within [ADDRESS_1115215] in those subjects who require rescue IV 
glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an 
Analysis of Covariance model, with treatment group modeled as a fixed effect and with the baseline plasma 
glucose modeled as a covariate. The dasiglucagon versus placebo treatment group difference will be 
evaluated inferentially as a least squares means contrast, using a two -sided t -test at the 0.[ADDRESS_1115216].  
The continuous clinical efficacy variables, the exploratory variables, and the pharmacokinetics variables 
will each be summarized des criptively by [CONTACT_64240]. The clinical efficacy variables will  be analyzed 
analogous to the plas ma glucose  CFB variables.   
The safety analyses will include by -treatment -group descriptive summaries of vital sign measurements, 
laboratory measures (including immunogeni city incidence), physical examination assessments, rescue IV 
glucose (incidence and amount of glucose infused), and adverse events. The number and percentage of 
subjects reporting specific events, such as nausea and vomiting, will be presented by [CONTACT_807482].  
Further details will be included in the Statistical Analysis Plan, to be completed before dat abase lock and 
treatment unmasking.   
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 15 of 81  
2 INTRODUCTION 
2.1 B ackground 
Zealand Pharma A/S (Zealand Pharma) is developi[INVESTIGATOR_807428], a physically and 
chemically stable peptide analog of human glucagon, in a ready- to-use liquid formulation 
for the acute treatment of severe hypoglycemia in patients with insulin-treated diabetes 
mellitus. Like native glucagon, dasiglucagon is comprised of 29 amino acids, but with 
7 substitutions which improve its physical and chemical stability in aqueous media. 
The
se amino acid substitutions make dasiglucagon suitable for a liquid formulation, 
while providing similar efficacy and safety as compared with recombinant glucagon in 
the clinical setting of acute treatment of severe hypoglycemia. 
2.1.1 Hypogly cemia 
Hypoglycemia in patients with diabetes is defined as epi[INVESTIGATOR_807429] (3). This i s a common, unpredictable, and potentially 
dangerous side effect of treatment of diabetes mellitus, especially with insulin or 
sulfonylureas. 
It is more frequent in patients with profound endogenous insulin 
deficiency, such as occurs in type 1 diabetes mellitus (T1DM) and advanced type 2 
diabetes mellitus (T2DM). Treatment of T2DM with insulin causes hypoglycemia 
progressively and more frequently over time, whereas in T1DM, hypoglycemia is 
experienced throughout the course of established disease ( 4).  
Symptoms and signs of hypoglycemia are not specific. Patients undergoing a 
hypoglycemic epi[INVESTIGATOR_460616], sweating, 
hunger, tremors, palpi[INVESTIGATOR_814], paresthesia, nausea and pallor. Depending on its severity, 
the hypoglycemia may lead to mild confusion, behavioral changes, loss of consciousness, 
seizures, coma, and death (5).  
The incidence of hypoglycemic events or even the fear of hypoglycemia influences 
patients’ adherence to prescribed treatment regimens for diabetes mellitus ( 6). This l eads 
to inadequate glycemic control, which in turn may lead to an increased risk of diabetic 
complications ( 5). Serious clinically significant hypoglycemia is now defined as plasma 
g
lucose <54 mg/dL (3.0 mmol/L), while the plasma glucose alert value is defined as 
<70 mg/dL (3.9 mmol/L) (7). W hen plasma glucose falls below these values, some kind 
of treatment strategy is needed. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 16 of 81  
2.1.2 Glucagon 
Glucagon is a naturally occurring hormone, secreted from the alpha cells of the 
pancreatic islets. Glucagon plays a central role in the regulation of glucose homeostasis 
and is the counterpart of insulin for controlling blood glucose levels (i.e. it acts in 
opposition to insulin in terms of effects on blood glucose levels) ( 8,9). Glucagon 
stimulates hepatic glycogenolysis and gluconeogenesis in hypoglycemic states, thereby 
[CONTACT_93406]. Glucagon receptor agonism has also been shown to exert 
effects on lipid metabolism, energy balance, body adipose tissue mass and food intake 
(10). Insulin decreases blood glucose levels and cases of hypoglycemia can be reversed 
by [CONTACT_41148]. Therefore, glucagon is indicated for the treatment of severe hypoglycemia. 
Besides intravenous (IV) glucose administration, an injectable form of glucagon is given 
as first aid in cases of severe hypoglycemia, when the patient is unconscious or for other 
reasons cannot take glucose orally. The approved glucagon dose for an adult is 1 mg, 
given by [CONTACT_33813] (IM), IV, or subcutaneous ( SC) injection, which quickly raises 
blood g
lucose levels. As current marketed recombinant glucagon is highly unstable when 
dissolved in solution, the injectable form has to be reconstituted prior to use in a 9-step 
procedure that requires a 
sterile diluent to be injected into a vial containing lyophilized 
powdered glucagon. When dissolved in a fluid state, glucagon can form amyloid fibrils 
(11), or ti ghtly woven chains of proteins made up of the individual glucagon peptides. 
The reconstitution process makes the use of marketed glucagon products cumbersome 
(12), and a more patient-friendly formulation is needed. Currently, the Food and Drug 
Administration (FDA ) approved instructions for commercially available glucagon allow 
only for immediate usage of glucagon after the powder is reconstituted in aqueous 
solution ( 13). Therefore, a glucagon analog with enhanced biophysical stability may 
represent a leap forward in terms of convenient therapeutic applications. 
2.1.3 Dasiglucagon 
Dasiglucagon (ZP4207) is a stable peptide analog of human glucagon, available in a 
ready- to-use liquid formulation. Dasiglucagon (hereinafter referred to as dasiglucagon) is 
in development for the treatme
nt of severe hypoglycemia in insulin-dependent patients 
with diabetes mellitus. Dasiglucagon is a specific and full glucagon receptor agonist 
designed to mimic the effects of glucagon, having a fast absorption and elimination 
(minutes). It is a peptide of 29 amino acids, with 7 amino acid substitutions compared to 
native glucagon. The main purpose of the substitutions is to increase the physical and 
chemical stability of the glucagon analog compared to marketed glucagon products such 
as Lilly Glucagon or GlucaGen® (hereafter referred to as GlucaGen). Dasiglucagon 
exhibits improved physical and chemical stability and is available in an aqueous solution 
at neutral pH  (14). 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115217] been completed with dasiglucagon: a first- in-human dose trial in 
healt
hy volunteers and subjects with T1DM (ZP4207-[ZIP_CODE]), a multiple-dose 
dose-esc
alation trial (ZP4207-[ZIP_CODE]) evaluating the safety, tolerability, pharmacokinetics 
(PK) and pharma
codynamics (PD) of dasiglucagon in healthy volunteers, and a phase 2 
crossover trial to ass
ess the PK and PD  of a single dose of an optimized formulation of 
da
siglucagon administered SC in subjects with T1DM (ZP4207-[ZIP_CODE]) ( 14). 
[IP_ADDRESS] Pharmac okinetics and pharmacodynamics of dasiglucagon 
The results of the phase [ADDRESS_1115218] absorption with a peak plasma 
concentration obtained after 35 minutes. Thereafter, the plasma concentration rapi[INVESTIGATOR_807430]-life of 28 minutes. The median time to the maximum 
plasma conce
ntration (t max) was [ADDRESS_1115219] 70 mg/dL (3.9 mmol/L) as well as an increase in plasma glucose by [CONTACT_2669] 
20 mg/dL (1.1 mmol/L) within 30 minutes after dosing. The PD  responses to 0.6 mg of 
dasiglucagon and 1 mg of GlucaGen were comparable. 
[IP_ADDRESS] Safety  of dasiglucagon 
The safety data for dasiglucagon do not give rise to any safety concerns. No new signals 
we
re observed, beyond those related to the pharmacological effect of glucagon agonism. 
All adve
rse events (AEs) recorded in the trials were of mild or moderate severity. The 
most frequently reported systemic AE was nausea, which is a known side effect 
following administration of glucagon. Headache was the next most frequently reported 
event, occurring in all dose groups in the phase [ADDRESS_1115220] (IMP) 
doses of at least 1 mg (4 with dasiglucagon and 1 with GlucaGen). This is not considered 
a safety concern; however, hemodynamic changes after dosing will be considered an 
a
dverse 
event of special interest (AESI). 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 18 of 81  
The phase 1 and 2 results and the safety profile described to date do not give rise to 
specific safety concerns. For further information, please refer to the Investigator’s 
Brochure (14). 
2.2 T rial rationale 
The aim of the current trial is to confirm the superiority of dasiglucagon for the treatment 
of insulin-induce d h
ypoglycemia in subjects with T1DM as compared to placebo for 
dasiglucagon (hereinafter placebo) and to compare the clinical efficacy and safety of 
da
siglucag
on with reference to GlucaGen. A randomized, controlled trial design was 
use
d. 
S
ee Section  4.[ADDRESS_1115221] s 
with known or suspected allergies to the trial medications or related products will be 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115222] relevant clinical effects in the acute severe hypoglycemia rescue setting and may be 
a
n effective and reliable emergency treatment for severe hypoglycemia. Overall, the 
antic
ipated benefits for subjects entering the ZP4207-[ZIP_CODE] trial are considered to justify 
the r
isks. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 20 of 81  
3 TRIAL OBJECTIVES AND ENDPOINTS 
3.1 P rimary objective 
 To demonstrate superiority of dasiglucagon compared to placebo following a single 
subcutaneous
 0.6 mg dose administered to subjects with type 1 diabetes mellitus with 
insulin-
induced hypoglycemia. 
3.2 S econdary objectives 
 To compare the glycemic response observed after dasiglucagon with that of 
GlucaGe
n. 
3.3 P rimary endpoint 
 Time to plasma glucose recovery. Plasma glucose recovery is defined as first increase 
in plasma g
lucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
clamp procedure without administration of rescue IV glucose.  
3.4 K ey secondary endpoints 
 P lasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 mi
nutes after study drug injection without administration of rescue IV 
glucose.
 
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
3.5 Oth er secondary endpoints 
 Clinical e fficacy (PD) endpoints: 
- Time to first 
plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without 
a
dministration of rescue IV glucose. 
- Plasma glucose response as area under the curve (AUC ) above baseline from time 
zero to 30 minutes, AUC 0-30min . 
 Ex posure (PK) endpoints: 
- Area under the drug concentration curve from time zero to 90 minutes, 
AUC 0-
90min. 
-  Maximum plasma drug concentration (C max). 
- Time to maximum plasma drug concentration (t max). 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 21 of 81  
 Safety endpoints:  
- Adverse events, clinical laboratory assessments (biochemistry, hematology, 
coagulation, urinalysis), vital signs, physical examination, electrocardiogram 
(ECG), and local tolerability. 
- Administration of rescue infusion of IV glucose during the hypoglycemic clamp 
procedur
e. 
- Time to first rescue infusion of IV glucose during the hypoglycemic clamp 
procedur
e. 
 I mmunogenicity endpoint: 
- Occurrence of anti-drug antibodies 
3.6 E xploratory endpoint 
 P lasma glucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL 
(1.1
 mmol/L) within 30 minutes after study drug injection without administration of 
re
scue
 IV glucose. 
 Plasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC 0 -60 min . 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 22 of 81  
4 OVERALL DESIGN AND PLAN OF THE TRIAL 
4.1 Over view 
This trial is a global, multicenter, randomized, parallel, double-blind, clinical trial 
c
onfirming
 the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in 
subjects wit
h T1DM. The subjects will be randomized 2:1:[ADDRESS_1115223] 28 day
s after receiving treatment. A total of 156 subjects with T1DM are expected 
to complete
 the tre
atment visit. The trial will be conducted in the European Union ( EU) 
and North America. See  F igure 1 for an overview of the trial design. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 23 of 81  
Figure 1 Trial design 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115224] selection and in the evaluation of clinical assessments, 
subjects will be randomly assigned 2:1:[ADDRESS_1115225] been used to 
establish that 0.6 mg of dasiglucagon is an effective dose and 
also represents a 
therapeutically equivalent dose to 1 mg of GlucaGen (see also Section  6.1). 
Dasiglucag
on, placebo, and GlucaGen will be administered in the abdomen, buttocks, or 
thi
gh by [CONTACT_10530], as this is one of the intended routes of administration for 
da
siglucag
on, besides IM and IV. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115226] 28 days after dosing in order to perform an adequate 
immunoge
nicity evaluation of treatment.  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 26 of 81  
5 TRIAL POPULATION 
5.1 Rat ionale for trial population 
Dasiglucagon is in development for the treatment of severe hypoglycemia in 
insulin-depende
nt patients with diabetes mellitus. In the present trial, subjects with 
T1DM are included in t
he evaluation of efficacy and safety of dasiglucagon under 
hypogly
cemic conditions as this is part of the intended target population. Subjects with 
T1DM are se
lected to avoid the endogenous glucagon counter-regulatory response to 
insulin-induced hypoglycemia that is present in patients with T2DM. The inclusion and 
exclusion crite
ria are set to include a trial population that represents the general 
population of subjects with T1DM.  
5.2 P lanned sample size and number of trial centers 
A total number of 156 subjects with T1DM are expected to complete the treatment visit 
(Visit 2). To qualify as completed, the subject must be dosed and have blood drawn for 
the PK and PD assessments described in the proto col. It is expected that up to 
[ADDRESS_1115227] 156 subjects completing Visit 2. Completion of 
156 subjects (78 subjects in the dasiglucag on group and 39 subjec ts in e ach of the 
placebo and GlucaGen groups) would be expected to provide adequate power for the 
primary efficacy evaluation, as described in Section  9.1. 
The planned da
te
 for first subject first visit is expected to take place in Q4, [ADDRESS_1115228] in Q3, 2018. 
This trial is planne
d to be conducted at 4 to 6 trial sites in the [LOCATION_002] of America 
[US], C
anada, and Europe. 
5.3 Inclusion criteria 
Subjects will be entered into this trial only if they meet all of the following criteria: 
1. Informed consent obtained before any trial-related activities (trial-related
activit
ies are any procedure that would not have been performed during normal
management of the subject).
2. Female or male subjects with T1DM for at least 1 year, diagnostic criteria as
defined by
 [CONTACT_11026] ( 3).
3.
Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
(defined a
s no more than a 10-unit daily variation in total daily insulin dose)
30 days prior to screening
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 27 of 81  
4. He moglobin A 1c <10%. 
5. Age d between [ADDRESS_1115229] meet one of the following criteria: 
a. Participant is of childbearing potential and agrees to use one of the 
accepted contraceptive regimens throughout the entire duration of the trial 
from screening and until last follow-up visit. Additionally, if the 
participant is using systemic contraceptives, she must use an additional 
form of acceptable contraception. An acceptable method of contraception 
includes one of the following: 
i. Abstinence from heterosexual intercourse; 
ii. Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/ 
insertable hormonal birth control products, transdermal patch); 
iii. Intrauterine device (with and without hormones); or 
iv. Condom with spermicide; or 
b. P articipant is of non-childbearing potential, defined as surgically sterile 
(i.e. has undergone complete hysterectomy, bilateral oophorectomy, or 
tubal ligation), or in a menopausal state (at least 1 year without menses). 
7. A ma le subject must meet the following criteria: Surgically sterilized or willing to 
refrain from sexual intercourse from screening and until last follow-up visit or, if 
sexually active, uses condom and partner practices contraception during the trial 
from scre
ening and until last follow-up visit. 
5.4 E xclusion criteria 
Subjects meeting any of the following criteria during screening evaluations will be 
excluded from trial participation: 
1. P reviously treated with dasiglucagon (previously referred to as ZP4207). 
2. Know n or suspected allergy to trial product(s) or related products. 
3. Hist ory of anaphylaxis or symptoms of severe systemic allergy (such as 
angioedema). 
4. P revious participation (randomization) in this trial. 
5. F emales who are pregnant according to a positive pregnancy test, are actively 
attempting to get pregnant, or are lactating. 
6. Hist ory of hypoglycemic events associated with seizures in the last year prior to 
scree
ning. 
7. Hist ory of severe hypoglycemia (defined as plasma glucose <54 mg/dL 
[3.0 mmol/L]) in the last month prior to screening. 
8. Receipt of any investigational drug within [ADDRESS_1115230] 5 years. 
10. Congestive heart failure, [LOCATION_001] Heart Association class II-IV. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 28 of 81  
11. Inadequately treated blood pressure, defined as systolic ≥160 mmHg or diastolic 
≥
90 mmHg) at screening (15).  
12. C urrent bleeding disorder, including anti-coagulant treatment. 
13. Know n presence or history of pheochromocytoma (i.e. adrenal gland tumor) or 
insulinoma (i.e. insulin secreting pancreas tumor). 
14. Use  of a daily systemic beta-blocker drug, indomethacin, warfarin or 
anticholine
rgic drugs in the previous 28 days before Day 1 of this trial. 
15. Aspa rtate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the 
upper limit of the normal range (ULN), bilirubin >1.5 × ULN, estimated 
glomerular filtration rate <30 mL/min/1.73 m2 according to the Modification of 
Diet in Renal Disease study definition (16), or altered electrolyte values of 
clinical relevance for cardiac conduction, as judged by [CONTACT_093]. 
16. C linically significant abnormal ECG at screening as judged by [CONTACT_093]. 
17. C linically significant illness within [ADDRESS_1115231] 2 months prior to 
screening. 
20. A posit ive result in the alcohol and/or urine drug screen at the screening visit. 
Significant history of alcoholism or drug abuse as judged by [CONTACT_460675] [ADDRESS_1115232]’s typi[INVESTIGATOR_93379], and 
should not exceed a near maximum intensity for more than 20 minutes per day, or 
moderate intensity for more than 90 minutes per day. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115233]. 
4. Not f asting from 22:00 hours the evening prior to dosing, apart from water. Small 
amounts of c
arbohydrates (up to 20 g) to prevent hypoglycemia are allowed. 
5. The  use of any non-prescribed systemic or topi[INVESTIGATOR_73201], except routine 
vitamins and occasional use (as judged by [CONTACT_093]) of acetylsalicylic acid 
and paracetamol within 2 weeks prior to dosing. Treatment with insulin, including 
ana
logs, is allowed. 
6. Use  of insulin Degludec or insulin Glargine U300 within 48 hours prior to dosing; 
or u
se of 
other long-acting insulins (e.g., insulin Glargine U100 or insulin 
Detemir) within 24 hours prior to dosing; or use of insulin Neutral protamine 
Ha
ge
dorn (NPH) within 16 hours prior to dosing. 
7. Use  of any short acting (bolus) insulin within 6 hours prior to dosing, except 
insulin glul
isine (Api[INVESTIGATOR_27976]®). 
8. C hanges in medical history or concomitant medication resulting in fulfillment of 
clinica
l exclusion criteria, as judged by [CONTACT_093]. 
9. P lasma glucose value <50 mg/dL (2.8 mmol/L) within the last 24 hours or plasma 
glucose v
alue <60 mg/dL (3.3 mmol/L) within the last [ADDRESS_1115234] has the right to withdraw from the 
trial at any time and for any reason. If he/she chooses to withdraw, the investigator must 
be informed immediately. The investigator has the right to terminate participation of any 
subject at any time if the investigator deems it in the subject's best interest. The reason 
and circumstances for withdrawal wi ll be documented in the electronic case report form 
(e
CRF). 
5.6.[ADDRESS_1115235] wil
l be discontinued from treatment if the following applies: 
 W ithdrawal of consent by [CONTACT_1130]. 
 If a protocol deviation occurs which, in the clinical judgement of the investigator, can 
invalidate the trial or
 endpoints or can interfere pharmacokinetically or 
pharmacodynamically with the trial product, the subject will be discontinued by [CONTACT_1275]. 
 Adve rse events occur which are considered unacceptable by [CONTACT_579585].  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115236] return and participate in the complete follow-up visit 
on Da y 28 (see Table 3) to avoid missing data. 
If trial parti
cipation is terminated due to an AE possibly related to any of the trial 
medications
 or trial examinations, the subject must be followed up by [CONTACT_168984] 
e
xaminations according to the medical judgment of the investigator until the abnormal 
condition is resolved or the investigator deems further observations or examinations to be 
no longer medically indicated. 
A total of [ADDRESS_1115237] complete the treatment visit (Visit 2). To qualify as 
c
ompleted, the subj
ect must be dosed and have blood drawn for the PK and PD 
assessments described in the protocol.  
5.6.2 C enter discontinuation 
The center can be closed and the trial terminated for the following reasons: 
The center is unlikely to be able to recruit sufficient subjects within the agreed time
frame.
The c
enter does not respond to trial management requests.
Repeat protocol violations.
5.6.3 Trial  termination 
The sponsor reserves the right to modify or terminate the trial at any time. Possible 
reasons for termination are: 
Safety reasons – the incidence of AEs in this or any other trial using the same trial
medic
ation indicates a potential health risk for the subjects.
New scientific knowledge becomes known that makes the objectives of the trial no
longer fe
asible/valid.
Unsatisfactory enrolment of subjects.
5.[ADDRESS_1115238] given written informed consent and meet all inclusion and none of the 
exclusion criteria will be randomized in a 2:1:1 ratio to either 0.6 mg dasiglucagon 
(n=78),  placebo (n=39), or 1 mg GlucaGen (n=39) via an Interactive Web Response 
S
ystem (IW
RS). Randomization will continue until [ADDRESS_1115239] completed Visit 2. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115240] code can be broken by [CONTACT_1275], preferably after consultation with the medical monitor. Emergency code 
breaks can be performed using the IWRS. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 32 of 81  
6 TRIAL D RUG  
6.1 Id entity 
The following trial drugs will be administered: 
Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a prefilled syringe.
Placebo, liquid formulation, 0.6 mL delivered in a prefilled syringe.
Recombinant glucagon hydrochloride, 1 mg for reconstitution (GlucaGen®, Novo
Nordisk) in [ADDRESS_1115241]  
Name  [CONTACT_807511]® 
Active 
substance  Dasiglucagon  N/A Recombinant 
glucagon 
hydrochloride  
Formulation  Liquid formulation, 
0.6 mL  Liquid formulation, 
0.6 mL  Powder and solvent 
for reconstitution as 1 
mL solution for 
injection  
Strength  1 mg/mL  N/A 1 mg  
Device  Single use pre -filled 
syringe  Single use pre -filled 
syringe  Powder and solvent 
for reconstitution 
packed together in a 
plastic box. A “hypo -
kit”. 
Manufacturer  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Novo Nordisk A/S, 
Bagsværd, Denmark  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115242]  
Storage 
requirements  Store between 2 and 
8°C Store between 2 and 
8°C Store between 2 and 
8°C 
The quantities of ingredients for dasiglucagon and placebo are provided in Table 2. 
Table 2 Quantities of ingredients in dasiglucagon and placebo injection 
Component  Amount per mL 
(dasiglucagon)  Amount per mL 
(placeb o) Function  
Dasiglucagon*  1.0 mg  N/A 
Sodium chloride  10.23 mg  10.23 mg  
Trometamol/Tromethamine  6.[ADDRESS_1115243] ochloric acid  q.s. q.s. 
*The quantity of drug substance to be used is calculated according to net peptide content and purity.
q.s. = quantum sufficit (quantity required). 
6.2 T reatment assignment and randomization 
Subjects successfully completing screening and who fulfill entry eligibility and 
randomization criteria will be randomized to one of three treatment groups in a ratio of 
2:1:1: 
Test trea
tment: Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a
prefilled syring
e.
Placebo treatment: Placebo, liquid formulation, 0.6 mL delivered in a prefilled
syringe
.
Reference treatment: Recombinant glucagon hydrochloride, 1 mg for reconstitution.
Randomiza
tion will be performed using a fixed-block randomization scheme. The 
randomization scheme will be generated prior to the initiation of the study by [CONTACT_807483]/programmer who will not be a member of the study team; all 
investigators will not be aware of the block size of the randomization scheme.  
Randomization will be stratified by [CONTACT_807449] (a bdomen, 
buttocks, or thigh) a
nd controlled via the IWRS.      

 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 34 of 81  
Subjects will be randomized to study treatment using an interactive, automated system 
which has be
en validated for the intended use under the International Society of 
Pharma
ceutical Engineers Good Automated Manufacturing Process guidelines, 21CFR 
Part 11 (FDA regulation for Electronic Records and Electronic Signatures) and the 
International Conference on Harmonization (ICH) Guidance E6 for Industry on Good 
Clinical Practice (GCP).   
6.3 Adm inistration 
Dasiglucagon, placebo, and GlucaGen will be administered by [CONTACT_807484]
, buttocks, or thigh.  
An unblinded pe
rson (a
ppropriately trained) authorized to prepare the dose and 
administer the treatment in accordance with the randomization will prepare the treatment 
re
quired for each subject on each dosing day. The dose will be administered by [CONTACT_807451], trained and qualified person. The content of the syringe has to be checked for 
clarity and absence of bubbles.. 
Syrin
ges will be discarded after dose administration. Used GlucaGen vials will be stored 
in a lockable box (separated from unused vials) at ambient temperature. 
6.[ADDRESS_1115244] label will be compliant with local laws and 
regulations.  
The study drug label will describe the storage conditions for study drug. The labels will 
supply no infor
mation about th e subjects. Each treatment kit (pre-filled syringe/vial for 
reconstitution) will have a unique Dispensing Unit Number for drug allocation, drug 
accountability, and traceability purposes. 
Labelling will be performed according to Annex [ADDRESS_1115245] ensure the availability of proper storage conditions. All study drug 
supplies provided for this study will be stored in a secure area with restricted access at the 
study site.  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115246] be stored in a refrigerator (at a temperature of 2– 8°C), 
and should be handled in accordance with guidelines from the sponsor. GlucaGen must 
also be stored in a refrigerator (at a temperature of 2–8°C), and should be handled in 
a
ccordance with the Summary of Product Characteristics ( 13).  
The
 unblinded person responsible for study drug handling must contact [CONTACT_807452].  
Please see the Pharmacy Manual for additional information on handling study drug. 
6.6 B linding and breaking the blind 
This is a double-blind trial. As the trial products are not identical in appearance, 
dasiglucagon and placebo being available as a liquid formulation and GlucaGen as a 
powde
r for r
econstitution, unblinded trial personnel will be responsible for handling, 
preparing (according to the prescription from the IWRS), and administering the trial 
medic
ati
on, as well as for keepi[INVESTIGATOR_807431]. To maintain double-blind 
c
onditions, all trial assessments at the trial center will be done by [CONTACT_807485]. However, exposure assessments 
and anti-drug antibody ( ADA ) assessments will be performed by [CONTACT_807454], to ensure that dasiglucagon, placebo, or GlucaGen administration 
is m
atched with the applicable bioanalytical assay. 
Treatment assignment will be kept strictly confidential and accessible only to authorized 
persons until after the time of unblinding. Codes with treatment assignment will, 
however, be readily available in the IWRS to the blinded personnel in case of an 
emergency. 
The code for a particular subject may be broken in a medical emergency if knowing the 
identity of the treatment allocation would influence the treatment of the subject. The 
emergency code break can be performed using the IWRS. Whenever a code is broken, the 
person breaking the code must record the time, date and reason as well as his/her initials 
in the source documents. The breaking of blinded codes in case of medical emergency for 
one subject should not unblind the trial personnel to the treatment information of other 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115247] be notified within 24 hours 
after the 
code has been broken. 
The pharmacovigilance unit (safety contract research organization [CRO];  see the list of 
trial personnel in Section  12.1) will be able to break the code in case of a serious 
unexpected suspected 
adverse reaction (S[LOCATION_003]R).  
The central and specialty laboratories will be provided with a copy of the randomization 
list. 
6.[ADDRESS_1115248] until approved by [CONTACT_1034].  
6.8 T reatment compliance 
All t
rial medications will be prepared and administered by [CONTACT_93400]. 
PK assessments will support the surveillance of compliance with IMP administration.  
6.9 P rior and concomitant medications 
Prior glucagon exposure will be recorded in the eCRF at screening. All concomitant 
medications will be recorded and/or updated in the eCRF at each visit.  
Subjects using any new concomitant medication resulting in fulfillment of a dosing day 
exclusion criterion (see Section  5.5) will be excluded from the dosing visit, but can be 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 37 of 81  
rescheduled to one of the following days (1–7 days later). The dosing visit can only be 
rescheduled once. 
6.9.1 Proh ibited medications 
The use of anti-coagulant treatments and medications (prescription and non-prescription) 
that are known to cause QT prolongation are prohibited during the course of the trial. 
W
ithin 28 days prior to dosing, the use of daily systemic beta-blockers, indomethacin, 
warfarin, and anticholinergic drugs is prohibited. 
Within 2 we
eks prior to dosing, the use of any non-prescribed systemic or topi[INVESTIGATOR_73264] (with the exception of vitamins and the occasional use of acetylsalicylic acid 
and paracetamol) is prohibited.  
Within 48 hours prior to dosing, the use of insulin Degludec or insulin Glargine U300 are 
prohibit
ed. 
Within 24 hours prior to dosing, the use of long-acting insulin (e.g., insulin Glargine 
U100 or insulin De
temir) is prohibited. 
Within 16
 hours prior to dosing, the use of insulin NPH is prohibited. 
W
ithi
n 6 hours prior to dosing, the use of any short acting (bolus) insulin, except insulin 
g
lulisine (Api[INVESTIGATOR_27976]®) is prohibited.  
During the insulin-induced hypoglycemic procedure, continuous SC insulin infusion must 
be
 stoppe
d. 
6.10 Local German requirements for insulin glulisine (Api[INVESTIGATOR_27976]®) 
Insulin glulisine (Api[INVESTIGATOR_27976]), the insulin used to induce hypoglycemia, will according to 
local requireme
nts be defined as an investigational medicinal product when used at 
Ge
rman site
s. The insulin will be provided by [CONTACT_807486]. In contrast to the trial drug for the 
randomized treatment, the insulin will be administered by [CONTACT_807487] [IP_ADDRESS]. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115249] be available prior 
to sample analyses. A bioanalytical report for each analysis of trial PD and PK samples 
will be prepare
d. 
7.1.1 Ph armacodynamic measurements 
The plasma glucose p
rofile for evaluation of the primary and secondary clinical efficacy 
endpoints will be assessed based on plasma concentration data (AUC 0-30min ) from samples 
collected at the dosing visit (Visit 2). The samples will be sent to the clinical laboratory 
and a
nalyzed using a sensitive and validated assay for glucose measurements.  
Samples will be collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 
75, and 90 minutes after dosing (see the schedule of procedures in Table 3). The actual 
time of blood sampling for evaluation of pla sma glucose shoul d not deviate from the 
nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point and by 
[CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as 
withi n 2 minutes prior to dosing. 
7.1.2 Ph armacokinetic measurements 
The exposure to trial medication (dasiglucagon or GlucaGen) for evaluation of PK will 
be assessed based on plasma concentration data (AUC 0-90 min , Cmax, tmax) from samples 
collected at the dosing visit (Visit 2).  
Samples (including back-up samples) will be collected pre-dose, and at 15, 30, 35, 40, 50, 
60, 90, and 120 m inutes after dosing (see the schedule of procedures in  Table 3 ). The 
actual time of 
blood sampling for exposure to trial medication should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to 
dosing. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 39 of 81  
7.2 Safety parameters 
7.2.1 A dverse events 
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an AE or serious adverse event (SAE), as provided in this 
protocol. During the trial, the investigator or center staff will be responsible for reporting 
AEs and SAEs, as de
tailed in this section of the protocol.  
Based on  the investigator’s clinical judgment it will be determined whether an AE is 
related to tre
atment and of sufficient severity to require the subject’s removal from 
treatment or from the trial. A subject may also voluntarily withdraw from treatment due 
to what he or she perceives as an intolerable AE. If either of these situations arises, the 
subject should be under medical supervision until symptoms cease or the condition 
becomes stable. 
[IP_ADDRESS] De finitions 
Adverse event 
An A
E is any untoward medical occurrence in a trial subject given an IMP which does 
not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and/or unintended sign (for example, an abnormal laboratory finding), 
s
ymptom, or disease temporally associated with the use of an IMP, whether or not 
considered related to the IMP.  
In this trial, only treatment-emergent adverse events (TEAEs) will be collected and 
reported. TEAEs are events that occur from the first trial-related activity after the subject 
ha
s signed the informed consent form until the end of the post-treatment follow-up 
period.  
AEs include: 
A clinically significant worsening of a concomitant illness.
A clinical laboratory abnormality which is clinically significant, i.e. any abnormality
that suggests a
 disease and/or organ toxicity and is of a severity that requires active
management. Active management includes active treatment or further investigations,
for example change of medicine dose or more frequent follow-up due to the
abnormality.
Hypoglycemic epi[INVESTIGATOR_1841] (see Section  7.2.2).
Injection site reactions (see Section  7.2.6).
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 40 of 81  
The following should not be recorded as AEs, if recorded at screening (on the Screening 
Form or eCRF): 
 P re-planned procedure, unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent.
 
 P re-existing conditions found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness). 
Serious a dverse event 
An SAE is any untoward medical occurrence that at any dose:  
 R esults in death  
 I s life-threatening  
 R equires inpatient hospi[INVESTIGATOR_1081] 
 R esults in persistent or significant disability or incapacity 
 I s a congenital anomaly or birth defect 
 I s medically important* 
*Medical judgement must be exercised in deciding whether an AE is believed to be 
‘me
dically important’. Medically important events may not be immediately 
life-
threatening or result in death or hospi[INVESTIGATOR_807432]. 
Adver
se drug reaction 
All noxious and unintended responses to an investigational product related to any dose 
should be considered adverse drug reactions. The phrase responses to an investigational 
produc
t means that a causal relationship between an investigational product and an 
adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out. 
 
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) 
An AE fulfilling one of the criteria of seriousness and being assessed as related to IMP 
application, the nature or severity of which is not consistent with the applicable reference 
document (e.g. dasiglucagon Investigator’s Brochure or package leaflet/Summary of 
Product Characteristics for GlucaGen ). 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115250] 
An AESI is an event which, in the evaluation of safety, has a special focus (e.g. required 
by [CONTACT_21652]). In this trial hemodynamic changes, as defined below, are 
considered AESIs: 
 P ost-dose clinical si gns, or measured vital signs, indicating a clinical ly significant 
drop 
in blood pressure including signs of orthostatic hypotension, vasovagal 
responses or bradycardia.   
 P ost-dose change in pulse or blood pressure considered an event of hypo- or 
hypertension as judged by [CONTACT_093]. 
 
Intensity of an adverse event 
The maximum intensity (severity) of all AEs must be assessed by [CONTACT_807457]. Severity should be graded when the AE outcome is known: 
Mild :  A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living. 
Moderate :  A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to 
the subject. 
Severe :  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
A ‘severe’ reaction does not necessarily deem the AE as ‘serious’ and an SAE may not 
ne
cessarily be ‘severe’ in nature. 
Causality relationship to trial medication 
The causality of each AE should be assessed by [CONTACT_807458]: 
Probable: Good reason and sufficient documentation to assume a causal relationship. 
Possible: A causal relationship is conceivable and cannot be dismissed. 
Unlikely: The event is most likely related to etiology other than the trial product. 
Not related:  No relationship to trial product. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 42 of 81  
[LOCATION_013] only: The investigator should assess the causality to 
dasiglucacon/placebo/GlucaGen and to insulin glulisine (Api[INVESTIGATOR_27976]®) respec tively. A 
spec
ial field applicable for [LOCATION_013] only will be present on the AE form in the eCRF to 
capture
 this data. 
Outcome of an adverse event 
The outcome of all AEs must be assessed by [CONTACT_807459]/her 
staff. The following definitions should be used: 
Recovered/resolved :  The subject has fully recovered, or by [CONTACT_807460]-related activity after 
the subject signed the informed consent.  
Recovering/resolving: The condition is improving and the subject is 
expected to recover from the event. This term is 
only applicable if the subject has completed the 
trial. 
Recovered/resolved with sequelae:  The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment 
or procedure. If a sequela meets an SAE criterion, 
the AE must be reported as an SAE. 
Not recovered/not resolved :  The condition of the subject has not improved and 
the symptoms are unchanged. 
Fatal:  This t erm is only applicable if the subject died from 
a condition related to the reported AE. Outcomes of 
other reported AEs in a subject before he/she died 
should be assessed as "recovered/resolved", 
"recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE 
with fatal outcome must be reported as an SAE. 
Unknown :  This term is only applicable if the subject is lost to 
follow-up.  
[IP_ADDRESS]  Collection, recording and reporting of adverse events 
All events meeting the definition of an AE must be collected and reported from the first 
trial related activity after the subject has signed the informed consent until the end of the 
post-treatment follow-up period. At each contact [CONTACT_49877] (visit or telephone, 
excluding visits where the subject is not seeing the investigator or his/her staff [e.g. visits 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 43 of 81  
to the laboratory]) the subject must be asked about AEs. All AEs, either observed by [CONTACT_299798], must be recorded by [CONTACT_36306]. 
The
 investigator should record the diagnosis, if possible. If no diagnosis can be made the 
investigator should record each sign and symptom as individual AEs. 
One single Adverse Event Form must be used per AE from start to resolution. For SAEs, 
the Serious Adverse Event form must also be completed. For AESIs, the AESI form must 
also be completed. 
AE information should include the following: 
Date and time of onset and resolution
Date and time of investigator’s first information on the (S)AE
Seriousness
Severity
Causal relationship with IMP
Interruption or withdrawal of treatment during IMP administration and other
measures take
n
Outcome.
All AEs are code
d; details are described in the trial-specific Data Management Plan. 
If an event classifie s as a AESI, the investigator must tick the AESI box on the AE form 
and comple te the AESI form. The AESI form will capture if the event wa s associated 
with any signs or symptoms and capture the highest/lowest blood pressure and pulse 
measured during the event. The investi gator must report all AESIs to the sponsor’s 
responsible pharmacovigilance unit (Safety CRO; see the list of trial personnel in 
Section  12.1) immediately (within 24 hours) after obtaining knowledge about the event. 
The investi gator must report initial infor mation electronically (e.g. in PDF format) on all 
SAEs to the sponsor’s responsible pharmacovigilance unit (Safety CRO; see the list of 
trial personnel in Section  12.1) immediately (within 24 hours) after obtaining knowledge 
about the event. 
The Safety CRO will inform the medic al monitor and the sponsor about 
the reported SAEs. 
It is the responsibility of the Safety CRO to report all S[LOCATION_003]Rs (see Section  [IP_ADDRESS]) that 
oc
cur in this trial to the Competent Authorities and Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) in accordance with the local requirements 
in force a nd ICH guideline for GCP . The trial monitor must be informed accordingly. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 44 of 81  
[IP_ADDRESS]  Follow-up of adverse events 
All AEs that are ongoing at the end of the subject’s participation in the trial will be 
followe
d-up until the event is resolved or reaches a satisfactory outcome as deemed by 
[CONTACT_807488], whichever 
oc
curs f
irst.   
Follow-up actions for all SAEs will be performed according to appropriate clinical care 
practices and may depend on the nature of the event. These will be determined after 
internal review and/or sponsor review. 
The follow-up information should only include new (updated and/or additional) 
information that reflects the situation at the time of the investigator’s signature. 
Follow-up information on (S)AEs will be updated using the (S)AE form. If a non-serious 
event becomes serious during the follow-up the AE form and SAE form have to be used 
and reporting timelines follow those of an SAE. 
The investi
gator must forward follow-up information on SAEs and if previously 
non-serious AEs become SAEs to the Safety CRO immediately (within 24 hours) after 
obtaining
 knowled
ge about the new information. 
The sponsor and/or CROs acting on behalf of the sponsor can upgrade a non-serious AE 
to an SAE. In these situations the investigator will be informed and asked to fill out an 
SAE form and forward to the Safety CRO immediately (within 24 hours). 
[IP_ADDRESS] C linical laboratory abnormalities and other abnormal assessments as adverse 
eve
nts or serious adverse events 
Abnormal l
aboratory findings (e.g. biochemistry, hematology, urinalysis) or other 
abnormal assessments (e.g. vital signs) that are judged by [CONTACT_807461]. 
C
linically significant abnormal laboratory findings or other abnormal assessments that 
are detected during the trial or are present at baseline and significantly worsen following 
the start of the 
trial will be reported as AEs or SAEs. However, clinically significant 
a
bnormal laboratory findings or other abnormal assessments that are associated with the 
disease being studied, unless judged by [CONTACT_652117]’s condition, or that are present or detected at the start of the trial and do not 
wor
sen, will not be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 45 of 81  
7.2.2 Hypoglycemia 
Hypoglycemia will be regarded as an AE and recorded and documented on an AE form 
(and SAE form, if appli
cable). 
Hypoglycemia is defined as a decline in plasma glucose to below 70 mg/dL 
(3.9 mmol/L). However, in the time period from initiation of the hypoglycemic clamp 
procedure (see Section  [IP_ADDRESS]) until 45 m inutes after dosing, hypoglycemia is defined as 
a decline in plasma glucose to below 45 mg/dL (2.5 mmol/L).  
Dur
ing the  dosi
ng visit, 
prior to administration of the IMP, a plasma glucose value of 
<45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463]. After administration 
of the
 IMP in the pe
riod from 8 minutes until 44 minutes after dosing, a plasma glucose 
value of <45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463], and if a 
plasma
 glucose value of ≥70 mg/dL (3.9 mmol/L) is not achieved within the [ADDRESS_1115251] experiences symptoms of hypoglycemia, a plasma glucose measurement 
should be taken in order to classify the event (plea se refer to Section 7.4.2 for additional 
de
tails).  
7.2.3 Ph ysical examination 
The physical examination will be carried out at screening (Visit 1) and at the follow-up 
visit (Visit 3; see Table 3).  
The ph
ysic
al ex
amination includes examination of the following body systems: head, 
ears, eyes, nose, throat, including the thyroid gland; heart, lung, chest; abdomen; skin and 
mucosae; musculoskeletal system; nervous system; lymph node; other findings. 
At the screening visit, any abnormality will be recorded and described in the eCRF, 
including the investigator’s assessment of clinical significance (‘abnormal, not clinically 
significant’ or ‘abnormal, clinically significant’). Clinically significant findings at the 
screening visit should be recorded as concomitant illness. 
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1). 
7.2.4 V ital signs 
An examination of the following vital signs will be performed at screening (Visit 1), the 
dosing visit (Visit 2) and at the follow-up visit (Visit 3):  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 46 of 81  
Diastolic and systolic blood pressure (mmHg) will be measured after at least
[ADDRESS_1115252]’s blood pressure in this trial.
Pulse (beats per min) measured after at least [ADDRESS_1115253] in a supi[INVESTIGATOR_2547].
Body temperature (°C).
At the dosing visit, measurements will be take n prior to the start of the insul in-induced 
hypoglycemic procedure (within 30 minutes) and at 
30, 90, and 300 minutes after dosing 
(see Table 3). The actual time of the assessment should not deviate from the nominal time 
by [CONTACT_726] ±[ADDRESS_1115254] 12-lead ECG will be perform ed at the screening visit (Visit 1), the dosing visit 
(Visit 2; prior to the start of the insul in-induced hypoglycemic procedure [within 
30 minutes])  and at 20, 35, 45, 60, and 300 minutes after dosing) and at the follow-up 
visit (Visit 3; see Table 3 ). The actual time of the assessment should not deviate from the 
nominal time by [CONTACT_726] ±5 minutes.  
ECG parameters (he
art r
ate, PQ, QRS, QT, QTcB) and any abnormality will be recorded 
and described in the eCRF including the investigator’s assessment of clinical significance 
(‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’).  
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1).  
7.2.6 Loc al tolerability 
Immediately prior to treatment administration, it should be verified that the injection site 
is normal. To ensure all injection site assessments are performed at the injection site, the 
site will be marked with a pen prior to injecti on. Assessment of local tolerability at the 
injection site will be performed at the dosing visit (Visit 
2; at 30, 120 and 300 minutes 
after dosing), and at the follow-up visit (Visit 3) (see  Table 3) and more frequently, if 
deemed necessary by [CONTACT_32595]. The actual time of the assessment should not 
deviate from the nomi nal time by [CONTACT_726] ±10 min utes. In the eCRF, the time of 
assessment and any injection site reaction observed will be recorde d. In case of an 
observa
tion, the Local Tolerability form will be completed, as well as the (S)AE form. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 47 of 81  
The local tolerability at the injection site will be evaluated by [CONTACT_807464]: spontaneous pain, pain on palpation, itching, redness, edema, 
induration/infiltration, and other. Each of these assessments will be reported on a scale of 
0 (none), 1 (mild), 2 (moderate), and 3 (severe). The evaluation and the actual time of the 
assessment will be
 rec
orded. The assessments will be performed by a trial physician or 
nurse.  
Digita
l pi[INVESTIGATOR_807433], and 
thereafter as often as judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_807434] a 
subject ide
ntifier, visit number, time after dosing, and a ruler for scaling. 
7.2.7 C linical laboratory assessments 
The safety parameters that will be assessed at the clinical laboratory are listed in  Table 3. 
Routine 
clinical laboratory tests will be perfor med centrally. Samples for clinical 
laboratory parameters (biochemistry , hematology , coagulation) will be collected at 
scree
ning (Visit 1), the dosing visit (Visit 2, prior to the start of the insul in-induced 
hypoglycemic procedure [within 30 minutes] ) and at 30 and 300 minutes after dosing), 
and at the follow- up visit (Visit 3). The actual time of the assessment should not deviate 
from the nomi nal time by [CONTACT_726] ±10 mi nutes. Samples for glycated hemoglobin 
(HbA 1c) will be collected at screening only (Visit 1). Samples for urina lysis will be 
collected at screening (Visit 1), at the dosing visit (Visit 2, prior to the start of the 
insulin-induced hypoglycemic procedure [within 120 minutes]) and at the follow -up visit 
(Visit 3). The following pa rameters will be assessed: 
Clinical biochemistry: sodium, potassium, calcium, glucose, urea, creatinine, total
bilirubin, AST, AL
T, gamma-glutamyltransferase, alkaline phosphatase, total protein,
C-reactive protein, HbA 1c, C-peptide.
Hematology: hemoglobin, red blood cell count (erythrocytes), hematocrit, platelet
count (thrombocytes)
, total white blood cell count (leukocytes).
Coagulation: international normalized ratio, fibrinogen (at screening visit only).
Urinalysis: pH, blood (leukocytes and erythrocytes), protein, glucose, ketones, nitrite.
Pregna
ncy tests will be performed at each visit for women of childbearing potential only. 
A serum pregnancy test will be performed at screening (Visit 1) and urine stick tests will 
be perfo
rmed at the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypoglycemic procedure) and the follow-up visit (Visit 3). Test sticks will be provided to 
the trial centers.
 
Alcohol breath tests and a urine drug screen will be performed at screening (Visit 1) and 
at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 48 of 81  
procedure ). Equipment for the alcohol breath test and uring drug screen will be provided 
to the trial centers.  
Re-assessment of laboratory parameters will be allowed on ly if handling issues, damaged 
sa
mples, or hemolyzed samples have confounded the measurement results.  
For further details of the clinical laboratory assessments, please refer to the laboratory 
manua
l.  
7.2.[ADDRESS_1115255]’s partner will be fully informed by a physician of 
her participation in capturing the outcome data, and will be asked to provide her written 
consent. 
The investi gator must report all infor mation on pregnancies on the Initial Pregnancy 
form. The completed Initial Pregnancy form must be forwarded to the sponsor 
immediately (within 24 hours), according to the procedure stated in Section  [IP_ADDRESS]. Any 
(S)AEs in the mother, a s well as other pregnancy complications (ectopic pregnancy) 
fulfilling the criteria of an (S)AE, must be reported on the (S)AE form.  
The following must be
 collected in the Initial Pregnancy form: 
Medical history of the mother
Family history
Course of the pregnancy, including expected delivery date.
The investi gator must follow the pregnancy until the pregnancy outcome and follow the 
newborn infant(s) until the age of [ADDRESS_1115256] information on 
the pregnancy and pregnancy complications as well as the pregnancy outcome including 
the health of the newborn infant(s) on the Pregnancy Outcome form. The completed 
Pregnancy Outcome form must be forwarded to the sponsor according to the procedure 
stated in Section  [IP_ADDRESS]. Any (S)AEs in the newborn must be reported on the (S)AE 
form. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115257] be reported include abnormal outcome, such as congenital 
anomalies, fetal death and termination of pregnancy (spontaneous or elective abortion), 
including any anomalies of the fetus observed at gross examination or during autopsy.  
The following must be collected in the Pregnancy Outcome form:  
 C ourse of the pregnancy 
 Outc ome of the pregnancy 
 C ondition of the newborn 
 An y AEs in the newborn infant must be followed until the age of [ADDRESS_1115258]’s participation in the trial, the 
investigator should ensure that adequate medical care is provided to the subject for any 
AEs, including clinically significant laboratory values related to the trial. The investigator 
should inform the subject when medical care is needed for intercurrent illnesses of which 
the investigator becomes aware.  
For further information on safety precautions for dasiglucagon and GlucaGen, please 
refer to the cur
rent version of the Investigator’s Brochure (14) and the Summary of 
P
roduct Characteristics for GlucaGen (13), respectively. 
7.2.[ADDRESS_1115259] the subjects. 
7.3 De mography , concomitant illness, medical history and concomitant 
medicati
on 
Demographics, body measurements, concomitant illness and medical history will be 
assessed only a
t screening (Visit 1). Concomitant medication will be assessed at 
scre
ening (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypoglycemic procedure) and at the follow-up visit (Visit 3). 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115260] demog
raphics and body measurements will include: 
Age
Race, ethnicity
Sex
Height (m e ters or inch), without shoes
Body weight (kg or lb), only wearing underwear and measured using standard scales
Body mass index (kg/m2) calculated based on height and body weight (body
we
ight/height2).
7.3.2 Concomitant illness and medical history 
A concomitant illness is
 any illness that is present at the start of the trial (i.e. at the 
screening visit). Concomitant illnesses present at the start of the trial will be recorded in 
the e
CRF at screening.  
Medical history is an account of medical events that the subject has experienced in the 
past, including prior medications. Relevant medical conditions/illnesses in the past 
obtained by
 [CONTACT_807489]/her medical records will be recorded 
in the eCRF at screening. History of alcohol or drug abuse will also be recorded. 
The information collecte
d for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution or continuation. 
Any change to a concomitant illness should be recorded during the trial, including end 
date, if applicable. A clinically significant worsening of a concomitant illness must be 
reported according to Section  7.2.1. 
All pre
vious and conc
omitant diseases will be coded with Medical Dictionary for 
Regulatory Activities (MedDRA), the version of which will be provided in the clinical 
trial report. 
7.3.3 Diabe tes diagnosis and current treatment 
The date of diagnosis of diabetes will be recorded as will the current diabetes treatment 
(start date, product name(s), dose(s)). 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 51 of 81  
7.3.4 Concomitant medication 
A concomitant medication is any medication, other than the trial products and current 
diabetes treatment (including insulin glulisine [Api[INVESTIGATOR_27976]®] for diabetes therapy wash-out), 
whic
h is taken during the trial, including screening and follow-up periods. 
Details of any concomitant medication must be recorded at trial entry (i.e. at screening). 
Any c
hanges in concomitant medication must be recorde d at each visit as they occur. The 
information collec
ted for each concomitant medication includes (at a minimum) trade 
name [CONTACT_18058], indication, 
start date and stop date or continuation. A change in 
medication due to an AE must be recorded and reported according to Section 7.2.1. If the 
chang
e in medication influences the subject’s eligibility to continue in the trial, the 
sponsor and tria l monitor must be infor med. 
7.[ADDRESS_1115261] dasiglucagon/GlucaGen will be measured at the dosing visit (Visit 2) 
and at follow-up (Visit 3). A
t the dosing visit (Visit 2), samples will be collected prior to 
the start of the insulin-induced hypogl
ycemic procedure.  
The clinical ADA assays, specific for dasiglucagon and GlucaGen, respectively, have 
been validated in accordance with existing guidelines and recommendations (17-21).  
Confirmed positive anti-dasiglucagon antibody samples (treatment-induced or 
treatment-boosted) from anti-dasiglucagon antibody-positive subjects will be evaluated 
for binding titer neutralizing potential and titer as well as cross-reactivity towards 
endogenous glucagon.  
No further serum sampling will be needed as the ADA samples can be used for 
neutralizing antibody analysis. 
The in vitro neutralizing effect of the antibodies will be measured using an assay based 
on glucagon receptor transfected human embryonic kidney cells (20,22) . T he calculated 
sensitivity in previous studies was about 51.8 ng/mL. The assay was also validated for 
recombinant glucagon with similar results (21,23) . In case of a positive result in the 
neutralizing antibody assay, a titer estimation will be performed. The cell-based 
neutralizing antibody analyses will be performed by a special laboratory, BioAgilytix, 
Durham, NC, [LOCATION_003]. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 52 of 81  
Residual and additional antibody serum samples may be stored until approval of market 
authorization by [CONTACT_93420]. Further characterization of the antibody response 
may be requested by [CONTACT_93420]. 
7.4.2 Plasm a glucose measurements for safety 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site. After the start of insulin infusion, plasma glucose should be checked every 
10 minutes while plasma glucose is above 110 md/dL, and every 5 minutes once plasma 
g
lucose is at or below 110 mg/dL and until after dosing when the subject’s plasma 
glucose is ≥70mg/dL (3.9 mmol/L). Hereafter, plasma glucose should be checked every 
30 minutes until 300 minutes (5 hours ) after dosing. Plasma glucose concentrations will 
be
 measure
d using a US FDA-approved glucose analyzer (e.g., YSI 2300, Yellow 
S
prings Instruments, Yellow Springs, OH). 
At the discretion of the investigator, additional plasma glucose measurements can be 
taken at any time during the trial, for example when there is a suspi[INVESTIGATOR_2798] (e.g. symptoms) 
of a
 hypo
glycemic epi[INVESTIGATOR_1865]. 
Plasma glucose measurements for safety should only be recorded in the eCRF if they are 
re
lated to an AE (e.g. a hypoglycemic epi[INVESTIGATOR_1865]). 
I
n case of persistent post-treatment hypoglycemia, subjects will receive rescue treatment 
with an IV glucose infusion (see Section [IP_ADDRESS] for details). Blood samples for PD and 
P
K assessments
 should still be taken at the specified timepoints. 
7.4.3 Plasm a insulin measurements 
Samples for insulin assessment will be collected at the dosing visit (Visit 2, pre-dose and 
at 30 and 60 minutes a
fter dosing). The actual time of blood sampling for evaluation of 
plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115262] 
8.1 Schedule of procedures 
The schedule of procedures is provided in  Table 3. Informed consent will be obtained 
prior to any trial-related procedures; see Section  10.8. 
8.2
 Procedures by [CONTACT_765] 
8.2.1 Visit 1 (screening, Day -30 to Day -3) 
Visi
t [ADDRESS_1115263] between 3 and 30 days before Visit 2, Day -1 to Day 1 (dosing 
day
). 
I
nformed consent can be obtained prior to or at Visit 1, however it must in any case be 
obtained prior to any trial
 related procedures. During the screening visit, the following 
assessments will take place: 
Informed consent (obtain or check)
Check of subject eligibility (inclusion/exclusion criteria)
Demography
Body measurements
Medical history, diabetes diagnosis, current diabetes treatment
Concomitant illnesses
Concomitant medications
History of alcohol/drug abuse
Physical examination
Vital signs
12-lead ECG
AE
s
Biochemistry, hematology, coagulation, HbA 1c
Serum pre g nancy test (women of childbearing potential only)
Urinalysis
Urine drug screen
Alcohol breath test
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 54 of 81  
Table  3 Schedule of procedures 
Visit number  V1 V2 V3 
Trial day  -3 -1 and 1 28 
Visit type  Screening  Dosing  Follow -up 
Window  -30 to -3  +[ADDRESS_1115264] related information/assessments     
Informed consent  x   
Inclusion/exclusion criteria  x x1,2  
Demography  x   
Body measurements  x   
Medical history, diabetes diagnosis, and current diabetes 
treatment  x   
Concomitant illness es x   
Concomitant medication s x x1 x 
History of alcohol/drug abuse  x   
Randomization   x1  
Withdrawal criteria   x1  
Dosing day exclusion criteria   x1  
Insulin -induced hypoglycemia   x  
Safety assessments     
Physical examination  x  x 
Vital signs  x x3 x 
12-lead ECG  x x4 x 
Local tolerability   x5 x 
Adverse events  x x x 
Laboratory     
Biochemistry, h ematology, coagulation, HbA 1c (HbA 1c at 
Visit 1  only)  x x6 x 
Pregnancy test (women of childbearing potential only)  x7 x1,[ADDRESS_1115265]  x x1  
PK/Clinical efficacy     
Plasma dasiglucagon /GlucaGen   x9  
Plasma glucose   x10  
Other assessments     
Antibodies against dasiglucagon /GlucaGen   x1 x11 
Plasma i nsulin   x12  
Trial material     
Administration of tr ial product  (during hypoglycemic clamp 
procedure)   x  
1Prior to the start of the insulin-induced hypoglycemic procedure. 
2Only check of dosing day exclusion criteria and changes between screening visit and Visit 2. 
3Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30, 90 and 300 minutes 
after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 55 of 81  
4Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 20, 35, 45, 60 and 300 
m
inutes after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±5 
minutes.  
5Local tolerability assessed at 30, 120, and 300 minutes after dosing. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes.  
6Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30 and 300 minutes after 
dosing . The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±[ADDRESS_1115266]. 
9Pre
-dose, and at 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling should not 
deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
10Pre-dose , and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, 90 minutes after dosing. The actual time of blood 
sa
mpling should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point 
and by [CONTACT_726] ±[ADDRESS_1115267] that tests positive for ADA will be monitored until the ADA levels return to baseline levels. 
12Pre-dose, and at 30 and 60 minutes after dosing. The actual time of blood sampling should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing.  
ADA = anti-drug antibodies; ECG = electrocardiogram; HbA 1c = glycated hemoglobin. 
Eligible or potentially eligible subjects (laboratory results pending) will be provided with 
an Identification card (ID card), stating that the subject is participating in the trial and 
whom to contact (site address, investigator name [CONTACT_41319]). The subjects 
should be instructed to return the ID card to the investigator at the last visit or to destroy 
the card after the last visit.  
8.2.2 In structions to subjects prior to the dosing visit (Visit 2) 
At the screening visit, the investi gator will inform the subject about the changes to his/her 
insulin therapy leading up to the start of the insulin-induced hypoglycemic procedure. 
The subject may be provided with insulin NPH in the wash-out period to cover the need 
of basal insulin, if deemed necessary by [CONTACT_093]. The subject’s current insulin 
therapy will be washed out as defined in Section  5.5.: 48 hours prior to dosing and during 
the dosing visit, tre
atment wit h  insulin Degludec and insuli n Glarg ine U300 are not 
allowed; 24 hour s prior to dosing and during the dosing visit, treatment with other long-
acting insul ins (e.g., insulin Glarg ine U100 or insulin De temir) is not allowed; 16 hours 
prior dosing and during the dosing visit treatme nt with insulin NPH is not allowe d; 6 
hours prior to dosing and during the dosing visit, treatment with any short acting (bolus) 
insulin, except insulin glulisine (Api[INVESTIGATOR_27976]®), is not allowed. The basal rate of insulin pumps 
(conti nuous SC insulin infusion) will be discontinue d on the morning of the dosing day 
(if using insul in g
lulisine [Api[INVESTIGATOR_27976]®]) OR at lea st 6 hours prior to dosing (i f using other 
insulins)
. 
On the day prior to dosing (Day -1), the subjects will need to attend the clinical center 
a
nd will be requir
ed to stay onsite overnight. On the morning of the dosing day (Day 1), 
patients ar
e required to be in a fasting condition, defined as having consumed only water 
since 22:00 hour
s the night before. However, the subjects are allowed to consume small 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 56 of 81  
amounts (up to 20 g) of carbohydrates to prevent hypoglycemia. The subjects must also 
not consume any alcohol within 24 hours prior to dosing (refer to Section 5.5 for all 
dosi
ng day exclusion criteria). 
8.2.3 V isit 2 (dosing visit) 
Visit [ADDRESS_1115268] on D ay -1 to Day 1. 
The
 subjects will attend the clinical center the day prior to dosing (Day -1) and subject 
eligibility is rechecked (check of changes between the screening visit and Visit 2) and 
those subj e
cts eligible to participate should stay onsite overnight. To target a glucose 
level around 90-110 mg/dL (5.0-6.1 mmol/L) the following morning, subjects may be 
a
dministe
red insulin glulisine (Api[INVESTIGATOR_27976]®) at the investigator’s discretion either by [CONTACT_27650], 
SC bolus or continuous SC insulin infusion. Dosing will take place the 
following morning (D
ay 1). 
On Day [ADDRESS_1115269]: 
 Doc ument all changes in concomitant medication (prior to the start of the 
insulin-induce
d hypoglycemic procedure) 
 C heck of withdrawal criteria (prior to the start of the insulin-induced hypoglycemic 
procedure
) 
 C heck of dosing day exclusion criteria (prior to the start of the insulin-induced 
hypog
lycemic procedure) 
 Vital si gns (prior to the start [within 30 minutes] of the insulin-induced hypoglycemic 
procedure
, and at 30, 90 and 300 min utes  after dosing). 12-lead ECG (prior to the 
star
t [
within 30 minutes] of the insulin-induced hypoglycemic procedure, and at 20, 
35, 45, 60, and 300 minutes  after dosing) 
 L ocal tolerability (at 30, 120, and 300 minutes after dosing) 
 AEs  
 B iochemistry, hematology, coagulation (prior to the start of the insulin-induced 
hypo
glycemic procedure [within 30 minutes], and at 30 and 300 minutes after dosing) 
 Ur ine stick pregnancy test (women of childbearing potential only; prior to the start of 
the insulin-induced hypoglycemic procedure) 
 Urinalysis (prior to the start of the insulin-induced hypoglycemic procedure [within 
120 minutes]) 
 Ur ine drug screen (prior to the start of the insulin-induced hypoglycemic procedure) 
 Alcohol breath test (prior to the start of the insulin-induced hypoglycemic procedure) 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 57 of 81  
Dasiglucagon/GlucaGen plasma concentrations:
- Pre-dose
, 15, 30, 35, 40, 50, 60, 90, and 120 min utes  after dosing. The actual time
of blood sa
mpling for exposure should not deviate from the nominal time by [CONTACT_26813] ±1 min ute. P re-dose is defined as within 2 min utes prior to dosing. 
Plasma glucose concentration s:
- Pre-dose, 4, 6, 8 ,10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, and 90 minutes after
dosing. The a
ctual time f
or blood sampling for plasma glucose should not deviate 
from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection 
time point and by [CONTACT_726] ±1 minute f
or the subsequent collection time points. 
Pre-dose is defined as within 2 minutes prior to dosing. 
Antibodies against dasiglucagon/GlucaGen (prior to the start of the insulin-induced
hypog
lyce
mic procedure).
Plasma insulin concentrations:
- Pre-dose
, 30 and 60 minutes after dosing. The actual time of blood sampling for
plasma insulin should not deviate from the nomi
nal time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
[IP_ADDRESS] Hy poglycemic clamp procedure and administration of trial medication 
The following procedure is based on precendent procedures for hypoglycemia induction 
in patients with T1DM [ 24, 25].  
The
 treatment day (Visit 2, Day 1) will be conducted after an overnight fast of at least 
8 hou rs, targeting a starting plasma glucose around 90 to 110 mg/dL (5.0-6.1 mmol/L).  
Subjects who meet one or more of the dosing day exclusion criteria (Section  5.5) at the 
dosi
ng visit will be excluded from the dosing visit, but the visi t can be rescheduled 
1-[ADDRESS_1115270]’s current insulin therapy will be washed out as defined in Section  5.5. For 
subj
ects using multiple daily injections, the date, time and the dose of the last basal 
insul in and the last short-acting insul in (except insulin glulisine [Api[INVESTIGATOR_27976]®]) administration 
prior to dosing will be captured. For subjects using an insulin pump, the time of 
discontinuation of the basal rate will be captured. Any use of insulin glulisine (Api[INVESTIGATOR_27976]®) 
in the last 5 hours prior to initiation of the hypo glycemia induction procedure will also be 
captured.  
At approximatel
y 08:00 hours, an infusion catheter will be inserted into each arm 
(forearm cephalic
 vein) for the manual glucose clamp procedure, with the glucose 
infusion in one arm and the insulin infusion in the opposite arm (if IV insulin glulisine 
[
Api[INVESTIGATOR_27976]®] has been administered during the night the same infusion catheter can be used). 
A third c
atheter for blood sampling
 will be placed into a metacarpel vein for blood 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 58 of 81  
sampling. This hand will be warmed (55-65ºC) to arterialize venous blood. If there are 
issues with blood sampl
ing from the metacarpal vein for the purpose of glucose 
measurements, a new and more proximal IV access may be used at the discretion of the 
investigator. 
H
ypoglycemia will be gradually induced by a fast-acting IV insulin glulisine (Api[INVESTIGATOR_27976]®) 
infusion (15 U [100 U/mL] in [ADDRESS_1115271]’s blood or plasma), 
ini
tially at 150% of the subject’s usual basal rate and can be increased or decreased over a 
range of 0% to 200% as judged necessary by [CONTACT_093], to achieve a controlled 
decline in plasma glucose, targeting a plasma glucos e level of 55 mg/dL (3.1 mmol/L).  
P
lasma glucose concentrations will be measured using a US  FDA-approved glucose 
analy
zer (e.g., YSI 2300, Yellow Springs Instruments, Yellow Springs, OH). After the 
start of the insulin infusion, plasma glucose will be measured every 10 minutes whil e 
plasma glucose is above 110 mg /dL, and every 5 minutes once plasma glucose is at or 
below 110 mg/dL
. 
Once the glucose concentration declines to <60 mg/dL (3.3 mmol/L), the insulin infusion 
will be stopped, a
nd 5 min later plasma glucose concentration will be measured at the 
glucose analyzer and blood samples for baseline assessment of plasma glucose, 
dasiglucagon/GlucaGen PK, and insulin PK will be collected. The samples are the 
ba
seline samples and should be collected within 2 minutes before IMP administration. 
If plasma glucose is ≥45 mg/dL and <60 mg/dL (2.5-3.3 mmol/L), study treatment
(
IMP) wil
l be administered, defining time, t=0. The study treatment will be delivered
in the abdomen, butt
ock, or thigh (according to stratification) via SC injection, with
the subject lyin
g in a lateral recumbent position.
If plasma glucose is <45 mg/dL (2.5 mmol/L), IV glucose solution will be
administ
ered sufficient to raise plasma glucose to within the 45-60 mg/dL target
range
. The run-in period will be adequately extended (at least 30 min) until the above
tar
get is ac
hieved and new baseline samples for plasma glucose,
dasiglucag
on/GlucaGen PK, and insulin PK will be collected. Glucose should not be
infused within [ADDRESS_1115272] should be rescheduled for a new
tre
atment
 visit within 7 days (+ 2 days).
Administra
tion of IMP should not occur earlier than 9:00 hours in the morning or later 
than 12:00 hours. 
As shown in Table 4 , serial blood samples for glucose will be collected at t=0, 4, 6, 8, 10, 
12, 15, 17, 20, 25, 30, 40, 50, 60, [ADDRESS_1115273]-dosing. Samples for assessing 
plasma dasiglucagon/GlucaGen concentration will be collected 
 at t=0, 15, 30, 35, 40, 50, 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 59 of 81  
60, 90, and 120 min utes. S amples for assessing plasma insulin concentration will be 
collected at t=0, 30, and [ADDRESS_1115274]-treatment blood sampling times 
Times  0 4 6 8 10 12 15 17 20 25 30 35 40 50 60 75 90 120 
Plasma glucose  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
PK 
Dasiglucagon/ 
GlucaGen  Y Y Y Y Y Y Y Y Y 
PK Insulin  Y Y Y 
Refer to Section 7.2.7  for details of laboratory safety sampling and to Section 7.4.2 for 
de
tails of blood glucose safety sampling.  
When the t=90-minute blood sampling for plasma glucose has been collected the subjects 
are allowed to eat moderately. Drinking of water is allowed ad libitum during the entire 
procedure.
 
Hypoglycemia Rescue Provisions 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site for safety reasons as described in Section  7.4.2. Subjects should receive 
post-treatment rescue glucose 
infusion to ameliorate persistent hypoglycemia, as follows. 
1. Glucose infusion should be initiated if a subject experiences severe alarming
escalation of s
ymptoms of hypoglycemia (e.g. symptoms suggesting a change in
consciousness) at any time during the trial; glucose infusion should be initiated
targeting a plasma glucose levels >70 mg/dL.
2. If plasma glucose is <45 mg/dL (2.5 mmol/L) between t=8 and t=44 minutes,
re
scue glucose infusion (1 -2 mg/kg administered IV over about 5 seconds) should
be initiated to maintain plasma
 glucose between 45 mg/dL and 55 mg/dL
(2.5-3.1 mmol/L). Pause glucose infusion if plasma glucose is >55 mg/dL.
3.
If plasma glucose is <70 mg/dL at t=45 minutes, rescue glucose infusion
(2-3 mg/kg administered IV over about 5 seconds ) should be initiated to maintain
plasma glucose between 70 mg/dL and 80 mg/dL (3.9-4.4 mmol/L). Pause
g
lucose infusion if plasma g
lucose is >75 mg/dL (4.2 mmol/L).
Subjects should remain in bed until
 completion of the test procedure 300 minutes after 
dosing (bathroom visits ar
e allowed).  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115275] m
ay stay at the trial center for a longer period. 
8.2.4 V isit 3  (follow- up visit) 
Visit [ADDRESS_1115276] on D ay 28 + [ADDRESS_1115277]: 
Document all changes in concomitant medication
Physical examination
Vital signs
12-lead ECG
L
ocal tolerability
AEs
Biochemi
stry, hematology, coagulation
Urine stick pregnancy test (women of childbearing potential only)
Urinalysis
Antibodies against dasiglucagon/GlucaGen.
After the follow-up visit the End of Trial form must be completed. Even if a subject is not 
a
ble to attend the follow-up visit, the End of Trial form, the eCRF 
Accountability/Affirmation Statement form and the Drug Accountability form must be 
c
ompleted. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 61 of 81  
9 STATISTICAL METHODS 
Before database lock and treatment unmasking, a separate statistical analysis plan (SAP) 
will be fina
lized, providing detailed methods for the analyses outlined below. Further 
analysis details may be added or refined in the SAP. 
Any deviations from the planned analyses will be described and justified in the final 
clinical tria
l report. 
9.[ADDRESS_1115278] s 
treated with dasiglucagon 0.6 mg. With a 2:1:1 randomization ratio for the three 
treatments, dasiglucagon 0.6 mg, placebo, and GlucaGen 1 mg, 78 subjects injected with 
dasiglucag
on and 39 subjects with placebo will yield a power of 90% at a 5% two-sided 
significance level to detect a treatment group difference in recovery incidence within 
20 minutes, assuming as low as 80% and as high as 50% recovery incidence for the 
da
siglucagon and placebo groups, respectively.  
9.2 T rial subjects 
9.2.1 A nalysis samples 
For presentation of data and reporting of the statistical analyses, th e following analysis 
sample
s will be used, depending on the context:  
S
afety analysis set (SAS): All randomized subjects who received at least one dose of
trial medica
tion.
Full analysis set (FAS): All randomized subjects who received at least one dose of
trial medicati
on and contributed valid information for at least one post-dose endpoint.
Per protocol (PP) set: All subjects of the FAS for whom no relevant protocol
deviations were
 documented. This sample will primarily be used for sensitivity
analysis
.
The analysis of the primary endpoint and secondary endpoints will be based on the FAS. 
A secondary analysis of the primary endpoint will be based on the PP set. All safety 
anal
yses will be based upon the SAS. 
The decision regarding whether a protocol deviation is relevant or not for the exclusion of 
subjects from the PP set will be made case-b y-case in a data review meeting prior to 
treatment unmasking and database lock (see Section 9.2.3 ). 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115279] the results will be identified and it will be evaluated if subjects and/or 
data should be e
xcluded from the analysis. Protocol deviations will be classified as minor 
or major in a c
onsistent way. Major deviations from the protocol may lead to the 
exclusion of a subject from the PP set. 
Major protocol deviations may include deviations related to trial inclusion or exclusion 
criteria, conduct of the trial, subject management or subject assessment. Unless explicitly 
decided otherwise during the masked data review, the following will be considered major 
protocol deviati
ons: 
 Violation of one  or more major inclusion/exclusion criteria 
 I nterruption of administration of trial product 
 Significant deviation from time windows  
 Incorrect treatment allocation 
 Missing primary endpoint. 
The viola
tion of several major inclusion/exclusion criteria or the complete absence of 
efficacy data might lead to exclusion of the subject from FAS. In that case, the decision 
should be taken at the masked data review meeting, and the exclusion from efficacy 
anal
ysis justified in the signed notes of the meeting. 
Obviously erroneous data points may be excluded from the analyses or re-analyzed (in 
case
 of e.g. serum concentrations). The decision to re-analyze or exclude data points from 
the statisti
cal analysis is the joint responsibility of the sponsor and the trial statistician.  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 63 of 81  
The subjects or observations to be excluded and the reason for their exclusion will be 
documented and signed by [CONTACT_93440]. The 
documentation will be stored together with the remaining trial documentation. The 
subjects and observations excluded from analysis sets, and the corresponding reasons, 
will be described in the clinical trial report. 
9.3 G eneral considerations 
All data obtained in this trial and documented in the eCRFs will be listed and 
summarized with statistics or frequency tables as appropriate. In case of termination of 
the trial, all data collected up to that timepoint will be included in the analysis. 
Raw data listings and summary tables will be generated using the software SAS© version 
9.[ADDRESS_1115280] deviations, medians, 
coefficients of variation, and minimum and maximum values.  
Other summaries (e.g. quartiles, 95% confidence intervals [CIs]) may be used as 
appropria
te. Categorical efficacy and safety variables will be summarized by [CONTACT_807466]. 
9.4 De mographics and baseline characteristics 
Ba
seline and demographic data will be summarized using descriptive statistics. Baseline 
ADA-positive subjects will be calculated as a percentage of the total number of subjects 
whose baseline samples were tested for ADA. 
All other data obtained in this trial and documented in the eCRF will be listed. 
9.5 E fficacy Analyses 
For the confirmatory analyses, the primary and key secondary endpoints for the 
dasiglucagon 0.6 mg and placebo treated subjects will be compared. A hierarchical 
proce
dure will be applied for the control of multiplicity. The primary and secondary 
endpoints will be evaluated on the full analysis set. In the primary analysis, those subjects 
who require rescue IV glucose will be censored at the time to plasma glucose recovery.  
In a sensitivity analysis, the time to plasma glucose recovery will be analyzed without 
censoring the subjects who received rescue IV glucose.   
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115281] the null 
h
ypothesis for a dasiglucagon versus placebo comparison: 
 P rimary:  Time to plasma glucose recovery 
 Ke y secondaries 1-4: Plasma glucose recovery within 30 minutes, within 20 minutes, 
within 15 minutes, and within 10 minutes after study drug injection without 
a
dministration of rescue IV glucose. 
 Ke y secondaries 5-8:  Plasma glucose changes from baseline (CFB) within [ADDRESS_1115282] increase in 
plasma g
lucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
c
lamp proc
edure without administration of rescue IV glucose.  
[IP_ADDRESS] Primary  analysis 
The primary endpoint will be summarized using Kaplan-Meier (KM) estimates stratified 
by
 [CONTACT_807467]. The treatment group difference between 
dasigluc
agon and placebo will be evaluated inferentially using a pairwise two-sided 
log-rank test. 
In the primary analysis, those subjects who require rescue IV glucose will be censored at 
the time of plasma glucose recovery. This approach is based on the assumption that 
rescue
 IV glucose administration will shorten the time to recovery. This assumption 
implies that censoring at the time of recovey after rescue therapy is valid as a time to 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 65 of 81  
recovery without rescue would be longer than the observed duration. If recovery has not 
occurred at 45 minutes after study drug injection, censoring will be applied irrespective 
of the use of rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without 
censoring at the time of recovery for those subjects who require rescue IV glucose before 
45 minutes and 2) with censoring at the time of administration of rescure IV glucose 
before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards 
(CPH) ti
me to event statistical model, if the hazards by [CONTACT_807490] a graphical comparison of log-minus-log survival curves and no more 
than two-thirds of the recovery times are censored in each treatment group. The CPH 
model will be use
d for inferences, with treatment group and injection site modeled as 
categorical effects, and baseline plasma glucose modeled as a continuous covariate. The 
treatment group rate ratios, active versus placebo, will be estimated together with the 
95% confidence intervals, and pairwise treatment group inferences (dasiglucagon vs 
placebo, GlucaGen vs placebo) will be evaluated using two-sided likelihood ratio tests. 
9.5.3 S econdary endpoints 
 P lasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
[IP_ADDRESS] C onfirmatory analysis 
The key secondary incidence variables (plasma glucose recovery within 30 minutes, 
within 20 minutes, within 15 minutes, within 10 minutes, in hierarchical order for 
inference) will be analyzed using descriptive statistics (frequency and percentage) by 
[CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise 
tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo) using Fisher’s exact test for each pairwise comparison. 
The key secondary endpoints of plasma glucose CFB within [ADDRESS_1115283] in 
those subjects who require rescue IV glucose before plasma glucose ≥20 mg/dL recovery. 
Each of these CFB variables will be analyzed using an Analysis of Covariance model, 
with treatment group modeled as a fixed effect and with the baseline plasma glucose 
modeled as a covariate. The dasiglucagon versus placebo treatment group difference will 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115284]. 
9.5.4 S econdary clinical efficacy (PD) endpoints 
 Time t o first plasma glucose concentration of ≥70 mg/dL (3.9 mmol/L) without 
administration of rescue IV glucose. 
 P lasma glucose response as area under the curve above baseline from time zero to 
30 minutes, AUC 0 -30min . 
S
econdary clinical efficacy endpoints will be assessed based on plasma concentration 
data from samples collected at the dosing visit (Visit 2).  
Unless othe
rwise stated, the population base of analysis will be the FAS. 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints 
1. Time to fir st plasma glucose concentration ≥70 mg/dL from baseline. This 
time-to-event endpoint will be evaluated using a Kaplan-Meier approach, with 
treatm
ent group as a stratification factor, analogous to that used for the primary 
endpoint analysis. Differences between the KM curves (dasiglucagon versus 
place
bo, GlucaGen versus placebo) will be evaluated inferentially using pairwise 
two-sided log rank tests. If the ≥70 mg/dL endpoint is not met within [ADDRESS_1115285] valid plasma glucose measurement up to 45 
minutes will be the censoring time.  
2. The  AUC will be calculated as the baseline-adjusted area under the plasma 
g
lucose profile over time: 
a. AUC 0-3
0min: restricting the time window to the 0 to 30 minutes interval. 
3. The  log-transformed AUC endpoint will be analyzed using an analysis of 
covarian
ce (ANCOVA) model with treatment as fixed effect and baseline plasma 
glucose
 modeled as a covariate. The least squares means treatment group 
differe
nces will be back-transformed (anti-logged) for presentation as a ratio of 
the trea
tment group geometric means, with their corresponding 95% CI. 
9.5.5 E xposure (PK) endpoints 
 Plasma dasiglucagon and GlucaGen concentrations from time zero to 90 minutes:  
AUC 0-9
0min, Cmax, and t max. 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
_____ ___________________________________________________________________  
Strictly Confidential    Page 67 of 81  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints 
AUC will be derived as the area under the individual plasma dasiglucagon/GlucaGen 
concentration profile for PK from [ADDRESS_1115286] valid measurement if this 
measurement is assessed sufficiently close to 90 minutes (decision to be taken at the 
masked data review meeting). The standard trapezoidal method will be used, based on 
a
ctual rather than nominal timepoints.  
Cmax will be determined as the maximum of all valid plasma dasiglucagon/GlucaGen 
c
oncentrations.  
Tmax will be determined as the timepoint where the maximum of all valid plasma 
dasiglucagon/GlucaGen concentration measurements for each measurement series is 
observed. 
The
 log-transformed PK endpoints AUC and C max will be analyzed in the same way as 
the A
UC endpoints. 
As 
tmax is a highly discrete endpoint, Wilcoxon’s rank sum test for unpaired observations 
will
 be used to assess differences between the two treatment group s. 
9.6 E xploratory analyses 
Exploratory analyses will include descriptive statistics and modeling analogous to that 
done for key secondary endpoints. However, treatment group comparisons will be 
summarized without
 inference intent. 
Plasma glucose conc entration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL
(1.1 mmol/L) within 30 minutes after study drug injection without administration
of rescue
 IV glucose.
Plasma insulin response as area under the curve above baseline from time zero to
60 minutes, AUC 0 -60 min .
Plasma insulin concentrations measured pre-dose and at 30 and 60 minutes after dosing 
(see Table 3) will be presented individually. A summary table per timepoint will be 
provided. The AUC 0-60min will be determined 
and a summary presented.  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115287] available version of the MedDRA, the version of 
which will be provided in the clinical trial report. AE summary tables will include the 
number and percentage of subjects who experienced AEs summarized by [CONTACT_42893] 
c
lass and preferred term. 
[LOCATION_013] only: The AE summary for AEs related to insulin glulisine (Api[INVESTIGATOR_27976]®) will be 
presented as an appendix to the clinical trial report, as insulin glulisine (Api[INVESTIGATOR_27976]®) is only 
consi
dered an IMP in [LOCATION_013]. 
 An overall summary table will be provided showing the number and percentage of 
subjects with any: 
 TEAE 
 S evere TEAE 
 S erious TEAE 
 Dr ug-related TEAE 
 Dr ug-related severe TEAE 
 Dr ug-related serious TEAE 
 TEAE leading to withdrawal 
 TEA E with outcome death 
 AE SI 
Refer to Section 7.2.[ADDRESS_1115288] results will be flagged as to whether the result is below, within or 
above the re
spective reference range. The number of values outside of the reference range 
will be counted. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 69 of 81  
9.7.4 Other safety data 
Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure will 
be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. 
Inferential treatment group comparisons will be assessed via pairwise tests of 
independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus 
placebo).  
Time to fir
st rescue infusion of IV glucose during the hypoglycemic clamp procedure 
will be evaluated using a KM time to event statistical model, with treatment group and 
injec
tion site as stratification factors. Differences between the KM curves (dasiglucagon 
versus 
placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise 
two-sided stratified log-rank tests. If the endpoint is never met, the time of the last plasma 
g
lucose measurement will be the censoring time. 
Vital si
gns, ph
ysical examination, 12-lead ECG and local tolerability data will be 
summa
rized using descriptive statistics. 
9.[ADDRESS_1115289] will be applied. For the primary analysis in the 
FAS, miss
ing values for the primary endpoint will be imputed by a conservative rule 
conside
ring any missing value as a failure. 
9.10 In terim analyses 
No inter
im analyses are currently planned. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115290] be consistent with 
the subje
cts’ source documentation (i.e. medical records). 
The investigator will permit trial-related monitoring, IRB/IEC review, and regulatory 
inspections, providing direct access to source data /documents. Sponsor-authorized 
quality assurance personnel may carry out audits for which the investigator must provide 
support. 
The
 trial monitor or a representative of the sponsor will cross-check the data entered in 
the eCRFs with the source data at the trial center and observe the trial procedures in order 
to verify
 adherence to the trial protocol. Any queries will be resolved by [CONTACT_111140]/her delegate. 
All of the
 clinical data will be captured via electronic data capture (EDC) using a 
web-based tool.  
The
 investigator center staff will enter and edit the data via a secure network, with secure 
a
cc
ess features (username [CONTACT_2383]). A complete electronic audit trail will be 
maintained. The investigator will approve the data using an electronic signature (Ref: 21 
CFR Part 11), and this approval is used to confirm the accuracy of the data recorded. 
eCRFs will be used for all subjects. The investigator’s data will be accessible from the 
investigator’s center throughout the trial. The eCRFs must be kept current to reflect 
subject status at each phase during the course of the trial. The eCRF will not capture 
personali
zed data. The investigator must make a separate confidential record of 
personalized details (name [CONTACT_93459]) on the subject identification and enrollment log. 
All changes to data are made by [CONTACT_15009]/her delegate through the EDC 
system. 
 
It is the responsibility of the principal investigator [INVESTIGATOR_807437]’s eCRF are also made on the subject’s medical records. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115291] leaving the trial should be completed at the time of the final 
visit or shortly thereafter. 
10.2  Electronic case report forms 
Remote data capture software will be used for data collection. Following training, tr ial 
staf
f will be given access to the software. Access to the software is restricted to staff 
participating in the trial and the extent of access will depend on the participants' user role 
in the 
trial. 
The
 subjects enrolled into the trial will be identified in the database by [CONTACT_18022] 
a
nd trial identification code. The investigator or delegate will enter subject data into the 
e
CRF promptly. All data is to be entered in English. Data recorded in the eCRFs will be 
accessible to the trial staff throughout the trial. 
After
 data entry, systematic data validation will be performed and data entry 
discrepancies will be presented electronically directly to the center staff. Queries for 
discrepa
nt data may be generated automatically by [CONTACT_727915]/or 
generated manually by [CONTACT_807470]. All queries, whether 
gen
erated by [CONTACT_727917], will be in electronic format. 
All sections of the
 eCRF are to be electronically approved by [CONTACT_1720] a 
medically qualified delegate after the data has been entered and all queries have been 
resolved. Changes to any eCRF page subsequent to the approval require a new approval 
signature. 
All queries and changes/corrections to the data are documented in the eCRF. 
10.[ADDRESS_1115292]’s medical records, assess drug 
accountability, and ensure that the trial is being conducted according to pertinent 
regulator
y requirements. 
Checking of the eCRFs for completeness and clarity, and cross-checking with source 
documents, will be required to monitor the progress of the trial. Moreover, regulatory 
authorities of certain countries, IRBs/IECs, and/or the sponsor may wish to carry out such 
source data checks and/or on-site audit inspections. Direct access to source data will be 
required for these inspections and audits; they will be carried out giving due 
consideration to data protection and medical confidentiality. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115293]’s medical records. If data are to be entered directly into the eCRF this must be 
spe
cified in a source data agreement prior to the start of the trial. 
eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that subject confidentiality is maintained. 
The trial monitor will check the eCRF for accuracy and completion and perform source 
da
ta verification. The trial monitor will document source data verification of all reviewed 
sections of the e
CRF. 
10.[ADDRESS_1115294] (e.g. informed consent forms, laboratory slips, medication 
inventory records, and other pertinent information) must be retained by [CONTACT_807471]. 
10.7  Good clinical practice 
The procedures set out in this trial protocol are designed to ensure that the sponsor and 
investiga
tor abide by [CONTACT_146018] ( 1), and of the 
Declara
tion of Helsinki (2008) ( 2). The trial also will be carried out in keepi[INVESTIGATOR_118483].  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115295] orally and in writing (subject information 
sheet) the nature, significance, risks and implications of the trial before inclusion. In 
particular, the subjects will be informed about the following: 
 The  possibility of withdrawing from the clinical trial at any time by [CONTACT_807472]. 
 How personal and health-related data will be collected and used during the trial. 
 Tha t his/her medical records may be examined by [CONTACT_807473], by [CONTACT_6667]/IEC 
members, and by [CONTACT_6668]. 
All subjects will receive a copy of the subject information sheet and a copy of their 
signed and dated informed consent form, both of which will be in the subject’s local 
language. 
I
f a protocol amendment is required, the informed consent form may need to be revised to 
reflect the changes to the protocol. If the consent form is revised, it must be reviewed and 
approved by [CONTACT_69869]/IRB, and signed by [CONTACT_807474]. 
10.9  Protocol a pproval and amendment 
Befo
re the start of the trial, the trial protocol and/or other relevant documents will be 
approve
d by [CONTACT_6179]/IRB/competent authorities, in accordance with local legal 
requirements. The sponsor must ensure that all ethical and legal requirements have been 
met before the first subject is enrolled in the trial. 
This protocol is to b
e followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive IRB/IEC/competent 
authority approval prior to implementation (if appropriate).  
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 74 of 81  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without 
the need for a formal amendment. All amendments will be distributed to all protocol 
recipi[INVESTIGATOR_840], with appropriate instructions. 
10.[ADDRESS_1115296] will be up to 63 days (including up to 
30 days for screening and up to 33 days until the follow-up visit).  
The trial will be closed when all subjects have completed Visit 3. 
10.11  Premature termination of the trial 
If the investigator, the sponsor (e.g. safety committee), or the safety medical monitor 
becomes a
ware of conditions or events that suggest a possible hazard to subject s if the 
trial continues, the trial may be terminated after appropriate consultation between the 
re
levant parties. The trial may also be terminated early at the sponsor’s discre tion in the 
absence of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
 The  discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the trial 
 Failure to enroll subjects at an acceptable rate. 
 A de cision on the part of the sponsor to suspend or discontinue development of the 
drug. 
The trial can be terminated prematurely by [CONTACT_807475]: 
 The center cannot comply with the requirements of the protocol. 
 I t is not possible for the center to comply with GCP standards. 
10.12  Confidentiality 
All 
trial findings and documents will be regarded as confidential. The investigator and 
membe
rs of his/
her research team must not disclose such information without prior 
written approval from the sponsor. 
The anonymity of participating subjects must be maintained. Subj ects will be identified 
on eCRFs submitted to the sponsor by [CONTACT_139927]. On the SAE reports and all 
other
 source
 documents, the subject will be identified via subject number. Documents not 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115297] (e.g. the signed informed consent 
form) must be ma
intained in confidence by [CONTACT_093].  
10.13  Other ethical and regulatory issues 
If a significant safety issue is identified, either from an individual case report or review of 
aggregate data, then the sponsor will issue prompt notification to all parties : reg ulatory 
authorities, investigators and IRB/IECs. 
A sig
nificant safety issue is one that has a significant impact on the course of the clinical 
trial or program (including the potential for suspension of the trial program or 
amendme
nts to protocols) or warrants immediate update of informed consent. 
10.[ADDRESS_1115298] resulted 
from participation in the clinical trial, or if he/she undergoes any other medical treatment 
without their consent before the clinical trial has been completely finished in so  far as the 
indi
vidual subject is concerned. 
An
y injury to health, which might have occurred as a result of participation in the clinical 
trial must be reported by [CONTACT_807476]. The investigator is 
obli
ge
d to make such a report in any case. 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 76 of 81  
10.15   Publication policy 
By [CONTACT_752373], the investigator agrees with the use of results of the trial for 
the purposes of national and international registration, publication and information for 
medical and pharmaceutical professionals. If necessary, the authorities will be notified of 
the investigator's name, address, qualifications and extent of involvement. 
A clinical trial report will be prepared and reviewed by [CONTACT_807477]-operation with 
the c
oordinating investigator. The coordinatoing investigator will be appointed by 
[CONTACT_807478]. A summary of the clinical trial report (according to CPMP/ICH137/95) 
should be sent to the regulatory authorities and IRB/IEC according to the relevant 
guidelines. 
According to the Declaration of Helsinki (2) investigators and sponsors ‘have ethical 
obli
gations with regard to the publication and dissemination of the results of research’.   
The trial design and results may be published as one or more original research 
manuscripts/abstrac
ts and presented at a scientific meeting. The original eCRFs and the 
data generated from the eCRFs or otherwise obtained during the trial under this trial 
protocol will become the property of the sponsor. Publication of the results of this trial by 
[CONTACT_807479]. 
Any material intended for publication will be given to the sponsor at least [ADDRESS_1115299] the right to comment on the intended 
publication and to take any reasonable measures for patent protection. Authorship on any 
publication(s) resulting from this clinical trial will be assigned according to the 
recommendations of the International Committee of Medicinal Journal Editors (26).  
Participating subjects will not be identified by [CONTACT_807480]. 
The sponsor is responsible for trial registration at ClinicalTrials.gov 
(www.clinicaltrials.gov) according to FDA requirements, as well as the European 
Medicines Age
ncy’s Clinical Trials Database (EudraCT).  
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115300]  
1.ICH Harmonised Tripartite G uideline. International Conference on Harmonisation. 
ICH Harmonised Tripartite G uideline. Integrated addendum t o ICH E6(R1): 
Guideline for Good Cli
nical Practice E6 (R2), Step 4. 09-Nov-2016. Available from: 
URL:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E  
6/E6_R2__Step_4.pdf
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical
Resea
rch Involving Human Subjects. 52nd WMA General Assembly, Edinburgh,
Scotland, October 2000. L
ast amended with Note of Clarification on Paragraph [ADDRESS_1115301] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.
Hypog
lycemia and diabetes: a report of a workgroup of the American Diabetes
Association and the Endocrine Society. Diabetes Care 2013 May;36:1384-95
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
5. America
n Diabetes Association Position Statement. Standards of medical care in
diabetes - 2017. Diabetes Care 2017;40(Supplement 1):S1-S135
6.
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world
factors aff
ecting adherence to insulin therapy in patients with Type 1 or Type 2
diabetes mellitus: a systematic review. Diabetic Medicine 2013;30:512-24
7. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0
mmol/L 
(54 mg/dL) should be reported in clinical trials: a joint position statement of
the American Diabetes Association and the European Association for the Study of
Diabetes. Diabetes Care 2017;40(1):155-57
8.Christensen M, Bagger JI, Vilsbøll T, Knop F K. The alpha -c ell as target for type 2
diabetes therapy. Rev Diabet Stud 2011;8:369 -81
9. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2
diabetes: the return o
f the alpha cell. Curr Diab Rep 2014;14:555
10. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The
metabolic a
ctions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-97
11. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the
therapeuti
c peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res
2004;21:1274-83
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.0 
  
 
 
 
_____ ___________________________________________________________________  
Strictly Confidential    Page 78 of 81  
12. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. 
Drug Discovery Today 2015;20:122-8 
13. Novo N ordisk Limited. SPC for GlucaGen Hypokit 1 mg. 2015. 
http:/
/www.medicines.org.uk/emc/medicine/4258/SPC/GlucaGen+Hypokit+1+mg - 
Acce
ssed 13 Mar 2017 . 
14. Z ealand Pharma A/S. Dasiglucagon Investigator's Brochure, Edition 3, 12 Dec 2016.  
15. The  Task Force for the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 
ESH/ESC
 guidelines for the management of arterial hypertension. European Heart 
Journal 2013;34:2159-219 
16. L evey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen BA, et al. Using 
standardized serum creat inine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of Internal Medicine 
2006;145:247 -54 
17. F ood and Drug Administration (FDA). Guidance for Industry on Bioanalytical 
Method Validation. Food and Drug Administration (FDA) [ADDRESS_1115302], Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. 
Quantitative bioanalytical methods validation and implementation: best practices for 
chromatographic and ligand binding assays. Pharm Res [ADDRESS_1115303];24:1962-[ADDRESS_1115304] biotechnology pro ducts. J Pharm Biomed Anal 2008 ;48:[ADDRESS_1115305] neutralizing antibodies to ZP4207 
by [CONTACT_807481] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-004-REP.  2016. Report No.: Zealand Pharma, 
study
 15-[ADDRESS_1115306] neutralizing antibodies to glucagon 
by [CONTACT_807481] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-005.  2016. Report No.: Zealand Pharma, Study 
15-040 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115307] glycemic control of insulin -dependent diabetes mellitus. 
N Eng J Med 1987; 316: 1376 -83. 
25. R ickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-
induced hypoglycemia in adults with type 1 diabetes: A randomized crossover 
noninferiority study. Diabetes Care 2016; 39: 264-70. 
26. I CMJE. Recommendations for the conduct, reporting, editing, and publication of 
scholarly work in medical journals. Updated December 2016 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115308] of trial personnel 
Sponsor  
Clinical Trial Manager   
 
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:  
Medical Officer   
Zealand Pharma  
Smedeland 36  
2600 Glo strup, Denmark  
Phone:   
Contract Research Organization  Chiltern International (Ltd)  
[ADDRESS_1115309]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:  +44 (0) [PHONE_16833]  
Project Manager   
Chiltern International (Ltd)  
[ADDRESS_1115310]  
Slough 
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:   
Senior Medical Officer  and 
Safety medical monitor   
Chiltern International kft  
Canada Square Office House  
Ganz u  

 
 
Dasiglucagon (ZP4207)  Date: 26-Jan 2018  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 4.[ADDRESS_1115311]  
Hungary  
Phone:   
Pharmac ovigilance unit  
Responsible for Serious Adverse 
Event (SAE) Management and 24 -
hour SAE reporting    
PharmaLex  
Agern Allé 24  
2970 Hørsholm, Denmark  
Phone:   (8 a.m. to 4 p.m.)  
Phone:  (outside 8 a.m. to 4 p.m.)  
Fax:  
email: [EMAIL_7118]   
Central laboratory  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (GlucaGen 
PK, insulin PK)  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (das iglucagon 
PK, dasiglucagon ADA, 
GlucaGen ADA)  York Bioanalytical Solutions (YBS)  
Cedar House  
Northminster Business Park  
Northfield Lane  
York, YO26 6QR, [LOCATION_008]  
Special laboratory  
(neutralizing antibodies)  BioAgilytix  
[ADDRESS_1115312] of all investigators, IECs and IRBs will be provided in a separate document and in  
the clinical t
rial report. 
 

 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115313] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 1 of 81  
CLINICAL TRIAL PROTOCOL 
 
A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen
® 
 
Sponsor:  Zealand Pharma A/S  
Sponsor Protocol No.:  ZP4207 -[ADDRESS_1115314] No. : 2017 -002449 -31  
IND No : 127866  
Trial  Drug Name:  [CONTACT_807506] * injection  
Date of Protocol:  [ADDRESS_1115315] 2017  
 
The trial will be conducted according to the protocol and in compliance with Good 
Clinical Practice (GCP), with the Declaration of Helsinki and with other applicable regulatory requirements. 
*Dasiglucagon is the proposed international nonproprietary name [CONTACT_807507]4207. 
The information in this document is confidential and is proprietary to Zealand Pharma. It is understood that 
information in this document shall not be disclosed to any third party, in any form, without prior written 
consent of an authorized officer of Zealand Pharma. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115316] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 3 of 81  
Declaration of the coordinating investigator 
[CONTACT_1641]:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen
® 
I have read this protocol. I approve this document and I agree that it contains all necessary details for carrying out the trial as described. I will conduct this trial in accordance with the design and specific provision of this protocol and will make a reasonable effort to complete the trial within the time designated. I will provide copi[INVESTIGATOR_807438] A/S to trial personnel under my supervision. I will discuss this material with them to ensure they are fully informed about the trial product and trial procedures. I will let them know that this information is confidential and proprietary to Zealand Pharma A/S and that it may not be further disclosed to third parties. I understand that the trial may be terminated or enrollment suspended at any time by [CONTACT_93442] A/S, with or without cause, or by [CONTACT_807442]. 
I agree that the trial will be carried out in accordance with GCP (1) , with the Declaration 
of Helsinki (with amendments) (2)  and with the laws and regulations of the countries in 
which the trial takes place.   _____________________________________ _____________________ 
Name       [CONTACT_807512]: + Fax: + 
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115317] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 4 of 81  
Declaration of the investigator 
Title:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen
® 
All documentation for this trial that is supplied to me and that has not been previously published will be kept in the strictest confidence. This documentation includes this trial protocol, Investigator's Brochure, Case Report Forms, and other scientific data. 
The trial will not be commenced without the prior written approval of a properly 
constituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC). No changes will be made to the trial protocol without the prior written approval of the sponsor and the IRB or IEC, except where necessary to eliminate an immediate hazard to the subjects. 
I have read and understood and agree to abide by [CONTACT_348232]. 
 
_____________________________________ _____________________ 
Signature      [CONTACT_1782] 
 
_____________________________________ Name (block letters) 
 
_____________________________________ Title (block letters) 
 
_____________________________________ Institution (block letters) 
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115318] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 5 of 81  
Table of contents 
DECLARATION OF SPONSOR OR RESPONSIBLE MEDICAL OFFICER .......... 2  
DECLARATION OF THE COORDINATING INVESTIGATOR .............................. 3  
DECLARATION OF THE INVESTIGATOR ............................................................... 4  
TABLE OF CONTENTS .................................................................................................. 5  
1 SYNOPSIS ............................................................................................................ 11  
2 INTRODUCTION................................................................................................ 15  
2.1 Background ...................................................................................................... 15  
2.1.1  Hypoglycemia ...................................................................................... 15  
2.1.2  Glucagon .............................................................................................. 16  
2.1.3  Dasiglucagon........................................................................................ 16  
[IP_ADDRESS]  Pharmacokinetics and pharmacodynamics of dasiglucagon ......... 17  
[IP_ADDRESS]  Safety of dasiglucagon ................................................................... 17  
2.2 Trial rationale .................................................................................................. 18  
2.3 Risk-benefit assessment .................................................................................. 18  
3 TRIAL OBJECTIVES AND ENDPOINTS ...................................................... 20  
3.1 Primary objective ............................................................................................ 20  
3.2 Secondary objectives ....................................................................................... 20  
3.3 Primary endpoint ............................................................................................ 20  
3.4 Key secondary endpoints ................................................................................ 20  
3.5 Other secondary endpoints ............................................................................. 20  
3.6 Exploratory endpoint ...................................................................................... 21  
4 OVERALL DESIGN AND PLAN OF THE TRIAL ........................................ 22  
4.1 Overview .......................................................................................................... 22  
4.2 Justification of the trial design ....................................................................... 24  
4.2.1  Justification for design and parameters ................................................ 24  
4.2.2  Justification for drug, route, dosage and treatment duration ............... 24  
5 TRIAL POPULATION ....................................................................................... 26  
5.1 Rationale for trial population ........................................................................ 26  
5.2 Planned sample size and number of trial centers ......................................... 26  
5.3 Inclusion criteria ............................................................................................. 26  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115319] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115320] identification and randomization ..................................................... 30  
6 TRIAL DRUG ...................................................................................................... 32  
6.1 Identity ............................................................................................................. 32  
6.2 Treatment assignment and randomization ................................................... 33  
6.3 Administration ................................................................................................. 34  
6.4 Packaging and labelling .................................................................................. 34  
6.5 Storage of study drugs .................................................................................... 34  
6.6 Blinding and breaking the blind .................................................................... 35  
6.7 Drug accountability ......................................................................................... 36  
6.8 Treatment compliance .................................................................................... 36  
6.9 Prior and concomitant medications ............................................................... 36  
6.9.1  Prohibited medications ......................................................................... 37  
7 PARAMETERS AND METHODS OF ASSESSMENT .................................. 38  
7.1 Efficacy parameters ........................................................................................ 38  
7.1.1  Pharmacodynamic measurements ........................................................ 38  
7.1.2  Pharmacokinetic measurements ........................................................... 38  
7.2 Safety parameters ............................................................................................ 39  
7.2.1  Adverse events ..................................................................................... 39  
[IP_ADDRESS]  Definitions ...................................................................................... 39  
[IP_ADDRESS]  Collection, recording and reporting of adverse events ................. 42  
[IP_ADDRESS]  Follow-up of adverse events .......................................................... 43  
[IP_ADDRESS]  Clinical laboratory abnormalities and other abnormal assessments as adverse events or serious adverse events .............. 44
 
7.2.2  Hypoglycemia ...................................................................................... 44  
7.2.3  Physical examination ........................................................................... 45  
7.2.4  Vital signs ............................................................................................ 45  
7.2.5  Electrocardiogram ................................................................................ 46  
7.2.6  Local tolerability .................................................................................. 46  
7.2.7  Clinical laboratory assessments ........................................................... 47  
7.2.8  Pregnancy ............................................................................................. 48  
7.2.9  Precautions ........................................................................................... 49  
7.2.10  Safety committee ................................................................................. 49  
7.3 Demography, concomitant illness, medical history and concomitant medication ........................................................................................................ 49
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115321] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115322] .............................................................................................. 53  
8.1 Schedule of procedures ................................................................................... 53  
8.2 Procedures by [CONTACT_765] .......................................................................................... 53  
8.2.1  Visit 1 (screening, Day -30 to Day - 3) ................................................. 53  
8.2.2  Instructions to subjects prior to the dosing visit (Visit 2) .................... 55  
8.2.3  Visit 2 (dosing visit)............................................................................. 56  
[IP_ADDRESS]  Hypoglycemic clamp procedure and administration of trial medication ...................................................................................... 57
 
8.2.4  Visit 3 (follow-up visit) ....................................................................... 60  
9 STATISTICAL METHODS ............................................................................... 61  
9.1 Determination of sample size ......................................................................... 61  
9.2 Trial subjects ................................................................................................... 61  
9.2.1  Analysis samples .................................................................................. 61  
9.2.2  Disposition of subjects ......................................................................... 62  
9.2.3  Protocol deviations ............................................................................... 62  
9.3 General considerations ................................................................................... 63  
9.4 Demographics and baseline characteristics .................................................. 63  
9.5 Efficacy Analyses ............................................................................................. 63  
9.5.1  Hierarchical testing procedure ............................................................. 64  
9.5.2  Primary confirmatory endpoint ............................................................ 64  
[IP_ADDRESS]  Primary analysis ............................................................................ 64  
9.5.3  Secondary endpoints ............................................................................ 65  
[IP_ADDRESS]  Confirmatory analysis .................................................................... 65  
9.5.4  Secondary clinical efficacy (PD) endpoints ......................................... 66  
[IP_ADDRESS]  Analysis of secondary clinical efficacy (PD) endpoints ................ 66  
9.5.5  Exposure (PK) endpoints ..................................................................... 66  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints ............................................. 67  
9.6 Exploratory analyses ....................................................................................... 67  
9.7 Safety analyses ................................................................................................. 68  
9.7.1  Adverse events ..................................................................................... 68  
9.7.2  Immunogenicity data ........................................................................... 68  
9.7.3  Clinical laboratory assessments ........................................................... 68  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115323] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115324]-treatment blood sampling times ................................................................ 59  
 
Figures in text 
Figure 1  Trial design ........................................................................................................ 23  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115325] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115326]  European Medicines Agency’s Clinical Trials Database  
FAS Full analysis set  
FDA  Food and Drug A dministration  
GCP  Good Clinical Practice  
HbA 1c Glycated hemoglobin  
ICH International Conference  on Harmonization  
ID card  Identification card  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IV Intravenous(ly)  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115327] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 10  of 81  
IWRS  Interactive Web Response System  
MedDRA  Medical Dictiona ry for Regulatory Activities  
NPH  Neutral protamine Hagedorn  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per protocol  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Safety analysis set  
SC Subcutaneous(ly)  
S[LOCATION_003]R  Serious unexpected suspec ted adverse reaction  
T1DM  Type [ADDRESS_1115328]  Upper limit of the normal range  
US [LOCATION_002] of America  
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115329] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 11  of 81  
1 SYNOPSIS 
Name [CONTACT_119019]:  
Zealand Pharma A/S  Trial ID:  
ZP4207 -[ZIP_CODE] 
Title of the trial:  
A phase 3, randomized, double -blind, parallel trial to confirm the clinical efficacy and safety of 
dasiglucagon  in the rescue treatment of hypoglycemia in subjects with type 1 diabetes m ellitus (T1DM) 
compared to placebo and with reference to GlucaGen® 
Trial design:  
The trial is a global, multicenter, randomized, parallel -group , double -blind, clinical trial confirming the 
efficacy and safety of dasiglucagon  for insulin -induced hypoglyce mia in subjects with type 1 diabetes  
mellitus . The subjects will be randomized 2:1:1 to receive a single fixed subcutaneous 0.6 mg dose of 
dasiglucagon  (hereinafter dasiglucagon) , placebo  for dasiglucagon (hereinafter referred to as placebo) , or a 
1 mg dose of GlucaGen® (hereafter referred to as GlucaGen) and followed for at least 28  days after 
treatment.  
Clinical phase of development:  
Phase 3 
Trial centers : 
This trial will be conducted at 4 to 6 sites in the [LOCATION_002] of America , Canada, and Europe . 
Planned trial start ( first subjec t first visit):  
Q4/2017 Planned trial end ( last subjec t last visit):  
Q3/2018  
Trial population:  
Male and female adult  subjects  with type [ADDRESS_1115330] one year   
Key objectives:  
Primary objective:   
 To demonstrate superiority  of dasiglucagon  compared to placebo  following a single subcutaneous  
0.6 mg dose administered to subjects with type 1 diabetes mellitus  with insulin -induced 
hypoglycemia . 
Secondary objective:   
 To compare the glyc emic response observed after  dasiglucagon  with that of  GlucaGen . 
Key endpoints:  
Primary endpoint:   
 Time to  plasma glucose  recovery. Plasma glucose recovery is defined as first increase in plasma 
glucose of  ≥20 mg/dL  (1.1 mmol/L) from baseline  during the hypoglycemic clamp procedure  
without administration of rescue intravenous ( IV) glucose .  
Key s econdary endpoint s: 
 Plasma glucose recovery  within 30 minutes, within 20 minutes , within 15 minutes, and within 
10 minutes  after study drug injection  without administration of rescue IV glucose . 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes , within 15 minutes, 
and within 10 minutes  after study drug injection  or at the time of rescue . 
Clini cal efficacy  (Pharmacodynamic ) endpoints:  
 Time to first plasma glucose concentration of ≥70 mg/dL ( 3.9 mmol/L ) without administration of 
rescue IV glucose . 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115331] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 12  of 81  
 Plasma glucose response as  area under the curve  above baseline  from time zero to 30 minutes, 
AUC0-30min. 
Exposure (Pharmacokinetic) endpoints:  
 Area under th e drug concentration curve from time zero to 90 minutes , AUC 0-90 min. 
 Maximum plasma drug concentration (C max). 
 Time to maximum plasma  drug concentration (t max). 
Safety endpoints:   
 Adverse events, clinical laboratory assessments (biochemistry, hematology, coagulation, urinalysis), 
vital signs, physical examination, electrocardiogram, and local tolerability.  
 Administration  of rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
 Time to first rescue infusion of IV glucose during the hypoglyc emic clamp procedure.  
Immunogenicity endpoint:  
 Occu rrence  of anti -drug antibodies  
Exploratory endpoint:  
 Plasma g lucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL (1.1 mmol/L) 
within 30  minutes after study drug injection  without administr ation of rescue IV glucose . 
 Plasma insulin response as area under the curve above baseline from time zero to  60 minutes , 
AUC 0-60 min. 
Key inclusion criteria:  
 Male and female subject s with type [ADDRESS_1115332] one year , 
diagnostic criteria as defined by [CONTACT_807443] n. 
 Stable  insulin treatment 30 days prior to screening, defined as no more than a 10 -unit daily variation 
in total  daily insulin dose . 
 Hemoglobin A 1c <10%.  
 Aged between 18 and 75 years, bo th inclusive . 
Key exclusion criteria:  
 Previously treated with dasiglucagon . 
 Known or suspected allergy to trial product(s) or related products.  
 History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).  
 Previous participation (rand omization) in this trial.  
Sample size:  
Approximately  [ADDRESS_1115333]:  
Test product: dasiglucagon  liquid form ulation in pre -filled syringes . 
Comparator  product s: Placebo and GlucaGen® lyophilized powder . 
Duration of treatment:  
Subjects will be randomized 2:1:[ADDRESS_1115334] 28 days after receiving treatment .  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115335] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 13  of 81  
Assessments:  
The plasma glucose profile for evaluation of the primary and secondary clinical efficacy 
(pharmacodynamic) endpoints will be assessed based  on plasma concentration data from samples collected 
at the dosing visit.  
The exposure to  trial medication (dasiglucagon , placebo , or GlucaGen) for evaluation of pharmacokinetics  
will also be assessed based on plasma concentration data .  
Statistical metho ds:  
Due to requirements in the size of the safety database, the sample size is set to 78 subjects treated with 
dasiglucagon 0.6  mg. With a 2:1:1 randomization ratio for the three treatments, dasiglucagon  0.6 mg, 
placebo , and GlucaGen 1 mg, 78 subjects inj ected with dasiglucagon and 39 subjects with placebo will 
yield a power of 90% at a 5% two -sided significance level to detect a treatment group difference in recovery 
incidence within 20 minutes, assuming as low as 80% and as high as 50% recovery incidence  for the 
dasiglucagon and placebo groups, respectively.  
For the confirmatory analyses, the primary and key secondary endpoints for the dasiglucagon 0.6  mg and 
placebo  treated subjects will be compared. A hierarchical procedure will be applied for the contr ol of 
multiplicity  in statistical inferences . The primary and secondary endp oints will be evaluated on the Full 
Analysis Set sample . The statistical inference comparisons with placebo will be conducted as superiority 
tests. The comparisons of  dasiglucagon versus GlucaGen will be summarized descriptively .    
The primary endpoint will be summarized using Kaplan -Meier  (KM)  estimates stratified by [CONTACT_807444]. The tre atment group difference between  dasiglucagon and placebo will be evaluat ed 
inferentially using a pairwise two -sided log -rank test.  
In the primary analysis, those subjects who require rescue IV glucose will be censored at the time of plasma 
glucose recovery. This approach is based on the assumption that rescue IV glucose admini stration will 
shorten the time to recovery. This assumption implies that censoring at the time of recove ry after rescue 
therapy is valid as a time to recovery without rescue would be longer than the observed duration. If recovery 
has not occurred at 45 min utes after study drug injection, censoring will be applied irrespective of the use of 
rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without censoring at the 
time of recovery for those subjects who requ ire rescue IV glucose before 45 minutes and 2) with censoring 
at the time of administration of rescu e IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards (CPH) time to event 
statistical model,  if the hazards by [CONTACT_807445] a graphical 
comparison of log -minus -log survival curves and no more than two -thirds of the recovery times are 
censored in each treatment group. The CPH model will be used for inferences, with treatment group and 
injection site modeled as categorical effects, and baseline plasma glucose modeled as a continuous 
covariate. The treatment group rate ratios, active versus placebo, will be estimated together with the 95% 
confidence intervals, and  pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs 
placebo) will be evaluated using two -sided likelihood ratio tests.  
The key secondary incidence variables (plasma glucose recovery within 30 minute s, within 20 minutes, 
within 15  minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive 
statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be 
assessed via pairwise tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115336] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 14  of 81  
versus placebo) using Fisher’s exact test for each pairwise comparison.  
The key secondary endpoints of plasma glucose changes from baseline (CFB) within [ADDRESS_1115337] in those subjects who require rescue IV 
glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an 
Analysis of Covariance model, with treatment group modeled as a fixed effect and with the baseline plasma 
glucose modeled as a covariate. The dasiglucagon versus placebo treatment gr oup difference will be 
evaluated inferentially as a least squares means contrast, using a two -sided t -test at the 0.[ADDRESS_1115338] asma glucose  CFB variables.   
The safety analyses will include by -treatment -group descriptive summaries of vital sign measurements, 
laboratory measures (including immunogenicity incidence), physical examination assessments, rescue IV 
glucose (incidence and  amount of glucose infused), and adverse events. The number and percentage of 
subjects reporting specific events, such as nausea and vomiting, will be presented by [CONTACT_430449].  
Further details will be included in the Statistical Analysis  Plan, to be completed before dat abase lock and 
treatment unmasking.   
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115339] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 15  of 81  
2 INTRODUCTION 
2.1 Background 
Zealand Pharma A/S (Zealand Pharma) is developi[INVESTIGATOR_807428], a physically and chemically stable peptide analog of human glucagon, in a ready- to-use liquid formulation 
for the acute treatment of severe hypoglycemia in patients with insulin-treated diabetes mellitus. Like native glucagon, dasiglucagon is comprised of 29 amino acids, but with 7 substitutions which improve its physical and chemical stability in aqueous media. These amino acid substitutions make dasiglucagon suitable for a liquid formulation, while providing similar efficacy and safety as compared with recombinant glucagon in the clinical setting of acute treatment of severe hypoglycemia. 
2.1.1 Hypoglycemia  
Hypoglycemia in patients with diabetes is defined as epi[INVESTIGATOR_807429] (3). This is a common, unpredictable, and potentially 
dangerous side effect of treatment of diabetes mellitus, especially with insulin or 
sulfonylureas. It is more frequent in patients with profound endogenous insulin 
deficiency, such as occurs in type 1 diabetes mellitus (T1DM) and advanced type 2 
diabetes mellitus (T2DM). Treatment of T2DM with insulin causes hypoglycemia progressively and more frequently over time, whereas in T1DM, hypoglycemia is experienced throughout the course of established disease (4). 
Symptoms and signs of hypoglycemia are not specific. Patients undergoing a hypoglycemic epi[INVESTIGATOR_460616], sweating, hunger, tremors, palpi[INVESTIGATOR_814], paresthesia, nausea and pallor. Depending on its severity, the hypoglycemia may lead to mild confusion, behavioral changes, loss of consciousness, seizures, coma, and death (5). 
The incidence of hypoglycemic events or even the fear of hypoglycemia influences patients’ adherence to prescribed treatment regimens for diabetes mellitus (6) . This leads 
to inadequate glycemic control, which in turn may lead to an increased risk of diabetic complications (5) . Serious clinically significant hypoglycemia is now defined as plasma 
glucose <54 mg/dL (3.0 mmol/L), while the plasma glucose alert value is defined as <70 mg/dL (3.9 mmol/L) (7). When plasma glucose falls below these values, some kind 
of treatment strategy is needed. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115340] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 16  of 81  
2.1.2 Glucagon 
Glucagon is a naturally occurring hormone, secreted from the alpha cells of the pancreatic islets. Glucagon plays a central role in the regulation of glucose homeostasis and is the counterpart of insulin for controlling blood glucose levels (i.e. it acts in opposition to insulin in terms of effects on blood glucose levels) (8,9). Glucagon stimulates hepatic glycogenolysis and gluconeogenesis in hypoglycemic states, thereby [CONTACT_93406]. Glucagon receptor agonism has also been shown to exert effects on lipid metabolism, energy balance, body adipose tissue mass and food intake (10). Insulin decreases blood glucose levels and cases of hypoglycemia can be reversed 
by [CONTACT_41148]. Therefore, glucagon is indicated for the treatment of severe hypoglycemia. 
Besides intravenous (IV) glucose administration, an injectable form of glucagon is given 
as first aid in cases of severe hypoglycemia, when the patient is unconscious or for other 
reasons cannot take glucose orally. The approved glucagon dose for an adult is 1 mg, 
given by [CONTACT_33813] (IM), IV, or subcutaneous ( SC) injection, which quickly raises 
blood glucose levels. As current marketed recombinant glucagon is highly unstable when dissolved in solution, the injectable form has to be reconstituted prior to use in a 9-step procedure that requires a sterile diluent to be injected into a vial containing lyophilized powdered glucagon. When dissolved in a fluid state, glucagon can form amyloid fibrils 
(11), or tightly woven chains of proteins made up of the individual glucagon peptides. 
The reconstitution process makes the use of marketed glucagon products cumbersome 
(12), and a more patient-friendly formulation is needed. Currently, the Food and Drug 
Administration (FDA ) approved instructions for commercially available glucagon allow 
only for immediate usage of glucagon after the powder is reconstituted in aqueous solution (13). Therefore, a glucagon analog with enhanced biophysical stability may 
represent a leap forward in terms of convenient therapeutic applications. 
2.1.3 Dasiglucagon 
Dasiglucagon (ZP4207) is a stable peptide analog of human glucagon, available in a ready- to-use liquid formulation. Dasiglucagon (hereinafter referred to as dasiglucagon) is 
in development for the treatment of severe hypoglycemia in insulin-dependent patients with diabetes mellitus. Dasiglucagon is a specific and full glucagon receptor agonist designed to mimic the effects of glucagon, having a fast absorption and elimination (minutes). It is a peptide of 29 amino acids, with 7 amino acid substitutions compared to native glucagon. The main purpose of the substitutions is to increase the physical and chemical stability of the glucagon analog compared to marketed glucagon products such as Lilly Glucagon or GlucaGen
® (hereafter referred to as GlucaGen). Dasiglucagon 
exhibits improved physical and chemical stability and is available in an aqueous solution at neutral pH (14) . 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115341] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115342] been completed with dasiglucagon: a first- in-human dose trial in 
healthy volunteers and subjects with T1DM (ZP4207-[ZIP_CODE]), a multiple-dose dose-escalation trial (ZP4207-[ZIP_CODE]) evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of dasiglucagon in healthy volunteers, and a phase 2 crossover trial to assess the PK and PD of a single dose of an optimized formulation of 
dasiglucagon administered SC in subjects with T1DM (ZP4207-[ZIP_CODE]) (14) . 
[IP_ADDRESS]  Pharmacokinetics and pharmacodynamics of dasiglucagon 
The results of the phase [ADDRESS_1115343] absorption with a peak plasma 
concentration obtained after 35 minutes. Thereafter, the plasma concentration rapi[INVESTIGATOR_93381]-life of 28 minutes. The median time to the maximum plasma concentration (t
max) was [ADDRESS_1115344] 70 mg/dL (3.9 mmol/L) as well as an increase in plasma glucose by [CONTACT_2669] 20 mg/dL (1.1 mmol/L) within 30 minutes after dosing. The PD  responses to 0.6 mg of 
dasiglucagon and 1 mg of GlucaGen were comparable. 
[IP_ADDRESS]  Safety of dasiglucagon 
The safety data for dasiglucagon do not give rise to any safety concerns. No new signals 
were observed, beyond those related to the pharmacological effect of glucagon agonism. All adverse events (AEs) recorded in the trials were of mild or moderate severity. The most frequently reported systemic AE was nausea, which is a known side effect following administration of glucagon. Headache was the next most frequently reported event, occurring in all dose groups in the phase [ADDRESS_1115345] (IMP) doses of at least 1 mg (4 with dasiglucagon and 1 with GlucaGen). This is not considered a safety concern; however, hemodynamic changes after dosing will be considered an adverse event of special interest (AESI). 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115346] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 18  of 81  
The phase 1 and 2 results and the safety profile described to date do not give rise to specific safety concerns. For further information, please refer to the Investigator’s Brochure ( 14). 
2.2 Trial rationale 
The aim of the current trial is to confirm the superiority of dasiglucagon for the treatment of insulin-induced hypoglycemia in subjects with T1DM as compared to placebo for dasiglucagon (hereinafter placebo) and to compare the clinical efficacy and safety of dasiglucagon with reference to GlucaGen. A randomized, controlled trial design was used. 
See Section  4.[ADDRESS_1115347] also been observed to a limited extent in the 3 clinical studies conducted to date with dasiglucagon. As with every novel drug substance, new and as yet unknown side effects may also occur. 
There are limited data available to assess the immunogenic potential of glucagon 
products available on the market, but the data available indicate that marketed glucagon only has a low immunogenic potential.  
Overall, dasiglucagon is judged to be a low-risk molecule, based upon the available 
clinical data. Administration of dasiglucagon may be associated with a risk of allergic 
reactions similar to those observed for other therapeutic peptides or proteins. Subjects 
with known or suspected allergies to the trial medications or related products will be 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115348] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115349] relevant clinical effects in the acute severe hypoglycemia rescue setting and may be 
an effective and reliable emergency treatment for severe hypoglycemia. Overall, the 
anticipated benefits for subjects entering the ZP4207-[ZIP_CODE] trial are considered to justify the risks. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115350] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 20  of 81  
3 TRIAL OBJECTIVES AND ENDPOINTS 
3.1 Primary objective 
 To demonstrate superiority of dasiglucagon compared to placebo following a single 
subcutaneous 0.6 mg dose administered to subjects with type 1 diabetes mellitus with 
insulin-induced hypoglycemia. 
3.2 Secondary objectives 
 To compare the glycemic response observed after dasiglucagon with that of 
GlucaGen. 
3.3 Primary endpoint 
 Time to plasma glucose recovery. Plasma glucose recovery is defined as first increase 
in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue IV glucose.  
3.4 Key secondary endpoints 
 Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
3.5 Other secondary endpoints 
 Clinical efficacy (PD) endpoints: 
- Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without 
administration of rescue IV glucose. 
- Plasma glucose response as area under the curve (AUC ) above baseline from time 
zero to 30 minutes, AUC
0-30min . 
 Exposure (PK) endpoints: 
- Area under the drug concentration curve from time zero to 90 minutes, AUC
0-90min . 
-  Maximum plasma drug concentration (C max). 
- Time to maximum plasma drug concentration (t max). 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115351] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 21  of 81  
 Safety endpoints:  
- Adverse events, clinical laboratory assessments (biochemistry, hematology, coagulation, urinalysis), vital signs, physical examination, electrocardiogram (ECG), and local tolerability. 
- Administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. 
- Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure. 
 Immunogenicity endpoint: 
- Occurrence of anti-drug antibodies 
3.6 Exploratory endpoint 
 Plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL 
(1.1 mmol/L) within 30 minutes after study drug injection without administration of rescue IV glucose. 
 Plasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC
0-60 min . 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115352] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 22  of 81  
4 OVERALL DESIGN AND PLAN OF THE TRIAL 
4.1 Overview 
This trial is a global, multicenter, randomized, parallel, double-blind, clinical trial 
confirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in subjects with T1DM. The subjects will be randomized 2:1:[ADDRESS_1115353] 28 days after receiving treatment. A total of 156 subjects with T1DM are expected to complete the treatment visit. The trial will be conducted in the European Union ( EU) 
and North America. See Figure 1 for an overview of the trial design. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115354] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 23  of 81  
Figure 1 Trial design 
 
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115355] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115356] selection and in the evaluation of clinical assessments, subjects will be randomly assigned 2:1:[ADDRESS_1115357] been used to 
establish that 0.6 mg of dasiglucagon is an effective dose and also represents a 
therapeutically equivalent dose to 1 mg of GlucaGen (see also Section  6.1). 
Dasiglucagon, placebo, and GlucaGen will be administered in the abdomen, buttocks, or 
thigh by [CONTACT_128193], as this is one of the intended routes of administration for 
dasiglucagon, besides IM and IV. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115358] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115359] 28 days after dosing in order to perform an adequate immunogenicity evaluation of treatment.  
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115360] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115361] ed to complete the treatment visit 
(Visit 2). To quali fy as completed, the subject must be dosed and have blood drawn for 
the PK and PD assessments describ ed in the protocol. It is expect ed that up to 
[ADDRESS_1115362] 156 subjects completing Visi t 2. Completion of 
156 subjects (78 subjec ts in the da siglucagon group and 39 subjects i n each of the 
placebo and GlucaGen groups) would be expected to provide adequate power for the 
primary efficacy evaluation, as described in Section  9.1. 
The planned date for first subject first visit is expected to take place in Q4, [ADDRESS_1115363] in Q3, 2018. 
This trial is planned to be conducted at 4 to 6 trial sites in the [LOCATION_002] of America 
[US], Canada, and Europe. 
5.3 Inclusion criteria 
Subjects will be entered into this trial only if they meet all of the following criteria: 
1. Informed consent obtained before any trial-related activities (trial-related
activities are any procedure that would not have been performed during normal
management of the subject).
2. Female or male subjects with T1DM for at least 1 year, diagnostic criteria as
defined by [CONTACT_11026] (3).
3. Treated with insulin for T1DM for at least 1 year and with stable insulin treatment
(defined as no more than a 10-unit daily variation in total daily insulin dose)
30 days prior to screening
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115364] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 27  of 81  
4. Hemoglobin A 1c <10%. 
5. Aged between [ADDRESS_1115365] meet one of the following criteria: 
a. Participant is of childbearing potential and agrees to use one of the accepted contraceptive regimens throughout the entire duration of the trial from screening and until last follow-up visit. Additionally, if the participant is using systemic contraceptives, she must use an additional form of acceptable contraception. An acceptable method of contraception includes one of the following: 
i. Abstinence from heterosexual intercourse; 
ii. Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/ insertable hormonal birth control products, transdermal patch); 
iii. Intrauterine device (with and without hormones); or 
iv. Condom with spermicide; or 
b. Participant is of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation), or in a menopausal state (at least 1 year without menses). 
7. A male subject must meet the following criteria: Surgically sterilized or willing to refrain from sexual intercourse from screening and until last follow-up visit or, if sexually active, uses condom and partner practices contraception during the trial 
from screening and until last follow-up visit. 
5.4 Exclusion criteria 
Subjects meeting any of the following criteria during screening evaluations will be 
excluded from trial participation: 
1. Previously treated with dasiglucagon (previously referred to as ZP4207). 
2. Known or suspected allergy to trial product(s) or related products. 
3. History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema). 
4. Previous participation (randomization) in this trial. 
5. Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating. 
6. History of hypoglycemic events associated with seizures in the last year prior to screening. 
7. History of severe hypoglycemia (defined as plasma glucose <54 mg/dL [3.0 mmol/L]) in the last month prior to screening. 
8. Receipt of any investigational drug within [ADDRESS_1115366] 5 years. 
10. Congestive heart failure, [LOCATION_001] Heart Association class II-IV. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115367] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 28  of 81  
11. Inadequately treated blood pressure, defined as systolic ≥160 mmHg or diastolic ≥90 mmHg) at screening (15) . 
12. Current bleeding disorder, including anti-coagulant treatment. 
13. Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or insulinoma (i.e. insulin secreting pancreas tumor). 
14. Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial. 
15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the upper limit of the normal range (ULN), bilirubin >1.5 × ULN, estimated glomerular filtration rate <30 mL/min/1.73 m
2 according to the Modification of 
Diet in Renal Disease study definition (16), or altered electrolyte values of 
clinical relevance for cardiac conduction, as judged by [CONTACT_093]. 
16. Clinically significant abnormal ECG at screening as judged by [CONTACT_093]. 
17. Clinically significant illness within [ADDRESS_1115368] 2 months prior to screening. 
20. A positive result in the alcohol and/or urine drug screen at the screening visit. 
Significant history of alcoholism or drug abuse as judged by [CONTACT_460675] [ADDRESS_1115369]’s typi[INVESTIGATOR_93379], and should not exceed a near maximum intensity for more than 20 minutes per day, or moderate intensity for more than 90 minutes per day. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115370] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115371]. 
4. Not fasting from 22:00 hours the evening prior to dosing, apart from water. Small amounts of carbohydrates (up to 20 g) to prevent hypoglycemia are allowed. 
5. The use of any non-prescribed systemic or topi[INVESTIGATOR_73201], except routine vitamins and occasional use (as judged by [CONTACT_093]) of acetylsalicylic acid and paracetamol within 2 weeks prior to dosing. Treatment with insulin, including 
analogs, is allowed. 
6. Use of insulin Degludec or insulin Glargine U300 within 48 hours prior to dosing; or use of other long-acting insulins (e.g., insulin Glargine U100 or insulin 
Detemir) within 24 hours prior to dosing; or use of insulin Neutral protamine 
Hagedorn (NPH) within 16 hours prior to dosing. 
7. Use of any short acting (bolus) insulin within 6 hours prior to dosing, except insulin glulisine (Api[INVESTIGATOR_27976]
®). 
8. Changes in medical history or concomitant medication resulting in fulfillment of clinical exclusion criteria, as judged by [CONTACT_093]. 
9. Plasma glucose value <50 mg/dL (2.8 mmol/L) within the last 24 hours or plasma glucose value <60 mg/dL (3.3 mmol/L) within the last [ADDRESS_1115372] has the right to withdraw from the 
trial at any time and for any reason. If he/she chooses to withdraw, the investigator must be informed immediately. The investigator has the right to terminate participation of any subject at any time if the investigator deems it in the subject's best interest. The reason and circumstances for withdrawal wi ll be documented in the electronic case report form 
(eCRF). 
5.6.[ADDRESS_1115373] will be discontinued from treatment if the following applies: 
 Withdrawal of consent by [CONTACT_1130]. 
 If a protocol deviation occurs which, in the clinical judgement of the investigator, can 
invalidate the trial or endpoints or can interfere pharmacokinetically or 
pharmacodynamically with the trial product, the subject will be discontinued by [CONTACT_093]. 
 Adverse events occur which are considered unacceptable by [CONTACT_579585]. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115374] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115375] return and participate in the complete follow-up visit on Da y 
28 (see Table 3) to avoid missing data. 
If trial participation is terminated due to an AE possibly related to any of the trial medications or trial examinations, the subject must be followed up by [CONTACT_807491]. 
A total of [ADDRESS_1115376] complete the treatment visit (Visit 2). To qualify as 
completed, the subject must be dosed and have blood drawn for the PK and PD 
assessments described in the protocol.  
5.6.2 Center discontinuation 
The center can be closed and the trial terminated for the following reasons: 
The center is unlikely to be able to recruit sufficient subjects within the agreed time
frame.
The center does not respond to trial management requests.
Repeat protocol violations.
5.6.3 Trial termination 
The sponsor reserves the right to modify or terminate the trial at any time. Possible 
reasons for termination are: 
Safety reasons – the incidence of AEs in this or any other trial using the same trial
medication indicates a potential health risk for the subjects.
New scientific knowledge becomes known that makes the objectives of the trial no
longer feasible/valid.
Unsatisfactory enrolment of subjects.
5.[ADDRESS_1115377] given written informed consent and meet all inclusion and none of the 
exclusion criteria will be randomized in a 2:1:1 ratio to either 0.6 mg dasiglucagon (n=78), placebo (n=39), or 1 mg GlucaGen (n= 39) via an Interactive Web Response 
System (IWRS). Randomization will continue until [ADDRESS_1115378] completed Visit 2. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115379] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115380] code can be broken by [CONTACT_093], preferably after consultation with the medical monitor. Emergency code breaks can be performed using the IWRS. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115381] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 32  of 81  
6 TRIAL DRUG 
6.1 Identity 
The following trial drugs will be administered: 
Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a prefilled syringe.
Placebo, liquid formulation, 0.6 mL delivered in a prefilled syringe.
Recombinant glucagon hydrochloride, 1 mg for reconstitution (GlucaGen®, Novo
Nordisk) in [ADDRESS_1115382]  
Name  [CONTACT_807511]® 
Active 
substance  Dasiglucagon  N/A Recombinant 
glucagon 
hydrochloride  
Formulation  Liquid formulation, 
0.6 mL  Liquid formulation, 
0.6 mL  Powder and solvent 
for reconstitution as 1 
mL solution for 
injection  
Strength  1 mg/mL  N/A 1 mg  
Device  Single use pre -filled 
syringe  Single use pre -filled 
syringe  Powder and solvent 
for reconstitution 
packed together in a 
plastic box. A “hypo -
kit”. 
Manufacturer  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Novo Nordisk A/S, 
Bagsværd, Denmark  
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115383] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115384]  
Storage 
requirements  Store between 2 and 
8°C Store between 2 and 
8°C Store between 2 and 
8°C 
The quantities of ingredients for dasiglucagon and placebo are provided in Table 2. 
Table [ADDRESS_1115385] bo injecti on 
Component  Amount per mL 
(dasiglucagon)  Amount per mL 
(placeb o) Function  
Dasiglucagon*  1.0 mg  N/A 
Sodium chloride  10.23 mg  10.23 mg  
Trometamol/Tromethamine  6.[ADDRESS_1115386] ochloric acid  q.s. q.s. 
*The quantity of drug substance to be used is calculated according to net peptide content and purity.
q.s. = quantum sufficit (quantity required). 
6.2 Treatment assignment and randomization 
Subjects successfully completing screening and who fulfill entry eligibility and 
randomization criteria will be randomized to one of three treatment groups in a ratio of 2:1:1: 
Test treatment: Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a
prefilled syringe.
Placebo treatment: Placebo, liquid formulation, 0.6 mL delivered in a prefilled
syringe.
Reference treatment: Recombinant glucagon hydrochloride, 1 mg for reconstitution.
Randomization will be performed using a fixed-block randomization scheme. The 
randomization scheme will be generated prior to the initiation of the study by [CONTACT_55467]/programmer who will not be a member of the study team; all investigators will not be aware of the block size of the randomization scheme.  
Randomization will be stratified by [CONTACT_807449] (a bdomen, 
buttocks, or thigh) and controlled via the IWRS.       

 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115387] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 34  of 81  
Subjects will be randomized to study treatment using an interactive, automated system which has been validated for the intended use under the International Society of 
Pharmaceutical Engineers Good Automated Manufacturing Process guidelines, 21CFR 
Part 11 (FDA regulation for Electronic Records and Electronic Signatures) and the International Conference on Harmonization (ICH) Guidance E6 for Industry on Good Clinical Practice (GCP).   
6.3 Administration 
Dasiglucagon, placebo, and GlucaGen will be administered by [CONTACT_807484], buttocks, or thigh.  
An unblinded person (appropriately trained) authorized to prepare the dose and 
administer the treatment in accordance with the randomization will prepare the treatment required for each subject on each dosing day. The dose will be administered by [CONTACT_353660], trained and qualified person. The content of the syringe has to be checked for clarity and absence of bubbles.. 
Syringes will be discarded after dose administration. Used GlucaGen vials will be stored 
in a lockable box (separated from unused vials) at ambient temperature. 
6.[ADDRESS_1115388] label will be compliant with local laws and regulations.  
The study drug label will describe the storage conditions for study drug. The labels will 
supply no information about th e subjects. Each treatment kit (pre-filled syringe/vial for 
reconstitution) will have a unique Dispensing Unit Number for drug allocation, drug accountability, and traceability purposes. 
Labelling will be performed according to Annex [ADDRESS_1115389] ensure the availability of proper storage conditions. All study drug 
supplies provided for this study will be stored in a secure area with restricted access at the 
study site.  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115390] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115391] be stored in a refrigerator (at a temperature of 2–8°C), 
and should be handled in accordance with guidelines from the sponsor. GlucaGen must also be stored in a refrigerator (at a temperature of 2–8°C), and should be handled in accordance with the Summary of Product Characteristics ( 13).  
The unblinded person responsible for study drug handling must contact [CONTACT_807452].  
Please see the Pharmacy Manual for additional information on handling study drug. 
6.6 Blinding and breaking the blind 
This is a double-blind trial. As the trial products are not identical in appearance, 
dasiglucagon and placebo being available as a liquid formulation and GlucaGen as a 
powder for reconstitution, unblinded trial personnel will be responsible for handling, preparing (according to the prescription from the IWRS), and administering the trial medication, as well as for keepi[INVESTIGATOR_807439]. To maintain double-blind conditions, all trial assessments at the trial center will be done by [CONTACT_460637]. However, exposure assessments and anti-drug antibody ( ADA) assessments will be performed by [CONTACT_807454], to ensure that dasiglucagon, placebo, or GlucaGen administration 
is matched with the applicable bioanalytical assay. 
Treatment assignment will be kept strictly confidential and accessible only to authorized 
persons until after the time of unblinding. Codes with treatment assignment will, however, be readily available in the IWRS to the blinded personnel in case of an emergency. 
The code for a particular subject may be broken in a medical emergency if knowing the 
identity of the treatment allocation would influence the treatment of the subject. The emergency code break can be performed using the IWRS. Whenever a code is broken, the person breaking the code must record the time, date and reason as well as his/her initials in the source documents. The breaking of blinded codes in case of medical emergency for 
one subject should not unblind the trial personnel to the treatment information of other 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115392] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115393] be notified within 24 hours after the code has been broken. 
The pharmacovigilance unit (safety contract research organization [CRO];  see the list of 
trial personnel in Section  12.1) will be able to break the code in case of a serious 
unexpect ed suspected adverse reaction (S[LOCATION_003]R).  
The central and specialty laboratories will be provided with a copy of the randomization list. 
6.[ADDRESS_1115394] until approved by [CONTACT_1034].  
6.8 Treatment compliance 
All trial medications will be prepared and administered by [CONTACT_93400]. 
PK assessments will support the surveillance of compliance with IMP administration.  
6.9 Prior and concomitant medications 
Prior glucagon exposure will be recorded in the eCRF at screening. All concomitant 
medications will be recorded and/or updated in the eCRF at each visit.  
Subjects using any new concomitant medication resulting in fulfillment of a dosing day 
exclusion criterion (see Section  5.5) will be excluded from the dosing visit, but can be 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115395] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 37  of 81  
rescheduled to one of the following days (1 –7 days later). The dosing visit can only be 
rescheduled once. 
6.9.1 Prohibited medications 
The use of anti-coagulant treatments and medications (prescription and non-prescription) 
that are known to cause QT prolongation are prohibited during the course of the trial. 
Within 28 days prior to dosing, the use of daily systemic beta-blockers, indomethacin, 
warfarin, and anticholinergic drugs is prohibited. 
Within 2 weeks prior to dosing, the use of any non-prescribed systemic or topi[INVESTIGATOR_73264] (with the exception of vitamins and the occasional use of acetylsalicylic acid and paracetamol) is prohibited.  
Within 48 hours prior to dosing, the use of insulin Degludec or insulin Glargine U300 are 
prohibited. 
Within 24 hours prior to dosing, the use of long-acting insulin (e.g., insulin Glargine 
U100 or insulin Detemir) is prohibited. 
Within 16 hours prior to dosing, the use of insulin NPH is prohibited. 
Within 6 hours prior to dosing, the use of any short acting (bolus) insulin, except insulin 
glulisine (Api[INVESTIGATOR_27976]
®) is prohibited.  
During the insulin-induced hypoglycemic procedure, continuous SC  insulin infusion must 
be stopped. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115396] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115397] be available prior to sample analyses. A bioanalytical report for each analysis of trial PD and PK samples will be prepared. 
7.1.1 Pharmacodynamic measurements 
The plasma glucose profile for evaluation of the primary and secondary clinical efficacy 
endpoints will be assessed based on plasma concentration data (AUC
0-30min ) from samples 
collected at the dosing visit (Visit 2). The samples will be sent to the clinical laboratory 
and analyzed using a sensitive and validated assay for glucose measurements.  
Samples will be collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 
75, and 90 minutes after dosing (see the schedule of procedures in Table 3). The actual 
time of blood sampling for evaluation of plasm a glucose should not deviate from the 
nominal time by [CONTACT_726] ±30 seconds until the 20 minute collecti on time point and by 
[CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as 
withi n 2 minutes prior to dosing. 
7.1.2 Pharmacokinetic measurements 
The exposure to trial medication (dasiglucagon or GlucaGen) for evaluation of PK  will 
be assessed based on plasma concentration data (AUC 0-90 min , Cmax, tmax) from samples 
collected at the dosing visit (Visit 2).  
Samples (including back-up samples) will be collected pre-dose, and at 15, 30, 35, 40, 50, 
60, 90, and 120 minutes after dosing (see the schedule of procedures in Table 3). The 
actual time of blood sampling for exposure to trial medication should not deviate from 
the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior 
to dosing. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115398] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 39  of 81  
7.2 Safety parameters 
7.2.1 Adverse events 
The investigator is responsible for the detection and documentation of events meeting the criteria and definition of an AE or serious adverse event (SAE), as provided in this protocol. During the trial, the investigator or center staff will be responsible for reporting AEs and SAEs, as detailed in this section of the protocol.  
Based on the investigator’s clinical judgment it will be determined whether an AE is 
related to treatment and of sufficient severity to require the subject’s removal from treatment or from the trial. A subject may also voluntarily withdraw from treatment due to what he or she perceives as an intolerable AE. If either of these situations arises, the subject should be under medical supervision until symptoms cease or the condition becomes stable. 
[IP_ADDRESS]  Definitions 
Adverse event 
An AE is any untoward medical occurrence in a trial subject given an IMP which does 
not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and/or unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not considered related to the IMP.  
In this trial, only treatment-emergent adverse events (TEAEs) will be collected and 
reported. TEAEs are events that occur from the first trial-related activity after the subject has signed the informed consent form until the end of the post-treatment follow-up period.  
AEs include: 
A clinically significant worsening of a concomitant illness.
A clinical laboratory abnormality which is clinically significant, i.e. any abnormality
that suggests a disease and/or organ toxicity and is of a severity that requires active
management. Active management includes active treatment or further investigations,for example change of medicine dose or more frequent follow-up due to theabnormality.

Hypoglycemic epi[INVESTIGATOR_1841] (see Section  7.2.2).
Injection site reactions (see Section  7.2.6).
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115399] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 40  of 81  
The following should not be recorded as AEs, if recorded at screening (on the Screening Form or eCRF): 
 Pre-planned procedure, unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent. 
 Pre-existing conditions found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness). 
Serious adverse event 
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  
 Is life-threatening  
 Requires inpatient hospi[INVESTIGATOR_1081] 
 Results in persistent or significant disability or incapacity 
 Is a congenital anomaly or birth defect 
 Is medically important* 
*Medical judgement must be exercised in deciding whether an AE is believed to be 
‘medically important’. Medically important events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_31348]. 
Adverse drug reaction 
All noxious and unintended responses to an investigational product related to any dose 
should be considered adverse drug reactions. The phrase responses to an investigational product means that a causal relationship between an investigational product and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out.  
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) 
An AE fulfilling one of the criteria of seriousness and being assessed as related to IMP 
application, the nature or severity of which is not consistent with the applicable reference document (e.g. dasiglucagon Investigator’s Brochure or package leaflet/Summary of Product Characteristics for GlucaGen).  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115400] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115401] 
An AESI is an event which, in the evaluation of safety, has a special focus (e.g. required 
by [CONTACT_21652]). In this trial hemodynamic changes, as defined below, are considered AESIs: 
 Post-dose clinical signs, or measured vital signs, indicating a clinical ly significant 
drop in blood pressure including signs of orthostatic hypotension, vasovagal 
responses or bradycardia.   
 Post-dose change in pulse or blood pressure considered an event of hypo- or 
hypertension as judged by [CONTACT_093].  
Intensity of an adverse event 
The maximum intensity (severity) of all AEs must be assessed by [CONTACT_807457]. Severity should be graded when the AE outcome is known: 
Mild :  A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living. 
Moderate :  A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. 
Severe :  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
A ‘severe’ reaction does not necessarily deem the AE as ‘serious’ and an SAE may not necessarily be ‘severe’ in nature. 
Causality relationship to trial medication 
The causality of each AE should be assessed by [CONTACT_807458]: 
Probable: Good reason and sufficient documentation to assume a causal relationship. 
Possible: A causal relationship is conceivable and cannot be dismissed. 
Unlikely: The event is most likely related to etiology other than the trial product. 
Not related :  No relationship to trial produ ct. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115402] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115403] be assessed by [CONTACT_807459]/her 
staff. The following definitions should be used: 
Recovered/resolved:  The subject has fully recovered, or by [CONTACT_807460]-related activity after the subject signed the informed consent.  
Recovering/resolving: The condition is improving and the subject is 
expected to recover from the event. This term is only applicable if the subject has completed the trial. 
Recovered/resolved with sequelae :  The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE criterion, the AE must be reported as an SAE. 
Not recovered/not resolved :  The condition of the subject has not improved and 
the symptoms are unchanged. 
Fatal :  This term is only applicable if the subject died from 
a condition related to the reported AE. Outcomes of other reported AEs in a subject before he/she died should be assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an SAE. 
Unknown :  This term is only applicable if the subject is lost to 
follow-up. 
[IP_ADDRESS]  Collection, recording and reporting of adverse events 
All events meeting the definition of an AE must be collected and reported from the first trial related activity after the subject has signed the informed consent until the end of the post-treatment follow-up period. At each contact [CONTACT_49877] (visit or telephone, excluding visits where the subject is not seeing the investigator or his/her staff [e.g. visits to the laboratory]) the subject must be asked about AEs. All AEs, either observed by [CONTACT_98138], must be recorded by [CONTACT_237215]. 
The investigator should record the diagnosis, if possible. If no diagnosis can be made the 
investigator should record each sign and symptom as individual AEs. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115404] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115405] also be completed. 
AE information should include the following: 
Date and time of onset and resolution
Date and time of investigator’s first information on the (S)AE
Seriousness
Severity
Causal relationship with IMP
Interruption or withdrawal of treatment during IMP administration and other
measures taken
Outcome.
All AEs are coded; details are described in the trial-specific Data Management Plan. 
If an event classifies as a AESI, the investigator must tick th e AESI box on the AE form 
and complet e the AESI form. The AESI form will capture if the even t was associated 
with any signs or symptoms and captur e the highest/lowest blood pressure and pulse 
measured during the event. The investigator must report all AESIs to the sponsor ’s 
responsible pharmacovigilance unit (Safety CRO; see the list of trial personnel in 
Section  12.1) immediately (within 24 hours) after obtaining knowledge about the event. 
The investigator must report initial information electronically (e.g. in PDF format) on all 
SAEs to the sponsor’s responsible pharmacovigilance unit (Safety CRO; see the list of 
trial personnel in Section  12.1) immediately (within 24 hours) after obtaining knowledge 
about the event. The Safety CRO will inform the medical monitor and the sponsor about 
the reported SAEs. 
It is the responsibility of the Safety CRO to report all S[LOCATION_003]Rs (see Section  [IP_ADDRESS]) that 
occur in this trial to the Competent Authorities and Institutional Review Boar ds 
(IRBs)/Independent Ethics Committees (IECs) in accordan ce with t he local requirements 
in force a nd ICH guideline for GC P. The trial monitor must be inform ed accordingly. 
[IP_ADDRESS]  Follow-up of adverse events 
All AEs that are ongoing at the end of the subject’s participation in the trial will be 
followed-up until the event is resolved or reaches a satisfactory outcome as deemed by [CONTACT_807492], whichever occurs first.   
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115406] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 44  of 81  
Follow-up actions for all SAEs will be performed according to appropriate clinical care practices and may depend on the nature of the event. These will be determined after internal review and/or sponsor review. 
The follow-up information should only include new (updated and/or additional) 
information that reflects the situation at the time of the investigator’s signature. 
Follow-up information on (S)AEs will be updated using the (S)AE form. If a non-serious 
event becomes serious during the follow-up the AE form and SAE form have to be used and reporting timelines follow those of an SAE. 
The investigator must forward follow-up information on SAEs and if previously 
non-serious AEs become SAEs to the Safety CRO immediately (within 24 hours) after obtaining knowledge about the new information. 
The sponsor and/or CROs acting on behalf of the sponsor can upgrade a non-serious AE 
to an SAE. In these situations the investigator will be informed and asked to fill out an 
SAE form and forward to the Safety CRO immediately (within 24 hours). 
[IP_ADDRESS]  Clinical laboratory abnormalities and other abnormal assessments as adverse 
events or serious adverse events 
Abnormal laboratory findings (e.g. biochemistry, hematology, urinalysis) or other 
abnormal assessments (e.g. vital signs) that are judged by [CONTACT_807493]. 
Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the trial or are present at baseline and significantly worsen following the start of the trial will be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by [CONTACT_479732]’s condition, or that are present or detected at the start of the trial and do not worsen, will not be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically significant. 
7.2.2 Hypoglycemia 
Hypoglycemia will be regarded as an AE and recorded and documented on an AE form 
(and SAE form, if applicable). 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115407] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 45  of 81  
Hypoglycemia is defined as a decline in plasma glucose to below 70 mg/dL 
(3.9 mmol/L). However, in the time period from initiation of the hypoglycemic clamp 
procedure (see Section [IP_ADDRESS]) until 45 minutes after dosing, hypoglycemia is defined as 
a decline in plasma glucose to below 45 mg/dL (2.5 mmol/L).  
During the dosing visit, prior to administration of the IMP, a plasma glucose value of 
<45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463]. After administration of the IMP in the period from 8 minutes until 44 minutes after dosing, a plasma glucose value of <45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463], and if a plasma glucose value of ≥70 mg/dL (3.9 mmol/L) is not achieved within the [ADDRESS_1115408] experiences symptoms of hypoglycemia, a plasma glucose measurement 
should be taken in order to classify the event (please refer to Section 7.4.2 for additional 
details).  
7.2.3 Physical examination 
The physical examination will be carried out at screening (Visit 1) and at the follow-up 
visit (Visit 3; see Table 3).  
The physical examination includes examination of the following body systems: head, 
ears, eyes, nose, throat, including the thyroid gland; heart, lung, chest; abdomen; skin and mucosae; musculoskeletal system; nervous system; lymph node; other findings. 
At the screening visit, any abnormality will be recorded and described in the eCRF, 
including the investigator’s assessment of clinical significance (‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’). Clinically significant findings at the screening visit should be recorded as concomitant illness. 
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1). 
7.2.4 Vital signs 
An examination of the following vital signs will be performed at screening (Visit 1), the dosing visit (Visit 2) and at the follow-up visit (Visit 3):  
Diastolic and systolic blood pressure (mmHg) will be measured after at least
[ADDRESS_1115409] in a supi[INVESTIGATOR_2547]. At Visit 1, blood pressure will be measured in
both arms. The blood pressure from the arm with the higher systolic value is
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115410] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115411]’s blood pressure in this trial.  
Pulse (beats per min) measured after at least [ADDRESS_1115412] in a supi[INVESTIGATOR_2547].
Body temperature (°C).
At the dosing visit, measurements will be taken prior to the start of the insulin-induced 
hypoglycemic procedure (within 30 minutes) and at 30, 90, and 300 minutes after dosing 
(see Table 3). The actual time of the assessment should not deviate from the nominal 
time by [CONTACT_726] ±[ADDRESS_1115413] 12-lead ECG will be performed at the screening visit (Visit 1), the dosing visit 
(Visit 2 ; prior to the start of the insulin-induced hypoglycemic procedure [within 
30 minutes])  and at 20, 35, 45, 60, and 300 minutes after dosing) and at the follow-up 
visit (Visit 3; see Table 3). The actual time of the assessment should not deviate from the 
nominal time by [CONTACT_726] ±5 minutes.  
ECG parameters (heart rate, PQ, QRS, QT, QTcB) and any abnormality will be recorded and described in the eCRF including the investigator’s assessment of clinical significance (‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’).  
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1).  
7.2.6 Local tolerability 
Immediately prior to treatment administration, it should be verif ied that the injection site 
is normal. To ensure all injection site assessments are performed at the injection site, the 
site will be marked with a pen prior to injecti on. Assessment of local tolerability at the 
injection site will be performed at the dosing visit (Visit 2; at 30, 120 and 300 minutes 
after dosing), and at the follow-up visit (Visit 3) (see  Table 3) and more frequently, if 
deemed necessary by [CONTACT_20616] r. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_622585] ±10 minut es. In the eCRF, the time of 
assessment and any injection sit e reaction observed will be recorded. I n case of an 
observation, the Local Tolerability form will be completed, as well as the (S)AE form. 
The local tolerability at the injection site will be evaluated by [CONTACT_807464]: spontaneous pain, pain on palpation, itching, redness, edema, 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115414] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 47  of 81  
induration/infiltration, and other. Each of these assessments will be reported on a scale of 0 (none), 1 (mild), 2 (moderate), and 3 (severe). The evaluation and the actual time of the assessment will be recorded. The assessments will be performed by a trial physician or nurse.  
Digital pi[INVESTIGATOR_807433], and 
thereafter as often as judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_807434] a subject identifier, visit number, time after dosing, and a ruler for scaling. 
7.2.7 Clinical laboratory assessments 
The safety parameters that will be assessed at the clinical laboratory are listed in Table 3. 
Routine clinical laboratory tests will be performed centrally. Samples for clinical laboratory parameters (biochemistry, hematology, coagulation) will be collected at screening (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypoglycemic procedure [within 30 minutes] ) and at 30 and 300 minutes after dosing), 
and at the follow-up visit (Visit 3). The actual time of the assessment should not deviate 
from the nominal time by [CONTACT_726] ±10 minutes. Samples for glycated hemoglobin (HbA
1c) will be collected at screening only (Visit 1). Samples for urinalysis will be 
collected at screening (Visit 1), at the dosing visit (Visit 2, prior to the start of the 
insulin-induced hypoglycemic procedure [within 120 minutes]) and at the follow-up visit 
(Visit 3) . The following parameters will be assessed: 
 Clinical biochemistry: sodium, potassium, calcium, glucose, urea, creatinine, total 
bilirubin, AST, ALT, gamma-glutamyltransferase, alkaline phosphatase, total protein, C-reactive protein, HbA
1c, C-peptide. 
 Hematology: hemoglobin, red blood cell count (erythrocytes), hematocrit, platelet 
count (thrombocytes), total white blood cell count (leukocytes). 
 Coagulation: international normalized ratio, fibrinogen (at screening visit only).  
 Urinalysis: pH, blood (leukocytes and erythrocytes), protein, glucose, ketones, nitrite. 
Pregnancy tests will be performed at each visit for women of childbearing potential only. A serum pregnancy test will be performed at screening (Visit 1) and urine stick tests will 
be performed at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic procedure) and the follow-up visit (Visit 3). Test sticks will be provided to the trial centers. 
Alcohol breath tests and a urine drug screen will be performed at screening (Visit 1) and 
at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic 
procedure ). Equipment for the alcohol breath test and uring drug screen will be provided 
to the trial centers.  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115415] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115416]’s partner will be fully informed by a physician of 
her participation in capturing the outcome data, and will be asked to provide her written consent. 
The investigator must report all information on pregnancies on the Initial Pregnancy 
form. The completed Initial Pregnancy form must be forwarded to the sponsor 
immediately (within 24 hours), according to the procedure stated in Section [IP_ADDRESS]. Any (S)AEs in the mother, as well as other pregnancy complications (ectopic pregnancy) fulfilling the criteria of an (S)AE, must be reported on the (S)AE form.  
The following must be collected in the Initial Pregnancy form:  
 Medical history of the mother 
 Family history 
 Course of the pregnancy, including expected delivery date. 
The investigator must follow the pregnancy until the pregnancy outcome and follow the 
newborn infant(s) until the age of [ADDRESS_1115417] information on the pregnancy and pregnancy complications as well as the pregnancy outcome including the health of the newborn infant(s) on the Pregnancy Outcome form. The completed Pregnancy Outcome form must be forwarded to the sponsor according to the procedure stated in Section [IP_ADDRESS]. Any (S)AEs in the newborn must be reported on the (S)AE form. 
The SAEs that must be reported include abnormal outcome, such as congenital 
anomalies, fetal death and termination of pregnancy (spontaneous or elective abortion), 
including any anomalies of the fetus observed at gross examination or during autopsy.  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115418] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115419] be collected in the Pregnancy Outcome form:  
 Course of the pregnancy 
 Outcome of the pregnancy 
 Condition of the newborn 
 Any AEs in the newborn infant must be followed until the age of [ADDRESS_1115420]’s participation in the trial, the investigator should ensure that adequate medical care is provided to the subject for any AEs, including clinically significant laboratory values related to the trial. The investigator should inform the subject when medical care is needed for intercurrent illnesses of which the investigator becomes aware.  
For further information on safety precautions for dasiglucagon and GlucaGen, please 
refer to the current version of the Investigator’s Brochure (14) and the Summary of 
Product Characteristics for GlucaGen (13), respectively. 
7.2.[ADDRESS_1115421] the subjects. 
7.3 Demography, concomitant illness, medical history and concomitant 
medication 
Demographics, body measurements, concomitant illness and medical history will be assessed only at screening  (Visit 1). Concomitant medication will be assessed at 
screening (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic procedure) and at the follow-up visit (Visit 3). 
7.3.[ADDRESS_1115422] demographics and body measurements will include: 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115423] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 50  of 81  
 Age  
 Race, ethnicity 
 Sex 
 Height (m eters or inch), without shoes 
 Body weight (kg or lb), only wearing underwear and measured using standard scales 
 Body mass index (kg/m2) calculated based on height and body weight (body 
weight/height2). 
7.3.2 Concomitant illness and medical history 
A concomitant illness is any illness that is present at the start of the trial (i.e. at the screening visit). Concomitant illnesses present at the start of the trial will be recorded in the eCRF at screening.  
Medical history is an account of medical events that the subject has experienced in the 
past, including prior medications. Relevant medical conditions/illnesses in the past obtained by [CONTACT_807489]/her medical records will be recorded in the eCRF at screening. History of alcohol or drug abuse will also be recorded. 
The information collected for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution or continuation. 
Any change to a concomitant illness should be recorded during the trial, including end 
date, if applicable. A clinically significant worsening of a concomitant illness must be 
reported according to Section 7.2.1.  
All previous and concomitant diseases will be coded with Medical Dictionary for 
Regulatory Activities (MedDRA), the version of which will be provided in the clinical trial report. 
7.3.3 Diabetes diagnosis and current treatment 
The date of diagnosis of diabetes will be recorded as will the current diabetes treatment 
(start date, product name(s), dose(s)). 
7.3.4 Concomitant medication 
A concomitant medication is any medication, other than the trial products and current 
diabetes treatment (including insulin glulisine [Api[INVESTIGATOR_27976]
®] for diabetes therapy wash-out), 
which is taken during the trial, including screening and follow-up periods. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115424] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115425] be recorded at trial entry (i.e. at screening). Any changes in concomitant medication must be recorded at each visit as they occur. The information collected for each concomitant medication includes (at a minimum) trade name [CONTACT_18058], indication, start date and stop date or continuation. A change in medication due to an AE must be recorded and reported according to Section 7.2.1. If the change in medication influences the subject’s eligibility to continue in the trial, the sponsor and trial monitor must be informed. 
7.[ADDRESS_1115426] dasiglucagon/GlucaGen will be measured at the dosing visit (Visit 2) 
and at follow-up (Visit 3). At the dosing visit (Visit 2), samples will be collected prior to the start of the insulin-induced hypoglycemic procedure.  
The clinical ADA assays, specific for dasiglucagon and GlucaGen, respectively, have 
been validated in accordance with existing guidelines and recommendations (17-21).  
Confirmed positive anti-dasiglucagon antibody samples (treatment-induced or 
treatment-boosted) from anti-dasiglucagon antibody-positive subjects will be evaluated for binding titer neutralizing potential and titer as well as cross-reactivity towards endogenous glucagon.  
No further serum sampling will be needed as the ADA samples can be used for 
neutralizing antibody analysis. 
The in vitro neutralizing effect of the antibodies will be measured using an assay based 
on glucagon receptor transfected human embryonic kidney cells (20,22). The calculated sensitivity in previous studies was about 51.8 ng/mL. The assay was also validated for recombinant glucagon with similar results (21,23). In case of a positive result in the 
neutralizing antibody assay, a titer estimation will be performed. The cell-based neutralizing antibody analyses will be performed by a special laboratory, BioAgilytix, Durham, NC, [LOCATION_003]. 
Residual and additional antibody serum samples may be stored until approval of market 
authorization by [CONTACT_93420]. Further characterization of the antibody response may be requested by [CONTACT_93420]. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115427] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 52  of 81  
7.4.2 Plasma glucose measurements for safety 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at site. After the start of insulin infusion, plasma glucose should be checked every 10 minutes while plasma glucose is above 110 md/dL, and every 5 minutes once plasma glucose is at or below 110 mg/dL and until after dosing when the subject’s plasma 
glucose is ≥70mg/dL (3.9 mmol/L). Hereafter, plasma glucose should be checked every 30 minutes until 300 minutes (5 hours ) after dosing. Plasma glucose concentrations will 
be measured using a US  FDA-approved glucose analyzer (e.g., YSI 2300, Yellow 
Springs Instruments, Yellow Springs, OH). 
At the discretion of the investigator, additional plasma glucose measurements can be 
taken at any time during the trial, for example when there is a suspi[INVESTIGATOR_2798] (e.g. symptoms) of a hypoglycemic epi[INVESTIGATOR_1865]. 
Plasma glucose measurements for safety should only be recorded in the eCRF if they are 
related to an AE (e.g. a hypoglycemic epi[INVESTIGATOR_1865]). 
In case of persistent post-treatment hypoglycemia, subjects will receive rescue treatment 
with an IV glucose infusion (see Section [IP_ADDRESS] for details). Blood samples for PD and 
PK assessments should still be taken at the specified timepoints. 
7.4.3 Plasma insulin measurements 
Samples for insulin assessment will be collected at the dosing visit (Visit 2, pre-dose and 
at 30 and 60 minutes after dosing). The actual time of blood sampling for evaluation of plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115428] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115429] 
8.1 Schedule of procedures 
The schedule of procedures is provided in Table 3 . Informed consent will be obtained 
prior to any trial-related procedures; see Section  10.8. 
8.2 Procedures by [CONTACT_765] 
8.2.1 Visit 1 (screening, Day -30 to Day - 3) 
Visit [ADDRESS_1115430] between 3 and 30 days before Visit 2, Day -1 to Day 1 (dosing day). 
Informed consent can be obtained prior to or at Visit 1, however it must in any case be 
obtained prior to any trial related procedures. During the screening visit, the following assessments will take place: 
Informed consent (obtain or check)
Check of subject eligibility (inclusion/exclusion criteria)
Demography
Body measurements
Medical history, diabetes diagnosis, current diabetes treatment
Concomitant illnesses
Concomitant medications
History of alcohol/drug abuse
Physical examination
Vital signs
12-lead ECG
AEs
Biochemistry, hematology, coagulation, HbA
1c
Serum pregnancy test (women of childbearing potential only)
Urinalysis
Urine drug screen
Alcohol breath test
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115431] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 54  of 81  
Table 3 Schedule of procedures 
Visit number  V1 V2 V3 
Trial day  -3 -1 and 1 28 
Visit type  Screening  Dosing  Follow -up 
Window  -30 to -3  +[ADDRESS_1115432] related information/as sessments     
Informed consent  x   
Inclusion/exclusion criteria  x x1,2  
Demography  x   
Body measurements  x   
Medical history, diabetes diagnosis, and current diabetes 
treatment  x   
Concomitant illness es x   
Concomitant medication s x x1 x 
History of alcohol/drug abuse  x   
Randomization   x1  
Withdrawal criteria   x1  
Dosing day exclusion criteria   x1  
Insulin -induced hypoglycemia   x  
Safety assessments     
Physical examination  x  x 
Vital signs  x x3 x 
12-lead ECG  x x4 x 
Local tolerability   x5 x 
Adverse events  x x x 
Laboratory     
Biochemistry, h ematology, coagulation, HbA 1c (HbA 1c at 
Visit 1  only)  x x6 x 
Pregnancy test (women of childbearing potential only)  x7 x1,[ADDRESS_1115433]  x x1  
PK/C linical efficacy     
Plasma dasiglucagon /GlucaGen   x9  
Plasma glucose   x10  
Other assessments     
Antibodies against dasiglucagon /GlucaGen   x1 x11 
Plasma i nsulin   x12  
Trial material     
Administration of trial product  (during hypoglycemic clamp 
proced ure)  x  
1Prior to the start of the insulin-induced hypoglycemic procedure. 
2Only check of dosing day exclusion criteria and changes between screening visit and Visit 2. 
3Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 30, 90 and 300 minutes 
after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115434] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 55  of 81  
4Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 20, 35, 45, 60 and 300 
minutes after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±5 
minutes.  
5Local tolerability assessed at 30, 120, and 300 minutes after dosing. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes.  
6Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30 and 300 minutes after 
dosing . The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±[ADDRESS_1115435]. 
9Pre-dose, and at 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling should not 
deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
10Pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, 90 minutes after dosing. The actual time of blood 
sampling should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point 
and by [CONTACT_726] ±[ADDRESS_1115436] that tests positive for ADA will be monitored until the ADA levels return to baseline levels. 
12Pre-dose, and at 30 and 60 minutes after dosing. The actual time of blood sampling should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing.  ADA = anti-drug antibodies; ECG = electrocardiogram; HbA
1c = glycated hemoglobin.
Eligible or potentially eligible subjects (laboratory results pending) will be provided with 
an Identification card (ID card), stating that the subject is participating in the trial and 
whom to contact (site address, investigator name [CONTACT_41319]). The subjects should be instructed to return the ID card to the investigator at the last visit or to destroy 
the card after the last visit.  
8.2.2 Instructions to subjects prior to the dosing visit (Visit 2) 
At the screening visit, the investigator wil l inform the subject about t he changes to his/her 
insul in therapy leading up to the start of the insulin-induced hypoglycemic procedure . 
The subjec t may be provided wit h insulin NPH in the wash-out period t o cover the need 
of basal insulin, if deemed necessary by [CONTACT_093]. The subject’s current insulin 
therapy will be washed out as defined in Section  5.5.: 48 hours prior to dosing and during 
the dosing visit , treatment wit h  insulin Degludec and insulin Glargine U300 are not 
allowed ; 24 hours prior to dosing and during the dosing visit, treatment with othe r long-
acting insuli ns (e.g., insulin Glargi ne U100 or insulin Detem ir) is not allowed; 16 hours 
prior dosing and duri ng the dosing visit treatment with insulin NPH is not allowed; 6 
hours prior to dosing and during the dosing visit, treatment with any shor t acting (bolus) 
insul in, except insulin glulisine (Api[INVESTIGATOR_27976]®), is no t allowed. The basa l rate of insulin pumps 
(continuous SC insul in infusion) will be dis continued on the morning of the dosing day 
(if using insulin glulisine [Api[INVESTIGATOR_27976]®]) OR at l east 6 hours prior to dosing (if using other 
insulins). 
On the day prior to dosing (Day -1), the subjects will need to attend the clinical center 
and will be required to stay onsite overnight. On the morning of the dosing day (Day 1), 
patients are required to be in a fasting condition, defined as having consumed only water 
since 22:00 hours the night before. However, the subjects are allowed to consume small 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115437] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 56  of 81  
amounts (up to 20 g) of carbohydrates to prevent hypoglycemia. The subjects must also not consume any alcohol within 24 hours prior to dosing (refer to Section 5.5 for all dosing day exclusion criteria). 
8.2.3 Visit 2 (dosing visit) 
Visit [ADDRESS_1115438] on D ay -1 to Day 1. 
The subjects will attend the clinical center the day prior to dosing (Day -1) and subject 
eligibility is rechecked (check of changes between the screening visit and Visit 2) and those subjects eligible to participate should stay onsite overnight. To target a glucose level around 90-110 mg/dL (5.0-6.1 mmol/L) the following morning, subjects may be administered insulin glulisine (Api[INVESTIGATOR_27976]
®) at the investigator’s discretion either by [CONTACT_27650], SC bolus or continuous SC insulin infusion. Dosing will take place the following morning (Day 1). 
On Day [ADDRESS_1115439]: 
 Document all changes in concomitant medication (prior to the start of the 
insulin-induced hypoglycemic procedure) 
 Check of withdrawal criteria (prior to the start of the insulin-induced hypoglycemic 
procedure) 
 Check of dosing day exclusion criteria (prior to the start of the insulin-induced 
hypoglycemic procedure) 
 Vital signs (prior to the start [within 30 minutes] of the insulin-induced hypoglycemic 
procedure, and at 30, 90 and 300 minutes after dosing). 12-lead ECG (prior to the 
start [within 30 minutes] of the insulin-induced hypoglycemic procedure, and at 20, 35, 45, 60, and 300 minutes after dosing) 
 Local tolerability (at 30, 120, and 300 minutes after dosing) 
 AEs  
 Biochemistry, hematology, coagulation (prior to the start of the insulin-induced 
hypoglycemic procedure [within 30 minutes], and at 30 and 300 minutes after dosing) 
 Urine stick pregnancy test (women of childbearing potential only; prior to the start of 
the insulin-induced hypoglycemic procedure) 
 Urinalysis (prior to the start of the insulin-induced hypoglycemic procedure [within 
120 minutes]) 
 Urine drug screen (prior to the start of the insulin-induced hypoglycemic procedure) 
 Alcohol breath test (prior to the start of the insulin-induced hypoglycemic procedure) 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115440] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 57  of 81  
Dasiglucagon/GlucaGen plasma concentrations:
- Pre-dose, 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual timeof blood sampling for exposure should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
Plasma glucose concentration s:
- Pre-dose, 4, 6, 8 ,10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, and 90 minutes after dosing. The actual time for blood sampling for plasma glucose should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point and by [CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as within 2 minutes prior to dosing. 
Antibodies against dasiglucagon/GlucaGen (prior to the start of the insulin-induced
hypoglycemic procedure). 
Plasma insulin concentrations:
- Pre-dose, 30 and 60 minutes after dosing. The actual time of blood sampling for plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
[IP_ADDRESS]  Hypoglycemic clamp procedure and administration of trial medication 
The following procedure is based on precendent procedures for hypoglycemia induction 
in patients with T1DM [24, 25].  
The treatment day (Visit 2, Day 1) will be conducted after an overnight fast of at least 
8 hours, targeting a starting plasma glucose around 90 to 110 mg/dL (5.0-6.1 mmol/L).  
Subjects who meet one or more of the dosing day exclusion criteria (Section  5.5) at the 
dosing visit will be excluded from the dosing visit, but the visit can be rescheduled 1-[ADDRESS_1115441]’s current insulin therapy will be washed out as defined in Section  5.5. For 
subjects usin g multipl e daily injections, the date, time and the dose of the last basal 
insulin and the last short-acting insulin (except insulin glulisine [Api[INVESTIGATOR_27976]®]) administration 
prior to dosing will be captured. For subjects using an insulin pump, the time of 
discontinuation of the basal rate will be captured. Any use of insulin glulisine (Apid ra®) 
in the last [ADDRESS_1115442] ion procedure will also be 
captured.  
At approximately 08:00 hours, an infusion catheter will be inserted into each arm 
(forearm cephalic vein) for the manual glucose clamp procedure, with the glucose 
infusion in one arm and the insulin infusion in the opposite arm (if IV insulin glulisine 
[Api[INVESTIGATOR_27976]®] has been administered during the night the same infusion catheter can be used). 
A third catheter for blood sampling will be placed into a metacarpel vein for blood 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115443] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 58 of 81  
sampling. This hand will be warmed (55-65ºC) to arterialize venous blood. If there are issues with blood sampling from the metacarpal vein for the purpose of glucose measurements, a new and more proximal IV access may be used at the discretion of the investigator. 
Hypoglycemia will be gradually induced by a fast-acting IV insulin glulisine (Api[INVESTIGATOR_27976]
®) 
infusion (15 U [100 U/mL] in [ADDRESS_1115444]’s blood or plasma), 
initially at 150% of the subject’s usual basal rate and can be increased or decreased over a range of 0% to 200% as judged necessary by [CONTACT_093], to achieve a controlled decline in plasma glucose, targeting a plasma glucose level of 55 mg/dL (3.1 mmol/L).  
Plasma glucose concentrations will be measured using a US FDA-approved glucose 
analyzer (e.g., YSI 2300, Yellow Springs Instruments, Yellow Springs, OH). After the start of the insulin infusion, plasma glucose will be measured every 10 minutes whil e 
plasma glucose is above 110 mg/dL, and every 5 minutes once plasma glucose is at or 
below 110 mg/dL. 
Once the glucose concentration declines to <60 mg/dL (3.3 mmol/L), the insulin infusion 
will be stopped, and 5 min later plasma glucose concentration will be measured at the glucose analyzer and blood samples for baseline assessment of plasma glucose, 
dasiglucagon/GlucaGen PK, and insulin PK will be collected. The samples are the 
baseline samples and should be collected within 2 minutes before IMP administration. 
If plasma glucose is ≥ 45 mg/dL and <60 mg/dL (2.5-3.3 mmol/L), study treatment
(IMP) will be administered, defining time, t=0. The study treatment will be delivered
in the abdomen, buttock, or thigh (according to stratification) via SC injection, withthe subject lying in a lateral recumbent position.
If plasma glucose is <45 mg/dL (2.5 mmol/L), IV glucose solution will be
administered sufficient to raise plasma glucose to within the 45-60 mg/dL target
range. The run-in period will be adequately extended (at least 30 min) until the abovetarget is achieved and new baseline samples for plasma glucose,dasiglucagon/GlucaGen PK, and insulin PK will be collected. Glucose should not beinfused within [ADDRESS_1115445] should be rescheduled for a newtreatment visit within 7 days (+ 2 days).
Administration of IMP should not occur earlier than 9:00 hours in the morning or later than 12:00 hours. 
As shown in  Table 4, serial blood samples for glucose will be collected at t=0, 4, 6, 8, 10, 
12, 15, 17, 20, 25, 30, 40, 50, 60, [ADDRESS_1115446]-dosing. Samples for assessing 
plasma dasiglucagon/GlucaGen concentration will be collected  at t=0, 15, 30, 35, 40, 50, 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115447] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 59  of 81  
60, 90, and 120 minutes. Samples for assessing plasma insulin concentration will be collected at t=0, 30, and [ADDRESS_1115448]-treatment blood sampling times 
Times  0 4 6 8 10 12 15 17 20 25 30 35 40 50 60 75 90 120 
Plasma glucose  Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y Y 
PK 
Dasiglucagon/ 
GlucaGen  Y Y Y Y Y Y Y Y Y 
PK Insulin  Y Y Y 
Refer to Section 7.2.7 for details of laboratory safety sampling and to Section 7.4.2 for 
details of blood glucose safety sampling.  
When the t=90-minute blood sampling for plasma glucose has been collected the subjects 
are allowed to eat moderately. Drinking of water is allowed ad libitum  during the entire 
procedure. 
Hypoglycemia Rescue Provisions 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site for safety reasons as described in Section  7.4.2. Subjects should receive 
post-treatment rescue glucose infusion to ameliorate persistent hypoglycemia, as follows. 
1. Glucose infusion should be initiated if a subject experiences severe alarming
escalation of symptoms of hypoglycemia (e.g. symptoms suggesting a change in
consciousness) at any time during the trial; glucose infusion should be initiatedtargeting a plasma glucose levels >70 mg/dL.
2. If plasma glucose is <45 mg/dL (2.5 mmol/L) between t=8 and t=44 minutes,
rescue glucose infusion (1 -2 mg/kg administered IV over about 5 seconds) should
be initiated to maintain plasma glucose between 45 mg/dL and 55 mg/dL(2.5-3.1 mmol/L). Pause glucose infusion if plasma glucose is >55 mg/dL.
3. If plasma glucose is <70 mg/dL at t=45 minutes, rescue glucose infusion
(2-3 mg/kg administered IV over about 5 seconds ) should be initiated to maintain
plasma glucose between 70 mg/dL and 80 mg/dL (3.9-4.4 mmol/L). Pauseglucose infusion if plasma glucose is >75 mg/dL (4.2 mmol/L).
Subjects should remain in bed until completion of the test procedure 300 minutes after dosing (bathroom visits are allowed).  
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115449] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115450] may stay at the trial center for a longer period. 
8.2.4 Visit 3 (follow- up visit) 
Visit [ADDRESS_1115451] on D ay 28 + [ADDRESS_1115452]: 
Document all changes in concomitant medication
Physical examination
Vital signs
12-lead ECG
Local tolerability
AEs
Biochemistry, hematology, coagulation
Urine stick pregnancy test (women of childbearing potential only)
Urinalysis
Antibodies against dasiglucagon/GlucaGen.
After the follow-up visit the End of Trial form must be completed. Even if a subject is not 
able to attend the follow-up visit, the End of Trial form, the eCRF Accountability/Affirmation Statement form and the Drug Accountability form must be completed. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115453] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 61  of 81  
9 STATISTICAL METHODS 
Before database lock and treatment unmasking, a separate statistical analysis plan (SAP) will be finalized, providing detailed methods for the analyses outlined below. Further analysis details may be added or refined in the SAP. 
Any deviations from the planned analyses will be described and justified in the final 
clinical trial report. 
9.[ADDRESS_1115454] s 
treated with dasiglucagon 0.6 mg. With a 2:1:1 randomization ratio for the three 
treatments, dasiglucagon 0.6 mg, placebo, and GlucaGen 1 mg, 78 subjects injected with dasiglucagon and 39 subjects with placebo will yield a power of 90% at a 5% two-sided significance level to detect a treatment group difference in recovery incidence within 
20 minutes, assuming as low as 80% and as high as 50% recovery incidence for the 
dasiglucagon and placebo groups, respectively.
9.2 Trial subjects 
9.2.1 Analysis samples 
For presentation of data and reporting of the statistical analyses, th e following analysis 
samples will be used, depending on the context:  
Safety analysis set (SAS): All randomized subjects who received at least one dose of
trial medication.
Full analysis set (FAS): All randomized subjects who received at least one dose of
trial medication and contributed valid information for at least one post-dose endpoint.
Per protocol (PP) set : All subjects of the FAS for whom no relevant protocol
deviations were documented. This sample will primarily be used for sensitivity
analysis.
The analysis of the primary endpoint and secondary endpoints will be based on the FAS. A secondary analysis of the primary endpoint will be based on the PP set . All safety 
analyses will be based upon the SAS. 
The decision regard ing whether a protocol deviation is relevant or no t for the exclusion of 
subjects from the PP set will be made case-by-case in a data review meeting prior to 
treatment unmasking and database lock (see Section  9.2.3).  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115455] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115456] the results will be identified and it will be evaluated if subjects and/or data should be excluded from the analysis. Protocol deviations will be classified as minor or major in a consistent way. Major deviations from the protocol may lead to the exclusion of a subject from the PP set. 
Major protocol deviations may include deviations related to trial inclusion or exclusion 
criteria, conduct of the trial, subject management or subject assessment. Unless explicitly decided otherwise during the masked data review, the following will be considered major protocol deviations: 
 Violation of one or more major inclusion/exclusion criteria 
 Interruption of administration of trial product 
 Significant deviation from time windows  
 Incorrect treatment allocation 
 Missing primary endpoint. 
The violation of several major inclusion/exclusion criteria or the complete absence of 
efficacy data might lead to exclusion of the subject from FAS. In that case, the decision should be taken at the masked data review meeting, and the exclusion from efficacy analysis justified in the signed notes of the meeting. 
Obviously erroneous data points may be excluded from the analyses or re-analyzed (in 
case of e.g. serum concentrations). The decision to re-analyze or exclude data points from the statistical analysis is the joint responsibility of the sponsor and the trial statistician.  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115457] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 63  of 81  
The subjects or observations to be excluded and the reason for their exclusion will be documented and signed by [CONTACT_93440]. The documentation will be stored together with the remaining trial documentation. The subjects and observations excluded from analysis sets, and the corresponding reasons, will be described in the clinical trial report. 
9.3 General considerations 
All data obtained in this trial and documented in the eCRFs will be listed and 
summarized with statistics or frequency tables as appropriate. In case of termination of the trial, all data collected up to that timepoint will be included in the analysis. 
Raw data listings and summary tables will be generated using the software SAS
© version 
9.[ADDRESS_1115458] deviations, medians, 
coefficients of variation, and minimum and maximum values.  
Other summaries (e.g. quartiles, 95% confidence intervals [CIs]) may be used as 
appropriate. Categorical efficacy and safety variables will be summarized by [CONTACT_807466]. 
9.4 Demographics and baseline characteristics 
Baseline and demographic data will be summarized using descriptive statistics. Baseline 
ADA -positive subjects will be calculated as a percentage of the total number of subjects 
whose baseline samples were tested for ADA. 
All other data obtained in this trial and documented in the eCRF will be listed. 
9.5 Efficacy Analyses 
For the confirmatory analyses, the primary and key secondary endpoints for the 
dasiglucagon 0.6 mg and placebo treated subjects will be compared. A hierarchical procedure will be applied for the control of multiplicity. The primary and secondary endpoints will be evaluated on the full analysis set. In the primary analysis, those subjects who require rescue IV glucose will be censored at the time to plasma glucose recovery.  In a sensitivity analysis, the time to plasma glucose recovery will be analyzed without censoring the subjects who received rescue IV glucose.   
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115459] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115460] the null hypothesis for a dasiglucagon versus placebo comparison: 
 Primary:  Time to plasma glucose recovery 
 Key secondaries 1-4: Plasma glucose recovery within 30 minutes, within 20 minutes, 
within 15 minutes, and within 10 minutes after study drug injection without 
administration of rescue IV glucose. 
 Key secondaries 5-8:  Plasma glucose changes from baseline (CFB) within [ADDRESS_1115461] increase in 
plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue IV glucose.  
[IP_ADDRESS]  Primary analysis 
The primary endpoint will be summarized using Kaplan-Meier (KM) estimates stratified 
by [CONTACT_807467]. The treatment group difference between dasiglucagon and placebo will be evaluated inferentially using a pairwise two-sided log-rank test. 
In the primary analysis, those subjects who require rescue IV glucose will be censored at 
the time of plasma glucose recovery. This approach is based on the assumption that rescue IV glucose administration will shorten the time to recovery. This assumption 
implies that censoring at the time of recovey after rescue therapy is valid as a time to 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115462] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 65  of 81  
recovery without rescue would be longer than the observed duration. If recovery has not occurred at 45 minutes after study drug injection, censoring will be applied irrespective of the use of rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without 
censoring at the time of recovery for those subjects who require rescue IV glucose before 45 minutes and 2) with censoring at the time of administration of rescure IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards 
(CPH) time to event statistical model, if the hazards by [CONTACT_807445] a graphical comparison of log-minus-log survival curves and no more than two-thirds of the recovery times are censored in each treatment group. The CPH model will be used for inferences, with treatment group and injection site modeled as 
categorical effects, and baseline plasma glucose modeled as a continuous covariate. The 
treatment group rate ratios, active versus placebo, will be estimated together with the 95% confidence intervals, and pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs placebo) will be evaluated using two-sided likelihood ratio tests. 
9.5.3 Secondary endpoints 
 Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
[IP_ADDRESS]  Confirmatory analysis 
The key secondary incidence variables (plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus placebo) using Fisher’s exact test for each pairwise comparison. 
The key secondary endpoints of plasma glucose CFB within [ADDRESS_1115463] in those subjects who require rescue IV glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an Analysis of Covariance model, 
with treatment group modeled as a fixed effect and with the baseline plasma glucose 
modeled as a covariate. The dasiglucagon versus placebo treatment group difference will 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115464] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115465]. 
9.5.4 Secondary clinical efficacy (PD) endpoints 
 Time to first plasma glucose concentration of ≥70 mg/dL (3.9 mmol/L) without 
administration of rescue IV glucose. 
 Plasma glucose response as area under the curve above baseline from time zero to 
30 minutes, AUC
0-30min . 
Secondary clinical efficacy endpoints will be assessed based on plasma concentration 
data from samples collected at the dosing visit (Visit 2).  
Unless otherwise stated, the population base of analysis will be the FAS. 
[IP_ADDRESS]  Analysis of secondary clinical efficacy (PD) endpoints 
1. Time to first plasma glucose concentration ≥70 mg/dL from baseline. This 
time- to-event endpoint will be evaluated using a Kaplan-Meier approach, with 
treatment group as a stratification factor, analogous to that used for the primary endpoint analysis. Differences between the KM curves (dasiglucagon versus placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise two-sided log rank tests. If the ≥70 mg/dL endpoint is not met within [ADDRESS_1115466] valid plasma glucose measurement up to 45 minutes will be the censoring time.  
2. The AUC will be calculated as the baseline-adjusted area under the plasma glucose profile over time: 
a. AUC
0-30min : restricting the time window to the 0 to 30 minutes interval. 
3. The log-transformed AUC endpoint will be analyzed using an analysis of covariance (ANCOVA) model with treatment as fixed effect and baseline plasma 
glucose modeled as a covariate. The least squares means treatment group differences will be back-transformed (anti-logged) for presentation as a ratio of the treatment group geometric means, with their corresponding 95% CI. 
9.5.5 Exposure (PK) endpoints 
 Plasma dasiglucagon and GlucaGen concentrations from time zero to 90 minutes:  
AUC
0-90min , Cmax, and t max. 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115467] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
________________________________________________________________________ 
Strictly Confidential    Page 67  of 81  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints 
AUC will be derived as the area under the individual plasma dasiglucagon/GlucaGen concentration profile for PK from [ADDRESS_1115468] valid measurement if this measurement is assessed sufficiently close to 90 minutes (decision to be taken at the masked data review meeting). The standard trapezoidal method will be used, based on actual rather than nominal timepoints.  
C
max will be determined as the maximum of all valid plasma dasiglucagon/GlucaGen 
concentrations.  T
max will be determined as the timepoint where the maximum of all valid plasma 
dasiglucagon/GlucaGen concentration measurements for each measurement series is 
observed. 
The log-transformed PK endpoints AUC and C max will be analyzed in the same way as 
the AUC endpoints. As t
max is a highly discrete endpoint, Wilcoxon’s rank sum test for unpaired observations 
will be used to assess differences between the two treatment group s. 
9.6 Exploratory analyses 
Exploratory analyses will include descriptive statistics and modeling analogous to that 
done for key secondary endpoints. However, treatment group comparisons will be summarized without inference intent. 
Plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL(1.1 mmol/L) within 30 minutes after study drug injection without administrationof rescue IV glucose.
Plasma insulin response as area under the curve above baseline from time zero to
60 minutes, AUC
0-60 min .
Plasma insulin concentrations measured pre-dose and at 30 and 60 minutes after dosing 
(see Table 3) will be presented individually. A summary table per timepoint will be 
provided. The AUC 0-60min will be determined and a summary presented.  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115469] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115470] available version of the MedDRA, the version of which will be provided in the clinical trial report . AE summary tables will include the 
number and percentage of subjects who experienced AEs summarized by [CONTACT_6657]. 
An overall summary table will be provided showing the number and percentage of 
subjects with any: 
 TEAE 
 Severe TEAE 
 Serious TEAE 
 Drug-related TEAE 
 Drug-related severe TEAE 
 Drug-related serious TEAE 
 TEAE leading to withdrawal 
 TEAE with outcome death 
 AESI 
Refer to Section 7.2.[ADDRESS_1115471] results will be flagged as to whether the result is below, within or 
above the respective reference range. The number of values outside of the reference range will be counted. 
9.7.4 Other safety da ta 
Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure will 
be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise tests o f 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115472] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 69  of 81  
independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus placebo ). 
Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure will be evaluated using a KM time to event statistical model, with treatment group and injection site as stratification factors. Differences between the KM curves (dasiglucagon versus placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise two-sided stratified log-rank tests. If the endpoint is never met, the time of the last plasma glucose measurement will be the censoring time. 
Vital signs, physical examination, 12-lead ECG and local tolerability data will be 
summarized using descriptive statistics. 
9.[ADDRESS_1115473] will be applied. For the primary analysis in the FAS, missing values for the primary endpoint will be imputed by a conservative rule considering any missing value as a failure. 
9.10 Interim analyses 
No interim analyses are currently planned. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115474] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115475] be consistent with the subjects’ source documentation (i.e. medical records). 
The investigator will permit trial-related monitoring, IRB/IEC review, and regulatory inspections, providing direct access to source data /documents. Sponsor-authorized quality assurance personnel may carry out audits for which the investigator must provide 
support. 
The trial monitor or a representative of the sponsor will cross-check the data entered in 
the eCRFs with the source data at the trial center and observe the trial procedures in order 
to verify adherence to the trial protocol. Any queries will be resolved by [CONTACT_15009]/her delegate. 
All of the clinical data will be captured via electronic data capture (EDC) using a 
web-based tool.  
The investigator center staff will enter and edit the data via a secure network, with secure 
access features (username [CONTACT_2383]). A complete electronic audit trail will be maintained. The investigator will approve the data using an electronic signature (Ref: 21 CFR Part 11), and this approval is used to confirm the accuracy of the data recorded. 
eCRFs will be used for all subjects. The investigator’s data will be accessible from the 
investigator’s center throughout the trial. The eCRFs must be kept current to reflect subject status at each phase during the course of the trial. The eCRF will not capture personalized data. The investigator must make a separate confidential record of personalized details (name [CONTACT_93459]) on the subject identification and enrollment log. All changes to data are made by [CONTACT_15009]/her delegate through the EDC system.  
It is the responsibility of the principal investigator [INVESTIGATOR_807440]’s eCRF are also made on the subject’s medical records. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115476] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115477] leaving the trial should be completed at the time of the final visit or shortly thereafter. 
10.2  Electronic case report forms 
Remote data capture software will be used for data collection. Following training, trial 
staff will be given access to the software. Access to the software is restricted to staff participating in the trial and the extent of access will depend on the participants' user role in the trial. 
The subjects enrolled into the trial will be identified in the database by [CONTACT_807494]. The investigator or delegate will enter subject data into the 
eCRF promptly. All data is to be entered in English. Data recorded in the eCRFs will be accessible to the trial staff throughout the trial. 
After data entry, systematic data validation will be performed and data entry 
discrepancies will be presented electronically directly to the center staff. Queries for 
discrepant data may be generated automatically by [CONTACT_727915]/or generated manually by [CONTACT_807470]. All queries, whether 
generated by [CONTACT_727917], will be in electronic format. 
All sections of the eCRF are to be electronically approved by [CONTACT_1720] a 
medically qualified delegate after the data has been entered and all queries have been resolved. Changes to any eCRF page subsequent to the approval require a new approval signature. 
All queries and changes/corrections to the data are documented in the eCRF. 
10.[ADDRESS_1115478]’s medical records, assess drug accountability, and ensure that the trial is being conducted according to pertinent regulatory requirements. 
Checking of the eCRFs for completeness and clarity, and cross-checking with source 
documents, will be required to monitor the progress of the trial. Moreover, regulatory authorities of certain countries, IRBs/IECs, and/or the sponsor may wish to carry out such source data checks and/or on-site audit inspections. Direct access to source data will be 
required for these inspections and audits; they will be carried out giving due 
consideration to data protection and medical confidentiality. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115479] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115480]’s medical records. If data are to be entered directly into the eCRF this must be specified in a source data agreement prior to the start of the trial. 
eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that subject confidentiality is maintained. 
The trial monitor will check the eCRF for accuracy and completion and perform source 
data verification. The trial monitor will document source data verification of all reviewed sections of the eCRF. 
10.[ADDRESS_1115481] (e.g. informed consent forms, laboratory slips, medication inventory records, and other pertinent information) must be retained by [CONTACT_807495]. 
10.7  Good clinical practice 
The procedures set out in this tri al protocol are designed to ensure that the sponsor and 
investigator abide by [CONTACT_146018] (1) , and of the 
Declaration of Helsinki (2008) (2) . The trial also will be carried out in keepi[INVESTIGATOR_118483].  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115482] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115483] orally and in writing (subject information 
sheet) the nature, significance, risks and implications of the trial before inclusion. In particular, the subjects will be informed about the following: 
 The possibility of withdrawing from the clinical trial at any time by [CONTACT_807472]. 
 How personal and health-related data will be collected and used during the trial. 
 That his/her medical records may be examined by [CONTACT_807473], by [CONTACT_6667]/IEC 
members, and by [CONTACT_6668]. 
All subjects will receive a copy of the subject information sheet and a copy of their 
signed and dated informed consent form, both of which will be in the subject’s local 
language. 
If a protocol amendment is required, the informed consent form may need to be revised to 
reflect the changes to the protocol. If the consent form is revised, it must be reviewed and approved by [CONTACT_69869]/IRB, and signed by [CONTACT_783292]. 
10.9  Protocol approval and amendment 
Before the start of the trial, the trial protocol and/or other relevant documents will be 
approved by [CONTACT_6179]/IRB/competent authorities, in accordance with local legal requirements. The sponsor must ensure that all ethical and legal requirements have been met before the first subject is enrolled in the trial. 
This protocol is to be followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive IRB/IEC/competent authority approval prior to implementation (if appropriate).  
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115484] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 74  of 81  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without the need for a formal amendment. All amendments will be distributed to all protocol recipi[INVESTIGATOR_840], with appropriate instructions. 
10.[ADDRESS_1115485] will be up to 63 days (including up to 
30 days for screening and up to 33 days until the follow-up visit).  
The trial will be closed when all subjects have completed Visit 3. 
10.11   Premature termination of the trial 
If the investigator, the sponsor (e.g. safety committee), or the safety medical monitor 
becomes aware of conditions or events that suggest a possible hazard to subject s if the 
trial continues, the trial may be terminated after appropriate consultation between the relevant parties. The trial may also be terminated early at the sponsor’s discretion in the 
absence of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
 The discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the trial 
 Failure to enroll subjects at an acceptable rate. 
 A decision on the part of the sponsor to suspend or discontinue development of the 
drug. 
The trial can be terminated prematurely by [CONTACT_807475]:  The center cannot comply with the requirements of the protocol. 
 It is not possible for the center to comply with GCP standards. 
10.12   Confidentiality 
All trial findings and documents will be regarded as confidential. The investigator and 
members of his/her research team must not disclose such information without prior written approval from the sponsor. 
The anonymity of participating subjects must be maintained. Subjects will be identified 
on eCRFs submitted to the sponsor by [CONTACT_139927]. On the SAE reports and all 
other source documents, the subject will be identified via subject number. Documents not 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115486] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115487] (e.g. the signed informed consent form) must be maintained in confidence by [CONTACT_093].  
10.13   Other ethical and regulatory issues 
If a significant safety issue is identified, either from an individual case report or review of 
aggregate data, then the sponsor will issue prompt notification to all parties : regulatory 
authorities, investigators and IRB/IECs. 
A significant safety issue is one that has a significant impact on the course of the clinical 
trial or program (including the potential for suspension of the trial program or amendments to protocols) or warrants immediate update of informed consent. 
10.[ADDRESS_1115488] resulted from participation in the clinical trial, or if he/she undergoes any other medical treatment without their consent before the clinical trial has been completely finished in so  far as the 
individual subject is concerned. 
Any injury to health, which might have occurred as a result of participation in the clinical 
trial must be reported by [CONTACT_807476]. The investigator is obliged to make such a report in any case. 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115489] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 76  of 81  
10.15   Publication policy 
By [CONTACT_752373], the investigator agrees with the use of results of the trial for the purposes of national and international registration, publication and information for medical and pharmaceutical professionals. If necessary, the authorities will be notified of the investigator's name, address, qualifications and extent of involvement. 
A clinical trial report will be prepared and reviewed by [CONTACT_807477]-operation with 
the coordinating investigator. The coordinatoing investigator will be appointed by [CONTACT_807496]. A summary of the clinical trial report (according to CPMP/ICH137/95) should be sent to the regulatory authorities and IRB/IEC according to the relevant guidelines. 
According to the Declaration of Helsinki (2)  investigators and sponsors ‘have ethical 
obligations with regard to the publication and dissemination of the results of research’.   The trial design and results may be published as one or more original research 
manuscripts/abstracts and presented at a scientific meeting. The original eCRFs and the data generated from the eCRFs or otherwise obtained during the trial under this trial protocol will become the property of the sponsor. Publication of the results of this trial by 
[CONTACT_807479]. 
Any material intended for publication will be given to the sponsor at least [ADDRESS_1115490] the right to comment on the intended publication and to take any reasonable measures for patent protection. Authorship on any publication(s) resulting from this clinical trial will be assigned according to the recommendations of the International Committee of Medicinal Journal Editors (26). 
Participating subjects will not be identified by [CONTACT_807497]. 
The sponsor is responsible for trial registration at ClinicalTrials.gov 
(www.clinicaltrials.gov) according to FDA requirements, as well as the European Medicines Agency’s Clinical Trials Database (EudraCT).  
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115491] 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115492] 
1.ICH Harmonised Tripartite Guideline. International Conference on Harmonisation. 
ICH Harmonised Tripartite Guideline. Integrated addendum to ICH E6(R1): 
Guideline for Good Clinical Practice E6 (R2), Step 4. 09-Nov-2016. Available from: 
URL:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E  
6/E6_R2__Step_4.pdf
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical
Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh,
Scotland, October 2000. Last amended with Note of Clarification on Paragraph [ADDRESS_1115493] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.
Hypoglycemia and diabetes: a report of a workgroup of the American DiabetesAssociation and the Endocrine Society. Diabetes Care 2013 May;36:1384-95
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
5. American Diabetes Association Position Statement. Standards of medical care in
diabetes - 2017. Diabetes Care 2017;40(Supplement 1):S1-S135
6. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world
factors affecting adherence to insulin therapy in patients with Type 1 or Type 2
diabetes mellitus: a systematic review. Diabetic Medicine 2013;30:512- 24
7. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0
mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement ofthe American Diabetes Association and the European Association for the Study ofDiabetes. Diabetes Care 2017;40(1):155-57
8. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2
diabetes therapy. Rev Diabet Stud 2011;8:369-81
9. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2
diabetes: the return of the alpha cell. Curr Diab Rep 2014;14:555
10. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The
metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-97
11. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the
therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res2004;21:1274-83
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115494] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.0 
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 78  of 81  
12. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. Drug Discovery Today 2015;20:122-8 
13. Novo Nordisk Limited. SPC for GlucaGen Hypokit 1 mg. 2015. http://www.medicines.org.uk/emc/medicine/4258/SPC/GlucaGen+Hypokit+1+mg - Accessed 13 Mar  2017 . 
14. Zealand Pharma A/S. Dasiglucagon Investigator's Brochure, Edition 3, 12 Dec 2016.  
15. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. European Heart Journal 2013;34:2159-219 
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen BA, et al. Using standardized serum creatinine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of Internal Medicine 
2006;145:247-54 
17. Food and Drug Administration (FDA). Guidance for Industry on Bioanalytical Method Validation. Food and Drug Administration (FDA) [ADDRESS_1115495], Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. 
Quantitative bioanalytical methods validation and implementation: best practices for 
chromatographic and ligand binding assays. Pharm Res [ADDRESS_1115496];24:1962-[ADDRESS_1115497] biotechnology products. J Pharm Biomed Anal 2008;48:1267-[ADDRESS_1115498] neutralizing antibodies to ZP4207 by [CONTACT_807481] (cAMP) in a glucagon receptor transfected cell line, BAL-14-206-004-REP.  2016. Report No.: Zealand Pharma, study 15-[ADDRESS_1115499] neutralizing antibodies to glucagon by [CONTACT_807481] (cAMP) in a glucagon receptor transfected cell line, BAL-14-206-005.  2016. Report No.: Zealand Pharma, Study 15-040 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115500] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115501] glycemic control of insulin-dependent diabetes mellitus. N Eng J Med 1987; 316: 1376-83. 
25. Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study. Diabetes Care 2016; 39: 264-70. 
26. ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated December 2016 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115502] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115503] of trial personnel 
Sponsor  
Clinical Trial Manager   
 
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Medical Officer   
Zealand Pharma  
Smedeland 36  
2600 Glo strup, Denmark  
Phone:   
Contract Research Organization  Chiltern International (Ltd)  
[ADDRESS_1115504]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:  +44 (0) [PHONE_16833]  
Project Manager   
Chiltern International (Ltd)  
[ADDRESS_1115505]  
Slough 
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:   
Senior Medical Officer  and 
Safety medical monitor   
Chiltern International kft  
Canada Square Office House  
Ganz u  

 
 
Dasiglucagon (ZP4207)  Date: [ADDRESS_1115506] 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 3.[ADDRESS_1115507]  
Hungary  
Phone:   
Pharmac ovigilance unit  
Responsible for Serious Adverse 
Event (SAE) Management and 24 -
hour SAE reporting    
PharmaLex  
Agern Allé 24  
2970 Hørsholm, Denmark  
Phone:   (8 a.m. to 4 p.m.)  
Phone:   (outside 8 a.m. to 4 p.m.)  
Fax:  
email: [EMAIL_7118]   
Central laboratory  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (GlucaGen 
PK, insulin PK)  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (das iglucagon 
PK, dasiglucagon ADA, 
GlucaGen ADA)  York Bioanalytical Solutions (YBS)  
Cedar House  
Northminster Business Park  
Northfield Lane  
York, YO26 6QR, [LOCATION_008]  
Special laboratory  
(neutralizing antibodies)  BioAgilytix  
[ADDRESS_1115508] of all investigators, IECs and IRBs will be provided in a separate document and in  
the clinical trial report. 
 

 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 1 of 80  
CLINICAL TRIAL PROTOCOL 
 
A phase 3, randomized, double-blind, parallel trial to 
confirm the clinical efficacy and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen
® 
 
Sponsor:  Zealand Pharma A/S  
Sponsor Protocol No.:  ZP4207 -[ADDRESS_1115509] No. : 2017 -002449 -31  
IND No : 127866  
Trial  Drug Name:  [CONTACT_807506] * injection  
Date of Protocol:  31 Aug 2017   
 
The trial will be conducted according to the protocol and in compliance with Good 
Clinical Practice (GCP), with the Declaration of Helsinki and with other applicable regulatory requirements. 
*Dasiglucagon is the proposed international nonproprietary name [CONTACT_807507]4207. 
The information in this document is confidential and is proprietary to Zealand Pharma. It is understood that 
information in this document shall not be disclosed to any third party, in any form, without prior written 
consent of an authorized officer of Zealand Pharma. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 3 of 80  
Declaration of the coordinating investigator 
[CONTACT_1641]:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen® 
I have read this protocol. I approve this document and I agree that it contains all necessary details for carrying out the trial as described. I will conduct this trial in accordance with the design and specific provision of this protocol and will make a reasonable effort to complete the trial within the time designated. I will provide copi[INVESTIGATOR_807438] A/S to trial personnel under my supervision. I will discuss this material with them to ensure they are fully informed about the trial product and trial procedures. I will let them know that this information is confidential and proprietary to Zealand Pharma A/S and that it may not be further disclosed to third parties. I understand that the trial may be terminated or enrollment suspended at any time by [CONTACT_93442] A/S, with or without cause, or by [CONTACT_807442]. 
I agree that the trial will be carried out in accordance with GCP ( 1), with the Declaration 
of Helsinki (with amendments) ( 2) and with the laws and regulations of the countries in 
which the trial takes place.   _____________________________________ _____________________ 
Name        [CONTACT_807512]: + Fax: + 
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 4 of 80  
Declaration of the investigator 
Title:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
and safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellitus (T1DM) compared to placebo and with reference to GlucaGen® 
All documentation for this trial that is supplied to me and that has not been previously published will be kept in the strictest confidence. This documentation includes this trial protocol, Investigator's Brochure, Case Report Forms, and other scientific data. 
The trial will not be commenced without the prior written approval of a properly 
constituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC). No changes will be made to the trial protocol without the prior written approval of the sponsor and the IRB or IEC, except where necessary to eliminate an immediate hazard to the subjects. 
I have read and understood and agree to abide by [CONTACT_348232]. 
 
_____________________________________ _____________________ 
Signature [CONTACT_1782] 
 
_____________________________________ Name (block letters) 
 
_____________________________________ Title (block letters) 
 
_____________________________________ Institution (block letters) 
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 5 of 80  
Table of contents 
DECLARATION OF SPONSOR OR RESPONSIBLE MEDICAL OFFICER .......... 2  
DECLARATION OF THE COORDINATING INVESTIGATOR .............................. 3  
DECLARATION OF THE INVESTIGATOR ............................................................... 4  
TABLE OF CONTENTS .................................................................................................. 5  
1 SYNOPS IS ............................................................................................................ 11  
2 INTRODUCTION................................................................................................ 15  
2.1 Background ...................................................................................................... 15  
2.1.1  Hypoglycemia ...................................................................................... 15  
2.1.2  Glucagon .............................................................................................. 16  
2.1.3  Dasiglucagon........................................................................................ 16  
[IP_ADDRESS]  Pharmacokinetics and pharmacodynamics of dasiglucagon ......... 17  
[IP_ADDRESS]  Safety of dasiglucagon ................................................................... 17  
2.2 Trial rationale .................................................................................................. 18  
2.3 Risk-benefit assessment .................................................................................. 18  
3 TRIAL OBJECTIVES AND ENDPOINTS ...................................................... 20  
3.1 Primary objective ............................................................................................ 20  
3.2 Secondary objectives ....................................................................................... 20  
3.3 Primary endpoint ............................................................................................ 20  
3.4 Key secondary endpoints ................................................................................ 20  
3.5 Other secondary endpoints ............................................................................. 20  
3.6 Exploratory endpoints .................................................................................... 21  
4 OVERALL DESIGN AND PLAN OF THE TRIAL ........................................ 22  
4.1 Overview .......................................................................................................... 22  
4.2 Justification of the trial design ....................................................................... 24  
4.2.1  Justification for design and parameters ................................................ 24  
4.2.2  Justification for drug, route, dosage and treatment duration ............... 24  
5 TRIAL POPULATION ....................................................................................... 26  
5.1 Rationale for trial population ........................................................................ 26  
5.2 Planned sample size and number of trial centers ......................................... 26  
5.3 Inclusion criteria ............................................................................................. 26  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115510] identification and randomization ..................................................... 30  
6 TRIAL DRUG ...................................................................................................... 31  
6.1 Identity ............................................................................................................. 31  
6.2 Treatment assignment and randomization ................................................... 32  
6.3 Administration ................................................................................................. 33  
6.4 Packaging and labelling .................................................................................. 33  
6.5 Storage of study drugs .................................................................................... 33  
6.6 Blinding and breaking the blind .................................................................... 34  
6.7 Drug accountability ......................................................................................... 35  
6.8 Treatment compliance .................................................................................... 35  
6.9 Prior and concomitant medications ............................................................... 35  
6.9.1  Prohibited medications ......................................................................... 36  
7 PARAMETERS AND METHODS OF ASSESSMENT .................................. 37  
7.1 Efficacy parameters ........................................................................................ 37  
7.1.1  Pharmacodynamic measurements ........................................................ 37  
7.1.2  Pharmacokinetic measurements ........................................................... 37  
7.2 Safety parameters  ............................................................................................ 38  
7.2.1  Adverse events ..................................................................................... 38  
[IP_ADDRESS]  Definitions ...................................................................................... 38  
[IP_ADDRESS]  Collection, recording and reporting of adverse events ................. 41  
[IP_ADDRESS]  Follow-up of adverse events .......................................................... 42  
[IP_ADDRESS]  Clinical laboratory abnormalities and other abnormal 
assessments as adverse events or serious adverse events .............. 43  
7.2.2  Hypoglycemia ...................................................................................... 43  
7.2.3  Physical examination ........................................................................... 44  
7.2.4  Vital signs ............................................................................................ 44  
7.2.5  Electrocardiogram ................................................................................ 45  
7.2.6  Local tolerability .................................................................................. 45  
7.2.7  Clinical laboratory assessments ........................................................... 46  
7.2.8  Pregnancy ............................................................................................. 47  
7.2.9  Precautions ........................................................................................... 48  
7.2.10  Safety committee ................................................................................. 48  
7.3 Demography, concomitant illness, medical history and concomitant medication ........................................................................................................ 48
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115511] .............................................................................................. 52  
8.1 Schedule of procedures ................................................................................... 52  
8.2 Procedures by [CONTACT_765] .......................................................................................... 52  
8.2.1  Visit 1 (screening, Day -30 to Day - 3) ................................................. 52  
8.2.2  Instructions to subjects prior to the dosing visit (Visit 2) .................... 54  
8.2.3  Visit 2 (dosing visit)............................................................................. 55  
[IP_ADDRESS]  Hypoglycemic clamp procedure and administration of trial 
medication ...................................................................................... 56  
8.2.4  Visit 3 (follow-up visit) ....................................................................... 58  
9 STATISTICAL METHODS ............................................................................... 60  
9.1 Determination of sample size ......................................................................... 60  
9.2 Trial subjects ................................................................................................... 60  
9.2.1  Analysis samples .................................................................................. 60  
9.2.2  Disposition of subjects ......................................................................... 61  
9.2.3  Protocol deviations ............................................................................... 61  
9.3 General considerations ................................................................................... 62  
9.4 Demographics and baseline characteristics .................................................. 62  
9.5 Efficacy Analyses ............................................................................................. 62  
9.5.1  Hierarchical testing procedure ............................................................. 63  
9.5.2  Primary confirmatory endpoint ............................................................ 63  
[IP_ADDRESS]  Primary analysis ............................................................................ 63  
9.5.3  Secondary endpoints ............................................................................ 64  
[IP_ADDRESS]  Confirmatory analys is .................................................................... 64  
9.5.4  Secondary clinical efficacy (PD) endpoints ......................................... 65  
[IP_ADDRESS]  Analysis of secondary clinical efficacy (PD) endpoints ................ 65  
9.5.5  Exposure (PK) endpoints ..................................................................... 65  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints ............................................. 66  
9.6 Exploratory analyses ....................................................................................... 66  
9.7 Safety analyses ................................................................................................. 67  
9.7.1  Adverse events ..................................................................................... 67  
9.7.2  Immunogenicity data ........................................................................... 67  
9.7.3  Clinical laboratory assessments ........................................................... 67  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115512]-treatment blood sampling times ................................................................ 57  
 
Figures in text 
Figure 1  Trial design ........................................................................................................ 23  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115513]  European Medicines Agency’s Clinical Trials Database  
FAS Full analysis set  
FDA  Food and Drug A dministration  
GCP  Good Clinical Practice  
HbA 1c Glycated hemoglobin  
ICH International Conference on Ha rmonization  
ID card  Identification card  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IV Intravenous(ly)  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 10  of 80  
IWRS  Interactive Web Response System  
MedDRA  Medical Dictionary for  Regulatory Activities  
NPH  Neutral protamine Hagedorn  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per protocol  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Safety analysis set  
SC Subcutaneous(ly)  
S[LOCATION_003]R  Serious unexpected suspected ad verse reaction  
T1DM  Type [ADDRESS_1115514]  Upper limit of the normal range  
US [LOCATION_002] of America  
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 11  of 80  
1 SYNOPSIS 
Name [CONTACT_119019]:  
Zealand Pharma A/S  Trial ID:  
ZP4207 -[ZIP_CODE] 
Title of the trial:  
A phase 3, randomized, double -blind, parallel trial to confirm the clinical efficacy and safety of 
dasiglucagon  in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitu s (T1DM) 
compared to placebo and with reference to GlucaGen® 
Trial design:  
The trial is a global, multicenter, randomized, parallel -group , double -blind, clinical trial confirming the 
efficacy and safety of dasiglucagon  for insulin -induced hypoglycemia in  subjects with type 1 diabetes  
mellitus . The subjects will be randomized 2:1:1 to receive a single fixed subcutaneous 0.6 mg dose of 
dasiglucagon  (hereinafter dasiglucagon) , placebo  for dasiglucagon (hereinafter referred to as placebo) , or a 
1 mg dose of GlucaGen® (hereafter referred to as GlucaGen) and followed for at least 28  days after 
treatment.  
Clinical phase of development:  
Phase 3 
Trial centers : 
This trial will be conducted at 4 to 6 sites in the [LOCATION_002] of America , Canada, and Europe . 
Plann ed trial start ( first subjec t first visit):  
Q4/2017 Planned trial end ( last subjec t last visit):  
Q3/2018  
Trial population:  
Male and female adult  subjects  with type [ADDRESS_1115515] one year   
Key objectives:  
Primary objective:   
 To demonstrate superiority  of dasiglucagon  compared to placebo  following a single subcutaneous  
0.6 mg dose administered to subjects with type 1 diabetes mellitus  with insulin -induced 
hypoglycemia . 
Secondary objective:   
 To compare the glycemic r esponse observed after  dasiglucagon  with that of  GlucaGen . 
Key endpoints:  
Primary endpoint:   
 Time to  plasma glucose  recovery. Plasma glucose recovery is defined as first increase in plasma 
glucose of  ≥20 mg/dL  (1.1 mmol/L) from baseline  during the hypoglycemic clamp procedure  
without administration of rescue intravenous ( IV) glucose .  
Key s econdary endpoint s: 
 Plasma glucose recovery  within 30 minutes, within 20 minutes , within 15 minutes, and within 
10 minutes  after study drug injection  without administration of rescue IV glucose . 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes , within 15 minutes, 
and within 10 minutes  after study drug injection  or at the time of rescue . 
Clini cal efficacy  (Pharmacodynamic ) endpoints:  
 Time to first plasma glucose concentration of ≥70 mg/dL ( 3.9 mmol/L ) without administration of 
rescue IV glucose . 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 12  of 80  
 Plasma glucose response as  area under the curve  above baseline  from time zero to 30 minutes, 
AUC0-30min. 
Exposure (Pharmacokinetic) endpoints:  
 Area under th e drug concentration curve from time zero to 90 minutes , AUC 0-90 min. 
 Maximum plasma drug concentration (C max). 
 Time to maximum plasma  drug concentration (t max). 
Safety endpoints:   
 Adverse events, clinical laboratory assessments (biochemistry, hematology, coagulation, urinalysis), 
vital signs, physical examination, electrocardiogram, and local tolerability.  
 Administration  of rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
 Time to first rescue infusion of IV glucose during the hypoglyc emic clamp procedure.  
Immunogenicity endpoint:  
 Occu rrence  of anti -drug antibodies  
Exploratory endpoint s: 
 Plasma g lucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL (1.1 mmol/L) 
within [ADDRESS_1115516] ration of rescue IV glucose . 
 Plasma insulin response as area under the curve above baseline from time zero to  60 minutes , 
AUC 0-60 min. 
Key inclusion criteria:  
 Male and female subject s with type [ADDRESS_1115517] one yea r, 
diagnostic criteria as defined by [CONTACT_807443] n. 
 Stable  insulin treatment 30 days prior to screening, defined as no more than a 10 -unit daily variation 
in total  daily insulin dose . 
 Hemoglobin A 1c <10%.  
 Aged between 18 and 75 years, b oth inclusive . 
Key exclusion criteria:  
 Previously treated with dasiglucagon . 
 Known or suspected allergy to trial product(s) or related products.  
 History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).  
 Previous participation (ran domization) in this trial.  
Sample size:  
Approximately  [ADDRESS_1115518]:  
Test product: dasiglucagon  liquid form ulation in pre -filled syringes . 
Comparator  product s: Placebo and GlucaGen® lyophilized powder . 
Duration of treatment:  
Subjects will be randomized 2:1:[ADDRESS_1115519] 28 days after receiving treatment .  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 13  of 80  
Assessments:  
The plasma glucose profile for evaluation of the primary and secondary clinical efficacy 
(pharmacodynamic) endpoints will be assessed base d on plasma concentration data from samples collected 
at the dosing visit.  
The exposure to  trial medication (dasiglucagon , placebo , or GlucaGen) for evaluation of pharmacokinetics  
will also be assessed based on plasma concentration data .  
Statistical meth ods:  
Due to requirements in the size of the safety database, the sample size is set to 78 subjects treated with 
dasiglucagon 0.6  mg. With a 2:1:1 randomization ratio for the three treatments, dasiglucagon  0.6 mg, 
placebo , and GlucaGen 1 mg, 78 subjects in jected with dasiglucagon and 39 subjects with placebo will 
yield a power of 90% at a 5% two -sided significance level to detect a treatment group difference in recovery 
incidence within 20 minutes, assuming as low as 80% and as high as 50% recovery incidenc e for the 
dasiglucagon and placebo groups, respectively.  
For the confirmatory analyses, the primary and key secondary endpoints for the dasiglucagon 0.6  mg and 
placebo  treated subjects will be compared. A hierarchical procedure will be applied for the cont rol of 
multiplicity  in statistical inferences . The primary and secondary endp oints will be evaluated on the Full 
Analysis Set sample . The statistical inference comparisons with placebo will be conducted as superiority 
tests. The comparisons of  dasiglucagon  versus GlucaGen will be summarized descriptively .    
The primary endpoint will be summarized using Kaplan -Meier (KM) estimates stratified by [CONTACT_807444]. The treatment group difference between dasiglucagon and placebo will be evalua ted 
inferentially using a pairwise two -sided log -rank test.  
In the primary analysis, those subjects who require rescue IV glucose will be censored at the time of plasma 
glucose recovery. This approach is based on the assumption that rescue IV glucose admin istration will 
shorten the time to recovery. This assumption implies that censoring at the time of recove ry after rescue 
therapy is valid as a time to recovery without rescue would be longer than the observed duration. If recovery 
has not occurred at 45 mi nutes after study drug injection, censoring will be applied irrespective of the use of 
rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without censoring at the 
time of recovery for those subjects who req uire rescue IV glucose before 45 minutes and 2) with censoring 
at the time of administration of rescu e IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards (CPH) time to event 
statistical model , if the hazards by [CONTACT_807445] a graphical 
comparison of log -minus -log survival curves and no more than two -thirds of the recovery times are 
censored in each treatment group. The CPH model will be used for inferences,  with treatment group and 
injection site modeled as categorical effects, and baseline plasma glucose modeled as a continuous 
covariate. The treatment group rate ratios, active versus placebo, will be estimated together with the 95% 
confidence intervals, an d pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs 
placebo) will be evaluated using two -sided likelihood ratio tests.  
The key secondary incidence variables (plasma glucose recovery within 30 minute s, within 20 minutes, 
within 15  minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive 
statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be 
assessed via pairwise tests of independent binomial  proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo) using Fisher’s exact test for each pairwise comparison.  
The key secondary endpoints of plasma glucose changes from baseline (CFB) within 30  minutes, within 
20 minutes, within 15 minutes, a nd within 10 minutes after study drug injection or at the time of rescue, will 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115520] in those subjects who require rescue IV 
glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an 
Analysis of Covariance model, with treatment group modeled as a fixed effect and with the baseline plasma 
glucose modeled as a covariate. The dasiglucagon versus placebo treatment gr oup difference will be 
evaluated inferentially as a least squares means contrast, using a two -sided t -test at the 0.[ADDRESS_1115521] asma glucose  CFB variables.   
The safety analyses will include by -treatment -group descriptive summaries of vital sign measurements, 
laboratory measures (including immunogenicity incidence), physical examination assessments, rescue IV 
glucose (incidence and  amount of glucose infused), and adverse events. The number and percentage of 
subjects reporting specific events, such as nausea and vomiting, will be presented by [CONTACT_430449].  
Further details will be included in the Statistical Analysis  Plan, to be completed before dat abase lock and 
treatment unmasking.    
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 15  of 80  
2 INTRODUCTION 
2.1 Background 
Zealand Pharma A/S (Zealand Pharma) is developi[INVESTIGATOR_807428], a physically and 
chemically stable peptide analog of human glucagon, in a ready- to-use liquid formulation 
for the acute treatment of severe hypoglycemia in patients with insulin-treated diabetes mellitus. Like native glucagon, dasiglucagon is comprised of 29 amino acids, but with 7 substitutions which improve its physical and chemical stability in aqueous media. These amino acid substitutions make dasiglucagon suitable for a liquid formulation, while providing similar efficacy and safety as compared with recombinant glucagon in the clinical setting of acute treatment of severe hypoglycemia. 
2.1.1 Hypoglycemia  
Hypoglycemia in patients with diabetes is defined as epi[INVESTIGATOR_807429] (3). This is a common, unpredictable, and potentially 
dangerous side effect of treatment of diabetes mellitus, especially with insulin or 
sulfonylureas. It is more frequent in patients with profound endogenous insulin 
deficiency, such as occurs in type 1 diabetes mellitus (T1DM) and advanced type 2 
diabetes mellitus (T2DM). Treatment of T2DM with insulin causes hypoglycemia progressively and more frequently over time, whereas in T1DM, hypoglycemia is experienced throughout the course of established disease (4). 
Symptoms and signs of hypoglycemia are not specific. Patients undergoing a hypoglycemic epi[INVESTIGATOR_460616], sweating, hunger, tremors, palpi[INVESTIGATOR_814], paresthesia, nausea and pallor. Depending on its severity, the hypoglycemia may lead to mild confusion, behavioral changes, loss of consciousness, seizures, coma, and death (5). 
The incidence of hypoglycemic events or even the fear of hypoglycemia influences patients’ adherence to prescribed treatment regimens for diabetes mellitus (6) . This leads 
to inadequate glycemic control, which in turn may lead to an increased risk of diabetic complications (5) . Serious clinically significant hypoglycemia is now defined as plasma 
glucose <54 mg/dL (3.0 mmol/L), while the plasma glucose alert value is defined as <70 mg/dL (3.9 mmol/L) (7). When plasma glucose falls below these values, some kind 
of treatment strategy is needed. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 16  of 80  
2.1.2 Glucagon 
Glucagon is a naturally occurring hormone, secreted from the alpha cells of the 
pancreatic islets. Glucagon plays a central role in the regulation of glucose homeostasis and is the counterpart of insulin for controlling blood glucose levels (i.e. it acts in opposition to insulin in terms of effects on blood glucose levels) (8,9). Glucagon stimulates hepatic glycogenolysis and gluconeogenesis in hypoglycemic states, thereby [CONTACT_93406]. Glucagon receptor agonism has also been shown to exert effects on lipid metabolism, energy balance, body adipose tissue mass and food intake (10). Insulin decreases blood glucose levels and cases of hypoglycemia can be reversed 
by [CONTACT_41148]. Therefore, glucagon is indicated for the treatment of severe hypoglycemia. 
Besides intravenous (IV) glucose administration, an injectable form of glucagon is given 
as first aid in cases of severe hypoglycemia, when the patient is unconscious or for other 
reasons cannot take glucose orally. The approved glucagon dose for an adult is 1 mg, 
given by [CONTACT_33813] (IM), IV, or subcutaneous ( SC) injection, which quickly raises 
blood glucose levels. As current marketed recombinant glucagon is highly unstable when dissolved in solution, the injectable form has to be reconstituted prior to use in a 9-step procedure that requires a sterile diluent to be injected into a vial containing lyophilized powdered glucagon. When dissolved in a fluid state, glucagon can form amyloid fibrils 
(11), or tightly woven chains of proteins made up of the individual glucagon peptides. 
The reconstitution process makes the use of marketed glucagon products cumbersome 
(12), and a more patient-friendly formulation is needed. Currently, the Food and Drug 
Administration (FDA ) approved instructions for commercially available glucagon allow 
only for immediate usage of glucagon after the powder is reconstituted in aqueous solution (13). Therefore, a glucagon analog with enhanced biophysical stability may 
represent a leap forward in terms of convenient therapeutic applications. 
2.1.3 Dasiglucagon 
Dasiglucagon (ZP4207) is a stable peptide analog of human glucagon, available in a ready- to-use liquid formulation. Dasiglucagon (hereinafter referred to as dasiglucagon) is 
in development for the treatment of severe hypoglycemia in insulin-dependent patients with diabetes mellitus. Dasiglucagon is a specific and full glucagon receptor agonist designed to mimic the effects of glucagon, having a fast absorption and elimination (minutes). It is a peptide of 29 amino acids, with 7 amino acid substitutions compared to native glucagon. The main purpose of the substitutions is to increase the physical and chemical stability of the glucagon analog compared to marketed glucagon products such as Lilly Glucagon or GlucaGen
® (hereafter referred to as GlucaGen). Dasiglucagon 
exhibits improved physical and chemical stability and is available in an aqueous solution at neutral pH (14) . 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115522] been completed with dasiglucagon: a first- in-human dose trial in 
healthy volunteers and subjects with T1DM (ZP4207-[ZIP_CODE]), a multiple-dose 
dose-escalation trial (ZP4207-[ZIP_CODE]) evaluating the safety, tolerability, pharmacokinetics (PK) and pharmacodynamics (PD) of dasiglucagon in healthy volunteers, and a phase 2 crossover trial to assess the PK and PD of a single dose of an optimized formulation of 
dasiglucagon administered SC in subjects with T1DM (ZP4207-[ZIP_CODE]) (14) . 
[IP_ADDRESS]  Pharmacokinetics and pharmacodynamics of dasiglucagon 
The results of the phase [ADDRESS_1115523] absorption with a peak plasma 
concentration obtained after 35 minutes. Thereafter, the plasma concentration rapi[INVESTIGATOR_93381]-life of 28 minutes. The median time to the maximum plasma concentration (t
max) was [ADDRESS_1115524] 70 mg/dL (3.9 mmol/L) as well as an increase in plasma glucose by [CONTACT_2669] 20 mg/dL (1.1 mmol/L) within 30 minutes after dosing. The PD  responses to 0.6 mg of 
dasiglucagon and 1 mg of GlucaGen were comparable. 
[IP_ADDRESS]  Safety of dasiglucagon 
The safety data for dasiglucagon do not give rise to any safety concerns. No new signals 
were observed, beyond those related to the pharmacological effect of glucagon agonism. All adverse events (AEs) recorded in the trials were of mild or moderate severity. The most frequently reported systemic AE was nausea, which is a known side effect following administration of glucagon. Headache was the next most frequently reported event, occurring in all dose groups in the phase [ADDRESS_1115525] (IMP) doses of at least 1 mg (4 with dasiglucagon and 1 with GlucaGen). This is not considered a safety concern; however, hemodynamic changes after dosing will be considered an adverse event of special interest (AESI). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 18  of 80  
The phase 1 and 2 results and the safety profile described to date do not give rise to 
specific safety concerns. For further information, please refer to the Investigator’s Brochure ( 14). 
2.2 Trial rationale 
The aim of the current trial is to confirm the superiority of dasiglucagon for the treatment of insulin-induced hypoglycemia in subjects with T1DM as compared to placebo for dasiglucagon (hereinafter placebo) and to compare the clinical efficacy and safety of dasiglucagon with reference to GlucaGen. A randomized, controlled trial design was used. 
See Section 4.[ADDRESS_1115526] also been observed to a limited extent in the 3 clinical studies conducted to date with dasiglucagon. As with every novel drug substance, new and as yet unknown side effects may also occur. 
There are limited data available to assess the immunogenic potential of glucagon 
products available on the market, but the data available indicate that marketed glucagon only has a low immunogenic potential.  
Overall, dasiglucagon is judged to be a low-risk molecule, based upon the available 
clinical data. Administration of dasiglucagon may be associated with a risk of allergic reactions similar to those observed for other therapeutic peptides or proteins. Subjects with known or suspected allergies to the trial medications or related products will be 
excluded from the trial. Mild or moderate allergic reactions may include symptoms of 
rash, fever, flu-like symptoms, nausea, headache, and myalgia. Acute generalized 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115527] relevant clinical effects in the acute severe hypoglycemia rescue setting and may be an effective and reliable emergency treatment for severe hypoglycemia. Overall, the anticipated benefits for subjects entering the ZP4207-[ZIP_CODE] trial are considered to justify 
the risks. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 20  of 80  
3 TRIAL OBJECTIVES AND ENDPOINTS 
3.1 Primary objective 
 To demonstrate superiority of dasiglucagon compared to placebo following a single 
subcutaneous 0.6 mg dose administered to subjects with type 1 diabetes mellitus with 
insulin-induced hypoglycemia. 
3.2 Secondary objectives 
 To compare the glycemic response observed after dasiglucagon with that of 
GlucaGen. 
3.3 Primary endpoint 
 Time to plasma glucose recovery. Plasma glucose recovery is defined as first increase 
in plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic 
clamp procedure without administration of rescue IV glucose.  
3.4 Key secondary endpoints 
 Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
3.5 Other secondary endpoints 
 Clinical efficacy (PD) endpoints: 
- Time to first plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) without 
administration of rescue IV glucose. 
- Plasma glucose response as area under the curve (AUC ) above baseline from time 
zero to 30 minutes, AUC 0-30min . 
 Exposure (PK) endpoints: 
- Area under the drug concentration curve from time zero to 90 minutes, AUC
0-90min . 
- Maximum plasma drug concentration (C max). 
- Time to maximum plasma drug concentration (t max). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 21  of 80  
 Safety endpoints:  
- Adverse events, clinical laboratory assessments (biochemistry, hematology, 
coagulation, urinalysis), vital signs, physical examination, electrocardiogram (ECG), and local tolerability. 
- Administration of rescue infusion of IV glucose during the hypoglycemic clamp procedure. 
- Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure. 
 Immunogenicity endpoint: 
- Occurrence of anti-drug antibodies 
3.6 Exploratory endpoints 
 Plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL 
(1.1 mmol/L) within 30 minutes after study drug injection without administration of rescue IV glucose. 
 Plasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC
0-60 min . 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 22  of 80  
4 OVERALL DESIGN AND PLAN OF THE TRIAL 
4.1 Overview 
This trial is a global, multicenter, randomized, parallel, double-blind, clinical trial 
confirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in 
subjects with T1DM. The subjects will be randomized 2:1:[ADDRESS_1115528] 28 days after receiving treatment. A total of 156 subjects with T1DM are expected to complete the treatment visit. The trial will be conducted in the European Union ( EU) 
and North America. See Figure 1 for an overview of the trial design. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 23  of 80  
Figure 1 Trial design 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115529] selection and in the evaluation of clinical assessments, 
subjects will be randomly assigned 2:1:[ADDRESS_1115530] been used to establish that 0.6 mg of dasiglucagon is an effective dose and also represents a therapeutically equivalent dose to 1 mg of GlucaGen (see also Section 6.1).  
Dasiglucagon, placebo, and GlucaGen will be administered in the abdomen, buttocks, or thigh by [CONTACT_128193], as this is one of the intended routes of administration for 
dasiglucagon, besides IM and IV. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115531] 28 days after dosing in order to perform an adequate 
immunogenicity evaluation of treatment.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 26  of 80  
5 TRIAL POPULATION 
5.1 Rationale for trial population 
Dasiglucagon is in development for the treatment of severe hypoglycemia in 
insulin-dependent patients with diabetes mellitus. In the present trial, subjects with T1DM are included in the evaluation of efficacy and safety of dasiglucagon under hypoglycemic conditions as this is part of the intended target population. Subjects with T1DM are selected to avoid the endogenous glucagon counter-regulatory response to insulin-induced hypoglycemia that is present in patients with T2DM. The inclusion and exclusion criteria are set to include a trial population that represents the general population of subjects with T1DM.  
5.2 Planned sample size and number of trial centers 
A total number of 156 subjects with T1DM are expected to complete the treatment visit 
(Visit 2). To qualify as completed, the subject must be dosed and have blood drawn for 
the PK and PD assessments described in the protocol. It is expected that up to [ADDRESS_1115532] 156 subjects completing Visit 2. Completion of 
156 subjects (78 subjects in the dasiglucagon group and 39 subjects in  each of the 
placebo and GlucaGen groups) would be expected to provide adequate power for the 
primary efficacy evaluation, as described in Section 9.1. 
The planned date for first subject first visit is expected to take place in Q4, [ADDRESS_1115533] in Q3, 2018. 
This trial is planned to be conducted at 4 to 6 trial sites in the [LOCATION_002] of America 
[US], Canada, and Europe. 
5.3 Inclusion criteria 
Subjects will be entered into this trial only if they meet all of the following criteria: 
1. Informed consent obtained before any trial-related activities (trial-related 
activities are any procedure that would not have been performed during normal management of the subject). 
2. Female or male subjects with T1DM for at least 1 year, diagnostic criteria as defined by [CONTACT_11026] ( 3). 
3. Treated with insulin for T1DM for at least 1 year and with stable insulin treatment (defined as no more than a 10-unit daily variation in total daily insulin dose) 30 days prior to screening 
4. Hemoglobin A
1c <10%. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115534] meet one of the following criteria: 
a. Participant is of childbearing potential and agrees to use one of the 
accepted contraceptive regimens throughout the entire duration of the trial from screening and until last follow-up visit. Additionally, if the participant is using systemic contraceptives, she must use an additional form of acceptable contraception. An acceptable method of contraception includes one of the following: 
i. Abstinence from heterosexual intercourse; 
ii. Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/ insertable hormonal birth control products, transdermal patch); 
iii. Intrauterine device (with and without hormones); or 
iv. Condom with spermicide; or 
b. Participant is of non-childbearing potential, defined as surgically sterile (i.e. has undergone complete hysterectomy, bilateral oophorectomy, or tubal ligation), or in a menopausal state (at least 1 year without menses). 
7. A male subject must meet the following criteria: Surgically sterilized or willing to refrain from sexual intercourse from screening and until last follow-up visit or, if sexually active, uses condom and partner practices contraception during the trial from screening and until last follow-up visit. 
5.4 Exclusion criteria 
Subjects meeting any of the following criteria during screening evaluations will be excluded from trial participation: 
1. Previously treated with dasiglucagon (previously referred to as ZP4207). 
2. Known or suspected allergy to trial product(s) or related products. 
3. History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema). 
4. Previous participation (randomization) in this trial. 
5. Females who are pregnant according to a positive pregnancy test, are actively attempting to get pregnant, or are lactating. 
6. History of hypoglycemic events associated with seizures in the last year prior to screening. 
7. History of severe hypoglycemia (defined as plasma glucose <54 mg/dL [3.0 mmol/L]) in the last month prior to screening. 
8. Receipt of any investigational drug within [ADDRESS_1115535] 5 years. 
10. Congestive heart failure, [LOCATION_001] Heart Association class II-IV. 
11. Inadequately treated blood pressure, defined as systolic ≥160 mmHg or diastolic 
≥90 mmHg) at screening ( 15). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 28  of 80  
12. Current bleeding disorder, including anti-coagulant treatment. 
13. Known presence or history of pheochromocytoma (i.e. adrenal gland tumor) or 
insulinoma (i.e. insulin secreting pancreas tumor). 
14. Use of a daily systemic beta-blocker drug, indomethacin, warfarin or anticholinergic drugs in the previous 28 days before Day 1 of this trial. 
15. Aspartate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the upper limit of the normal range (ULN), bilirubin >1.5 × ULN, estimated glomerular filtration rate <30 mL/min/1.73 m
2 according to the Modification of 
Diet in Renal Disease study definition (16), or altered electrolyte values of 
clinical relevance for cardiac conduction, as judged by [CONTACT_093]. 
16. Clinically significant abnormal ECG at screening as judged by [CONTACT_093]. 
17. Clinically significant illness within [ADDRESS_1115536] 2 months prior to screening. 
20. A positive result in the alcohol and/or urine drug screen at the screening visit. Significant history of alcoholism or drug abuse as judged by [CONTACT_460672] [ADDRESS_1115537]’s typi[INVESTIGATOR_93379], and should not exceed a near maximum intensity for more than 20 minutes per day, or moderate intensity for more than 90 minutes per day. 
2. Clinically significant illness within 4 weeks before dosing, as judged by [CONTACT_093]. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115538]. 
4. Not fasting from 22:00 hours the evening prior to dosing, apart from water. Small amounts of carbohydrates (up to 20 g) to prevent hypoglycemia are allowed. 
5. The use of any non-prescribed systemic or topi[INVESTIGATOR_73201], except routine vitamins and occasional use (as judged by [CONTACT_093]) of acetylsalicylic acid and paracetamol within 2 weeks prior to dosing. Treatment with insulin, including 
analogs, is allowed. 
6. Use of any basal insulin within 16 hours prior to dosing. 
7. Use of any short acting (bolus) insulin within 6 hours prior to dosing, except insulin glulisine (Api[INVESTIGATOR_27976]
®). 
8. Changes in medical history or concomitant medication resulting in fulfillment of 
clinical exclusion criteria, as judged by [CONTACT_093]. 
9. Plasma glucose value <50 mg/dL (2.8 mmol/L) within the last 24 hours or plasma 
glucose value <60 mg/dL (3.3 mmol/L) within the last [ADDRESS_1115539] has the right to withdraw from the trial at any time and for any reason. If he/she chooses to withdraw, the investigator must 
be informed immediately. The investigator has the right to terminate participation of any 
subject at any time if the investigator deems it in the subject's best interest. The reason and circumstances for withdrawal will be documented in the electronic case report form (eCRF). 
5.6.[ADDRESS_1115540] will be discontinued from treatment if the following applies: 
 Withdrawal of consent by [CONTACT_1130]. 
 If a protocol deviation occurs which, in the clinical judgement of the investigator, can 
invalidate the trial or endpoints or can interfere pharmacokinetically or 
pharmacodynamically with the trial product, the subject will be discontinued by [CONTACT_093]. 
 Adverse events occur which are considered unacceptable by [CONTACT_579585]. 
If discontinuation occurs following administration of trial medication, every effort should be made to have the subject return and participate in the complete follow-up visit on Day 28 (see Table 3) to avoid missing data. 
If trial participation is terminated due to an AE possibly related to any of the trial medications or trial examinations, the subject must be followed up by [CONTACT_807498] (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115541] complete the treatment visit (Visit 2). To qualify as 
completed, the subject must be dosed and have blood drawn for the PK and PD 
assessments described in the protocol.  
5.6.2 Center discontinuation 
The center can be closed and the trial terminated for the following reasons: 
 The center is unlikely to be able to recruit sufficient subjects within the agreed time 
frame. 
 The center does not respond to trial management requests. 
 Repeat protocol violations. 
5.6.3 Trial termination 
The sponsor reserves the right to modify or terminate the trial at any time. Possible 
reasons for termination are: 
 Safety reasons – the incidence of AEs in this or any other trial using the same trial 
medication indicates a potential health risk for the subjects. 
 New scientific knowledge becomes known that makes the objectives of the trial no 
longer feasible/valid. 
 Unsatisfactory enrolment of subjects. 
5.[ADDRESS_1115542] given written informed consent and meet all inclusion and none of the exclusion criteria will be randomized in a 2:1:1 ratio to either 0.6 mg dasiglucagon (n=78), placebo (n=39), or 1 mg GlucaGen (n= 39) via an Interactive Web Response 
System (IWRS). Randomization will continue until [ADDRESS_1115543] code can be broken by [CONTACT_093], preferably after consultation with the medical monitor. Emergency code 
breaks can be performed using the IWRS. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 31  of 80  
6 TRIAL DRUG 
6.1 Identity 
The following trial drugs will be administered: 
 Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a prefilled syringe. 
 Placebo, liquid formulation, 0.6 mL delivered in a prefilled syringe. 
 Recombinant glucagon hydrochloride, 1 mg for reconstitution (GlucaGen®, Novo 
Nordisk) in [ADDRESS_1115544]  
Name  [CONTACT_93458]® 
Active 
substance  Dasiglucagon  N/A Recombinant 
glucagon 
hydrochloride  
Formulation  Liquid formulation, 
0.6 mL  Liquid formulation, 
0.6 mL  Powder and solve nt 
for reconstitution as 1 
mL solution for 
injection  
Strength  1 mg/mL  N/A 1 mg  
Device  Single use pre -filled 
syringe  Single use pre -filled 
syringe  Powder and solvent 
for reconstitution 
packed together in a 
plastic box. A “hypo -
kit”. 
Manufacturer  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Novo Nordisk A/S, 
Bagsværd, Denmark  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115545]  
Storage 
requirements  Store between 2 and 
8°C Store between 2 and 
8°C Store between 2 and 
8°C 
The quantities of ingredients for dasiglucagon and placebo are provided in  Table 2. 
Table 2 Quantities of ingredients in dasiglucagon and placebo injection 
Component  Amount per mL 
(dasiglucagon)  Amount per mL 
(placebo)  Function  
Dasiglucagon*  1.0 mg  N/A 
Sodium chloride  10.23 mg  10.23 mg  
Trometamol/Tromethamine  6.06 mg  6.06 mg  
Water for injection  To make 1 mL  To make 1 mL  
Sodium hydroxide  q.s. q.s. 
Hydrochlo ric acid  q.s. q.s. 
*The quantity of drug substance to be used is calculated according to net peptide content and purity.  
q.s. = quantum sufficit (quantity required). 
6.2 Treatment assignment and randomization 
Subjects successfully completing screening and who fulfill entry eligibility and 
randomization criteria will be randomized to one of three treatment groups in a ratio of 2:1:1: 
 Test treatment: Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a 
prefilled syringe. 
 Placebo treatment: Placebo, liquid formulation, 0.6 mL delivered in a prefilled 
syringe. 
 Reference treatment: Recombinant glucagon hydrochloride, 1 mg for reconstitution. 
Randomization will be performed using a fixed-block randomization scheme. The 
randomization scheme will be generated prior to the initiation of the study by [CONTACT_55467]/programmer who will not be a member of the study team; all investigators will not be aware of the block size of the randomization scheme.  
Randomization will be stratified by [CONTACT_807449] (a bdomen, 
buttocks, or thigh) and controlled via the IWRS.       

 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 33  of 80  
Subjects will be randomized to study treatment using an interactive, automated system 
which has been validated for the intended use under the International Society of 
Pharmaceutical Engineers Good Automated Manufacturing Process guidelines, 21CFR 
Part 11 (FDA regulation for Electronic Records and Electronic Signatures) and the International Conference on Harmonization (ICH) Guidance E6 for Industry on Good Clinical Practice (GCP).   
6.3 Administration 
Dasiglucagon, placebo, and GlucaGen will be administered by [CONTACT_807484], buttocks, or thigh.  
An unblinded person (appropriately trained) authorized to prepare the dose and 
administer the treatment in accordance with the randomization will prepare the treatment required for each subject on each dosing day. The dose will be administered by [CONTACT_353660], trained and qualified person. The content of the syringe has to be checked for clarity and absence of bubbles. To ensure proper administration, the unblinded person should administer the SC injection at a [ADDRESS_1115546] finger. The injection should be given within 5 seconds. 
Syringes will be discarded after dose administration. Used GlucaGen vials will be stored 
in a lockable box (separated from unused vials) at ambient temperature. 
6.[ADDRESS_1115547] label will be compliant with local laws and regulations.  
The study drug label will describe the storage conditions for study drug. The labels will 
supply no information about the subjects. Each treatment kit (pre-filled syringe/vial for reconstitution) will have a unique Dispensing Unit Number for drug allocation, drug accountability, and traceability purposes. 
Labelling will be performed according to Annex [ADDRESS_1115548] ensure the availability of proper storage conditions. All study drug 
supplies provided for this study will be stored in a secure area with restricted access at the 
study site.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115549] be stored in a refrigerator (at a temperature of 2–8°C), 
and should be handled in accordance with guidelines from the sponsor. GlucaGen must also be stored in a refrigerator (at a temperature of 2–8°C), and should be handled in accordance with the Summary of Product Characteristics ( 13).  
The unblinded person responsible for study drug handling must contact [CONTACT_807452].  
Please see the Pharmacy Manual for additional information on handling study drug. 
6.6 Blinding and breaking the blind 
This is a double-blind trial. As the trial products are not identical in appearance, 
dasiglucagon and placebo being available as a liquid formulation and GlucaGen as a 
powder for reconstitution, unblinded trial personnel will be responsible for handling, 
preparing (according to the prescription from the IWRS), and administering the trial medication, as well as for keepi[INVESTIGATOR_807439]. To maintain double-blind conditions, all trial assessments at the trial center will be done by [CONTACT_460637]. However, exposure assessments and anti-drug antibody ( ADA) assessments will be performed by [CONTACT_807454], to ensure that dasiglucagon, placebo, or GlucaGen administration 
is matched with the applicable bioanalytical assay. 
Treatment assignment will be kept strictly confidential and accessible only to authorized 
persons until after the time of unblinding. Codes with treatment assignment will, however, be readily available in the IWRS to the blinded personnel in case of an emergency. 
The code for a particular subject may be broken in a medical emergency if knowing the 
identity of the treatment allocation would influence the treatment of the subject. The emergency code break can be performed using the IWRS. Whenever a code is broken, the person breaking the code must record the time, date and reason as well as his/her initials in the source documents. The breaking of blinded codes in case of medical emergency for one subject should not unblind the trial personnel to the treatment information of other 
subjects. The person performing the unblinding should inform as few people as possible 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115550] be notified within 24 hours after the code has been broken. 
The pharmacovigilance unit (safety contract research organization [ CRO] ; see the list of 
trial personnel in Section 12.1) will be able to break the code in case of a serious 
unexpected suspected adverse reaction (S[LOCATION_003]R).  The central and specialty laboratories will be provided with a copy of the randomization 
list. 
6.[ADDRESS_1115551] until approved by [CONTACT_1034].  
6.8 Treatment compliance 
All trial medications will be prepared and administered by [CONTACT_93400]. 
PK assessments will support the surveillance of compliance with IMP administration.  
6.9 Prior and concomitant medications 
Prior glucagon exposure will be recorded in the eCRF at screening. All concomitant 
medications will be recorded and/or updated in the eCRF at each visit.  
Subjects using any new concomitant medication resulting in fulfillment of a dosing day 
exclusion criterion (see Section 5.5 ) will be excluded from the dosing visit, but can be 
rescheduled to one of the following days (1 –7 days later). The dosing visit can only be 
rescheduled once. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 36  of 80  
6.9.1 Prohibited medications 
The use of anti-coagulant treatments and medications (prescription and non-prescription) 
that are known to cause QT prolongation are prohibited during the course of the trial. 
Within 28 days prior to dosing, the use of daily systemic beta-blockers, indomethacin, 
warfarin, and anticholinergic drugs is prohibited. 
Within 2 weeks prior to dosing, the use of any non-prescribed systemic or topi[INVESTIGATOR_73264] (with the exception of vitamins and the occasional use of acetylsalicylic acid and paracetamol) is prohibited.  
Within 16 hours prior to dosing, the use of any basal insulin is prohibited. Within 6 hours prior to dosing, the use of any short acting (bolus) insulin, except insulin 
glulisine (Api[INVESTIGATOR_27976]
®) is prohibited.  
During the insulin-induced hypoglycemic procedure, continuous SC  insulin infusion must 
be stopped. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115552] be available prior to sample analyses. A bioanalytical report for each analysis of trial PD and PK samples will be prepared. 
7.1.1 Pharmacodynamic measurements 
The plasma glucose profile for evaluation of the primary and secondary clinical efficacy 
endpoints will be assessed based on plasma concentration data (AUC
0-30min ) from samples 
collected at the dosing visit (Visit 2). The samples will be sent to the clinical laboratory 
and analyzed using a sensitive and validated assay for glucose measurements.  
Samples will be collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 
75, and 90 minutes after dosing (see the schedule of procedures in Table 3). The actual 
time of blood sampling for evaluation of plasma glucose should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point and by [CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as within 2 minutes prior to dosing. 
7.1.2 Pharmacokinetic measurements 
The exposure to trial medication (dasiglucagon or GlucaGen) for evaluation of PK  will 
be assessed based on plasma concentration data (AUC
0-90 min , Cmax, tmax) from samples 
collected at the dosing visit (Visit 2).  
Samples (including back-up samples) will be collected pre-dose, and at 15, 30, 35, 40, 50, 
60, 90, and 120 minutes after dosing (see the schedule of procedures in Table 3). The actual time of blood sampling for exposure to trial medication should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 38  of 80  
7.2 Safety parameters 
7.2.1 Adverse events 
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an AE or serious adverse event (SAE), as provided in this protocol. During the trial, the investigator or center staff will be responsible for reporting AEs and SAEs, as detailed in this section of the protocol.  
Based on the investigator’s clinical judgment it will be determined whether an AE is 
related to treatment and of sufficient severity to require the subject’s removal from treatment or from the trial. A subject may also voluntarily withdraw from treatment due to what he or she perceives as an intolerable AE. If either of these situations arises, the subject should be under medical supervision until symptoms cease or the condition becomes stable. 
[IP_ADDRESS]  Definitions 
Adverse event 
An AE is any untoward medical occurrence in a trial subject given an IMP which does 
not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and/or unintended sign (for example, an abnormal laboratory finding), symptom, or disease temporally associated with the use of an IMP, whether or not considered related to the IMP.  
In this trial, only treatment-emergent adverse events (TEAEs) will be collected and 
reported. TEAEs are events that occur from the first trial-related activity after the subject has signed the informed consent form until the end of the post-treatment follow-up period.  
AEs include: 
 A clinically significant worsening of a concomitant illness. 
 A clinical laboratory abnormality which is clinically significant, i.e. any abnormality 
that suggests a disease and/or organ toxicity and is of a severity that requires active 
management. Active management includes active treatment or further investigations, for example change of medicine dose or more frequent follow-up due to the abnormality. 
 Hypoglycemic epi[INVESTIGATOR_1841] (see Section 7.2.2 ). 
 Injection site reactions (see Section 7.2.6). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 39  of 80  
The following should not be recorded as AEs, if recorded at screening (on the Screening 
Form or eCRF): 
 Pre-planned procedure, unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent. 
 Pre-existing conditions found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness). 
Serious adverse event 
An SAE is any untoward medical occurrence that at any dose:  
 Results in death  
 Is life-threatening  
 Requires inpatient hospi[INVESTIGATOR_1081] 
 Results in persistent or significant disability or incapacity 
 Is a congenital anomaly or birth defect 
 Is medically important* 
*Medical judgement must be exercised in deciding whether an AE is believed to be 
‘medically important’. Medically important events may not be immediately 
life-threatening or result in death or hospi[INVESTIGATOR_31348]. 
Adverse drug reaction 
All noxious and unintended responses to an investigational product related to any dose 
should be considered adverse drug reactions. The phrase responses to an investigational product means that a causal relationship between an investigational product and an adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out.  
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) 
An AE fulfilling one of the criteria of seriousness and being assessed as related to IMP 
application, the nature or severity of which is not consistent with the applicable reference document (e.g. dasiglucagon Investigator’s Brochure or package leaflet/Summary of Product Characteristics for GlucaGen).  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115553] 
An AESI is an event which, in the evaluation of safety, has a special focus (e.g. required 
by [CONTACT_21652]). In this trial hemodynamic changes, as defined below, are considered AESIs: 
 Post-dose clinical signs, or measured vital signs, indicating a clinical ly significant 
drop in blood pressure including signs of orthostatic hypotension, vasovagal 
responses or bradycardia.   
 Post-dose change in pulse or blood pressure considered an event of hypo- or 
hypertension as judged by [CONTACT_093].  
Intensity of an adverse event 
The maximum intensity (severity) of all AEs must be assessed by [CONTACT_807457]. Severity should be graded when the AE outcome is known: 
Mild :  A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living. 
Moderate :  A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, causing discomfort but poses no significant or permanent risk of harm to the subject. 
Severe :  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
A ‘severe’ reaction does not necessarily deem the AE as ‘serious’ and an SAE may not necessarily be ‘severe’ in nature. 
Causality relationship to trial medication 
The causality of each AE should be assessed by [CONTACT_807458]: 
Probable: Good reason and sufficient documentation to assume a causal relationship. 
Possible: A causal relationship is conceivable and cannot be dismissed. 
Unlikely: The event is most likely related to etiology other than the trial product. 
Not related :  No relationship to trial product. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115554] be assessed by [CONTACT_807459]/her 
staff. The following definitions should be used: 
Recovered/resolved:  The subject has fully recovered, or by [CONTACT_807460]-related activity after the subject signed the informed consent.  
Recovering/resolving: The condition is improving and the subject is 
expected to recover from the event. This term is only applicable if the subject has completed the trial. 
Recovered/resolved with sequelae :  The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment or procedure. If a sequela meets an SAE criterion, the AE must be reported as an SA E. 
Not recovered/not resolved :  The condition of the subject has not improved and 
the symptoms are unchanged. 
Fatal :  This term is only applicable if the subject died from 
a condition related to the reported AE. Outcomes of other reported AEs in a subjec t before he/she died 
should be assessed as "recovered/resolved", "recovering/resolving", "recovered/resolved with sequelae" or "not recovered/not resolved". An AE with fatal outcome must be reported as an SAE. 
Unknown :  This term is only applicable if the subject is lost to 
follow-up. 
[IP_ADDRESS]  Collection, recording and reporting of adverse events 
All events meeting the definition of an AE must be collected and reported from the first trial related activity after the subject has signed the informed consent until the end of the post-treatment follow-up period. At each contact [CONTACT_49877] (visit or telephone, excluding visits where the subject is not seeing the investigator or his/her staff [e.g. visits to the laboratory]) the subject must be asked about AEs. All AEs, either observed by [CONTACT_98138], must be recorded by [CONTACT_237215]. 
The investigator should record the diagnosis, if possible. If no diagnosis can be made the 
investigator should record each sign and symptom as individual AEs. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115555] also be completed. 
AE information should include the following: 
 Date and time of onset and resolution 
 Date and time of investigator’s first information on the (S)AE 
 Seriousness 
 Severity 
 Causal relationship with IMP 
 Interruption or withdrawal of treatment during IMP administration and other 
measures taken 
 Outcome. 
All AEs are coded; details are described in the trial-specific Data Management Plan.  
If an event classifies as a AESI, the investigator must tick the AESI box on the AE form 
and complete the AESI form. The AESI form will capture if the event was associated with any signs or symptoms and capture the highest/lowest blood pressure and pulse 
measured during the event. The investigator must report all AESIs to the sponsor’s 
responsible pharmacovigilance unit (Safety CRO; see the list of trial personnel in Section 12.1 ) immediately (within 24 hours) after obtaining knowledge about the event. 
The investigator must report initial information electronically (e.g. in PDF format) on all SAEs to the sponsor’s responsible pharmacovigilance unit (Safety CRO; see the list of 
trial personnel in Section 12.1) immediately (within 24 hours) after obtaining knowledge about the event. The Safety CRO will inform the medical monitor and the sponsor about the reported SAEs. 
It is the responsibility of the Safety CRO to report all S[LOCATION_003]Rs (see Section [IP_ADDRESS]) that 
occur in this trial to the Competent Authorities and Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) in accordance with the local requirements in force and ICH guideline for GCP. The trial monitor must be informed accordingly. 
[IP_ADDRESS]  Follow-up of adverse events 
All AEs that are ongoing at the end of the subject’s participation in the trial will be 
followed-up until the event is resolved or reaches a satisfactory outcome as deemed by [CONTACT_807492], whichever occurs first.   
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 43  of 80  
Follow-up actions for all SAEs will be performed according to appropriate clinical care 
practices and may depend on the nature of the event. These will be determined after internal review and/or sponsor review. 
The follow-up information should only include new (updated and/or additional) 
information that reflects the situation at the time of the investigator’s signature. 
Follow-up information on (S)AEs will be updated using the (S)AE form. If a non-serious event becomes serious during the follow-up the AE form and SAE form have to be used and reporting timelines follow those of an SAE. 
The investigator must forward follow-up information on SAEs and if previously 
non-serious AEs become SAEs to the Safety CRO immediately (within 24 hours) after obtaining knowledge about the new information. 
The sponsor and/or CROs acting on behalf of the sponsor can upgrade a non-serious AE 
to an SAE. In these situations the investigator will be informed and asked to fill out an 
SAE form and forward to the Safety CRO immediately (within 24 hours). 
[IP_ADDRESS]  Clinical laboratory abnormalities and other abnormal assessments as adverse 
events or serious adverse events 
Abnormal laboratory findings (e.g. biochemistry, hematology, urinalysis) or other 
abnormal assessments (e.g. vital signs) that are judged by [CONTACT_807493]. 
Clinically significant abnormal laboratory findings or other abnormal assessments that are detected during the trial or are present at baseline and significantly worsen following the start of the trial will be reported as AEs or SAEs. However, clinically significant abnormal laboratory findings or other abnormal assessments that are associated with the disease being studied, unless judged by [CONTACT_479732]’s condition, or that are present or detected at the start of the trial and do not worsen, will not be reported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically significant. 
7.2.2 Hypoglycemia 
Hypoglycemia will be regarded as an AE and recorded and documented on an AE form 
(and SAE form, if applicable). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 44  of 80  
Hypoglycemia is defined as a decline in plasma glucose to below 70 mg/dL 
(3.9 mmol/L). However, in the time period from initiation of the hypoglycemic clamp procedure (see Section [IP_ADDRESS]) until 45 minutes after dosing, hypoglycemia is defined as 
a decline in plasma glucose to below 45 mg/dL (2.5 mmol/L).  
During the dosing visit, prior to administration of the IMP, a plasma glucose value of 
<45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463]. After administration 
of the IMP in the period from 8 minutes until 44 minutes after dosing, a plasma glucose value of <45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463], and if a plasma glucose value of ≥70 mg/dL (3.9 mmol/L) is not achieved within the [ADDRESS_1115556] experiences symptoms of hypoglycemia, a plasma glucose measurement 
should be taken in order to classify the event (please refer to Section 7.4.2 for additional 
details).  
7.2.3 Physical examination 
The physical examination will be carried out at screening (Visit 1) and at the follow-up 
visit (Visit 3; see Table 3 ).  
The physical examination includes examination of the following body systems: head, ears, eyes, nose, throat, including the thyroid gland; heart, lung, chest; abdomen; skin and mucosae; musculoskeletal system; nervous system; lymph node; other findings. 
At the screening visit, any abnormality will be recorded and described in the eCRF, 
including the investigator’s assessment of clinical significance (‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’). Clinically significant findings at the screening visit should be recorded as concomitant illness. 
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see Section 7.2.1). 
7.2.4 Vital sig ns 
An examination of the following vital signs will be performed at screening (Visit 1), the 
dosing visit (Visit 2) and at the follow-up visit (Visit 3):  
 Diastolic and systolic blood pressure (mmHg) will be measured after at least 
[ADDRESS_1115557] in a supi[INVESTIGATOR_2547]. At Visit 1, blood pressure will be measured in 
both arms. The blood pressure from the arm with the higher systolic value is 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115558]’s blood pressure in this trial.  
 Pulse (beats per min) measured after at least [ADDRESS_1115559] in a supi[INVESTIGATOR_2547]. 
 Body temperature (°C). 
At the dosing visit, measurements will be taken prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) and at 30, 90, and 300 minutes after dosing 
(see Table 3 ). The actual time of the assessment should not deviate from the nominal time 
by [CONTACT_726] ±[ADDRESS_1115560] 12-lead ECG will be performed at the screening visit (Visit 1), the dosing visit 
(Visit 2; prior to the start of the insulin-induced hypoglycemic procedure [within 30 minutes] ) and at 20, 35, 45, 60, and 300 minutes after dosing) and at the follow-up 
visit (Visit 3; see Table 3 ). The actual time of the assessment should not deviate from the 
nominal time by [CONTACT_726] ±5 minutes.  
ECG parameters (heart rate, PQ, QRS, QT, QTcB) and any abnormality will be recorded 
and described in the eCRF including the investigator’s assessment of clinical significance (‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’).  
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see Section 7.2.1).  
7.2.6 Local tolerability 
Immediately prior to treatment administration, it should be verified that the injection site is normal. To ensure all injection site assessments are performed at the injection site, the site will be marked with a pen prior to injection. Assessment of local tolerability at the injection site will be performed at the dosing visit (Visit 2; at 30, 120 and 300 minutes after dosing), and at the follow-up visit (V isit 3) (see Table 3 ) and more frequently, if 
deemed necessary by [CONTACT_093]. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. In the eCRF, the time of assess ment and any injection site reaction observed will be recorded. In case of an 
observation, the Local Tolerability form will be completed, as well as the (S)AE form. 
The local tolerability at the injection site will be evaluated by [CONTACT_807464]: spontaneous pain, pain on palpation, itching, redness, edema, 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 46  of 80  
induration/infiltration, and other. Each of these assessments will be reported on a scale of 
0 (none), 1 (mild), 2 (moderate), and 3 (severe). The evaluation and the actual time of th e 
assessment will be recorded. The assessments will be performed by a trial physician or nurse.  
Digital pi[INVESTIGATOR_807433], and 
thereafter as often as judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_807434] a subject identifier, visit number, time after dosing, and a ruler for scaling. 
7.2.7 Clinical laboratory assessments 
The safety parameters that will be assessed at the clinical laboratory are listed in Table 3. 
Routine clinical laboratory tests will be performed centrally. Samples for clinical laboratory parameters (biochemistry, hematology, coagulation) will be collected at screening (Visit 1), the dosing visit (Visit 2, prior to the start of the insul in-induced 
hypoglycemic procedure [within 30 minutes] ) and at 30 and 300 minutes after dosing), 
and at the follow-up visit (Visit 3). The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. Samples for glycated hemoglobin (HbA
1c) will be collected at screening only (Visit 1). Samples for urinalysis will be 
collected at screening (Visit 1), at the dosing visit (Visit 2, prior to the start of the 
insulin-induced hypoglycemic procedure [within 120 minutes]) and at the follow-up visit 
(Visit 3) . The following parameters will be assessed: 
 Clinical biochemistry: sodium, potassium, calcium, glucose, urea, creatinine, total 
bilirubin, AST, ALT, gamma-glutamyltransferase, alkaline phosphatase, total protein, C-reactive protein, HbA
1c, C-peptide. 
 Hematology: hemoglobin, red blood cell count (erythrocytes), hematocrit, platelet 
count (thrombocytes), total white blood cell count (leukocytes). 
 Coagulation: international normalized ratio, fibrinogen (at screening visit only).  
 Urinalysis: pH, blood (leukocytes and erythrocytes), protein, glucose, ketones, nitrite. 
Pregnancy tests will be performed at each visit for women of childbearing potential only. A serum pregnancy test will be performed at screening (Visit 1) and urine stick tests will 
be performed at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic procedure) and the follow-up visit (Visit 3). Test sticks will be provided to the trial centers. 
Alcohol breath tests and a urine drug screen will be performed at screening (Visit 1) and 
at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic 
procedure ). Equipment for the alcohol breath test and uring drug screen will be provided 
to the trial centers.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115561]’s partner will be fully informed by a physician of 
her participation in capturing the outcome data, and will be asked to provide her written 
consent. 
The investigator must report all information on pregnancies on the Initial Pregnancy 
form. The completed Initial Pregnancy form must be forwarded to the sponsor 
immediately (within 24 hours), according to the procedure stated in Section [IP_ADDRESS]. Any (S)AEs in the mother, as well as other pregnancy complications (ectopic pregnancy) fulfilling the criteria of an (S)AE, must be reported on the (S)AE form.  
The following must be collected in the Initial Pregnancy form:  
 Medical history of the mother 
 Family history 
 Course of the pregnancy, including expected delivery date. 
The investigator must follow the pregnancy until the pregnancy outcome and follow the 
newborn infant(s) until the age of [ADDRESS_1115562] information on the pregnancy and pregnancy complications as well as the pregnancy outcome including the health of the newborn infant(s) on the Pregnancy Outcome form. The completed Pregnancy Outcome form must be forwarded to the sponsor according to the procedure stated in Section [IP_ADDRESS]. Any (S)AEs in the newborn must be reported on the (S)AE form. 
The SAEs that must be reported include abnormal outcome, such as congenital 
anomalies, fetal death and termination of pregnancy (spontaneous or elective abortion), 
including any anomalies of the fetus observed at gross examination or during autopsy.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115563] be collected in the Pregnancy Outcome form:  
 Course of the pregnancy 
 Outcome of the pregnancy 
 Condition of the newborn 
 Any AEs in the newborn infant must be followed until the age of [ADDRESS_1115564]’s participation in the trial, the investigator should ensure that adequate medical care is provided to the subject for any AEs, including clinically significant laboratory values related to the trial. The investigator should inform the subject when medical care is needed for intercurrent illnesses of which the investigator becomes aware.  
For further information on safety precautions for dasiglucagon and GlucaGen, please 
refer to the current version of the Investigator’s Brochur e (14) and the Summary of 
Product Characteristics for GlucaGen (13), respectively. 
7.2.[ADDRESS_1115565] the subjects. 
7.3 Demography, concomitant illness, medical history and concomitant 
medication 
Demographics, body measurements, concomitant illness and medical history will be assessed only at screening  (Visit 1). Concomitant medication will be assessed at 
screening (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic procedure) and at the follow-up visit (Visit 3). 
7.3.[ADDRESS_1115566] demographics and body measurements will include: 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 49  of 80  
 Age  
 Race, ethnicity 
 Sex 
 Height (m eters or inch), without shoes 
 Body weight (kg or lb), only wearing underwear and measured using standard scales 
 Body mass index (kg/m2) calculated based on height and body weight (body 
weight/height2). 
7.3.2 Concomitant illness and medical history 
A concomitant illness is any illness that is present at the start of the trial (i.e. at the 
screening visit). Concomitant illnesses present at the start of the trial will be recorded in the eCRF at screening.  
Medical history is an account of medical events that the subject has experienced in the 
past, including prior medications. Relevant medical conditions/illnesses in the past obtained by [CONTACT_807489]/her medical records will be recorded in the eCRF at screening. History of alcohol or drug abuse will also be recorded. 
The information collected for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution or continuation. 
Any change to a concomitant illness should be recorded during the trial, including end 
date, if applicable. A clinically significant worsening of a concomitant illness must be 
reported according to Section 7.2.1. 
All previous and concomitant diseases will be coded with Medical Dictionary for 
Regulatory Activities (MedDRA), the version of which will be provided in the clinical trial report. 
7.3.3 Diabetes diagnosis and current treatment 
The date of diagnosis of diabetes will be recorded as will the current diabetes treatment 
(start date, product name(s), dose(s)). 
7.3.4 Concomitant medication 
A concomitant medication is any medication, other than the trial products and current 
diabetes treatment (including insulin glulisine [Api[INVESTIGATOR_27976]
®] for diabetes therapy wash-out), 
which is taken during the trial, including screening and follow-up periods. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115567] be recorded at trial entry (i.e. at screening). 
Any changes in concomitant medication must be recorded at each visit as they occur. The information collected for each concomitant medication includes (at a minimum) trade name [CONTACT_18058], indication, start date and stop date or continuation. A change in medication due to an AE must be recorded and reported according to Section 7.2.1. If the change in medication influences the subject’s eligibility to continue in the trial, the sponsor and trial monitor must be informed. 
7.[ADDRESS_1115568] dasiglucagon/GlucaGen will be measured at the dosing visit (Visit 2) 
and at follow-up (Visit 3). At the dosing visit (Visit 2), samples will be collected prior to the start of the insulin-induced hypoglycemic procedure.  
The clinical ADA assays, specific for dasiglucagon and GlucaGen, respectively, have 
been validated in accordance with existing guidelines and recommendations (17-21) .  
Confirmed positive anti-dasiglucagon antibody samples (treatment-induced or 
treatment-boosted) from anti-dasiglucagon antibody-positive subjects will be evaluated 
for binding titer neutralizing potential and titer as well as cross-reactivity towards endogenous glucagon.  
No further serum sampling will be needed as the ADA samples can be used for 
neutralizing antibody analysis. 
The in vitro neutralizing effect of the antibodies will be measured using an assay based 
on glucagon receptor transfected human embryonic kidney cells (20,22). The calculated sensitivity in previous studies was about 51.8 ng/mL. The assay was also validated for recombinant glucagon with similar results (21,23). In case of a positive result in the 
neutralizing antibody assay, a titer estimation will be performed. The cell-based neutralizing antibody analyses will be performed by a special laboratory, BioAgilytix, Durham, NC, [LOCATION_003]. 
Residual and additional antibody serum samples may be stored until approval of market 
authorization by [CONTACT_93420]. Further characterization of the antibody response may be requested by [CONTACT_93420]. 
7.4.2 Plasma glucose measurement s for safety 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site. After the start of insulin infusion, plasma glucose should be checked every 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 51  of 80  
10 minutes while plasma glucose is above 110 md/dL, and every 5 minutes once plasma 
glucose is at or below 110 mg/dL and until after dosing when the subject’s plasma glucose is ≥70mg/dL (3.9 mmol/L). Hereafter, plasma glucose should be checked every 30 minutes until 300 minutes (5 hours ) after dosing. Plasma glucose concentrations will 
be measured using a US  FDA-approved glucose analyzer (e.g., YSI 2300, Yellow 
Springs Instruments, Yellow Springs, OH). 
At the discretion of the investigator, additional plasma glucose measurements can be 
taken at any time during the trial, for example when there is a suspi[INVESTIGATOR_2798] (e.g. symptoms) of a hypoglycemic epi[INVESTIGATOR_1865]. 
Plasma glucose measurements for safety should only be recorded in the eCRF if they are 
related to an AE (e.g. a hypoglycemic epi[INVESTIGATOR_1865]). 
In case of persistent post-treatment hypoglycemia, subjects will receive rescue treatment 
with an IV glucose infusion (see Section [IP_ADDRESS] for details). Blood samples for PD and 
PK assessments should still be taken at the specified timepoints. 
7.4.3 Plasma insulin measurements 
Samples for insulin assessment will be collected at the dosing visit (Visit 2, pre-dose and 
at 30 and 60 minutes after dosing). The actual time of blood sampling for evaluation of plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115569] 
8.1 Schedule of procedures 
The schedule of procedures is provided in Table 3. Informed consent will be obtained 
prior to any trial-related procedures; see Section 10.8. 
8.2 Procedures by [CONTACT_765] 
8.2.1 Visit 1 (screening, Day -30 to Day - 3) 
Visit [ADDRESS_1115570] between 3 and 30 days before Visit 2, Day -1 to Day 1 (dosing 
day). 
Informed consent can be obtained prior to or at Visit 1, however it must in any case be 
obtained prior to any trial related procedures. During the screening visit, the following assessments will take place: 
 Informed consent (obtain or check) 
 Check of subject eligibility (inclusion/exclusion criteria) 
 Demography  
 Body measurements 
 Medical history, diabetes diagnosis, current diabetes treatment 
 Concomitant illnesses 
 Concomitant medications 
 History of alcohol/drug abuse 
 Physical examination 
 Vital signs 
 12-lead ECG 
 AEs  
 Biochemistry, hematology, coagulation, HbA
1c 
 Serum pre gnancy test (women of childbearing potential only) 
 Urinalysis  
 Urine drug screen 
 Alcohol breath test 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 53  of 80  
Table 3 Schedule of procedures 
Visit number  V1 V2 V3 
Trial day  -3 -1 and 1 28 
Visit type  Screening  Dosing  Follow -up 
Window  -30 to -3  +[ADDRESS_1115571] related information/assessments     
Informed consent  x   
Inclusion/exclusion criteria  x x1,2  
Demography  x   
Body measurements  x   
Medical history, diabetes diagnosis, and current diabetes 
treatment  x   
Concomitant illness es x   
Concomitant medication s x x1 x 
History of alcohol/drug abuse  x   
Randomization   x1  
Withdrawal criteria   x1  
Dosing day exclusion criteria   x1  
Insulin -induced hypoglycemia   x  
Safety assessments     
Physical examination  x  x 
Vital signs  x x3 x 
12-lead ECG  x x4 x 
Local tolerability   x5 x 
Adverse events  x x x 
Laboratory     
Biochemistry, h ematology, coagulation, HbA 1c (HbA 1c at 
Visit 1  only)  x x6 x 
Pregnancy test (women of childbearing potential only)  x7 x1,[ADDRESS_1115572]  x x1  
PK/Clinical efficacy     
Plasma dasiglucagon /GlucaGen   x9  
Plasma glucose   x10  
Other assessments     
Antibodies against dasiglucagon /GlucaGen   x1 x11 
Plasma i nsulin   x12  
Trial material     
Administration of tr ial product  (during hypoglycemic clamp 
procedure)   x  
1Prior to the start of the insulin-induced hypoglycemic procedure. 
2Only check of dosing day exclusion criteria and changes between screening visit and Visit 2. 
3Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30, 90 and 300 minutes 
after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 54  of 80  
4Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 20, 35, 45, 60 and 300 
minutes after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±5 
minutes.  
5Local tolerability assessed at 30, 120, and 300 minutes after dosing. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes.  
6Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30 and 300 minutes after 
dosing . The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±[ADDRESS_1115573]. 
9Pre-dose, and at 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling should not 
deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
10Pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, 90 minutes after dosing. The actual time of blood 
sampling should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point 
and by [CONTACT_726] ±[ADDRESS_1115574] that tests positive for ADA will be monitored until the ADA levels return to baseline levels. 
12Pre-dose, and at 30 and 60 minutes after dosing. The actual time of blood sampling should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing.  ADA = anti-drug antibodies; ECG = electrocardiogram; HbA
1c = glycated hemoglobin. 
Eligible or potentially eligible subjects (laboratory results pending) will be provided with 
an Identification card (ID card), stating that the subject is participating in the trial and 
whom to contact (site address, investigator name [CONTACT_41319]). The subjects should be instructed to return the ID card to the investigator at the last visit or to destroy 
the card after the last visit.  
8.2.2 Instructions to subjects prior to the dosing visit (Visit 2) 
At the screening visit, the investigator will inform the subject about the changes to his/her 
insulin therapy leading up to the start of the insulin-induced hypoglycemic procedure . 
The subject’s current insulin therapy will be washed out as defined in Section 5.5: 
16 hours prior to dosing and during the dosing visit, treatment with any basal insulin is not allowed; 6 hours prior to dosing and during the dosing visit, treatment with any short acting (bolus) insulin, except insulin glulisine (Api[INVESTIGATOR_27976]
®), is not allowed. The basal rate of 
insulin pumps (continuous SC insulin infusion) will be discontinued on the morning of 
the dosing day OR 6 hours prior to dosing. 
On the day prior to dosing (Day -1), the subjects will need to attend the clinical center 
and will be required to stay onsite overnight. On the morning of the dosing day (Day 1), patients are required to be in a fasting condition, defined as having consumed only water since 22:00 hours the night before. However, the subjects are allowed to consume small amounts (up to 20 g) of carbohydrates to prevent hypoglycemia. The subjects must also not consume any alcohol within 24 hours prior to dosing (refer to Section 5.5 for all dosing day exclusion criteria). 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 55  of 80  
8.2.3 Visit 2 (dosing visit) 
Visit [ADDRESS_1115575] on D ay -1 to Day 1. 
The subjects will attend the clinical center the day prior to dosing (Day -1) and should 
stay onsite overnight. Dosing will take place the following morning (Day 1). 
On Day [ADDRESS_1115576] 
eligibility is rechecked (check of changes between the screening visit and Visit 2) and those subjects eligible to participate will be randomized to treatment with dasiglucagon, placebo, or GlucaGen.  
The following assessments will also take place: 
 Document all changes in concomitant medication (prior to the start of the 
insulin-induced hypoglycemic procedure) 
 Check of withdrawal criteria (prior to the start of the insulin-induced hypoglycemic 
procedure) 
 Check of dosing day exclusion criteria (prior to the start of the insulin-induced 
hypoglycemic procedure) 
 Vital signs (prior to the start [within 30 minutes] of the insul in-induced hypoglycemic 
procedure, and at 30, 90 and 300 minutes after dosing). Blood pressure should be 
measured first in sitting and then in standing. 
 12-lead ECG (prior to the start [within 30 minutes] of the insulin-induced 
hypoglycemic procedure, and at 20, 35, 45, 60, and 300 minutes after dosing) 
 Local tolerability (at 30, 120, and 300 minutes after dosing) 
 AEs  
 Biochemistry, hematology, coagulation (prior to the start of the insulin-induced 
hypoglycemic procedure [within 30 minutes], and at 30 and 300 minutes after dosing) 
 Urine stick pregnancy test (women of childbearing potential only; prior to the start of 
the insulin-induced hypoglycemic procedure) 
 Urinalysis (prior to the start of the insulin-induced hypoglycemic procedure [within 
120 minutes]) 
 Urine drug screen (prior to the start of the insulin-induced hypoglycemic procedure) 
 Alcohol breath test (prior to the start of the insulin-induced hypoglycemic procedure) 
 Dasiglucagon/GlucaGen plasma concentrations: 
- Pre-dose, 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling for exposure should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
 Plasma glucose concentration s:  
- Pre-dose, 4, 6, 8 ,10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, and 90 minutes after dosing. The actual time for blood sampling for plasma glucose should not deviate 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 56  of 80  
from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection 
time point and by [CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as within 2 minutes prior to dosing. 
 Antibodies against dasiglucagon/GlucaGen (prior to the start of the insulin-induced 
hypoglycemic procedure). 
 Plasma insulin concentrations: 
- Pre-dose, 30 and 60 minutes after dosing. The actual time of blood sampling for plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
[IP_ADDRESS]  Hypoglycemic clamp procedure and administration of trial medication 
The following procedure is based on precendent procedures for hypoglycemia induction in patients with T1DM [24, 25].  
The treatment day (Visit 2, Day 1) will be conducted after an overnight fast of at least 8 hours, targeting a starting plasma glucose around 90 to 110 mg/dL (5.0-6.1 mmol/L).   
Subjects who meet one or more of the dosing day exclusion criteria (Section 5.5) at the 
dosing visit will be excluded from the dosing visit, but the visit can be rescheduled 
1-[ADDRESS_1115577]’s current insulin therapy will be washed out as defined in Section 5.5. For 
subjects using multiple daily injections, the date, time and the dose of the last basal insulin administration prior to dosing will be captured. 
At approximately 08:00 hours, an infusion catheter will be inserted into each arm 
(forearm cephalic vein) for the manual glucose clamp procedure, with the glucose infusion in one arm and the insulin infusion in the opposite arm. A third catheter for blood sampling will be placed into a metacarpel vein for blood sampling. This hand wi ll 
be warmed (55-65ºC) to arterialize venous blood.   
Hypoglycemia will be gradually induced by a fast-acting IV insulin glulisine (Api[INVESTIGATOR_27976]
®) 
infusion (15 U [100 U/mL] in [ADDRESS_1115578]’s blood or plasma), 
initially at 150% of the subject’s usual basal rate and can be increased or decreased over a range of 75% to 200% as judged necessary by [CONTACT_093], to achieve a controlled decline in plasma glucose, targeting a plasma glucose level of 55 mg/dL (3.1 mmol/L).  
Plasma gluco se concentrations will be measured using a US  FDA-approved glucose 
analyzer (e.g., YSI 2300, Yellow Springs Instruments, Yellow Springs, OH). After the 
start of the insulin infusion, plasma glucose will be measured every 10 minutes whil e 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 57  of 80  
plasma glucose is above 110 mg/dL, and every 5 minutes once plasma glucose is at or 
below 110 mg/dL. 
Once the glucose concentration declines to <60 mg/dL (3.3 mmol/L), the insulin infusion 
will be stopped, and 5 min later plasma glucose concentration will be measured at the glucose analyzer and blood samples for baseline assessment of plasma glucose, dasiglucagon/GlucaGen PK, and insulin PK will be collected. The samples are the 
baseline samples and should be collected within 2 minutes before IMP administration. 
 If plasma glucose is >45 mg/dL and <60 mg/dL (2.5-3.3 mmol/L), study treatment 
(IMP) will be administered, defining time, t=0. The study treatment will be delivered 
in the abdomen, buttock, or thigh (according to stratification) via SC injection, with the subject lying in a lateral recumbent position. 
 If plasma glucose is <45 mg/dL (2.5 mmol/L), IV glucose solution will be 
administered sufficient to raise plasma glucose to within the 45-60 mg/dL target 
range. The run-in period will be adequately extended (at least 30 min) until the above target is achieved and new baseline samples for plasma glucose, dasiglucagon/GlucaGen PK, and insulin PK will be collected. Glucose should not be infused within [ADDRESS_1115579] should be rescheduled for a new 
treatment visit within 7 days (+ 2 days). 
Administration of IMP should not occur earlier than 9:00 hours in the morning or later 
than 12:00 hours. 
As shown in Table 4, serial blood samples for glucose will be collected at t=0, 4, 6, 8, 10, 
12, 15, 17, 20, 25, 30, 40, 50, 60, [ADDRESS_1115580]-dosing. Samples for assessing plasma dasiglucagon/GlucaGen concentration will be collected  at t=0, 15, 30, 35, 40, 50, 60, 90, and 120 minutes. Samples for assessing plasma insulin concentration will be collected at t=0, 30, and [ADDRESS_1115581]-treatment blood sampling times 
Times  0 4 6 8 10 12 15 17 20 25 30 35 40 50 60 75 90 120 
Plasma glucose  Y Y Y Y Y Y Y Y Y Y Y  Y Y Y Y Y  
PK 
Dasiglucagon/ 
GlucaGen  Y      Y    Y Y Y Y Y  Y Y 
PK Insulin  Y          Y    Y    
Refer to Section 7.2.7 for details of laboratory safety sampling and to Section 7.4.2 for 
details of blood glucose safety sampling.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 58  of 80  
When the t=90-minute blood sampling for plasma glucose has been collected the subjects 
are allowed to eat moderately. Drinking of water is allowed ad libitum  during the entire 
procedure. 
Hypoglycemia Rescue Provisions 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site for safety reasons as described in Section 7.4.2. Subjects should receive post-treatment rescue glucose infusion to ameliorate persistent hypoglycemia, as follows. 
1. Glucose infusion should be initiated if a subject experiences severe alarming escalation of symptoms of hypoglycemia (e.g. symptoms suggesting a change in consciousness) at any time during the trial; glucose infusion should be initiated targeting a plasma glucose levels >70 mg/dL. 
2. If plasma glucose is <45 mg/dL (2.5 mmol/L) between t=8 and t=44 minutes, 
rescue glucose infusion (1 -2 mg/kg administered IV over about 5 seconds) should 
be initiated to maintain plasma glucose between 45 mg/dL and 55 mg/dL (2.5-3.1 mmol/L). Pause glucose infusion if plasma glucose is >55 mg/dL. 
3. If plasma glucose is <70 mg/dL at t=45 minutes, rescue glucose infusion (2-3 mg/kg administered IV over about 5 seconds ) should be initiated to maintain 
plasma glucose between 70 mg/dL and 80 mg/dL (3.9-4.4 mmol/L). Pause glucose infusion if plasma glucose is >75 mg/dL (4.2 mmol/L). 
Subjects should remain in bed until completion of the test procedure 300 minutes after dosing (bathroom visits are allowed).  
The IMP will be administered SC according to Section 6.3. The time of IMP 
administration will be recorded. At the timepoint when the insulin infusion is stopped, the 
total insulin dose which was required to induce hypoglycemia will be recorded. 
AEs will be specifically recorded during the procedure at several timepoints. The investigator must provide information to th e subjects on how to resume their usual 
diabetes treatment. The subject may be released from the clinical center if the investigator does not have any 
safety concerns based on the last safety plasma glucose value and the general condition of the subject. However, at the discretion of the investigator or on request of the subject, the 
subject may stay at the trial center for a longer period. 
8.2.4 Visit 3 (follow- up visit) 
Visit [ADDRESS_1115582] on D ay 28 + [ADDRESS_1115583] does not need to be fasting. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115584]: 
 Document all changes in concomitant medication  
 Physical examination 
 Vital signs 
 12-lead ECG 
 Local tolerability 
 AEs  
 Biochemistry, hematology, coagulation 
 Urine stick pregnancy test (women of childbearing potential only) 
 Urinalysis 
 Antibodies against dasiglucagon/GlucaGen. 
After the follow-up visit the End of Trial form must be completed. Even if a subject is not 
able to attend the follow-up visit, the End of Trial form, the eCRF Accountability/Affirmation Statement form and the Drug Accountability form must be completed. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 60  of 80  
9 STATISTICAL METHODS 
Before database lock and treatment unmasking, a separate statistical analysis plan (SAP) 
will be finalized, providing detailed methods for the analyses outlined below. Further analysis details may be added or refined in the SAP. 
Any deviations from the planned analyses will be described and justified in the final 
clinical trial report. 
9.[ADDRESS_1115585] s 
treated with dasiglucagon 0.6 mg. With a 2:1:1 randomization ratio for the three 
treatments, dasiglucagon 0.6 mg, placebo, and GlucaGen 1 mg, 78 subjects injected with dasiglucagon and 39 subjects with placebo will yield a power of 90% at a 5% two-sided significance level to detect a treatment group difference in recovery incidence within 
20 minutes, assuming as low as 80% and as high as 50% recovery incidence for the 
dasiglucagon and placebo groups, respectively.  
9.2 Trial subjects 
9.2.1 Analysis samples 
For presentation of data and reporting of the statistical analyses, th e following analysis 
samples will be used, depending on the context:  
 Safety analysis set (SAS): All randomized subjects who received at least one dose of 
trial medication.  
 Full analysis set (FAS): All randomized subjects who received at least one dose of 
trial medication and contributed valid information for at least one post-dose endpoint. 
 Per protocol (PP) set : All subjects of the FAS for whom no relevant protoco l 
deviations were documented. This sample will primarily be used for sensitivity 
analysis.  
The analysis of the primary endpoint and secondary endpoints will be based on the FAS. A secondary analysis of the primary endpoint will be based on the PP set . All safety 
analyses will be based upon the SAS. 
The decision regarding whether a protocol deviation is relevant or not for the exclusion of 
subjects from the PP set  will be made case-by-case in a data review meeting prior to 
treatment unmasking and database lock (see Section 9.2.3).  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115586] the results will be identified and it will be evaluated if subjects and/or data should be excluded from the analysis. Protocol deviations will be classified as minor or major in a consistent way. Major deviations from the protocol may lead to the exclusion of a subject from the PP set. 
Major protocol deviations may include deviations related to trial inclusion or exclusion 
criteria, conduct of the trial, subject management or subject assessment. Unless explicitly decided otherwise during the masked data review, the following will be considered major protocol deviations: 
 Violation of one or more major inclusion/exclusion criteria 
 Interruption of administration of trial product 
 Significant deviation from time windows  
 Incorrect treatment allocation 
 Missing primary endpoint. 
The violation of several major inclusion/exclusion criteria or the complete absence of 
efficacy data might lead to exclusion of the subject from FAS. In that case, the decision should be taken at the masked data review meeting, and the exclusion from efficacy analysis justified in the signed notes of the meeting. 
Obviously erroneous data points may be excluded from the analyses or re-analyzed (in 
case of e.g. serum concentrations). The decision to re-analyze or exclude data points from the statistical analysis is the joint responsibility of the sponsor and the trial statistician.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 62  of 80  
The subjects or observations to be excluded and the reason for their exclusion will be 
documented and signed by [CONTACT_93440]. The documentation will be stored together with the remaining trial documentation. The subjects and observations excluded from analysis sets, and the corresponding reasons, will be described in the clinical trial report. 
9.3 General considerations 
All data obtained in this trial and documented in the eCRFs will be listed and 
summarized with statistics or frequency tables as appropriate. In case of termination of the trial, all data collected up to that timepoint will be included in the analysis. 
Raw data listings and summary tables will be generated using the software SAS
© version 
9.[ADDRESS_1115587] deviations, medians, 
coefficients of variation, and minimum and maximum values.  
Other summaries (e.g. quartiles, 95% confidence intervals [CIs]) may be used as 
appropriate. Categorical efficacy and safety variables will be summarized by [CONTACT_807466]. 
9.4 Demographics and baseline characteristics 
Baseline and demographic data will be summarized using descriptive statistics. Baseline 
ADA -positive subjects will be calculated as a percentage of the total number of subjects 
whose baseline samples were tested for ADA. 
All other data obtained in this trial and documented in the eCRF will be listed. 
9.5 Efficacy Analyses 
For the confirmatory analyses, the primary and key secondary endpoints for the 
dasiglucagon 0.6 mg and placebo treated subjects will be compared. A hierarchical procedure will be applied for the control of multiplicity. The primary and secondary endpoints will be evaluated on the full analysis set. In the primary analysis, those subjects who require rescue IV glucose will be censored at the time to plasma glucose recovery.  In a sensitivity analysis, the time to plasma glucose recovery will be analyzed without censoring the subjects who received rescue IV glucose.   
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115588] the null hypothesis for a dasiglucagon versus placebo comparison: 
 Primary:  Time to plasma glucose recovery 
 Key secondaries 1-4: Plasma glucose recovery within 30 minutes, within 20 minutes, 
within 15 minutes, and within 10 minutes after study drug injection withou t 
administration of rescue IV glucose. 
 Key secondaries 5-8:  Plasma glucose changes from baseline (CFB) within [ADDRESS_1115589] increase in 
plasma glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp procedure without administration of rescue IV glucose.  
[IP_ADDRESS]  Primary analysis 
The primary endpoint will be summarized using Kaplan-Meier (KM) estimates stratified 
by [CONTACT_807467]. The treatment group difference between dasiglucagon and placebo will be evaluated inferentially using a pairwise two-sided log-rank test. 
In the primary analysis, those subjects who require rescue IV glucose will be censored at 
the time of plasma glucose recovery. This approach is based on the assumption that rescue IV glucose administration will shorten the time to recovery. This assumption 
implies that censoring at the time of recovey after rescue therapy is valid as a time to 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 64  of 80  
recovery without rescue would be longer than the observed duration. If recovery has not 
occurred at 45 minutes after study drug injection, censoring will be applied irrespective of the use of rescue IV glucose.  
In sensitivity analyses, the time to plasma glucose recovery will be analyzed 1) without 
censoring at the time of recovery for those subjects who require rescue IV glucose before 45 minutes and 2) with censoring at the time of administration of rescure IV glucose before 45 minutes.   
The primary endpoint will additionally be analyzed using a Cox proportional hazards 
(CPH) time to event statistical model, if the hazards by [CONTACT_807445] a graphical comparison of log-minus-log survival curves and no more than two-thirds of the recovery times are censored in each treatment group. The CPH model will be used for inferences, with treatment group and injection site modeled as 
categorical effects, and baseline plasma glucose modeled as a continuous covariate. The 
treatment group rate ratios, active versus placebo, will be estimated together with the 95% confidence intervals, and pairwise treatment group inferences (dasiglucagon vs placebo, GlucaGen vs placebo) will be evaluated using two-sided likelihood ratio tests. 
9.5.3 Secondary endpoints 
 Plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, 
and within 10 minutes after study drug injection without administration of rescue IV 
glucose. 
 Plasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
[IP_ADDRESS]  Confirmatory analysis 
The key secondary incidence variables (plasma glucose recovery within 30 minutes, within 20 minutes, within 15 minutes, within 10 minutes, in hierarchical order for inference) will be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus placebo) using Fisher’s exact test for each pairwise comparison. 
The key secondary endpoints of plasma glucose CFB within [ADDRESS_1115590] in those subjects who require rescue IV glucose before plasma glucose ≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an Analysis of Covariance model, 
with treatment group modeled as a fixed effect and with the baseline plasma glucose 
modeled as a covariate. The dasiglucagon versus placebo treatment group difference will 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115591]. 
9.5.4 Secondary clinical efficacy (PD) endpoints 
 Time to first plasma glucose concentration of ≥70 mg/dL (3.9 mmol/L) without 
administration of rescue IV glucose. 
 Plasma glucose response as area under the curve above baseline from time zero to 
30 minutes, AUC 0-30min . 
Secondary clinical efficacy endpoints will be assessed based on plasma concentration 
data from samples collected at the dosing visit (Visit 2).  
Unless otherwise stated, the population base of analysis will be the FAS. 
[IP_ADDRESS]  Analysis of secondary clinical efficacy (PD) endpoints 
1. Time to first plasma glucose concentration ≥70 mg/dL from baseline. This 
time- to-event endpoint will be evaluated using a Kaplan-Meier approach, with 
treatment group as a stratification factor, analogous to that used for the primary endpoint analysis. Differences between the KM curves (dasiglucagon versus placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise two-sided log rank tests. If the ≥70 mg/dL endpoint is not met within [ADDRESS_1115592] valid plasma glucose measurement up to 45 minutes will be the censoring time.  
2. The AUC will be calculated as the baseline-adjusted area under the plasma glucose profile over time: 
a. AUC
0-30min : restricting the time window to the 0 to 30 minutes interval. 
3. The log-transformed AUC endpoint will be analyzed using an analysis of covariance (ANCOVA) model with treatment as fixed effect and baseline plasma 
glucose modeled as a covariate. The least squares means treatment group differences will be back-transformed (anti-logged) for presentation as a ratio of the treatment group geometric means, with their corresponding 95% CI. 
9.5.5 Exposure (PK) endpoints 
 Plasma dasiglucagon and GlucaGen concentrations from time zero to 90 minutes:  
AUC
0-90min , Cmax, and t max. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 66  of 80  
[IP_ADDRESS]  Analysis of exposure (PK) endpoints 
AUC will be derived as the area under the individual plasma dasiglucagon/GlucaGen 
concentration profile for PK from [ADDRESS_1115593] valid measurement if this measurement is assessed sufficiently close to 90 minutes (decision to be taken at the masked data review meeting). The standard trapezoidal method will be used, based on actual rather than nominal timepoints.  
C
max will be determined as the maximum of all valid plasma dasiglucagon/GlucaGen 
concentrations.  T
max will be determined as the timepoint where the maximum of all valid plasma 
dasiglucagon/GlucaGen concentration measurements for each measurement series is 
observed. 
The log-transformed PK endpoints AUC and C max will be analyzed in the same way as 
the AUC endpoints. As t
max is a highly discrete endpoint, Wilcoxon’s rank sum test for unpaired observations 
will be used to assess differences between the two treatment group s. 
9.6 Exploratory analyses 
Exploratory analyses will include descriptive statistics and modeling analogous to that 
done for key secondary endpoints. However, treatment group comparisons will be summarized without inference intent. 
 Plasma glucose concentration ≥70 mg/dL (3.9 mmol/L) or increase of ≥20 mg/dL (1.1 mmol/L) within 30 minutes after study drug injection without administration of rescue IV glucose. 
 Plasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC
0-60 min . 
Plasma insulin concentrations measured pre-dose and at 30 and 60 minutes after dosing 
(see Table 3 ) will be presented individually. A summary table per timepoint will be 
provided. The AUC 0-60min will be determined and a summary presented.  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115594] available version of the MedDRA, the version of 
which will be provided in the clinical trial report . AE summary tables will include the 
number and percentage of subjects who experienced AEs summarized by [CONTACT_6657]. 
An overall summary table will be provided showing the number and percentage of 
subjects with any: 
 TEAE 
 Severe TEAE 
 Serious TEAE 
 Drug-related TEAE 
 Drug-related severe TEAE 
 Drug-related serious TEAE 
 TEAE leading to withdrawal 
 TEAE with outcome death 
 AESI 
Refer to Section 7.2.[ADDRESS_1115595] results will be flagged as to whether the result is below, within or 
above the respective reference range. The number of values outside of the reference range will be counted. 
9.7.4 Other safety da ta 
Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure will 
be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise tests o f 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 68  of 80  
independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus 
placebo ). 
Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure will be evaluated using a KM time to event statistical model, with treatment group and injection site as stratification factors. Differences between the KM curves (dasiglucagon versus placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise two-sided stratified log-rank tests. If the endpoint is never met, the time of the last plasma glucose measurement will be the censoring time. 
Vital signs, physical examination, 12-lead ECG and local tolerability data will be 
summarized using descriptive statistics. 
9.[ADDRESS_1115596] will be applied. For the primary analysis in the FAS, missing values for the primary endpoint will be imputed by a conservative rule considering any missing value as a failure. 
9.10 Interim analyses 
No interim analyses are currently planned. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115597] be consistent with the subjects’ source documentation (i.e. medical records). 
The investigator will permit trial-related monitoring, IRB/IEC review, and regulatory inspections, providing direct access to source data /documents. Sponsor-authorized quality assurance personnel may carry out audits for which the investigator must provide 
support. 
The trial monitor or a representative of the sponsor will cross-check the data entered in 
the eCRFs with the source data at the trial center and observe the trial procedures in order 
to verify adherence to the trial protocol. Any queries will be resolved by [CONTACT_15009]/her delegate. 
All of the clinical data will be captured via electronic data capture (EDC) using a 
web-based tool.  
The investigator center staff will enter and edit the data via a secure network, with secure 
access features (username [CONTACT_2383]). A complete electronic audit trail will be maintained. The investigator will approve the data using an electronic signature (Ref: 21 CFR Part 11), and this approval is used to confirm the accuracy of the data recorded. 
eCRFs will be used for all subjects. The investigator’s data will be accessible from the 
investigator’s center throughout the trial. The eCRFs must be kept current to reflect subject status at each phase during the course of the trial. The eCRF will not capture personalized data. The investigator must make a separate confidential record of personalized details (name [CONTACT_93459]) on the subject identification and enrollment log. All changes to data are made by [CONTACT_15009]/her delegate through the EDC system.  
It is the responsibility of the principal investigator [INVESTIGATOR_807440]’s eCRF are also made on the subject’s medical records. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115598] leaving the trial should be completed at the time of the final 
visit or shortly thereafter. 
10.2  Electronic case report forms 
Remote data capture software will be used for data collection. Following training, trial 
staff will be given access to the software. Access to the software is restricted to staff participating in the trial and the extent of access will depend on the participants' user role in the trial. 
The subjects enrolled into the trial will be identified in the database by [CONTACT_807494]. The investigator or delegate will enter subject data into the 
eCRF promptly. All data is to be entered in English. Data recorded in the eCRFs will be accessible to the trial staff throughout the trial. 
After data entry, systematic data validation will be performed and data entry 
discrepancies will be presented electronically directly to the center staff. Queries for 
discrepant data may be generated automatically by [CONTACT_727915]/or generated manually by [CONTACT_807470]. All queries, whether generated by [CONTACT_727917], will be in electronic format. 
All sections of the eCRF are to be electronically approved by [CONTACT_1720] a 
medically qualified delegate after the data has been entered and all queries have been resolved. Changes to any eCRF page subsequent to the approval require a new approval signature. 
All queries and changes/corrections to the data are documented in the eCRF. 
10.[ADDRESS_1115599]’s medical records, assess drug accountability, and ensure that the trial is being conducted according to pertinent regulatory requirements. 
Checking of the eCRFs for completeness and clarity, and cross-checking with source 
documents, will be required to monitor the progress of the trial. Moreover, regulatory authorities of certain countries, IRBs/IECs, and/or the sponsor may wish to carry out such source data checks and/or on-site audit inspections. Direct access to source data will be required for these inspections and audits; they will be carried out giving due consideration to data protection and medical confidentiality. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115600]’s medical records. If data are to be entered directly into the eCRF this must be specified in a source data agreement prior to the start of the trial. 
eCRF entries will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that subject confidentiality is maintained. 
The trial monitor will check the eCRF for accuracy and completion and perform source 
data verification. The trial monitor will document source data verification of all reviewed sections of the eCRF. 
10.[ADDRESS_1115601] (e.g. informed consent forms, laboratory slips, medication inventory records, and other pertinent information) must be retained by [CONTACT_807495]. 
10.7  Good clinical practice 
The procedures set out in this tri al protocol are designed to ensure that the sponsor and 
investigator abide by [CONTACT_146018] ( 1), and of the 
Declaration of Helsinki (2008) ( 2). The trial also will be carried out in keepi[INVESTIGATOR_118483].  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115602] orally and in writing (subject information 
sheet) the nature, significance, risks and implications of the trial before inclusion. In particular, the subjects will be informed about the following: 
 The possibility of withdrawing from the clinical trial at any time by [CONTACT_807472]. 
 How personal and health-related data will be collected and used during the trial. 
 That his/her medical records may be examined by [CONTACT_807473], by [CONTACT_6667]/IEC 
members, and by [CONTACT_6668]. 
All subjects will receive a copy of the subject information sheet and a copy of their 
signed and dated informed consent form, both of which will be in the subject’s local 
language. 
If a protocol amendment is required, the informed consent form may need to be revised to 
reflect the changes to the protocol. If the consent form is revised, it must be reviewed and approved by [CONTACT_69869]/IRB, and signed by [CONTACT_783292]. 
10.9  Protocol approval and amendment 
Before the start of the trial, the trial protocol and/or other relevant documents will be 
approved by [CONTACT_6179]/IRB/competent authorities, in accordance with local legal requirements. The sponsor must ensure that all ethical and legal requirements have been met before the first subject is enrolled in the trial. 
This protocol is to be followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive IRB/IEC/competent authority approval prior to implementation (if appropriate).  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without 
the need for a formal amendment. All amendments will be distributed to all protocol 
recipi[INVESTIGATOR_840], with appropriate instructions. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115603] will be up to 63 days (including up to 
30 days for screening and up to 33 days until the follow-up visit).  
The trial will be closed when all subjects have completed Visit 3. 
10.11   Premature termination of the trial 
If the investigator, the sponsor (e.g. safety committee), or the safety medical monitor 
becomes aware of conditions or events that suggest a possible hazard to subject s if the 
trial continues, the trial may be terminated after appropriate consultation between the relevant parties. The trial may also be terminated early at the sponsor’s discretion in the absence of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
 The discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the trial 
 Failure to enroll subjects at an acceptable rate. 
 A decision on the part of the sponsor to suspend or discontinue development of the 
drug. 
The trial can be terminated prematurely by [CONTACT_807475]:  The center cannot comply with the requirements of the protocol. 
 It is not possible for the center to comply with GCP standards. 
10.12   Confidentiality 
All trial findings and documents will be regarded as confidential. The investigator and 
members of his/her research team must not disclose such information without prior written approval from the sponsor. 
The anonymity of participating subjects must be maintained. Subjects will be identified 
on eCRFs submitted to the sponsor by [CONTACT_139927]. On the SAE reports and all other source documents, the subject will be identified via subject number. Documents not to be submitted to the sponsor that identify the subject (e.g. the signed informed consent form) must be maintained in confidence by [CONTACT_093].  
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 74  of 80  
10.13   Other ethical and regulatory issues 
If a significant safety issue is identified, either from an individual case report or review of 
aggregate data, then the sponsor will issue prompt notification to all parties : regulatory 
authorities, investigators and IRB/IECs. 
A significant safety issue is one that has a significant impact on the course of the clinical 
trial or program (including the potential for suspension of the trial program or amendments to protocols) or warrants immediate update of informed consent. 
10.[ADDRESS_1115604] resulted from participation in the clinical trial, or if he/she undergoes any other medical treatment without their consent before the clinical trial has been completely finished in so  far as the 
individual subject is concerned. 
Any injury to health, which might have occurred as a result of participation in the clinical 
trial must be reported by [CONTACT_807476]. The investigator is obliged to make such a report in any case. 
10.15   Publication policy 
By [CONTACT_752373], the investigator agrees with the use of results of the trial for 
the purposes of national and international registration, publication and information for medical and pharmaceutical professionals. If necessary, the authorities will be notified of the investigator's name, address, qualifications and extent of involvement. 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 75  of 80  
A clinical trial report will be prepared and reviewed by [CONTACT_807477]-operation with 
the coordinating investigator. The coordinatoing investigator will be appointed by [CONTACT_807496]. A summary of the clinical trial report (according to CPMP/ICH137/95) should be sent to the regulatory authorities and IRB/IEC according to the relevant guidelines. 
According to the Declaration of Helsinki ( 2) investigators and sponsors ‘have ethical 
obligations with regard to the publication and dissemination of the results of research’.   The trial design and results may be published as one or more original research 
manuscripts/abstracts and presented at a scientific meeting. The original eCRFs and the data generated from the eCRFs or otherwise obtained during the trial under this trial protocol will become the property of the sponsor. Publication of the results of this trial by 
[CONTACT_807479]. 
Any material intended for publication will be given to the sponsor at least [ADDRESS_1115605] the right to comment on the intended publication and to take any reasonable measures for patent protection. Authorship on any publication(s) resulting from this clinical trial will be assigned according to the recommendations of the International Committee of Medicinal Journal Editors ( 26). 
Participating subjects will not be identified by [CONTACT_807497]. 
The sponsor is responsible for trial registration at ClinicalTrials.gov 
(www.clinicaltrials.gov) according to FDA requirements, as well as the European Medicines Agency’s Clinical Trials Database (EudraCT).  
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115606] 
1.ICH Harmonised Tripartite Guideline. International Conference on Harmonisation. 
ICH Harmonised Tripartite Guideline. Integrated addendum to ICH E6(R1): 
Guideline for Good Clinical Practice E6 (R2), Step 4. 09-Nov-2016. Available from: 
URL:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E  
6/E6_R2__Step_4.pdf
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical
Research Involving Human Subjects. 52nd WMA General Assembly, Edinburgh,
Scotland, October 2000. Last amended with Note of Clarification on Paragraph [ADDRESS_1115607] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.
Hypoglycemia and diabetes: a report of a workgroup of the American DiabetesAssociation and the Endocrine Society. Diabetes Care 2013 May;36:1384-95
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
5. American Diabetes Association Position Statement. Standards of medical care in
diabetes - 2017. Diabetes Care 2017;40(Supplement 1):S1-S135
6. Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world
factors affecting adherence to insulin therapy in patients with Type 1 or Type 2
diabetes mellitus: a systematic review. Diabetic Medicine 2013;30:512- 24
7. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0
mmol/L (54 mg/dL) should be reported in clinical trials: a joint position statement ofthe American Diabetes Association and the European Association for the Study ofDiabetes. Diabetes Care 2017;40(1):155-57
8. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2
diabetes therapy. Rev Diabet Stud 2011;8:369-81
9. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2
diabetes: the return of the alpha cell. Curr Diab Rep 2014;14:555
10. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The
metabolic actions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-97
11. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the
therapeutic peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res2004;21:1274-83
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.0  
  
 
 
 
________________________________________________________________________  
Strictly Confidential    Page 77  of 80  
12. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. 
Drug Discovery Today 2015;20:122-8 
13. Novo Nordisk Limited. SPC for GlucaGen Hypokit 1 mg. 2015. http://www.medicines.org.uk/emc/medicine/4258/SPC/GlucaGen+Hypokit+1+mg - Accessed 13 Mar  2017 . 
14. Zealand Pharma A/S. Dasiglucagon Investigator's Brochure, Edition 3, 12 Dec 2016.  
15. The Task Force for the management of arterial hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 ESH/ESC guidelines for the management of arterial hypertension. European Heart Journal 2013;34:2159-219 
16. Levey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen BA, et al. Using standardized serum creatinine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of Internal Medicine 
2006;145:247-54 
17. Food and Drug Administration (FDA). Guidance for Industry on Bioanalytical Method Validation. Food and Drug Administration (FDA) [ADDRESS_1115608], Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. 
Quantitative bioanalytical methods validation and implementation: best practices for 
chromatographic and ligand binding assays. Pharm Res [ADDRESS_1115609];24:1962-[ADDRESS_1115610] biotechnology p roducts. J Pharm Biomed Anal 2008;48:1267-[ADDRESS_1115611] neutralizing antibodies to ZP4207 by [CONTACT_807481] (cAMP) in a glucagon receptor transfected cell line, BAL-14-206-004-REP.  2016. Report No.: Zealand Pharma, study 15-[ADDRESS_1115612] neutralizing antibodies to glucagon by [CONTACT_807481] (cAMP) in a glucagon receptor transfected cell line, BAL-14-206-005.  2016. Report No.: Zealand Pharma, Study 15-040 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115613] glycemic control of insulin-dependent diabetes mellitus. N Eng J Med 1987; 316: 1376-83. 
25. Rickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-induced hypoglycemia in adults with type 1 diabetes: A randomized crossover noninferiority study. Diabetes Care 2016; 39: 264-70. 
26. ICMJE. Recommendations for the conduct, reporting, editing, and publication of scholarly work in medical journals. Updated December 2016 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115614] of trial personnel 
Sponsor  
Clinical Trial Manager   
 
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Medical Officer   
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Contract Research Organization  Chiltern International (Ltd)  
[ADDRESS_1115615]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:  +44 (0) [PHONE_16833]  
Project Manager   
Chiltern International (Ltd)  
[ADDRESS_1115616]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:   
Senior Medical Officer  and 
Safety medical monitor   
Chiltern International kft  
Canada Square Office House  
Ganz u  

 
 
Dasiglucagon (ZP4207)  Date: 31 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protocol Version: Final 2.[ADDRESS_1115617]  
Hungary  
Phone:   
Pharmacovigilance unit  
Responsible for Serious Adverse 
Event (SAE) Management and 24 -
hour SAE reporting    
PharmaLex  
Agern Allé 24  
2970 Hørsholm, Denmark  
Phone:  (8 a.m. to 4 p.m.)  
Phone:   (outside 8 a.m. to 4 p.m.)  
Fax:  
email: [EMAIL_7118]   
Central laboratory  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (GlucaGen 
PK, insulin PK)  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Möncheng ladbach  
[LOCATION_013]  
Special laboratory (dasiglucagon 
PK, dasiglucagon ADA, 
GlucaGen ADA)  York Bioanalytical Solutions (YBS)  
Cedar House  
Northminster Business Park  
Northfield Lane  
York, YO26 6QR, [LOCATION_008]  
Special laboratory  
(neutralizing antibodies)  BioAgilytix  
[ADDRESS_1115618] of all investigators, IECs and IRBs will be provided in a separate document and in  
the clinical trial report. 
 

 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 1 of 79  
CLINICAL TRIAL PROTOCOL 
 
A phase 3, randomized, double-blind, parallel trial to 
confirm the clinical efficacy and safety of dasiglucagon 
in the rescue treatment of hypoglycemia in subjects with 
type 1 diabetes mellitus (T1DM) compared to placebo 
and with reference to GlucaGen® 
 
Sponsor:  Zealand Pharma A/S  
Sponsor Protocol No.:  ZP4207 -[ADDRESS_1115619] No. : 2017 -002449 -31  
IND No : 127866  
Trial  Drug Name:  [CONTACT_807506] * injection  
Date of Protocol:  29 Aug 2017  
 
The trial will be conducted according to the protocol and in compliance with Good 
C
linical Practice (GCP), with the Declaration of Helsinki and with other applicable 
regulatory
 requirements. 
*Dasiglucagon is the proposed international nonproprietary name [CONTACT_807507]4207. 
The information in this document is confidential and is proprietary to Zealand Pharma. It is understood that 
information in this document shall not be disclosed to any third party, in any form, without prior written 
consent of an authorized officer of Zealand Pharma. 
Dasigluca gon (ZP4207) 
Study ID: ZP4207-16 137 Date: 29 Aug 2017 
Protocol Version: Final 1.0 ZEALAND PHARMA 
Declaration of sponsor or responsible medical officer 
Title: A phase 3, randomized, double -blind , parallel trial to confirm the clinical efficacy 
and safety of dasiglucagon in the rescue treatment of hypo glycemia in subjects with type 
1 diabetes mellitus (Tl DM) compared to placebo and with reference to GlucaGen ® 
This trial protocol was subjected to critical review. The information it contains is 
consistent with current knowledge of the risks and benefits of the investigational product, 
as well as with the moral, ethical and scientific principles governing clinical research as 
set out in the Declaration ofHelsinki and the guidelines on Good Clinical Practice (GCP) 
(1 ). 
Title 
Institution Clinical Trial Manager 
Zealand Pharma 
Smedeland 36 
2600 Glostrup, Denmark 
Institution 
Phone : Zealand Pharma 
Smedeland 36 
2600 Glostrup, Denmark 
Strictly Confidential Date 
Page 2 of79 

 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 3 of 79  
Declaration of the coordinating investigator 
[CONTACT_1641]:  A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellitus (T1D
M) compared to placebo and with reference to GlucaGen® 
I have read this protocol. I approve this document and I agree that it contains all 
necessary details for carrying out the trial as described. I will conduct this trial in 
accordanc
e with the design and specific provision of this protocol and will make a 
reasonable effort to complete the trial within the time designated. I will provide copi[INVESTIGATOR_807427] A/S to trial 
personnel under my supervision. I will discuss this material with them to ensure they are 
fully informed about the trial product and trial procedures. I will let them know that this 
information is confidential and proprietary to Zealand Pharma A/S and that it may not be 
further disclosed to third partie
s. I understand that the trial may be terminated or 
enrollment suspended at any time by [CONTACT_93442] A/S, with or without cause, or by 
[CONTACT_807442]. 
I agree that the trial will be carried out in accordance with GCP (1), with t he Declaration 
of Helsinki (with amendments) (2) and with the laws and regulations of the countries in 
whic
h the trial takes place. 
 
 
_____________________________________ _____________________ 
Name        [CONTACT_807510]: + 
Fax: + 
 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 4 of 79  
Declaration of the investigator 
T
itle: A phase 3, randomized, double-blind, parallel trial to confirm the clinical efficacy 
a
nd safety of dasiglucagon in the rescue treatment of hypoglycemia in subjects with type 
1 diabetes mellit
us (T1DM) compared to placebo and with reference to GlucaGen® 
All documentation for this trial that is supplied to me and that has not been previously 
published will be
 kept in the strictest confidence. This documentation includes this trial 
protocol, Investigator's Brochure, Case Report Forms, and other scientific data. 
The trial will not be commenced without the prior written approval of a properly 
c
onstituted Institutional Review Board (IRB) or Independent Ethics Committee (IEC). 
No changes will be made to the trial protocol without the prior written approval of the 
sponsor and the I
RB or IEC, except where necessary to eliminate an immediate hazard to 
the subjects. 
I have read and understood and agree to abide by [CONTACT_348232]. 
 
_____________________________________ _____________________ 
S
ignature Date 
 
_____________________________________ 
Name (block letters) 
 
_____________________________________ 
Title (block letters) 
 
_____________________________________
 
Institution (block letters) 
 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 5 of 79  
Table of contents 
DECLARATION OF SPONSOR OR RESPONSIBLE MEDICAL OFFICER  .......... 2 
DECLARA
TION OF THE COORDINATING INVESTIGATOR  ..............................  3 
DECLARA
TION OF THE INVESTIGATOR  ...............................................................  4 
T
ABLE OF CONTENTS  ................................ ................................................................ .. 5 
1 S YNOPSIS  ................................................................ ................................ ............ 11 
2 INTRODUC TION ................................ ................................................................  15 
2.1 B ackground ................................ ................................ ................................ ...... 15 
2.1.1 H ypoglycemia  ................................ ................................ ......................  15 
2.1.2 Gluc agon  ................................ ................................ ..............................  16 
2.1.3 Da siglucagon ................................ ................................ ........................  16 
[IP_ADDRESS] Pharmac okinetics and pharmacodynami cs of dasiglucagon  ......... 17 
[IP_ADDRESS] Safety  of dasiglucagon  ................................ ................................ ... 17 
2.2 T rial rationale  ................................ ................................ ................................ .. 18 
2.3 Risk -b enefit assessment  ................................ ................................ .................. 18 
3 T RIAL OBJECTIVES AND  ENDPOINTS .......................................................  20 
3.1 P rimary objective  ................................ ............................................................  20 
3.2 S econdary objectives  ................................ .......................................................  20 
3.3 P rimary endpoint  ................................ ............................................................  20 
3.4 K ey secondary endpoints  ................................ ................................ ................ 20 
3.5 Oth er secondary endpoints  ................................ ................................ ............. 20 
3.6 E xploratory endpoint  ................................ ......................................................  21 
4 OVE RA LL DESIGN AND PLAN  OF THE TRIAL  ................................ ........ 22 
4.1 Over view  ................................ ................................ ................................ .......... 22 
4.2 Ju stification of the trial design  ................................ ................................ ....... 22 
4.2.1 J ustification for design and parameters ................................ ................ 22 
4.2.2 J ustification for drug, route, dosage and treatment duration  ............... 23 
5 T RIAL POPULATION  ................................ .......................................................  24 
5.1 Rat ionale for trial population  ................................ ................................ ........ 24 
5.2 P lanned sample size and number of trial cen ters ................................ ......... 24 
5.3 In clusion criteria  ................................ .............................................................  24 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115620] ug accountability  ................................ .........................................................  34 
6.8 T reatment compliance  ................................ ................................ .................... 34 
6.9 P rior and concomitant medications  ...............................................................  35 
6.9.1 P rohibited medications ................................ ................................ ......... 35 
7 P ARAMETERS AND METHO DS OF ASSESSMENT  ................................ .. 36 
7.1 E ffica cy parameters  ................................ ........................................................  36 
7.1.1 P harmacodynamic measurements  ................................ ........................  36 
7.1.2 P harmacokinetic measurements  ................................ ...........................  36 
7.2 S afety parameters  ................................ ............................................................  37 
7.2.1 Adve rse events  ................................ ................................ ..................... 37 
[IP_ADDRESS] De finitions  ................................ ................................ ......................  37 
[IP_ADDRESS] C ollection, recording and reporting of adverse events  ................. 40 
[IP_ADDRESS] Follo w -up of adverse events  ................................ ..........................  41 
[IP_ADDRESS] C linical laboratory abnormalities and other abnormal 
assessments as adverse events or serious adverse events  .............. 42 
7.2.2 H ypoglycemia  ................................ ................................ ......................  42 
7.2.3 P hysical examination  ................................ ................................ ........... 43 
7.2.4 Vital si gns ................................ ................................ ............................  43 
7.2.5 Ele ctrocardiogram  ................................ ................................ ................ 44 
7.2.6 L ocal tolerability  ................................ ................................ .................. 44 
7.2.7 C linical laboratory assessments  ................................ ...........................  45 
7.2.8 P regnancy  ................................ .............................................................  46 
7.2.9 P recautions  ................................ ................................ ...........................  47 
7.2.10 S afety committee  ................................ ................................ ................. 47 
7.3 De mography,  concomitant illness, medical history and concomitant 
medication  ................................................................ ................................ ........ 47 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115621]  ................................ ..............................................................  51 
8.1 S chedule of procedures  ................................ ................................ ................... 51 
8.2 P rocedures by [CONTACT_765]  ................................ ..........................................................  51 
8.2.1 Visi t 1 (screening, Day -30 to Day -3) ................................ ................. 51 
8.2.2 I nstructions to subjects prior to the dosing visit (Visit 2)  .................... 53 
8.2.3 Visi t  2 (dosing visit)................................ ................................ ............. 54 
[IP_ADDRESS] Hy poglycemic clamp procedure and administration of trial 
medication  ................................ ......................................................  55 
8.2.4 Visi t 3  (follow -up vis it) ................................ ................................ ....... 57 
9 S TATISTICAL METHODS  ................................ ................................ ............... 59 
9.1 De termination of sample size  ................................ ................................ ......... 59 
9.2 T rial subjects  ................................ ................................ ................................ ... 59 
9.2.1 Ana lysis samples  ................................ ................................ .................. 59 
9.2.2 Disposi tion of subjects  ................................ ................................ ......... 60 
9.2.3 P rotocol deviations ................................ ................................ ............... 60 
9.3 G eneral considerations  ................................ ................................ ................... 61 
9.4 De mographics and baseline characteristics  ................................ .................. 61 
9.5 E fficacy Analyses  ................................ .............................................................  61 
9.5.1 Hie rarchical testing procedure  ................................ .............................  62 
9.5.2 P rimary confirmatory endpoint  ................................ ............................  62 
[IP_ADDRESS] Primary  analysis  ................................ ................................ ............ 62 
9.5.3 S econdary endpoints  ................................ ................................ ............ 63 
[IP_ADDRESS] C onfirmatory analy sis ................................ ................................ .... 63 
9.5.4 S econdary clinical efficacy (PD) endpoints  ................................ ......... 63 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints  ................ 64 
9.5.5 Ex posure (PK) endpoints  ................................ ................................ ..... 64 
[IP_ADDRESS] Analy sis of exposure (PK) endpoints  ................................ ............. 64 
9.6 E xploratory analyses  ................................ .......................................................  65 
9.7 S afety analyses  ................................ ................................................................ . 65 
9.7.1 Adve rse events  ................................ ................................ ..................... 65 
9.7.2 I mmunogenicity data  ................................ ................................ ........... 66 
9.7.3 C linical laboratory assessments  ................................ ...........................  66 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115622]-treatm ent blood sampling times  ................................................................  56 
 
F
igures in text 
Figure 1  Tr ial design  ................................................................ ................................ ........ 22 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115623]  European Medicines Agency’s Clinical Trials Database  
FAS Full analysis set  
FDA  Food and Drug A dministration  
GCP  Good Clinical Practice  
HbA 1c Glycated hemoglobin  
ICH International Conference on Harmonization  
ID card  Identific ation card  
IEC Independent Ethics Committee  
IM Intramuscular(ly)  
IMP Investigational medicinal product  
IRB Institutional Review Board  
IV Intravenous(ly)  
IWRS  Interactive Web Response System  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 10 of 79  
MedDRA  Medical Dictionary for Regulatory Activities  
NPH  Neutral protamine Hagedorn  
PD Pharmacodynamics  
PK Pharmacokinetics  
PP Per protocol  
SAE  Serious adverse event  
SAP Statistical analysis plan  
SAS Safety analysis set  
SC Subcutaneous(ly)  
S[LOCATION_003]R  Serious unexpected suspected adverse reaction  
T1DM  Type [ADDRESS_1115624]  Upper limit of the normal range  
US [LOCATION_002] of America  
 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 11 of 79  
1 SYNOPSIS 
Name [CONTACT_119019]:  
Zealand Pharma A/S  Trial ID:  
ZP4207 -[ZIP_CODE] 
Title of the trial:  
A phase 3, randomized, double -blind, parallel trial to confirm the clinical efficacy and safety of 
dasiglucagon  in the rescue treatment of hypoglycemia in subjects with type 1 diabetes mellitus (T1DM) 
compared to placebo a nd with reference to GlucaGen® 
Trial design:  
The trial is a global, multicenter, randomized, parallel -group , double -blind, clinical trial confirming the 
efficacy and safety of dasiglucagon  for insulin -induced hypoglycemia in subjects with type 1 diabetes  
mellitus . The subjects will be randomized 2:1:1 to receive a single fixed subcutaneous 0.6 mg dose of 
dasiglucagon  (hereinafter dasiglucagon) , placebo  for dasiglucagon (hereinafter referred to as placebo) , or 
a 1 mg dose of GlucaGen® (hereafter referred t o as GlucaGen) and followed for at least 28  days after 
treatment.  
Clinical phase of development:  
Phase 3 
Trial centers : 
This trial will be conducted at 4 to 6 sites in the [LOCATION_002] of America , Canada, and Europe . 
Planned trial start ( first subjec t first visit):  
Q4/2017 Planned trial end ( last subjec t last visit):  
Q3/2018  
Trial population:  
Male and female adult  subjects  with type [ADDRESS_1115625] one year   
Key objectives:  
Primary objective:   
 To demonstrate sup eriority  of dasiglucagon  compared to placebo  following a single subcutaneous  
0.6 mg dose administered to subjects with type 1 diabetes mellitus  with insulin -induced 
hypoglycemia . 
Secondary objective:   
 To compare the glycemic response observed after  dasiglu cagon  with that of  GlucaGen . 
Key endpoints:  
Primary endpoint:   
 Time to  plasma glucose  ≥20 mg/dL  recovery, defined as  first increase in plasma glucose of 
≥20 mg/dL ( 1.1 mmol/L ) from baseline  during the hypoglycemic clamp procedure . In the primary 
analysis, those subjects who require rescue intravenous (IV) glucose will be censored at the ti me 
to plasma glucose recovery. In a sensitivity analysis, the time to plasma glucose recovery will be 
analyzed without censoring those subjects who req uire rescue IV glucose before 45  minutes.   
Key s econdary endpoint s: 
 Plasma glucose changes from baseline  within 30 minutes, within 20 minutes , within 15 minutes, 
and within 10  minutes  after study drug injection  or at the time of rescue . 
 Incidences of plasma glucose recovery (achieving a plasma g lucose concentration  increase of ≥20 
mg/dL [ 1.1 mmol/L ]) within 30 minutes, within 20 minutes , within 15 minutes, and within 10 
minutes  after study drug injection.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 12 of 79  
Clinical efficacy  (Pharmacodynamic ) endpoints:  
 Time to first plasma glucose concentration of ≥70 mg/dL ( 3.9 mmol /L). 
 Plasma glucose response as  area under the curve  above baseline  from time zero to 30 minutes, 
AUC0-30min. 
Exposure (Pharmacokinetic) endpoints:  
 Area under the drug concentration curve from time zero to 90 minutes , AUC 0-90 min. 
 Maximum plasma drug conce ntration (C max). 
 Time to maximum plasma  drug concentration (t max). 
Safety endpoints:   
 Adverse events, clinical laboratory assessments (biochemistry, hematology, coagulation, 
urinalysis), vital signs, physical examination, electrocardiogram, and local toler ability.  
 Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
 Time to first rescue infusion of IV glucose during the hypoglycemic clamp procedure.  
Immunogenicity endpoint:  
 Incidence of anti -drug antibodies  
Exploratory endpoin t: 
 Incidence  of plasma glucose recovery (achieving a plasma glucose concentration ≥70 mg/dL [3.9 
mmol/L] or an increase of ≥20 mg/dL [1.1 mmol/L]) within 30 minutes after study drug 
injection.  
 Plasma insulin response as area under the curve above baseline from time ze ro to  60 minutes , 
AUC 0-60 min. 
Key inclusion criteria:  
 Male and female subject s with type [ADDRESS_1115626] one year, 
diagnostic criteria as defined by [CONTACT_807443] n. 
 Stable  insulin treatment 30 days prior to screening, defined as no more than a 10 -unit daily 
variation in total  daily insulin dose . 
 Hemoglobin A 1c <10%.  
 Aged between 18 and 75 years, both inclusive . 
Key exclusion criteria:  
 Previously treated with dasiglucagon . 
 Known or suspected allergy to trial product(s) or related products.  
 History of anaphylaxis or symptoms of severe systemic allergy (such as angioedema).  
 Previous participation (randomization) in this trial.  
Sample size:  
Approximately  [ADDRESS_1115627]:  
Test product: dasiglucagon  liquid form ulation in pre -filled syringes . 
Comparator  product s: Placebo and GlucaGen® lyophilized powder . 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 13 of 79  
Duration of treatment:  
Subjects will be randomized 2:1:[ADDRESS_1115628] 28 days after receiving treatment .  
Assessments:  
The plasma glucose profile for evaluation of the primary and secondary clinical efficacy 
(pharmacodynamic) endpoints will be assessed based on plasma concentration data from samples 
collected at the dosing visit.  
The exposure to  trial medicat ion (dasiglucagon , placebo , or GlucaGen) for evaluation of pharmacokinetics  
will also be assessed based on plasma concentration data .  
Statistical methods:   
Due to requirements in the size of the safety database, the sample size is set to 78 subjects trea ted with 
dasiglucagon 0.6  mg. With a 2:1:1 randomization ratio for the three treatments, dasiglucagon  0.6 mg, 
placebo , and GlucaGen 1 mg, 78 subjects injected with dasiglucagon and 39 subjects with placebo will 
yield a power of 90% at a 5% two -sided signif icance level to detect a treatment group difference in 
recovery incidence within 20 minutes, assuming as low as 80% and as high as 50% recovery incidence for 
the dasiglucagon and placebo groups, respectively.  
For the confirmatory analyses, the primary and key secondary endpoints for the dasiglucagon 0.6  mg and 
placebo  treated subjects will be compared. A hierarchical procedure will be applied for the control of 
multiplicity  in statistical inferences . The primary and secondary endp oints will be evaluated on the Full 
Analysis Set sample . The statistical inference comparisons with placebo will be conducted as superiority 
tests. The comparisons of  dasiglucagon versus GlucaGen will be summarized descriptively .    
The primary endpoint of time to plasma glucose ≥20 mg/dL recovery, is defined as first increase from 
baseline in plasma glucose of ≥20 mg/dL (1.1 mmol/L) during t he hypoglycemic clamp procedure.  If the 
hazards by [CONTACT_807445] a graphical comparison of the Nelson -
Aalen estimates, a Cox proportional hazards  (CPH)  model will be used for inferences, with treatment 
group and injection site modeled as categorical effects, and baseline plasma glucose modeled as a 
continuous covariate. The treatment group rate ratios, active ve rsus placebo, will be estimated together 
with the 95% confidence intervals , and pairwise treatment group inferences (dasiglucagon vs placebo, 
GlucaGen vs placebo) will be evaluated using t wo-sided likelihood ratio tests .   
If the PH assumption  for treatmen t groups  is not met , the primary endpoint will be analyzed using a 
Kaplan -Meier (KM) time to event statistical model, with treatment group and injection site as 
stratification factors. Treatment group differences between the KM curves (dasiglucagon vs plac ebo, 
GlucaGen vs placebo) will be evaluated inferentially using pairwise two -sided log -rank tests.  
In the primary analysis, subjects who require rescue IV glucose will be censored at the t ime to plasma 
glucose ≥20  mg/dL recovery.  In a sensitivity analysis, the time to plasma glucose  ≥20 mg/dL  recovery 
will be analyzed without censoring the subjects who received rescue IV glucose  before 45  minutes .   
The key secondary endpoints of plasma glu cose changes from baseline (CFB) within [ADDRESS_1115629] in those subjects wh o require 
rescue IV glucose before plasma glucose ≥20 mg/dL recovery . Each of these CFB variables will be 
analyzed using an Analysis of Covariance model, with treatment group modeled as a fixed  effect and with 
the baseline plasma glucose  modeled as a covariate. The dasiglucagon versus place bo treatment group 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115630].  
The key s econdary incidence variables (plasma glucose  recovery within 30 minutes, within 20 minute s, 
within 15  minutes, within 10  minutes, in hierarchical order for inference) will be analyzed using 
descriptive stati stics (frequency and p ercentage) by [CONTACT_1570]. Inferential treatment group 
comparisons will be assessed via pairwise tests of independent binomial proportions (dasiglucagon vs 
placebo, Gluc aGen vs placebo ).    
The continuous clinical efficacy variabl es, the exploratory variables, and the pharmacokinetics variables 
will each be summarized des criptively by [CONTACT_1570]. The clinical efficacy variables will  be analyzed 
analogous to the plas ma glucose  CFB variables.   
The safety analyses will include b y-treatment -group descriptive summaries of vital sign measurements, 
laboratory measures (including immunogenicity incidence), physical examination assessments, rescue IV 
glucose (incidence and amount of glucose infused), and adverse events. The number and percentage of 
subjects reporting specific events, such as nausea and vomiting, will be presented by [CONTACT_430449].  
Further details will be included in the Statistical Analysis Plan, to be completed before dat abase lock and 
treatment unmask ing.   
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 15 of 79  
2 INTRODUCTION 
2.1 B ackground 
Zealand Pharma A/S (Zealand Pharma) is developi[INVESTIGATOR_807428], a physically and 
chemically stable peptide analog of human glucagon, in a ready- to-use liquid formulation 
for the acute treatment of severe hypoglycemia in patients with insulin-treated diabetes 
mellitus. Like native glucagon, dasiglucagon is comprised of 29 amino acids, but with 
7 substitutions which improve its physical and chemical stability in aqueous media. 
The
se amino acid substitutions make dasiglucagon suitable for a liquid formulation, 
while providing similar efficacy and safety as compared with recombinant glucagon in 
the clinical setting of acute treatment of severe hypoglycemia. 
2.1.1 Hypogly cemia 
Hypoglycemia in patients with diabetes is defined as epi[INVESTIGATOR_807441] (3). This i s a common, unpredictable, and potentially 
dangerous side effect of treatment of diabetes mellitus, especially with insulin or 
sulfonylureas. It i
s more frequent in patients with profound endogenous insulin 
deficiency, such as occurs in type 1 diabetes mellitus (T1DM) and advanced type 2 
diabetes mellitus (T2DM). Treatment of T2DM with insulin causes hypoglycemia 
progressively and more frequently over time, whereas in T1DM, hypoglycemia is 
experienced throughout the course of established disease ( 4).  
Symptoms and signs of hypoglycemia are not specific. Patients undergoing a 
hypoglycemic epi[INVESTIGATOR_460616], sweating, 
hunger, tremors, palpi[INVESTIGATOR_814], paresthesia, nausea and pallor. Depending on its severity, 
the hypoglycemia may lead to mild confusion, behavioral changes, loss of consciousness, 
seizures, coma, and death (5).  
The incidence of hypoglycemic events or even the fear of hypoglycemia influences 
patients’ adherence to pr
escribed treatment regimens for diabetes mellitus (6). This leads 
to inadequate glycemic control, which in turn may lead to an increased risk of diabetic 
complications ( 5). Seriou s clinically significant hypoglycemia is now defined as plasma 
glucose <54 mg/dL (3.0 mmol/L), while the plasma glucose alert value is defined as 
<70 mg/dL (3.9 mmol/L) (7). W hen plasma glucose falls below these values, some kind 
of treatment strategy is needed. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 16 of 79  
2.1.2 Glucagon 
Glucagon is a naturally occurring hormone, secreted from the alpha cells of the 
pancreatic islets. Glucagon plays a central role in the regulation of glucose homeostasis 
and is the counterpart of insulin for controlling blood glucose levels (i.e. it acts in 
opposition to insulin in terms of effects on blood glucose levels) ( 8,9). Glucagon 
stimulates hepatic glycogenolysis and gluconeogenesis in hypoglycemic states, thereby 
[CONTACT_93406]. Glucagon receptor agonism has also been shown to exert 
effects on lipid metabolism, energy balance, body adipose tissue mass and food intake 
(10). Insulin decreases blood glucose levels and cases of hypoglycemia can be reversed 
by [CONTACT_41148]. Therefore, glucagon is indicated for the treatment of severe hypoglycemia. 
Besides intravenous (IV) glucose administration, an injectable form of glucagon is given 
as first aid in cases of severe hypoglycemia, when the patient is unconscious or for other 
reasons cannot take glucose orally. The approved glucagon dose for an adult is 1 mg, 
given by [CONTACT_33813] (IM), IV, or subcutaneous ( SC) injection, which quickly raises 
blood g
lucose levels. As current marketed recombinant glucagon is highly unstable when 
dissolved in solution, the injectable form has to be reconstituted prior to use in a 9-step 
procedure that requires a ster
ile diluent to be injected into a vial containing lyophilized 
powdered glucagon. When dissolved in a fluid state, glucagon can form amyloid fibrils 
(11), or ti ghtly woven chains of proteins made up of the individual glucagon peptides. 
The reconstitution process makes the use of marketed glucagon products cumbersome 
(12), and a more patient-friendly formulation is needed. Currently, the Food and Drug 
Administration (FDA ) approved instructions for commercially available glucagon allow 
only for immediate usage of glucagon after the powder is reconstituted in aqueous 
solution ( 13). Therefore, a glucagon analog with enhanced biophysical stability may 
represent a leap forward in terms of convenient therapeutic applications. 
2.1.3 Dasiglucagon 
Dasiglucagon (ZP4207) is a stable peptide analog of human glucagon, available in a 
ready- to-use liquid formulation. Dasiglucagon (hereinafter referred to as dasiglucagon) is 
in development for the treatment of sev
ere hypoglycemia in insulin-dependent patients 
with diabetes mellitus. Dasiglucagon is a specific and full glucagon receptor agonist 
designed to mimic the effects of glucagon, having a fast absorption and elimination 
(minutes). It is a peptide of 29 amino acids, with 7 amino acid substitutions compared to 
native glucagon. The main purpose of the substitutions is to increase the physical and 
chemical stability of the glucagon analog compared to marketed glucagon products such 
as Lilly Glucagon or GlucaGen® (hereafter referred to as GlucaGen). Dasiglucagon 
exhibits improved physical and chemical stability and is available in an aqueous solution 
at neutral pH  (14). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115631] been completed with dasiglucagon: a first- in-human dose trial in 
health
y volunteers and subjects with T1DM (ZP4207-[ZIP_CODE]), a multiple-dose 
dose-esca
lation trial (ZP4207-[ZIP_CODE]) evaluating the safety, tolerability, pharmacokinetics 
(PK) and pharmac
odynamics (PD) of dasiglucagon in healthy volunteers, and a phase 2 
crossover trial to asse
ss the PK and PD  of a single dose of an optimized formulation o f 
da
siglucagon administered SC in subjects with T1DM (ZP4207-[ZIP_CODE]) ( 14). 
[IP_ADDRESS] Pharmac okinetics and pharmacodynamics of dasiglucagon 
The results of the phase [ADDRESS_1115632] absorption with a peak plasma 
concentration obtained after 35 minutes. Thereafter, the plasma concentration rapi[INVESTIGATOR_807430]-life of 28 minutes. The median time to the maximum 
plasma concent
ration (t max) was [ADDRESS_1115633] 70 mg/dL (3.9 mmol/L) as well as an increase in plasma glucose by [CONTACT_2669] 
20 mg/dL (1.1 mmol/L) within 30 minutes after dosing. The PD  responses to 0.6 mg of 
dasiglucagon and 1 mg of GlucaGen were comparable. 
[IP_ADDRESS] Safety  of dasiglucagon 
The safety data for dasiglucagon do not give rise to any safety concerns. No new signals 
were
 observed, beyond those related to the pharmacological effect of glucagon agonism. 
All adve
rse events (AEs) recorded in the trials were of mild or moderate severity. The 
most frequently reported systemic AE was nausea, which is a known side effect 
following administration of glucagon. Headache was the next most frequently reported 
event, occurring in all dose groups in the phase [ADDRESS_1115634] (IMP) 
doses of at least 1 m
g (4 with dasiglucagon and 1 with GlucaGen). This is not considered 
a safety concern; however, hemodynamic changes after dosing will be considered an 
a
dverse e
vent of special interest (AESI). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 18 of 79  
The phase 1 and 2 results and the safety profile described to date do not give rise to 
specific safety concerns. For further information, please refer to the Investigator’s 
Brochure (14). 
2.2 T rial rationale 
The aim of t he current trial is to confirm the superiority of dasiglucagon for the treatment 
of insuli
n-induced hy
poglycemia in subjects with T1DM as compared to placebo for 
dasiglucagon (hereinafter placebo) and to compare the clinical efficacy and safety of 
da
siglucagon
 with reference to GlucaGen. A randomized, controlled trial design was 
use
d. 
S
ee Section  4.[ADDRESS_1115635] s 
with known or suspected allergies to the trial medications or related products will be 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115636] relevant clinical effects in the acute severe hypoglycemia rescue setting and may be 
a
n effective and reliable emergency treatment for severe hypoglycemia. Overall, the 
anticipate
d benefits for subjects entering the ZP4207-[ZIP_CODE] trial are considered to justify 
the risks
. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 20 of 79  
3 TRIAL OBJECTIVES AND ENDPOINTS 
3.1 P rimary objective 
 To demonstrate superiority of dasiglucagon compared to placebo following a single 
subcutaneous
 0.6 mg dose administered to subjects with type 1 diabetes mellitus with 
insulin-induce
d hypoglycemia. 
3.2 Secondary objectives 
 To compare the glycemic response observed after dasiglucagon with that of 
GlucaGen. 
3.3 P rimary endpoint 
 Time to pl asma glucose ≥20 mg/dL recovery, defined as first increase in plasma 
glucose of ≥20 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp 
procedure. In the primary analysis, those subjects who require rescue intravenous (IV) 
glucose will be censored at the time to plasma glucose recovery. In a sensitivity 
analysis, the time to plasma glucose recovery will be analyzed without censoring 
those subjects who require rescue IV glucose before 45 minutes.     
3.4 Key secondary endpoints 
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
 I ncidences of plasma glucose recovery (achieving a plasma glucose concentration 
increase of ≥20 mg/dL [1.1 mmol/L]) within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection. 
3.5 Oth er secondary endpoints 
 Clinic al efficacy (PD) endpoints: 
- Time to first plasma
 glucose concentration ≥70 mg/dL (3.9 mmol/L). 
- Plasma glucose
 response as area under the curve (AUC ) above baseline from time 
zero to 30 minutes, AUC 0-30min . 
 Ex posure (PK) endpoints: 
- Area under the drug concentration curve from time zero to 90 minutes, 
AUC 0-90
min. 
-  Maximum plasma drug concentration (C max). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 21 of 79  
- Time to maximum plasma drug concentration (t max). 
 S afety endpoints:  
- Adverse events, clinical laboratory assessments (biochemistry, hematology, 
coagulation, urinalysis), vital signs, physical examination, electrocardiogram 
(ECG), a
nd local tolerability. 
- Incidence of rescue infusion of IV glucose during the hypoglycemic clamp 
procedure. 
- Time to first rescue infusion of IV glucose during the hypoglycemic clamp 
procedure. 
 I mmunogenicity endpoint: 
- Incidence of anti-drug antibodies 
3.6 Exploratory endpoint 
 I ncidences of plasma glucose recovery (achieving a plasma glucose concentration 
≥70
 mg/dL [3.9 mmol/L] or an increase of ≥20 mg/dL [1.1 mmol/L]) within 
30 minutes after study drug injection. 
 P lasma insulin response as area under the curve above baseline from time zero to 
60 minutes, AUC 0 -60 min . 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 22 of 79  
4 OVERALL DESIGN AND PLAN OF THE TRIAL 
4.1 Over view 
This trial is a global, multicenter, randomized, parallel, double-blind, clinical trial 
c
onfirming the efficacy and safety of dasiglucagon for insulin-induced hypoglycemia in 
subjects wit
h T1DM. The subjects will be randomized 2:1:[ADDRESS_1115637] 28 da
ys after receiving treatment. A total of 156 subjects with T1DM are expected 
to complete
 the tre
atment visit. The trial will be conducted in the European Union ( EU) 
and North America. 
F
igure 1 Trial design 
 
Patients with type T1DM 
made hypoglycemic by 
[CONTACT_807499] 0.6 mg
N=78
Placebo
N=39
GlucaGen 1 mg
N=39N=[ADDRESS_1115638] selection and in the evaluation of clinical assessments, 
subjects will be randomly assigned 2:1:[ADDRESS_1115639] 
c
omparison of the clinical efficacy of the treatments.  
The trial is double-blind to increase trial validity and to reduce bias during evaluation of 
the treatm
ents. However, since the trial medications are not identical in appearance, the 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115640] been used to 
establish that 0.6 mg of dasiglucagon is an effective dose and also represents a 
therapeutically equivalent dose to 1 mg of GlucaGen (see also Section  6.1). 
Da
siglucag
on, placebo, and GlucaGen will be administered in the abdomen, buttocks, or 
thi
gh by [CONTACT_10530], as this is one of the intended routes of administration for 
da
siglucag
on, besides IM and IV. 
Subjects will be followed for at least 28 days after dosing in order to perform an adequate 
immunogenicity e
valuation of treatment.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 24 of 79  
5 TRIAL POPULATION 
5.1 Rat ionale for trial population 
Dasiglucagon is in development for the treatment of severe hypoglycemia in 
insulin-depende
nt patients with diabetes mellitus. In the present trial, subjects with 
T1DM are included in the evaluation of efficacy and safety of dasiglucagon under 
hypogl
ycemic conditions as this is part of the intended target population. Subjects with 
T1DM are se
lected to avoid the endogenous glucagon counter-regulatory response to 
insulin-induced hypoglycemia that is present in patients with T2DM. The inclusion and 
exclusion crite
ria are set to include a trial population that represents the general 
population of subjects with T1DM.  
5.2 P lanned sample size and number of trial centers 
A total number of 156 subjects with T1DM are expected to complete the treatment visit 
(Visit 2). To qualify as completed, the subject must be dosed and have blood drawn for 
the PK a
nd PD assessments described in the protocol. It is expected that up to 
[ADDRESS_1115641] 156 subjects completing Visit 2. Completion of 
156 subjects (78 subjects in the dasiglucagon group and 39 subjects in each of the 
placebo and GlucaGen groups) would be expected to provide adequate power for the 
prima
ry efficacy evaluation, as described in Section  9.1. 
The planned dat
e for first subject first visit is expected to take place in Q4, [ADDRESS_1115642] in Q3, 2018. 
This trial is planne
d to be conducted at 4 to 6 trial sites in the [LOCATION_002] of America 
[US], C
anada, and Europe. 
5.3 Inclusion criteria 
Subjects will be entered into this trial only if they meet all of the following criteria: 
1. I nformed consent obtained before any trial-related activities (trial-related 
activities are any procedure that would not have been performed during normal 
management of the subject). 
2. F emale or male subjects with T1DM for at least 1 year, diagnostic criteria as 
defined by [CONTACT_11026] ( 3).  
3. Tr eated with insulin for T1DM for at least 1 year and with stable insulin treatment 
(defined as no more than a 10-unit daily variation in total daily insulin dose) 
30 days prior to screening 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 25 of 79  
4. He moglobin A 1c <10%. 
5. Age d between [ADDRESS_1115643] meet one of the following criteria: 
a. Participant is of childbearing potential and agrees to use one of the 
accepted contraceptive regimens throughout the entire duration of the trial 
from screening and until last follow-up visit. Additionally, if the 
participant is using systemic contraceptives, she must use an additional 
form of acceptable contraception. An acceptable method of contraception 
includes one of the following: 
i. Abstinence from heterosexual intercourse; 
ii. Systemic contraceptives (birth control pi[INVESTIGATOR_3353], injectable/implant/ 
insertable hormonal birth control products, transdermal patch); 
iii. Intrauterine device (with and without hormones); or 
iv. Condom with spermicide; or 
b. P articipant is of non-childbearing potential, defined as surgically sterile 
(i.e. has undergone complete hysterectomy, bilateral oophorectomy, or 
tubal ligation), or in a menopausal state (at least 1 year without menses). 
7. A ma le subject must meet the following criteria: Surgically sterilized or willing to 
refrain from sexual intercourse from screening and until last follow-up visit or, if 
sexually active, uses condom and partner practices contraception during the trial 
from scree
ning and until last follow-up visit. 
5.4 E xclusion criteria 
Subjects meeting any of the following criteria during screening evaluations will be 
excluded from trial participation: 
1. P reviously treated with dasiglucagon (previously referred to as ZP4207). 
2. Know n or suspected allergy to trial product(s) or related products. 
3. Hist ory of anaphylaxis or symptoms of severe systemic allergy (such as 
angioedema). 
4. P revious participation (randomization) in this trial. 
5. F emales who are pregnant according to a positive pregnancy test, are actively 
attempting to get pregnant, or are lactating. 
6. Hist ory of hypoglycemic events associated with seizures in the last year prior to 
screenin
g. 
7. Hist ory of severe hypoglycemia (defined as plasma glucose <54 mg/dL 
[3.0 mmol/L]) in the last month prior to screening. 
8. Receipt of any investigational drug within [ADDRESS_1115644] 5 years. 
10. Congestive heart failure, [LOCATION_001] Heart Association class II-IV. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 26 of 79  
11. Inadequately treated blood pressure, defined as systolic ≥160 mmHg or diastolic 
≥90 mmHg) at screening (15). 
12. C urrent bleeding disorder, including anti-coagulant treatment. 
13. Know n presence or history of pheochromocytoma (i.e. adrenal gland tumor) or 
insulinoma (i.e. insulin secreting pancreas tumor). 
14. Use  of a daily systemic beta-blocker drug, indomethacin, warfarin or 
anticholiner
gic drugs in the previous 28 days before Day 1 of this trial. 
15. Aspa rtate aminotransferase (AST) or alanine aminotransferase (ALT) >2.5 × the 
upper limit of the normal ra
nge (ULN), bilirubin >1.5 × ULN, estimated 
glomerular filtration rate <30 mL/min/1.73 m2 according to the Modification of 
Die
t in Renal Disease study definition (16), or a ltered electrolyte values of 
clinical relevance for cardiac conduction, as judged by [CONTACT_093]. 
16. C linically significant abnormal ECG at screening as judged by [CONTACT_093]. 
17. C linically significant illness within [ADDRESS_1115645] 2 months prior to 
screening. 
20. A posit ive result in the alcohol and/or urine drug screen at the screening visit. 
Significant history of alcoholism or drug abuse as judged by [CONTACT_460675] [ADDRESS_1115646]’s typi[INVESTIGATOR_93379], and 
should not exceed a near maximum intensity for more than 20 minutes per day, or 
moderate intensity for more than 90 minutes per day. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115647].
4. Not fasting from 22:00 hours the evening prior to dosing, apart from water. Small
amounts of ca
rbohy
drates (up to 20 g) to prevent hypoglycemia are allowed.
5. The use of any non-prescribed systemic or topi[INVESTIGATOR_73201], except routine
vitamins a
nd occasional use (as judged by [CONTACT_093]) of acetylsalicylic acid
and paracetamol within 2 weeks prior to dosing. Treatment with insulin, including
analogs
, is allowed.
6.
Use of any basal insulin within 24 hours prior to dosing.
7.
Use of any short acting (bolus) insulin within 12 hours prior to dosing.
8. Chang
es in medical history or concomitant medication resulting in fulfillment of
clinical ex
clusion criteria, as judged by [CONTACT_093].
9. Plasma glucose value <50 mg/dL (2.8 mmol/L) within the last 24 hours or plasma
glucose va
lue <60 m
g/dL (3.3 mmol/L) within the last [ADDRESS_1115648] has the right to withdraw from the 
trial at any time a
nd for any reason. If he/she chooses to withdraw, the investigator must 
be informed immediately. The investigator has the right to terminate participation of any 
subject at any time if the investigator deems it in the subject's best interest. The reason 
and circumstances for withdrawal will be documented in the electronic case report form 
(eCRF)
. 
5.6.[ADDRESS_1115649] will be discontinue
d from treatment if the following applies: 
Withdrawal of consent by [CONTACT_1130].
If a protocol deviation occurs which, in the clinical judgement of the investigator, can
invalidate the trial or e
ndpoints or can interfere pharmacokinetically or
pharmacodynamically with the trial product, the subject will be discontinued by [CONTACT_31035].
Adverse 
events occur which are considered unacceptable by [CONTACT_807500].
If discontinuation occurs following administration of trial medication, every effort should 
be made to have the subject return and participate in the complete follow-up visit on Da y 
28 (see Table 3) to avoid missing data. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115650] complete the treatment visit (Visit 2). To qualify as 
c
ompleted, the subject must be dosed and have blood drawn for the PK and PD 
assessments described in the protocol.  
5.6.2 C enter discontinuation 
The center can be closed and the trial terminated for the following reasons: 
 The  center is unlikely to be able to recruit sufficient subjects within the agreed time 
frame. 
 The center does not respond to trial management requests. 
 R epeat protocol violations. 
5.6.3 Trial  termination 
The sponsor reserves the right to modify or terminate the trial at any time. Possible 
reasons for termination are: 
 S afety reasons – the incidence of AEs in this or any other trial using the same trial 
medication indi
cates a potential health risk for the subjects. 
 Ne w scientific knowledge becomes known that makes the objectives of the trial no 
longer feasible/valid. 
 Unsatisfactory enrolment of subjects. 
5.[ADDRESS_1115651] given written informed consent and meet all inclusion and none of the 
exclusi
on criteria will be randomized in a 2:1:1 ratio to either 0.6 mg dasiglucagon 
(n=78), placebo (n=39), or 1 mg GlucaGen (n=39) via an Interactive Web Response 
S
ystem (I
WRS). Randomization will continue until [ADDRESS_1115652] code can be broken by [CONTACT_807448] (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 29 of 79  
investigator, preferably after consultation with the medical monitor. Emergency code 
breaks can be performed using the IWRS. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 30 of 79  
6 TRIAL D RUG  
6.1 Id entity 
The following trial drugs will be administered: 
 Da siglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a prefilled syringe. 
 P lacebo, liquid formulation, 0.6 mL delivered in a prefilled syringe. 
 R ecombinant glucagon hydrochloride, 1 mg for reconstitution (GlucaGen®, Novo 
Nordisk) in [ADDRESS_1115653]  
Name  [CONTACT_93458]® 
Active 
substance  Dasiglucagon  N/A Recombinant 
gluca gon 
hydrochloride  
Formulation  Liquid formulation, 
0.6 mL  Liquid formulation, 
0.6 mL  Powder and solvent 
for reconstitution as 1 
mL solution for 
injection  
Strength  1 mg/mL  N/A 1 mg  
Device  Single use pre -filled 
syringe  Single use pre -filled 
syringe  Powder and solvent 
for reconstitution 
packed together in a 
plastic box. A “hypo -
kit”. 
Manufacturer  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Zealand Pharma A/S, 
Glostrup 
(Copenhagen), 
Denmark  Novo Nordisk A/S, 
Bagsværd, Denmark  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115654]  
Storage 
requirements  Store between 2 and 
8°C Store between 2 and 
8°C Store between 2 and 
8°C 
The quantities of ingredients for dasiglucagon and placebo are provided in Table 2.  
T
able 2 Quantities of ingredients in dasiglucagon and placebo injection 
Component  Amount per mL 
(dasiglucagon)  Amount per mL 
(placebo)  Function  
Dasiglucagon*  1.0 mg  N/A 
Sodium chloride  10.23 mg  10.23 mg  
Trometamol/Tromethamine  6.06 mg  6.06 mg  
Water  for injection  To make 1 mL  To make 1 mL  
Sodium hydroxide  q.s. q.s. 
Hydrochloric acid  q.s. q.s. 
*The quantity of drug substance to be used is calculated according to net peptide content and purity.  
q.s. = quantum sufficit (quantity required). 
6.2 T reatment assignment and randomization 
Subjects successfully completing screening and who fulfill entry eligibility and 
randomization criteria will be randomized to one of three treatment groups in a ratio of 
2:1:1: 
 Te st treatmen t: Dasiglucagon, liquid formulation, 1 mg/mL, 0.6 mL delivered in a 
prefilled syringe. 
 Placebo treatment: Placebo, liquid formulation, 0.6 mL delivered in a prefilled 
syringe. 
 Reference treatment: Recombinant glucagon hydrochloride, 1 mg for reconstitution. 
Randomization will be performed using a fixed-block randomization scheme. The 
randomization scheme will be generated prior to the initiation of the study by [CONTACT_76691]/programmer who will not be a member of the study team; all 
investigators will not be aware of the block size of the randomization scheme.  
Randomization will be stratified by [CONTACT_807449] (a bdomen, 
buttocks, or thigh) a
nd controlled via the IWRS.       

 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 32 of 79  
Subjects will be randomized to study treatment using an interactive, automated system 
which has bee
n validated for the intended use under the International Society of 
Pharmac
eutical Engineers Good Automated Manufacturing Process guidelines, 21CFR 
Part 11 (FDA regulation for Electronic Records and Electronic Signatures) and the 
International Conference on Harmonization (ICH) Guidance E6 for Industry on Good 
Clinical Practice (GCP).   
6.3 Adm inistration 
Dasiglucagon, placebo, and GlucaGen will be administered by [CONTACT_807450] 
a
bdomen, buttocks, or thigh.  
An unblinded pe
rson (ap
propriately trained) authorized to prepare the dose and 
administer the treatment in accordance with the randomization will prepare the treatment 
required for each subject on each dosing day. The dose will be administered by [CONTACT_807451], trained and qualified person. The content of the syringe has to be checked for 
c
larity and absence of bubbles. To ensure proper administration, the unblinded person 
should administer the SC injection at a [ADDRESS_1115655] finger. The injection should be given within 5 seconds. 
Syring
es will be discarded after dose administration. Used GlucaGen vials will be stored 
in a lockable box (separated from unused vials) at ambient temperature. 
6.[ADDRESS_1115656] ug. The labels wil l 
supply no information about the subjects. Each treatment kit (pre-filled syringe/vial for 
reconstitution) will have a unique Dispensing Unit Number for drug allocation, drug 
accountability, and traceability purposes. 
Labelling will be performed according to Annex 13 of the Good Manufacturing Practice 
guidelines of the European Commission, ICH GCP guidelines, and local law. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115657] be stored in a refrigerator (at a temperature of 2–8°C), 
and should be handled in
 accordance with guidelines from the sponsor. GlucaGen must 
also be stored in a refrigerator (at a temperature of 2–8°C), and should be handled in 
accorda
nce with the Summary of Product Characteristics ( 13).  
The
 unblinded person responsible for study drug handling must contact [CONTACT_807452].  
Please see the Pharmacy Manual for additional information on handling study drug. 
6.6 B linding and breaking the blind 
This is a double-blind trial. As the trial products are not identical in appearance, 
dasiglucagon and placebo being available as a liquid formulation and GlucaGen as a 
powde
r for re
constitution, unblinded trial personnel will be responsible for handling, 
preparing (according to the prescription from the IWRS), and administering the trial 
medic
ation
, as well as for keepi[INVESTIGATOR_807431]. To maintain double-blind 
conditions, all trial assessments at the trial center will be done by [CONTACT_807485]. However, exposure assessments 
and anti-drug antibody ( ADA ) assessments will be performed by [CONTACT_807454], to ensure that dasiglucagon, placebo, or GlucaGen administration 
is ma
tched with the applicable bioanalytical assay. 
Treatment assignment will be kept strictly confidential and accessible only to authorized 
persons until after the time of unblinding. Codes with treatment assignment will, 
however, be readily available in the IWRS to the blinded personnel in case of an 
emergen
cy. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115658] the time, date and reason as well as his/her initials 
in the source documents. The breaking of blinded codes in case of medical emergency for 
one subject should not unblind the trial personnel to the treatment information of other 
subjects. The person performing the unblinding should inform as few people as possible 
about the result of the unblinding. All persons unblinded for a specific subject should be 
documented. 
I
f the trial center needs to break the code, the medical monitor should, if at all possible, 
be
 contacte
d prior to breaking the code and the monitor must be notified within 24 hours 
after the 
code has been broken. 
The pharmacovigilance unit (safety contract research organization [CRO];  see the list 
of trial personnel in Section  12.1) will be able to break the code in case of a serious 
une
xpected suspec ted adverse reaction (S[LOCATION_003]R).  
The central and specialty laboratories will be provided with a copy of the randomization 
li
st. 
6.[ADDRESS_1115659] until approved by [CONTACT_1034].  
6.8 T reatment compliance 
All t
rial medications will be prepared and administered by [CONTACT_93400]. 
PK assessments will support the surveillance of compliance with IMP administration.  
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 35 of 79  
6.9 Prior and concomitant medications 
Prior glucagon exposure will be recorded in the eCRF at screening. All concomitant 
medications will be recorded and/or updated in the eCRF at each visit.  
Subjects using any new concomitant medication resulting in fulfillment of a dosing day 
exclusion criterion (see Section  5.5) will be excluded from the dosing visit, but can be 
re
scheduled to one of the following days (1–7 da ys later). The dosing visit can only be 
rescheduled once. 
6.9.1 Proh ibited medications 
The use of anti-coagulant treatments and medications (prescription and non-prescription) 
that are known to cause QT prolongation are prohibited during the course of the trial. 
W
ithin 28 days prior to dosing, the use of daily systemic beta-blockers, indomethacin, 
warfarin, and anticholinergic drugs is prohibited. 
Within 2 weeks prior to dos
ing, the use of any non-prescribed systemic or topi[INVESTIGATOR_73264] (with the e
xception of vitamins and the occasional use of acetylsalicylic acid 
and paracetamol) is prohibited.  
Within 24 hours prior to dosing, the use of any basal insulin is prohibited. 
W
ithin 12 hours prior to dosing, the use of any short acting (bolus) insulin, except insulin 
glulisine (Api[INVESTIGATOR_27976]®) is prohibited.  
During the insulin-induced hypoglycemic procedure, continuous SC insulin infusion must 
be
 stopped. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115660] be available prior 
to sample analyses. A bioanalytical report for each analysis of trial PD and PK samples 
will be prepared.
 
7.1.1 Pharmacodynamic measurements 
The plasma glucose prof
ile for evaluation of the primary and secondary clinical efficacy 
endpoints will be assessed based on plasma concentration data (AUC 0-30min ) from samples 
collected at the dosing visit (Visit 2). The samples will be sent to the clinical laboratory 
and ana
lyzed using a sensitive and validated assay for glucose measurements.  
Samples will be collected pre-dose, and at 4, 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 
75, and 90 minutes after dosing (see the schedule of procedures in Table 3). The actual 
time of 
blood sampling for evaluation of pla sma glucose shoul d not deviate from the 
nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point and by 
[CONTACT_726] ±1 minute for the subsequent collection time points. Pre-dose is defined as 
withi n 2 minutes prior to dosing. 
7.1.2 Ph armacokinetic measurements 
The exposure to trial medication (dasiglucagon or GlucaGen) for evaluation of PK will 
be assessed based on plasma concentration data (AUC 0-90 min , Cmax, tmax) from samples 
collected at the dosing visit (Visit 2).  
Samples (including back-up samples) will be collected pre-dose, and at 15, 30, 35, 40, 50, 
60, 90, and 120 m inutes after dosing (see the schedule of procedures in  Table 3). The 
actual time of blood sampling for exposure 
to trial medication should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to 
dosing. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 37 of 79  
7.2 Safety parameters 
7.2.1 A dverse events 
The investigator is responsible for the detection and documentation of events meeting the 
criteria and definition of an AE or serious adverse event (SAE), as provided in this 
protocol. During the trial, the investigator or center staff will be responsible for reporting 
AEs and SAEs, as detaile
d in this section of the protocol.  
Based on  the investigator’s clinical judgment it will be determined whether an AE is 
related to trea
tment and of sufficient severity to require the subject’s removal from 
treatment or from the trial. A subject may also voluntarily withdraw from treatment due 
to what he or she perceives as an intolerable AE. If either of these situations arises, the 
subject should be under medical supervision until symptoms cease or the condition 
becomes stable. 
[IP_ADDRESS] De finitions 
Adverse event 
An A
E is any untoward medical occurrence in a trial subject given an IMP which does 
not necessarily have a causal relationship with the treatment. An AE can therefore be any 
unfavorable and/or unintended sign (for example, an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of an IMP, whether or not 
considered related to the IMP.  
In this trial, only treatment-emergent adverse events (TEAEs) will be collected and 
reported. TEAEs are events that occur from the first trial-related activity after the subject 
has signed the infor
med consent form until the end of the post-treatment follow-up 
period.  
AEs include: 
A clinically significant worsening of a concomitant illness.
A clinical laboratory abnormality which is clinically significant, i.e. any abnormality
that suggests a
 disease and/or organ toxicity and is of a severity that requires active
management. Active management includes active treatment or further investigations,
for example change of medicine dose or more frequent follow-up due to the
abnormality.
Hypoglycemic epi[INVESTIGATOR_1841] (see Section  7.2.2).
Injection site reactions (see Section  7.2.6).
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 38 of 79  
The following should not be recorded as AEs, if recorded at screening (on the Screening 
Form or eCRF): 
 P re-planned procedure, unless the condition for which the procedure was planned has 
worsened from the first trial related activity after the subject has signed the informed 
consent. 
 P re-existing conditions found as a result of screening procedures (pre-existing 
conditions should be reported as medical history or concomitant illness). 
Serious a dverse event 
An SAE is any untoward medical occurrence that at any dose:  
 R esults in death  
 I s life-threatening  
 R equires inpatient hospi[INVESTIGATOR_1081] 
 R esults in persistent or significant disability or incapacity 
 I s a congenital anomaly or birth defect 
 I s medically important* 
*Medical judgement must be exercised in deciding whether an AE is believed to be 
‘me
dically important’. Medically important events may not be immediately 
life-thre
atening or result in death or hospi[INVESTIGATOR_807432]. 
Adver
se drug reaction 
All noxious and unintended responses to an investigational product related to any dose 
should be considered adverse drug reactions. The phrase responses to an investigational 
product m
eans that a causal relationship between an investigational product and an 
adverse event is at least a reasonable possibility, i.e. the relationship cannot be ruled out. 
 
Suspected unexpected serious adverse reactions (S[LOCATION_003]Rs) 
An AE fulfilling one of the criteria of seriousness and being assessed as related to IMP 
application, the nature or severity of which is not consistent with the applicable reference 
document (e.g. dasiglucagon Investigator’s Brochure or package leaflet/Summary of 
Product Characteristics for GlucaGen ). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115661] 
An AESI is an event which, in the evaluation of safety, has a special focus (e.g. required 
by [CONTACT_21652]). In this trial hemodynamic changes, as defined below, are 
considered AESIs: 
 P ost-dose clinical si gns, or measured vital signs, indicating a clinical ly significant 
drop 
in blood pressure including signs of orthostatic hypotension, vasovagal 
responses or bradycardia.   
 P ost-dose change in pulse or blood pressure considered an event of hypo- or 
hypertension as judged by [CONTACT_093]. 
 
Intensity of an adverse event 
The maximum intensity (severity) of all AEs must be assessed by [CONTACT_807457]. Severity should be graded when the AE outcome is known: 
Mild :  A type of AE that is usually transient and may require only minimal 
treatment or therapeutic intervention. The event does not generally 
interfere with usual activities of daily living. 
Moderate :  A type of AE that is usually alleviated with additional specific therapeutic 
intervention. The event interferes with usual activities of daily living, 
causing discomfort but poses no significant or permanent risk of harm to 
the subject. 
Severe :  A type of AE that interrupts usual activities of daily living, or significantly 
affects clinical status, or may require intensive therapeutic intervention. 
A ‘severe’ reaction does not necessarily deem the AE as ‘serious’ and an SAE may not 
nece
ssarily be ‘severe’ in nature. 
Causality relationship to trial medication 
The causality of each AE should be assessed by [CONTACT_807458]: 
Probable: Good reason and sufficient documentation to assume a causal relationship. 
Possible: A causal relationship is conceivable and cannot be dismissed. 
Unlikely: The event is most likely related to etiology other than the trial product. 
Not related:  No relationship to trial product. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115662] be assessed by [CONTACT_807459]/her 
staff. The following definitions should be used: 
Recovered/resolved :  The subject has fully recovered, or by [CONTACT_807460]-related activity after 
the subject signed the informed consent.  
Recovering/resolving: The condition is improving and the subject is 
expected to recover from the event. This term is 
only applicable if the subject has completed the 
trial. 
Recovered/resolved with sequelae:  The subject has recovered from the condition, but 
with lasting effect due to a disease, injury, treatment 
or procedu
re. If a sequela meets an SAE criterion, 
the AE must be reported as an SAE. 
Not recovered/not resolved :  The condition of the subject has not improved and 
the symptoms are unchanged. 
Fatal:  This t erm is only applicable if the subject died from 
a condition related to the reported AE. Outcomes of 
other reported AEs in a subject before he/she died 
should be assessed as "recovered/resolved", 
"recovering/resolving", "recovered/resolved with 
sequelae" or "not recovered/not resolved". An AE 
with fatal outcome must be
 reported as an SAE. 
Unknown :  This term is only applicable if the subject is lost to 
follow-up. 
[IP_ADDRESS]  Collection, recording and reporting of adverse events 
All events meeting the definition of an AE must be collected and reported from the first 
trial related activity after the subject has signed the informed consent until the end of the 
post-treatment follow-up period. At each contact [CONTACT_49877] (visit or telephone, 
excluding visits where the subject is not seeing the investigator or his/her staff [e.g. visits 
to the laboratory]) the subject must be asked about AEs. All AEs, either observed by [CONTACT_299798], must be recorded by [CONTACT_36306].  
The investigator should record the diagnosis, if possible. If no diagnosis can be made the 
investigator should record each sign and symptom as individual AEs. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115663] 
also be completed. 
AE information shoul
d include the following: 
Date and time of onset and resolution
Date and time of investigator’s first information on the (S)AE
Seriousness
Severity
Causal relationship with IMP
Interruption or withdrawal of treatment during IMP administration and other
measures take
n
Outcome.
All AEs a
re code
d; details are described in the trial-specific Data Management Plan. 
If an event classifie s as a AESI, the investigator must tick the AESI box on the AE form 
and comple te the AESI form. The AESI form will capture if the event wa s associated 
with any signs or symptoms and capture the highest/lowest blood pressure and pulse 
measured during the event. The investi gator must report all AESIs to the sponsor’s 
responsible pharmacovigilance unit (Safety CRO; see the list of trial personnel in 
Section  12.1) immediately (within 24 hours) after obtaining knowledge about the event. 
The investi gator must report initial infor mation electronically (e.g. in PDF format) on all 
SAEs to the sponsor’s responsible pharmacovigilance unit (Safety CRO; see the list of 
trial personnel in Section  12.1)  immediately (within 24 hours) after obtaining knowledge 
about the event. The Safety CRO will inform the medic al monitor and the sponsor about 
the reported SAEs. 
It is the responsibility of the Safety CRO to report all S[LOCATION_003]Rs (see Section  [IP_ADDRESS]) that 
oc
cur in this trial to the Competent Authorities and Institutional Review Boards 
(IRBs)/Independent Ethics Committees (IECs) in accordance with the local requirements 
in force a nd ICH guideline for GCP . The trial monitor must be informed accordingl y. 
[IP_ADDRESS] Follo w-up of adverse events 
All AEs that are ongoing at the end of the subject’s participation in the trial will be 
followed-up until the event is resolved or reaches a satisfactory outcome as deemed by 
[CONTACT_807501], whichever 
occurs first.   
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 42 of 79  
Follow-up actions for all SAEs will be performed according to appropriate clinical care 
practices and may depend on the nature of the event. These will be determined after 
internal review and/or sponsor review. 
The follow-up information should only include new (updated and/or additional) 
information that reflects the situation at the time of the investigator’s signature. 
Follow-up information on (S)AEs will be updated using the (S)AE form. If a non-serious 
event becomes serious during the follow-up the AE form and SAE form have to be used 
and reporting timelines follow those of an SAE. 
The investiga
tor must forward follow-up information on SAEs and if previously 
non-serious AEs become SAEs to the Safe ty CRO immediately (within 24 hours) after 
obtaining knowledge
 about the new information. 
The sponsor and/or CROs acting on behalf of the sponsor can upgrade a non-serious AE 
to an SAE. In these situations the investigator will be informed and asked to fill out an 
SAE form and forward to the Safety CRO immediately (within 24 hours). 
[IP_ADDRESS]  Clinical laboratory abnormalities and other abnormal assessments as adverse 
events or
 serious adverse events 
Abnormal la
boratory findings (e.g. biochemistry, hematology, urinalysis) or other 
abnormal assessments (e.g. vital signs) that are judged by [CONTACT_807502]. 
C
linically significant abnormal laboratory findings or other abnormal assessments that 
are detected during the trial or are present at baseline and significantly worsen following 
the start of the tria
l will be reported as AEs or SAEs. However, clinically significant 
abnormal la
boratory findings or other abnormal assessments that are associated with the 
disease being studied, unless judged by [CONTACT_652117]’s condition, or that are present or detected at the start of the trial and do not 
worsen, will not be r
eported as AEs or SAEs. 
The investigator will exercise his or her medical and scientific judgment in deciding 
whether an abnormal laboratory finding or other abnormal assessment is clinically 
significant. 
7.2.2 Hypogly cemia 
Hypoglycemia will be regarded as an AE and recorded and documented on an AE form 
(and SAE for
m, if applicable). 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 43 of 79  
Hypoglycemia is defined as a decline in plasma glucose to below 70 mg/dL 
(3.9 mmol/L). However, in the time period from initiation of the hypoglycemic clamp 
procedure (see Section  [IP_ADDRESS]) until 45 m inutes after dosing, hypoglycemia is defined 
as a decline in plasma glucose 
to below 45 mg/dL (2.2 mmol/L).  
During
 the dosi
ng visit, p
rior to administration of the IMP, a plasma glucose value of 
<45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463]. After administration 
of the
 IMP in the period f
rom 8 minutes until 44 minutes after dosing, a plasma glucose 
value of <45 mg/dL (2.5 mmol/L) will be treated by [CONTACT_807463], and if a 
plasma
 glucose value of ≥70 mg/dL (3.9 mmol/L) is not achieved within the [ADDRESS_1115664] experiences symptoms of hypoglycemia, a plasma glucose measurement 
should be taken in order to classify the event (plea se refer to Sec tion 7.4.2 f or additional 
details).  
7.2.3 Ph ysical examination 
The physical examination will be carried out at screening (Visit 1) and at the follow-up 
visit (Visit 3; see Table 3 ).  
The
 physic
al exa
mination includes examination of the following body systems: head, 
ears, eyes, nose, throat, including the thyroid gland; heart, lung, chest; abdomen; skin and 
mucosae; musculoskeletal system; nervous system; lymph node; other findings. 
At the screening visit, any abnormality will be recorded and described in the eCRF, 
including the investigator’s assessment of clinical significance (‘abnormal, not clinically 
significant’ or ‘abnormal, clinically significant’). Clinically significant findings at the 
screening visit should be recorded as concomitant illness. 
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1 ). 
7.2.4 V ital signs 
An examination of the following vital signs will be performed at screening (Visit 1), the 
dosing visit (Visit 2) and at the follow-up visit (Visit 3):  
Diastolic and systolic blood pressure (mmHg) will be measured after at least
[ADDRESS_1115665] in a supi[INVESTIGATOR_2547]. At Visit 1, blood pressure will be measured in
both 
arms. The blood pressure from t
he arm with the higher systolic value is
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115666]’s blood pressure in this trial.  
Pulse (beats per min) measured after at least [ADDRESS_1115667] in a supi[INVESTIGATOR_2547].
Body temperature (°C).
At the dosing visit, measurements will be taken prior to the start of the insul in-induced 
hypoglycemic procedure (within 30 minutes) and at 30, 90, and 300 minutes after dosing 
(see Table 3). The actual time of the assessment should not deviate from the nominal time 
by [CONTACT_726] ±[ADDRESS_1115668] 12-lead ECG will be performed at the screening visit (Visit 1), the dosing visit 
(Visit 2; prior to the start of the insul in-induced hypoglycemic procedure [within 
30 minutes])  and at 20, 35, 45, 60, and 300 minutes after dosing) and at the follow-up 
visit (Visit 3; see Table 3 ). The actual time of the assessment should not deviate from the 
nomi
nal time by [CONTACT_726] ±5 minutes.  
ECG parameters (he
art ra
te, PQ, QRS, QT, QTcB) and any abnormality will be recorded 
and described in the eCR
F including the investigator’s assessment of clinical significance 
(‘abnormal, not clinically significant’ or ‘abnormal, clinically significant’).  
At subsequent visits, any clinically significant deterioration of a pre-existing condition as 
well as any new clinically significant findings will be recorded as AEs (see 
Section  7.2.1). 
7.2.6 Loc al tolerability 
Immediately prior to treatment administration, it should be verified that the injection site 
is normal. To ensure all injection site assessments are performed at the injection site, the 
site will be marked with a pen prior to injecti on. Assessment of local tolerability at the 
injection site will be performed at the dosing visit (Visit 2; at 30, 120 and 300 minutes 
after dosing), and at the follow-up visit (Visit 3) (see Table 3) and more frequently, if 
deemed ne
cessary by [CONTACT_32595]. The actual time of the assessment should not 
deviate from the nomi nal time by [CONTACT_726] ±10 mi nutes. In the eCRF, the time of 
assessment and any injection site reaction observed will be recorde d. In case of an 
observation, the Local Tolerability form will be completed, as well as the (S)AE form. 
The local tolera
bility at t
he injection site will be evaluated by [CONTACT_807464]: spontaneous pain, pain on palpation, itching, redness, edema, 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 45 of 79  
induration/infiltration, and other. Each of these assessments will be reported on a scale of 
0 (none), 1 (mild), 2 (
moderate), and 3 (severe). The evaluation and the actual time of the 
assessment will be
 recorded. The assessments will be performed by a trial physician or 
nurse.  
Digita
l pi[INVESTIGATOR_807433], and 
thereafter as often as judged necessary by [CONTACT_093]. The pi[INVESTIGATOR_807434] a 
subject identifier, visit number, time after dosing, and a ruler for scaling. 
7.2.7 C linical laboratory assessments 
The safety parameters that will be assessed at the clinical laboratory are listed in Table 3. 
R
outine clinical laboratory tests will be performed centrally. Samples for clinical 
labor
atory parameters (biochemistry, hematology, coagulation) will be collected at 
screening (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced 
h
ypoglycemic procedure [within 30 minutes] ) and at 30 and 300 minutes after dosing), 
and at the follow-up visit (Visit 3). The actual time of the assessment should not deviate 
fr
om the nomina
l time by [CONTACT_726] ±10 minutes. Samples for glycated hemoglobin 
(HbA 1c) will be collected at screening only (Visit 1). Samples for urinalysis will be 
c
ollected at screening (Visit 1), at the dosing visit (Visit 2, prior to the start of the 
insulin-
induced hypoglycemic procedure [within 120 minutes]) and at the follow-up visit 
(Visit 3). The following parameters will be assessed: 
 C linical biochemistry: sodium, potassium, calcium, glucose, urea, creatinine, total 
bilirubin, AST, ALT, gamma-glutamyltransferase, alkaline phosphatase, total protein, 
C-reactive protein, HbA 1c, C-peptide. 
 He matology: hemoglobin, red blood cell count (erythrocytes), hematocrit, platelet 
count (thrombocytes), total white blood cell count (leukocytes). 
 Coagulation: international normalized ratio, fibrinogen (at screening visit only).  
 Urinalysis: pH, blood (leukocytes and erythrocytes), protein, glucose, ketones, nitrite. 
Pregna
ncy tests will be performed at each visit for women of childbearing potential only. 
A serum pregnancy test will be performed at screening (Visit 1) and urine stick tests will 
be perfo
rmed at the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypoglycemic procedure) and the follow-up visit (Visit 3). Test sticks will be provided to 
the trial centers. 
Alcohol breath tests and a urine drug screen will be performed at screening (Visit 1) and 
at the dosing visit (Visit 2, prior to the start of the insulin-induced hypoglycemic 
procedure ). Equipment for the alcohol breath test and uring drug screen will be provided 
to the trial centers.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115669]’s partner will be fully informed by a physician of 
her participation in capturing the outcome data, and will be asked to provide her written 
consent. 
The investigator must report all information on pregnancies on the Initial Pregnancy 
form. The completed Initial Pregnancy form must be forwarded to the sponsor 
immediately (within 24 hours), according to the procedure stated in Section  [IP_ADDRESS]. Any 
(S)A
Es in the mother, as well as other pregnancy complications (ectopic pregnancy) 
fulfilling the criteria of an (S)AE, must be reported on the (S)AE form.  
The following must be collected in the Initial Pregnancy form:  
 Me dical history of the mother 
 F amily history 
 C ourse of the pregnancy, including expected delivery date. 
The investigator must follow the pregnancy until the pregnancy outcome and follow the 
newborn infant(s)
 until the age of [ADDRESS_1115670] information on 
the pr
egnancy and pregnancy complications as well as the pregnancy outcome including 
the health of the newborn infant(s) on the Pregnancy Outcome form. The completed 
Pregnancy Outcome form must be forwarded to the sponsor according to the procedure 
stated in Section [IP_ADDRESS] . Any (S)AEs in the newborn must be reported on the (S)AE 
form. 
The SAEs that must be reported include abnormal outcome, such as congenital 
anomalies, fetal death and termination of pregnancy (spontaneous or elective abortion), 
including any anomalies of the fetus observed at gross examination or during autopsy.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115671] be collected in the Pregnancy Outcome form:  
 C ourse of the pregnancy 
 Outc ome of the pregnancy 
 C ondition of the newborn 
 An y AEs in the newborn infant must be followed until the age of [ADDRESS_1115672]’s participation in the trial, the 
investigator should ensure that adequate medical care is provided to the subject for any 
AEs, including clinically significant laboratory values related to the trial. The investigator 
should inform the subject when medical care is needed for intercurrent illnesses of which 
the investigator becomes aware.  
For further information on safety precautions for dasiglucagon and GlucaGen, please 
refer to the curre
nt version of the Investigator’s Brochure (14) and the Summary of 
P
roduct Characteristics for GlucaGen (13), respectively. 
7.2.[ADDRESS_1115673] the subjects. 
7.3 De mography, concomitant illness, medical history and concomitant 
medication 
De
mographics, body measurements, concomitant illness and medical history will be 
assessed only at scr
eening (Visit 1). Concomitant medication will be assessed at 
scree
ning (Visit 1), the dosing visit (Visit 2, prior to the start of the insulin-induced 
hypogly
cemic procedure) and at the follow-up visit (Visit 3). 
7.3.[ADDRESS_1115674] demogr
aphics and body measurements will include: 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 48 of 79  
 Age  
 R ace, ethnicity 
 S ex 
 He ight (m e ters or inch), without shoes 
 B ody weight (kg or lb), only wearing underwear and measured using standard scales 
 B ody mass index (kg/m2) calculated based on height and body weight (body 
weight/height2). 
7.3.2 Concomitant illness and medical history 
A concomitant illnes
s is any illness that is present at the start of the trial (i.e. at the 
screening visit). Concomitant illnesses present at the start of the trial will be recorded in 
the e
CRF at screening.  
Medical history is an account of medical events that the subject has experienced in the 
past, including prior medications. Relevant medical conditions/illnesses in the past 
obtained by 
[CONTACT_807489]/her medical records will be recorded 
in the eCRF at screening. History of alcohol or drug abuse will also be recorded. 
The information collecte
d for concomitant illness and medical history should include 
diagnosis, date of onset, date of resolution or continuation. 
Any change to a concomitant illness should be recorded during the trial, including end 
date, if applicable. A clinically significant worsening of a concomitant illness must be 
reported according to Section 7.2.1. 
All pre
vious and concomitant diseases will be coded with Medical Dictionary for 
Regulatory Activities (MedDRA), the version of which will be provided in the clinical 
trial report. 
7.3.3 Diabe tes diagnosis and current treatment 
The date of diagnosis of diabetes will be recorded as will the current diabetes treatment 
(start date, product name(s), dose(s)). 
7.3.4 C oncomitant medication 
A concomitant medication is any medication, other than the trial products and current 
diabetes treatment (including insulin glulisine [Api[INVESTIGATOR_27976]®] for diabetes therapy wash-out), 
which is taken during the trial, including screening and follow-up periods. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115675] be recorded at trial entry (i.e. at screening). 
Any changes in concomitant medication must be recorded at each visit as they occur. The 
information collected for each concomitant medication includes (at a minimum) trade 
name [CONTACT_18058], indication, start date and stop date or continuation. A change in 
medication due to an AE must be recorded and reported according to Section 7.2.1. If the 
c
hange in medication influences the subject’s eligibility to continue in the trial, the 
sponsor and trial monitor must be informed. 
7.[ADDRESS_1115676] dasiglucagon/GlucaGen will be measured at the dosing visit (Visit 2) 
and at follow-up (Visit 3). At t
he dosing visit (Visit 2), samples will be collected prior to 
the start of the insulin-induced hypogl
ycemic procedure.  
The clinical ADA assays, specific for dasiglucagon and GlucaGen, respectively, have 
been validated in accordance with existing guidelines and recommendations (17-21).  
Confirmed positive anti-dasiglucagon antibody samples (treatment-induced or 
treatment-boosted) from anti-dasiglucagon antibody-positive subjects will be evaluated 
for binding titer neutralizing potential and titer as well as cross-reactivity towards 
endogenous glucagon.  
No further serum sampling will be needed as the ADA samples can be used fo r 
neutralizing antibody analysis. 
The in vitro neutralizing effect of the antibodies will be measured using an assay based 
on glucagon receptor transfected human embryonic kidney cells (20,22) . T he calculated 
sensitivity in previous studies was about 51.8 ng/mL. The assay was also validated for 
recombinant glucagon with similar results (21,23). In case of a positive result in the 
neutralizing antibody assay, a titer estimation will be performed. The cell-based 
neutralizing antibody analyses will be performed by a special laboratory, BioAgilytix, 
Durham, NC, [LOCATION_003]. 
Residual and additional antibody serum samples may be stored until approval of market 
authorization by [CONTACT_93420]. Further characterization of the antibody response 
may be requested by [CONTACT_93420]. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 50 of 79  
7.4.2 Plasma glucose measurements for safety 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site. After the start of insulin infusion, plasma glucose should be checked every 
10 minutes while plasma glucose is above 110 md/dL, and every 5 minutes once plasma 
g
lucose is at or below 110 mg/dL and until after dosing when the subject’s plasma 
glucose is ≥70mg/dL (3.9 mmol/L). Hereafter, plasma glucose should be checked every 
30 minutes until 300 minutes (5 hours ) a fter dosing. Plasma glucose concentrations will 
be
 measured 
using a US  FDA-approved glucose analyzer (e.g., YSI 2300, Yellow 
Springs I
nstruments, Yellow Springs, OH). 
At the discretion of the investigator, additional plasma glucose measurements can be 
taken at any time during the trial, for example when there is a suspi[INVESTIGATOR_2798] (e.g. symptoms) 
of a
 hypog
lycemic epi[INVESTIGATOR_1865]. 
Plasma glucose measurements for safety should only be recorded in the eCRF if the y are 
related to an AE (e.g. a hypoglycemic epi[INVESTIGATOR_1865]). 
I
n case of persistent post-treatment hypoglycemia, subjects will receive rescue treatment 
with an IV glucose infusion (see Section [IP_ADDRESS]  for details). Blood samples for PD and 
P
K assessments should still be taken at the specified timepoints. 
7.4.3 Plasm a insulin measurements 
Samples for insulin assessment will be collected at the dosing visit (Visit 2, pre-dose and 
at 30 and 60 minutes after dosing). The actual time of blood sampling for evaluation of 
plasma insulin should not deviate from the nominal time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115677] 
8.1 S chedule of procedures 
The schedule of procedures is provided in Table 3.  Informed consent will be obtained 
prior to any tria
l-related procedures; see Section 10.8. 
8.2 P rocedures by [CONTACT_765] 
8.2.1 V isit 1 (screening, Day -30 to Day -3) 
Visit [ADDRESS_1115678] between 3 and 30 days before Visit 2, Day -1 to Day 1 (dosing 
da
y). 
I
nformed consent can be obtained prior to or at Visit 1, however it must in any case be 
obtained prior to any trial related procedures. During the screening visit, the following 
assessments will take place: 
 I nformed consent (obtain or check) 
 C heck of subject eligibility (inclusion/exclusion criteria) 
 Demography  
 B ody measurements 
 Me dical history, diabetes diagnosis, current diabetes treatment 
 C oncomitant illnesses 
 C oncomitant medications 
 Hist ory of alcohol/drug abuse 
 P hysical examination 
 Vital signs 
 12-lead ECG 
 AE s  
 Biochemistry, hematology, coagulation, HbA 1c 
 S erum p regnancy test (women of childbearing potential only) 
 Urinalysis  
 Urine drug screen 
 Alcohol breath test 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 52 of 79  
Table  3 Schedule of procedures 
Visit number  V1 V2 V3 
Trial day  -3 -1 and 1 28 
Visit type  Screening  Dosing  Follow -up 
Window  -30 to -3  +[ADDRESS_1115679] related information/assessments     
Informed consent  x   
Inclusion/exclusion criteria  x x1,2  
Demography  x   
Body measurements  x   
Medical history, diabetes diagnosis, and current diabetes 
treatment  x   
Concomitant illness es x   
Concomitant medication s x x1 x 
History of alcohol/drug abuse  x   
Randomization   x1  
Withdrawal criteria   x1  
Dosing day exclusion criteria   x1  
Insulin -induced hypoglycemia   x  
Safety assessments     
Physical examination  x  x 
Vital signs  x x3 x 
12-lead ECG  x x4 x 
Local tolerability   x5 x 
Adverse events  x x x 
Laboratory     
Biochemistry, h ematology, c oagulation, HbA 1c (HbA 1c at 
Visit 1  only)  x x6 x 
Pregnancy test (women of childbearing potential only)  x7 x1,[ADDRESS_1115680]  x x1  
PK/Clinical efficacy     
Plasma dasiglucagon /GlucaGen   x9  
Plasma gl ucose   x10  
Other assessments     
Antibodies against dasiglucagon /GlucaGen   x1 x11 
Plasma i nsulin   x12  
Trial material     
Administration of trial product  (during hypoglycemic clamp 
procedure)   x  
1Prior to the start of the insulin-induced hypoglycemic procedure. 
2Only check of dosing day exclusion criteria and changes between screening visit and Visit 2. 
3Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30, 90 and 300 minutes 
after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±10 minutes. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 53 of 79  
4Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes) , and at 20, 35, 45, 60 and 300 
m
inutes after dosing. The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±5 
minutes.  
5Local tolerability assessed at 30, 120, and 300 minutes after dosing. The actual time of the assessment should not 
deviate from the nominal time by [CONTACT_726] ±10 minutes.  
6Prior to the start of the insulin-induced hypoglycemic procedure (within 30 minutes), and at 30 and 300 minutes after 
dosing . The actual time of the assessment should not deviate from the nominal time by [CONTACT_726] ±[ADDRESS_1115681]. 
9Pre
-dose, and at 15, 30, 35, 40, 50, 60, 90, and 120 minutes after dosing. The actual time of blood sampling should not 
deviate from the nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing. 
10Pre-dose , and a t 4 , 6, 8, 10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, 90 minutes after dosing. The actual time of blood 
sampling should not deviate from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection time point 
and by [CONTACT_726] ±[ADDRESS_1115682] that tests positive for ADA will be monitored until the ADA levels return to baseline levels. 
12Pre-dose, and at 30 and 60 minutes after dosing. The actual time of blood sampling should not deviate from the 
nominal time by [CONTACT_726] ±1 minute. Pre-dose is defined as within 2 minutes prior to dosing.  
ADA = anti-drug antibodies; ECG = electrocardiogram; HbA 1c = glycated hemoglobin; NPH = neutral protamine 
Hagedorn. 
Eligible or potentially eligible subjects (laboratory results pending) will be provided with 
an Identification card (ID card), stating that the subject is participating in the trial and 
whom to contact (site address, investigator name [CONTACT_41319]). The subjects 
should be instructed to return the ID card to the investigator at the last visit or to destroy 
the card after the last visit.  
8.2.2 In structions to subjects prior to the dosing visit (Visit 2) 
At the screening visit, the investigator will inform the subject about the changes to his/her 
insulin therapy
 leading up to the start of the insulin-induced hypoglycemic procedure. 
The subject’s current insulin therapy will be washed out as defined in Section 5.5: 
24 hours prior to dosing and during the dosing visit, treatment with any basal insulin is 
not allowe
d; 12 hours prior to dosing and during the dosing visit, treatment with any short 
a
cting (bolus) insulin, except insulin glulisine (Api[INVESTIGATOR_27976]®), is not allowed. The basal rate of 
insul
in pumps (continuous SC insulin infusion) will be discontinued on the morning of 
the dosing
 day. 
On the day prior to dosing (Day -1), the subjects will need to attend the clinical center 
a
nd will be require
d to stay onsite overnight. On the morning of the dosing day (Day 1), 
patients are
 required to be in a fasting condition, defined as having consumed only water 
since 22:00 hours the night befor
e. However, the subjects are allowed to consume small 
amounts (up to 20 g) of carbohydrates to prevent hypoglycemia. The subjects must also 
not consume any alcohol 
within 24 hours prior to dosing (refer to Section 5.5 for all 
dosi
ng day exclusion criteria). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 54 of 79  
8.2.3 Visit 2 (dosing visit) 
Visit [ADDRESS_1115683] on D ay -1 to Day 1. 
The
 subjects will attend the clinical center the day prior to dosing (Day -1) and should 
stay onsite overnight. Dosing will take place the following morning (Day 1). 
On Day [ADDRESS_1115684] 
e
ligibi
lity is rechecked (check of changes between the screening visit and Visit 2) and 
those subjects eligible to participate will be randomized to treatment with dasiglucagon, 
placebo, or GlucaGen.  
The
 following assessments will also take place: 
 Doc ument all changes in concomitant medication (prior to the start of the 
insulin-induce
d hypoglycemic procedure) 
 C heck of withdrawal criteria (prior to the start of the insulin-induced hypoglycemic 
procedure
) 
 C heck of dosing day exclusion criteria (prior to the start of the insulin-induced 
hypog
lycemic procedure) 
 Vital si gns (prior to the start [within 30 minutes] of the insulin-induced hypoglycemic 
procedure
, and at 30, 90 and 300 min utes  after dosing). Blood pressure should be 
mea
sured first in sitting and then in standing. 
 12-lead ECG (prior to the start [within 30 minutes] of the insulin-induced 
hypoglycemic procedure, and at 20, 35, 45, 60, and 300 minutes after dosing) 
 L ocal tolerability (at 30, 120, and 300 minutes after dosing) 
 AE s  
 B iochemistry, hematology, coagulation (prior to the start of the insulin-induced 
hypo
glycemic procedure [within 30 minutes], and at 30 and 300 minutes after dosing) 
 Ur ine stick pregnancy test (women of childbearing potential only; prior to the start of 
the insulin-induced hypoglycemic procedure) 
 Urinalysis (prior to the start of the insulin-induced hypoglycemic procedure [within 
120 minutes]) 
 Ur ine drug screen (prior to the start of the insulin-induced hypoglycemic procedure) 
 Alc ohol breath test (prior to the start of the insulin-induced hypoglycemic procedure) 
 Dasiglucagon/GlucaGen plasma concentrations: 
- Pre-dose, 15, 30, 35, 40, 50, 60, 90, and 120 min utes  after dosing. The actual time 
of blood sampling for exposure should not deviate from the nominal time by [CONTACT_26813] ±1 minute. Pre-dose is defined as within 2 min utes  prior to dosing. 
 P lasma glucose concentration s:  
- P
re-dose, 4, 6, 8 ,10, 12, 15, 17, 20, 25, 30, 40, 50, 60, 75, and 90 minutes after 
dosi
ng. The 
actual time for blood sampling for plasma glucose should not deviate 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 55 of 79  
from the nominal time by [CONTACT_726] ±30 seconds until the 20 minute collection 
time point and by [CONTACT_726] ±1 minute f
or the subsequent collection time points. 
Pre-dose is defined as within 2 minutes prior to dosing. 
Antibodies against dasiglucagon/GlucaGen (prior to the start of the insulin-induced
h
ypoglyce
mic procedure). 
Plasma insulin concentrations:
- Pre-dose
, 30 and 60 minutes after dosing. The actual time of blood sampling for 
plasma insulin should not deviate from the nomin
al time by [CONTACT_726] ±1 minute. 
Pre-dose is defined as within 2 minutes prior to dosing. 
[IP_ADDRESS] Hy poglycemic clamp procedure and administration of trial medication 
The following procedure is based on precendent procedures for hypoglycemia induction 
in patients with T1DM [ 24, 25].  
The
 treatment day (Visit 2, Day 1) will be conducted after an overnight fast of at least 
8 hours, targeting a starting plasma glucose around 90 to 110 mg/dL (5.0-6.1 mmol/L).  
Subjects who meet one or more of the dosing day exclusion criteria (Section  5.5) at the 
dosi
ng visit will be excluded from the dosing visit, but the visi t can be rescheduled 
1-[ADDRESS_1115685] 24 hours before testing.  
At approximately 08:00 hours, an infusion catheter will be inserted into each arm 
(forearm cephalic vein) for the manual glucose clamp procedure, with the glucose 
infusion in one arm and the insulin infusion in the opposite arm. A third catheter for 
blood sampling will be plac
ed into a metacarpel vein for blood sampling. This hand wi ll 
be warmed (55-65ºC) to arterialize venous blood.   
H
ypoglycemia will be gradually induced by a fast-acting IV insulin glulisine (Api[INVESTIGATOR_27976]®) 
infusion (15 U [100 U/mL] in [ADDRESS_1115686]’s blood or plasma), 
initially at 150
% of the subject’s usual basal rate and can be increased or decreased over a 
range of 75% to 200% as judged necessary by [CONTACT_093], to achieve a controlled 
decline in plasma glucose, targeting a plasma glucose level of 55 mg/dL (3.0 mmol/L).  
Plasma glucose concentrations will be measured using a US  FDA-approved glucose 
analyzer (
e.g., YSI 2300, Yellow Springs Instruments, Yellow Springs, OH). After the 
start of the insulin infusion, plasma glucose will be measured every 10 minutes whil e 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 56 of 79  
plasma glucose is above 110 mg /dL, and every 5 minutes once plasma glucose is at or 
below 110 mg/dL. 
Onc
e the glucose concentration declines to <60 mg/dL (3.3 mmol/L), the insulin infusion 
will be stopped, and 5 min late
r plasma glucose concentration will be measured at the 
glucose analyzer and blood samples for baseline assessment of plasma glucose, 
dasiglucagon/GlucaGen PK, and insulin PK will be collected. The samples are the 
ba
seline samples and should be collected within 2 minutes before IMP administration. 
 I f plasma glucose is >45 mg/dL and <60 mg/dL (3.0-3.3 mmol/L), study treatment 
(IMP) wil
l be admi
nistered, defining time, t=0. The study treatment will be delivered 
in the abdomen, buttock
, or thigh (according to stratification) via SC injection, with 
the subject lying in a la
teral recumbent position. 
 I f plasma glucose is <45 mg/dL (2.8 mmol/L), IV glucose solution will be 
administered suff
icient to raise plasma glucose to within the 45-60 mg/dL target 
range. The run-in period will be adequately extended (at least 30 min) until the above 
tar
get is achieved and new baseline samples for plasma glucose, 
dasiglucagon/GlucaG
en PK, and insulin PK will be collected. Glucose should not be 
infused within [ADDRESS_1115687] should be rescheduled for a new 
tre
atment visit within 7 days (+ 2 days). 
Admini
stration of 
IMP should not occur earlier than 9:00 hours in the morning or later 
than 12:00 hours. 
As shown in Table 4, serial blood samples for glucose will be collected at t=0, 4, 6, 8, 10, 
12, 15, 17, 20, 25, 30, 40, 50, 60, [ADDRESS_1115688]-dosing. Samples for assessing 
plasma
 dasiglucag
on/GlucaGen concentration will be collected  at t=0, 15, 30, 35, 40, 50, 
60, 90, and 120 minutes. Samples for assessing plasma insulin concentration will be 
c
ollected at t=0, 30, and [ADDRESS_1115689]-treatment blood sampling times 
Times  0 4 6 8 10 12 15 17 20 25 30 35 40 50 60 75 90 120 
Plasma glucose  Y Y Y Y Y Y Y Y Y Y Y  Y Y Y Y Y  
PK 
Dasiglucagon/ 
GlucaGen  Y      Y    Y Y Y Y Y  Y Y 
PK Insulin  Y          Y    Y    
Refer to Section 7.2.7  for details of laboratory safety sampling and to Section 7.4.2 for 
de
tails of blood glucose safety sampling.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 57 of 79  
When the t=90-minute blood sampling for plasma glucose has been collected the subjects 
are allowed to eat moderately. Drinking of water is allowed ad libitum during the entire 
proc
edure. 
Hypoglycemia Rescue Provisions 
During insulin-induced hypoglycemia, plasma glucose levels will be monitored closely at 
site for safety reasons as described in Section 7.4.[ADDRESS_1115690] experiences severe alarming 
escalation of symptoms of hypoglycemia (e.g. symptoms suggesting a change in 
consciousness) at any time during the trial; glucose infusion should be initiated 
targeting a plasma glucose levels >70 mg/dL. 
2. I f plasma glucose is <45 mg/dL (2.5 mmol/L) between t=8 and t=44 minutes, 
rescue g
lucose infusion (1 -2 mg/kg administered IV over about 5 seconds) should 
be initiated to maintain 
plasma glucose between 45 mg/dL and 55 mg/dL 
(2.5-3.0 mmol/L). Pause glucose infusion if plasma glucose is >55 mg/dL. 
3. I f plasma glucose is <70 mg/dL at t=45 minutes, rescue glucose infusion 
(2-3 mg/kg administered IV over about 5 seconds ) shoul d be initiated to maintain 
plasma glucose between 70 mg/dL and 80 mg/dL (3.9-4.4 mmol/L). Pause 
g
lucose infusion if plasma glu
cose is >75 mg/dL (4.2 mmol/L). 
Subjects should remain
 in bed until completion of the test procedure 300 minutes after 
dosing (bathroom visi
ts are allowed).  
The IMP will be administered SC according to Section 6.3. The time of IMP 
a
dministration will be recorded. At the timepoint when the insulin infusion is stopped, the 
tot
al insulin dose which was required to induce hypoglycemia will be recorded. 
AEs will be specific
ally recorded during the procedure at several timepoints. 
The investigator must provide information to the subjects on how to resume their usual 
diabe
tes treatment. 
The subject may be released from the clinical center if the investigator does not have any 
sa
fety c
oncerns based on the last safety plasma glucose value and the general condition of 
the subject. However, at the discretion of the investigator or on request of the subject, the 
subject ma
y stay at the trial center for a longer period. 
8.2.4 V isit 3  (follow- up visit) 
Visit [ADDRESS_1115691] on D ay 28 + [ADDRESS_1115692] does not need to be fasting. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115693]: 
 Doc ument all changes in concomitant medication  
 P hysical examination 
 Vital si gns 
 12-lead ECG 
 L ocal tolerability 
 AE s  
 B iochemistry, hematology, coagulation 
 Ur ine stick pregnancy test (women of childbearing potential only) 
 Ur inalysis 
 A ntibodies against dasiglucagon/GlucaGen. 
After the follow-up visit the End of Trial f orm m ust be completed. Even if a subject is not 
able to attend the follow-up visit, the End of Trial form, the eCRF 
Accountability/Affirmation Statement form and the Drug Accountability form must be 
c
ompleted. 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 59 of 79  
9 STATISTICAL METHODS 
Before database lock and treatment unmasking, a separate statistical analysis plan (SAP) 
will be finali
zed, providing detailed methods for the analyses outlined below. Further 
analysis details may be added or refined in the SAP. 
Any deviations from the planned analyses will be described and justified in the final 
clinical trial
 report. 
9.[ADDRESS_1115694] s 
treated with dasiglucagon 0.6 mg. With a 2:1:1 randomization ratio for the thre e 
treatments, dasiglucagon 0.6 mg, placebo, and GlucaGen 1 mg, 78 subjects injected with 
dasiglucagon a
nd 39 subjects with placebo will yield a power of 90% at a 5% two-sided 
significance level to detect a treatment group difference in recovery incidence within 
20 minutes, assuming as low as 80% and as high as 50% recovery incidence for the 
da
siglucagon and placebo groups, respectively.  
9.2 T rial subjects 
9.2.1 A nalysis samples 
For presentation of data and reporting of the statistical analyses, th e following analysis 
samples
 will be used, depending on the context:  
S
afety analysis set (SAS): All randomized subjects who received at least one dose of
trial medica
tion.
Full analysis set (FAS): All randomized subjects who received at least one dose of
trial medica
tion a
nd contributed valid information for at least one post-dose endpoint.
Per protocol (PP) set: All subjects of the FAS for whom no relevant protocol
deviations were doc
umented. This sample will primarily be used for sensitivity
analysis.
The
 analysis of the primary endpoint and secondary endpoints will be based on the FAS. 
A secondary analysis of the primary endpoint will be based on the PP set. All safety 
analys
es will be based upon the SAS. 
The decision regarding whether a protocol deviation is relevant or not for the exclusion of 
subjects from the PP set will be made case-b y-case in a data review meeting prior to 
treatment unmasking and database lock (see Section  9.2.3).  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115695] the results will be identified and it will be evaluated if subjects and/or 
data should be excluded from the analysis. Protocol deviations will be classified as minor 
or major in a c
onsistent way. Major deviations from the protocol may lead to the 
exclusion of a subject from the PP set. 
Major protocol deviations may include deviations related to trial inclusion or exclusion 
criteria, conduct of the trial, subject management or subject assessment. Unless explicitly 
decide
d otherwise during the masked data review, the following will be considered major 
protocol deviations:
 
 Violation of one  or more major inclusion/exclusion criteria 
 I nterruption of administration of trial produ ct 
 S ignificant deviation from time windows  
 Incorrect treatment allocation 
 Missing primary endpoint. 
The violati
on of several major inclusion/exclusion criteria or the complete absence of 
efficacy data might lead to exclusion of the subject from FAS. In that case, the decision 
should be taken at the masked data review meeting, and the exclusion from efficacy 
analy
sis justified in the signed notes of the meeting. 
Obviously erroneous data points may be excluded from the analyses or re-analyzed (in 
case of 
e.g. serum concentrations). The decision to re-analyze or exclude data points from 
the statistic
al analysis is the joint responsibility of the sponsor and the trial statistician.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 61 of 79  
The subjects or observations to be excluded and the reason for their exclusion will be 
documented and signed by [CONTACT_93440]. The 
documentation will be stored together with the remaining trial documentation. The 
subjects and observations excluded from analysis sets, and the corresponding reasons, 
will be described in the clinical trial report. 
9.3 G eneral considerations 
All data obtained in this trial and documented in the eCRFs will be listed and 
summarized with statistics or frequency tables as appropriate. In case of termination of 
the trial, all data collected up to that timepoint will be included in the analysis. 
Raw data listings and summary tables will be generated using the software SAS© version 
9.[ADDRESS_1115696] deviations, medians, 
coefficients of variation, and minimum and maximum values.  
Other summaries (e.g. quartiles, 95% confidence intervals [CIs]) may be used as 
appropriate. Cat
egorical efficacy and safety variables will be summarized by [CONTACT_807466]. 
9.4 De mographics and baseline characteristics 
Base
line and demographic data will be summarized using descriptive statistics. Baseline 
ADA-positive subjects will be calculated as a percentage of the total number of subjects 
whose baseline samples were tested for ADA. 
All other data obtained in this trial and documented in the eCRF will be listed. 
9.5 E fficacy Analyses 
For the confirmatory analyses, the primary and key secondary endpoints for the 
dasiglucagon 0.6 mg and placebo treated subjects will be compared. A hierarchical 
procedur
e will be applied for the control of multiplicity. The primary and secondary 
endpoints will be evaluated on the full analysis set. In the primary analysis, those subjects 
who require rescue IV glucose will be censored at the time to plasma glucose recovery.  
In a sensitivity analysis, the time to plasma glucose recovery will be analyzed without 
censoring the subjects who received rescue IV glucose.   
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115697] the null 
h
ypothesis for a dasiglucagon versus placebo comparison: 
 P rimary:  Time to plasma glucose ≥20 mg/dL recovery 
 S econdaries 1-4: Plasma glucose changes from baseline within 30 minutes, within 
20 minutes, within 15 minutes, and within 10 minutes after study drug injection or at 
the tim
e of re
scue. 
 Secondaries 5-8:  Incidences of plasma glucose recovery within 30 minutes, within 
20 minutes, within 15 minutes, and within 10 minutes after study drug injection. 
The
 GlucaG
en versus placebo comparisons will not be included in the inferential testing 
hierarchy, since the efficacy of GlucaGen is previously established, and these 
comparisons a
re intended to support the validity of the study for the dasiglucagon versus 
placebo comp
arisons. 
Analogous supportive sensitivity analyses will be conducted in the PP set, but without 
inference intent. 
9.5.2 Prim ary confirmatory endpoint 
 Time to  plasma glucose ≥20 mg/dL recovery, defined as first increase in plasma 
glucose of ≥20
 mg/dL (1.1 mmol/L) from baseline during the hypoglycemic clamp 
procedure
.  
[IP_ADDRESS]  Primary analysis 
The primary endpoint of time to plasma glucose ≥20 mg/dL recovery will be analyzed 
using a
 Cox proportional hazards (CPH) time to event statistical model, if the hazards by 
[CONTACT_807503] a graphical comparison of the 
Nelson-Aalen estimates. The CPH model will be used for inferences, with treatment 
group and inj
ection site modeled as categorical effects, and baseline plasma glucose 
modeled as a continuous covariate. The treatment group rate ratios, active versus placebo, 
will be estimated together with the 95% confidence intervals, and pairwise treatment 
group inferences (dasiglucagon vs placebo, GlucaGen vs placebo) will be evaluated using 
two-sided likelihood ratio tests.  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 63 of 79  
If the PH assumption for treatment groups is not met, the primary endpoint will be 
analyzed using a Kaplan-Meier (KM) time to event statistical model, with treatment 
group and injection site as stratification factors. Treatment group differences between the 
KM curves (dasiglucagon vs placebo, GlucaGen vs placebo) will be evaluated 
inferentially using pairwise two-sided log-rank tests. 
In the pri mary analysis, those subjects who require rescue IV glucose will be censored at 
the time to plasma glucose recovery. In a sensitivity analysis, the time to plasma glucose 
recovery will be analyzed without censoring those subjects who require rescue IV 
glucose before 45 minutes.   
9.5.3 S econdary endpoints 
 P lasma glucose changes from baseline within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection or at the time of rescue. 
 Incidences of plasma glucose recovery (achieving a plasma glucose concentration 
increase of ≥20 mg/dL [1.1 mmol/L]) within 30 minutes, within 20 minutes, within 
15 minutes, and within 10 minutes after study drug injection. 
[IP_ADDRESS] C onfirmatory analysis 
The key secondary endpoints of plasma glucose changes from baseline (CFB) within 
[ADDRESS_1115698] in those subjects who require rescue IV glucose before plasma glucose 
≥20 mg/dL recovery. Each of these CFB variables will be analyzed using an Analysis of 
Covariance model, with treatment group modeled as a fixed effect and with the baseline 
plasma glucose modeled as a covariate. The dasiglucagon versus placebo treatment group 
differen
ce will be evaluated inferentially as a least squares means contrast, using a 
two-sided t-test at the 0.[ADDRESS_1115699]. 
The
 key secondary incidence variables (plasma glucose recovery within 30 minutes, 
within 20 minutes, within 15 minutes, within 10 minutes, in hierarchical order for 
inference) will be analyzed using descriptive statistics (frequency and percentage) by 
[CONTACT_1570]. Inferential treatment group comparisons will be assessed via pairwise 
tests of independent binomial proportions (dasiglucagon versus placebo, GlucaGen 
versus placebo).    
9.5.4 S econdary clinical efficacy (PD) endpoints 
 Time to first plasma glucose concentration of ≥70 mg/dL (3.9 mmol/L). 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 64 of 79  
 Plasma glucose response as area under the curve above baseline from time zero to 
30 minutes, AUC 0 -30min . 
S
econdary clinical efficacy endpoints will be assessed based on plasma concentration 
data from samples collected at the dosing visit (Visit 2).  
Unless otherw
ise stated, the population base of analysis will be the FAS. 
[IP_ADDRESS] Analy sis of secondary clinical efficacy (PD) endpoints 
1. Time to fir st plasma glucose concentration ≥70 mg/dL from baseline. This 
time-to-event endpoint will be evaluated using a KM time to event statistical 
model, with treatm
ent group as a stratification factor, analogous to that used for 
the primary endpoint analysis. Differences between the KM curves (dasiglucagon 
versus place
bo, GlucaGen versus placebo) will be evaluated inferentially using 
pairwise two-sided stratified log rank tests. If the ≥70 mg/dL endpoint is not met 
within [ADDRESS_1115700] valid plasma glucose 
measurement up to 45 minutes will be the censoring time.  
2. The  AUC will be calculated as the baseline-adjusted area under the plasma 
g
lucose profile over time: 
a. AUC 0-3
0min: restricting the time window to the 0 to 30 minutes interval. 
3. The log-transformed AUC endpoint will be analyzed using an analysis of 
covarianc
e (ANCOVA) model with treatment as fixed effect and baseline plasma 
glucose modeled as a covariate. The least squares means treatment group 
diff
erences will be back-transformed (anti-logged) for presentation as a ratio of 
the trea
tment group geometric means, with their corresponding 95% CI. 
9.5.5 E xposure (PK) endpoints 
 Plasma dasiglucagon and GlucaGen concentrations from time zero to 90 minutes:  
AUC 0-90
min, Cmax, and t max. 
[IP_ADDRESS]  Analysis of exposure (PK) endpoints 
AUC will be derived as the area under the individual plasma dasiglucagon/GlucaGen 
concentr
ation profile for PK from [ADDRESS_1115701] valid measurement if this 
measurement is assessed sufficiently close to 90 minutes (decision to be taken at the 
masked data review meeting). The standard trapezoidal method will be used, based on 
a
ctual ra
ther than nominal timepoints.  
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
________________________________________________________________________ 
Strictly Confidential    Page 65 of 79  
Cmax will be determined as the maximum of all valid plasma dasiglucagon/GlucaGen 
concentrati
ons.  
Tmax will be determined as the timepoint where the maximum of all valid plasma 
da
siglucagon/GlucaGen concentration measurements for each measurement series is 
observed. 
The
 log-transformed PK endpoints AUC and C max will be analyzed in the same way as 
the A
UC endpoints. 
As 
tmax is a highly discrete endpoint, Wilcoxon’s rank sum test for unpaired observations 
will
 be used to assess differences between the two treatment group s. 
9.6 E xploratory analyses 
Exploratory ana
lyses will include descriptive statistics and modeling analogous to that 
done for key secondary endpoints. However, treatment group comparisons will be 
summarized without inference intent. 
Incidence of plasma glucose recovery (achieving a plasma glucose concentration
≥70 mg/dL [3.9 mmol/L] or an increase of ≥20 mg/dL [1.1 mmol/L]) within
30 minutes after study drug injection.
P
lasma insulin response as area under the curve above baseline from time zero to
60 minutes, AUC 0 -60 min .
Plasma insulin concentrations measured pre-dose and at 30 and 60 minutes after dosing 
(see Table 3) will be presented individually. A summary table per timepoint will be 
provided. The AUC 0-60min will be determined and a summary presented.  
9.[ADDRESS_1115702] available version of the MedDRA, the version of 
which will be provided in the clinical trial report. AE summary tables will include the 
number and percent
age of subjects who experienced AEs summarized by [CONTACT_59134]. 
An overall summary table will be provided showing the number and percentage of 
subjects with any: 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 66 of 79  
 TEAE 
 S evere TEAE 
 S erious TEAE 
 Dr ug-related TEAE 
 Dr ug-related severe TEAE 
 Dr ug-related serious TEAE 
 TEA E leading to withdrawal 
 TEA E with outcome death 
 AE SI 
Refer to Section 7.2.[ADDRESS_1115703] results will be flagged as to whether the result is below, within or 
above the respe
ctive reference range. The number of values outside of the reference range 
will be counted. 
9.7.4 Oth er safety data 
Incidence of rescue infusion of IV glucose during the hypoglycemic clamp procedure will 
be analyzed using descriptive statistics (frequency and percentage) by [CONTACT_1570]. 
Inferential treatment group comparisons will be assessed via pairwise tests of 
independent binomial proportions (dasiglucagon versus placebo, GlucaGen versus 
placebo).  
Time to fir
st rescue infusion of IV glucose during the hypoglycemic clamp procedure 
will be evaluated using a KM time to event statistical model, with treatment group and 
injection si
te as stratification factors. Differences between the KM curves (dasiglucagon 
versus placebo, GlucaGen versus placebo) will be evaluated inferentially using pairwise 
two-sided stratified log-rank tests. If the endpoint is never met, the time of the last plasma 
g
lucose measurement will be the censoring time. 
Vital signs, physical examination, 12-lead ECG and local tolerability data will be 
summarize
d using descriptive statistics. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115704] will be applied. For the primary analysis in the 
FAS, missi
ng values for the primary endpoint will be imputed by a conservative rule 
considerin
g any missing value as a failure. 
9.10 In terim analyses 
No inter
im analyses are currently planned. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115705] be consistent with 
the subjec
ts’ source documentation (i.e. medical records). 
The investigator will permit trial-related monitoring, IRB/IEC review, and regulatory 
inspections, providing direct access to source data /documents. Sponsor-authorized 
quality assurance personnel may carry out audits for which the investigator must provide 
support. 
The
 trial monitor or a representative of the sponsor will cross-check the data entered in 
the eCRFs with the source data at the trial center and observe the trial procedures in order 
to verify a
dherence to the trial protocol. Any queries will be resolved by [CONTACT_111140]/her delegate. 
All of the clinical data will be captured via electronic data capture (EDC) using a 
web-based tool.  
The
 investigator center staff will enter and edit the data via a secure network, with secure 
a
cce
ss features (username [CONTACT_2383]). A complete electronic audit trail will be 
maintained. The investigator will approve the data using an electronic signature (Ref: 21 
CFR Part 11), and this approval is used to confirm the accuracy of the data recorded. 
eCRFs will be used for all subjects. The investigator’s data will be accessible from the 
investigator’s center throughout the trial. The eCRFs must be kept current to reflect 
subject st
atus at each phase during the course of the trial. The eCRF will not capture 
personalized data. The investigator must make a separate confidential record of 
personalized details (name [CONTACT_93459]) on the subject identification and enrollment log. 
All changes to data are made by [CONTACT_15009]/her delegate through the EDC 
system. 
 
It is the responsibility of the principal investigator [INVESTIGATOR_807440]’s eCRF are also made on the subject’s medical records. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115706] leaving the trial should be completed at the time of the final 
visit or shortly thereafter. 
10.2  Electronic case report forms 
Remote data capture software will be used for data collection. Following training, trial 
staff wil
l be given access to the software. Access to the software is restricted to staff 
participating in the trial and the extent of access will depend on the participants' user role 
in the tria
l. 
The
 subjects enrolled into the tri al will be identified in the database by [CONTACT_18022] 
a
nd trial identification code. The investigator or delegate will enter subject data into the 
e
CRF promptly. All data is to be entered in English. Data recorded in the eCRFs will be 
accessible to the trial staff throughout the trial. 
Af
ter dat
a entry, systematic data validation will be performed and data entry 
discrepancies will be presented electronically directly to the center staff. Queries for 
discrepant dat
a may be generated automatically by [CONTACT_727915]/or 
generated manually by [CONTACT_807470]. All queries, whether 
gene
rated by [CONTACT_727917], will be in electronic format. 
All sections of the e
CRF are to be electronically approved by [CONTACT_1720] a 
medically qualified delegate after the data has been entered and all queries have been 
resolved. Changes to any eCRF page subsequent to the approval require a new approval 
signature. 
All queries and changes/corrections to the data are documented in the eCRF. 
10.[ADDRESS_1115707]’s medical records, assess drug 
accountability, and ensure that the trial is being conducted according to pertinent 
regulatory
 requirements. 
Checking of the eCRFs for completeness and clarity, and cross-checking with source 
documents, will be required to monitor the progress of the trial. Moreover, regulatory 
authorities of certain countries, IRBs/IECs, and/or the sponsor may wish to carry out such 
source data checks and/or on-site audit inspections. Direct access to source data will be 
required for these inspections and audits; they will be carried out giving due 
consideration to data protection and medical confidentiality. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115708]’s medical records. If data are to be entered directly into the eCRF this must be 
specified in a sour
ce data agreement prior to the start of the trial. 
eCRF entrie
s will be verified with source documentation. The review of medical records 
will be performed in a manner to ensure that subject confidentiality is maintained. 
The trial monitor will check the eCRF for accuracy and completion and perform source 
da
ta verification. The trial monitor will document source data verification of all reviewed 
sections of the eC
RF. 
10.[ADDRESS_1115709] (e.g. informed consent forms, laboratory slips, medication 
inventory records, and other pertinent information) must be retained by [CONTACT_807471]. 
10.7  Good clinical practice 
The procedures set out in this trial protocol are designed to ensure that the sponsor and 
investigator abide by [CONTACT_146018] ( 1), a nd of the 
Declara
tion of Helsinki (2008) ( 2). The trial also will be carried out in keepi[INVESTIGATOR_118483].  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115710] orally and in writing (subject information 
sheet) the nature, significance, risks and implications of the trial before inclusion. In 
pa
rticular, the subjects will be informed about the following: 
 The possibility of withdrawing from the clinical trial at any time by [CONTACT_807472]. 
 How personal and health-related data will be collected and used during the trial. 
 Tha t his/her medical records may be examined by [CONTACT_807473], by [CONTACT_6667]/IEC 
members, and by [CONTACT_6668]. 
All su
bjects will receive a copy of the subject information sheet and a copy of their 
signed and dated informed consent form, both of which will be in the subject’s local 
language. 
I
f a protocol amendment is required, the informed consent form may need to be revised to 
reflect the changes to the protocol. If the consent form is revised, it must be reviewed and 
approved by [CONTACT_69869]/IRB, and signed by [CONTACT_807504]. 
10.9  Protocol a pproval and amendment 
Before
 the start of the trial, the trial protocol and/or other relevant documents will be 
approved b
y the IEC/IRB/competent authorities, in accordance with local legal 
requirements. The sponsor must ensure that all ethical and legal requirements have been 
met before the first subject is enrolled in the trial. 
This protocol is to be
 followed exactly. To alter the protocol, amendments must be 
written, receive approval from the appropriate personnel, and receive IRB/IEC/competent 
authority approval prior to implementation (if appropriate).  
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 72 of 79  
Administrative changes (not affecting the subject benefit/risk ratio) may be made without 
the need for a formal amendment. All amendments will be distributed to all protocol 
recipi[INVESTIGATOR_840], with appropriate instructions. 
10.[ADDRESS_1115711] will be up to 63 days (including up to 
30 days for screening and up to 33 days until the follow-up visit).  
The
 trial will be closed when all subjects have completed Visit 3. 
10.11  Premature termination of the trial 
If the investigator, the sponsor (e.g. safety committee), or the safety medical monitor 
becomes aw
are of conditions or events that suggest a possible hazard to subject s if the 
trial continues, the trial may be terminated after appropriate consultation between the 
re
levant parties. The trial may also be terminated early at the sponsor’s discretion in the 
absence
 of such a finding. 
Conditions that may warrant termination include, but are not limited to: 
 The  discovery of an unexpected, significant, or unacceptable risk to the subjects 
enrolled in the trial 
 Failure to enroll subjects at an acceptable rate. 
 A de cision on the part of the sponsor to suspend or discontinue development of the 
drug. 
The trial can be terminated prematurely by [CONTACT_807475]: 
 The center cannot comply with the requirements of the protocol. 
 I t is not possible for the center to comply with GCP standards. 
10.12  Confidentiality 
All 
trial findings and documents will be regarded as confidential. The investigator and 
membe
rs of his/he
r research team must not disclose such information without prior 
written approval from the sponsor. 
The anonymity of participating subjects must be maintained. Subjects will be identified 
on eCRFs submitted to the sponsor by [CONTACT_139927]. On the SAE reports and all 
other source d
ocuments, the subject will be identified via subject number. Documents not 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115712] (e.g. the signed informed consent 
form) must be maint
ained in confidence by [CONTACT_093].  
10.13  Other ethical and regulatory issues 
If a significant safety issue is identified, either from an individual case report or review of 
aggregate data, then the sponsor will issue prompt notification to all parties : r egulatory 
authorities, investigators and IRB/IECs. 
A sig
nificant safety issue is one that has a significant impact on the course of the clinical 
trial or program (including the potential for suspension of the trial program or 
a
mendments to pro
tocols) or warrants immediate update of informed consent. 
10.[ADDRESS_1115713] resulted 
from participation in the clinical trial, or if he/she undergoes any other medical treatment 
without their consent before the clinical trial has been completely finished in so far as the 
individual subj
ect is concerned. 
An
y injury to health, which might have occurred as a result of participation in the clinical 
trial must be reported by [CONTACT_807476]. The investigator is 
obli
ged to m
ake such a report in any case. 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 74 of 79  
10.15   Publication policy 
By [CONTACT_752373], the investigator agrees with the use of results of the trial for 
the purposes of national and international registration, publication and information for 
medical and pharmace
utical professionals. If necessary, the authorities will be notified of 
the investigator's name, address, qualifications and extent of involvement. 
A clinical trial report will be prepared and reviewed by [CONTACT_807477]-operation with 
the c
oordinating investigator. The coordinatoing investigator will be appointed by 
[CONTACT_807478]. A summary of the clinical trial report (according to CPMP/ICH137/95) 
should be sent to the regulatory authorities and IRB/IEC according to the relevant 
guidelines. 
According to the Declaration of Helsinki (2) investigators and sponsors ‘have ethical 
obli
gations with regard to the publication and dissemination of the results of research’.   
The trial design and results may be published as one or more original research 
manuscripts/abstracts and presented at a scientific meeting. The original eCRFs and the 
data generated from the eCRFs or otherwise obtained during the trial under this trial 
protocol will become the property of the sponsor. Publication of the results of this trial by 
[CONTACT_807479]. 
Any material intended for publication will be given to the sponsor at least [ADDRESS_1115714] the right to comment on the intended 
publication and to take any reasonable measures for patent protection. Authorship on any 
publication(s) resulting from this clinical trial will be assigned according to the 
recommendations of the International Committee of Medicinal Journal Editors (26).  
Participating subjects will not be identified by [CONTACT_807480]. 
The sponsor is responsible for trial registration at ClinicalTrials.gov 
(www.clinicalt
rials.gov) according to FDA requirements, as well as the European 
Medicines Agen
cy’s Clinical Trials Database (EudraCT).  
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115715]  
1.ICH Harmonised Tripartite G uideline. International Conference on Harmonisation.  
ICH Harmonised Tripartite G uideline. Integrated addendum t o ICH E6(R1): 
Guideline for Good Clinical Practice E6 (R2), Step 4. 09-Nov-2016. Available from: 
URL:
http://www.ich.org/fileadmin/Public_Web_Site/ICH_Products/Guidelines/Efficacy/E  
6/E6_R2__Step_4.pdf
2. World Medical Association. Declaration of Helsinki. Ethical Principles for Medical
Resea
rch Involving Human Subjects. 52nd WMA General Assembly, Edinburgh,
Scotland, October 2000. Last amended with Note of Clarification on Paragraph [ADDRESS_1115716] ER, Anderson J, Childs B, Cryer P, Dagogo-Jack S, Fish L, et al.
Hypog
lycemia and diabetes: a report of a workgroup of the American Diabetes
Association and the Endocrine Society. Diabetes Care 2013 May;36:1384-95
4. Cryer PE. The barrier of hypoglycemia in diabetes. Diabetes 2008;57:3169-76
5. America
n Diabetes Association Position Statement. Standards of medical care in
diabetes - 2017. Diabetes Care 2017;40(Supplement 1):S1-S135
6.
Davies MJ, Gagliardino JJ, Gray LJ, Khunti K, Mohan V, Hughes R. Real-world
factors a
ffecting adherence to insulin therapy in patients with Type 1 or Type 2
diabetes mellitus: a systematic review. Diabetic Medicine 2013;30:512-24
7. International Hypoglycaemia Study Group. Glucose concentrations of less than 3.0
mmol/L 
(54 mg/dL) should be reported in clinical trials: a joint position statement of
the American Diabetes Association and the European Association for the Study of
Diabetes. Diabetes Care 2017;40(1):155-57
8. Christensen M, Bagger JI, Vilsbøll T, Knop FK. The alpha-cell as target for type 2
diabetes thera
py. Rev Diabet Stud 2011;8:369-81
9. Lund A, Bagger JI, Christensen M, Knop FK, Vilsbøll T. Glucagon and type 2
diabetes: the return o
f the alpha cell. Curr Diab Rep 2014;14:555
10. Habegger KM, Heppner KM, Geary N, Bartness TJ, DiMarchi R, Tschöp MH. The
metabolic a
ctions of glucagon revisited. Nat Rev Endocrinol 2010;6:689-97
11. Onoue S, Ohshima K, Debari K, Koh K, Shioda S, Iwasa S, et al. Mishandling of the
therapeuti
c peptide glucagon generates cytotoxic amyloidogenic fibrils. Pharm Res
2004;21:1274-83
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.0  
  
 
 
 
________________________________________________________________________ 
Strictly Confidential    Page 76 of 79  
12. Fosgerau K, Hoffmann T. Peptide therapeutics: current status and future directions. 
Drug Discovery Today 2015;20:122-8 
13. Novo N ordisk Limited. SPC for GlucaGen Hypokit 1 mg. 2015. 
http://www
.medicines.org.uk/emc/medicine/4258/SPC/GlucaGen+Hypokit+1+mg - 
Access
ed 13 Mar 2017 . 
14. Z ealand Pharma A/S. Dasiglucagon Investigator's Brochure, Edition 3, 12 Dec 2016.  
15. The  Task Force for the management of arterial hypertension of the European Society 
of Hypertension (ESH) and of the European Society of Cardiology (ESC). 2013 
ESH/ESC g
uidelines for the management of arterial hypertension. European Heart 
Journal 2013;34:2159-219 
16. L evey AS, Coresh J, Greene T, Stevens LA, Zhang Y, Hendriksen BA, et al. Using 
standardized serum creatinine values in the modification of diet in renal disease study 
equation for estimating glomerular filtration rate. Annals of Internal Medicine 
2006;145:247-54 
17. F ood and Drug Administration (FDA). Guidance for Industry on Bioanalytical 
Method Validation. Food and Drug Administration (FDA) [ADDRESS_1115717], Bansal S, Booth B, DeStefano AJ, Rose MJ, Sailstad J, et al. 
Quantitative bioanalytical methods validation and implementation: best practices for 
chromatographic and ligand binding assays. Pharm Res [ADDRESS_1115718];24:1962-[ADDRESS_1115719] biotechnology products. J Pharm Biomed Anal 2008;48:1267-[ADDRESS_1115720] neutralizing antibodies to ZP4207 
by [CONTACT_807481] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-004-REP.  2016. Report No.: Zealand Pharma, 
study [ADDRESS_1115721] neutralizing antibodies to glucagon 
by [CONTACT_807505] (cAMP) in a glucagon receptor 
transfected cell line, BAL-14-206-005.  2016. Report No.: Zealand Pharma, Study 
15-040 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115722] glycemic control of insulin-dependent diabetes mellitus. 
N Eng J Med 1987; 316: 1376-83. 
25. R ickels MR, Ruedy KJ, Foster NC, et al. Intranasal glucagon for treatment of insulin-
induced hypoglycemia in adults with type 1 diabetes: A randomized crossover 
noninferiority study. Diabetes Care 2016; 39: 264-70. 
26. I CMJE. Recommendations for the conduct, reporting, editing, and publication of 
scholarly work in medical journals. Updated December 2016 
 
 
 
 
 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115723] of trial personnel 
Sponsor  
Clinical Trial Manager   
 
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Medical Officer   
Zealand Pharma  
Smedeland 36  
2600 Glostrup, Denmark  
Phone:   
Contract Research Organization  Chiltern International (Ltd)  
[ADDRESS_1115724]  
Slough  
Berkshire  
SL1 4AA  
[LOCATION_008]  
Phone:  +44 (0) [PHONE_16833]  
Project Manager   
Chiltern International (Ltd)  
[ADDRESS_1115725]  
Slough  
Berkshire  
SL1 4AA  
United  Kingdom  
Phone:   
Senior Medical Officer  and 
Safety medical monitor   
Chiltern International kft  
Canada Square Office House  
Ganz u  

 
 
Dasiglucagon (ZP4207)  Date: 29 Aug 2017  
 Study ID:  ZP4207 -[ZIP_CODE]  Protoco l Version: Final 1.[ADDRESS_1115726]  
Hungary  
Phone:   
Pharmacovigilance unit  
Responsible for Serious Adverse 
Event (SAE) Management and 24 -
hour SAE reporting    
PharmaLex  
Agern Allé 24  
2970 Hørsholm, Denmark  
Phone:   (8 a.m. to 4 p.m.)  
Phone:   (outside 8 a.m. to 4 p.m.)  
Fax:  
email: [EMAIL_7118]   
Central laboratory  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (GlucaGen 
PK, insulin PK)  MLM Laboratory  
Dohrweg 63  
[ZIP_CODE] Mönchengladbach  
[LOCATION_013]  
Special laboratory (dasiglucagon 
PK, dasiglucagon ADA, 
GlucaGen ADA)  York Bioanalytical Solutions (YBS)  
Cedar House  
Northminster Business Park  
Northfield Lane  
York, YO26 6QR, [LOCATION_008]  
Special laboratory  
(neutralizing antibodies)  BioAgilytix  
[ADDRESS_1115727] of all investigators, IECs and IRBs will be provided in a separate document and in  
the clinical tria
l report. 
 
